{
	"meta": {
		"totalResults": 468,
		"from": 0
	},
	"results": [
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MZP"
				},
				{
					"type": "NSCNumber",
					"name": "382050"
				}
			],
			"definition": {
				"html": "An antifolate derived from diaminopyrimidine with cytotoxic properties.  With a mechanism of action similar to that of methotrexate (MTX), m-azidopyrimethamine blocks tetrahydrofolate synthesis, resulting in depletion of nucleotide precursors and inhibition of DNA, RNA and protein synthesis. This agent is more lipophilic but less potent than MTX.",
				"text": "An antifolate derived from diaminopyrimidine with cytotoxic properties.  With a mechanism of action similar to that of methotrexate (MTX), m-azidopyrimethamine blocks tetrahydrofolate synthesis, resulting in depletion of nucleotide precursors and inhibition of DNA, RNA and protein synthesis. This agent is more lipophilic but less potent than MTX."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2366",
			"nciConceptName": "M-Azidopyrimethamine",
			"termId": 40860,
			"name": "m-azidopyrimethamine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "m-azidopyrimethamine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "therapeutic gamma-retroviral vector M87o-transduced CD34+ peripheral blood stem cells"
				},
				{
					"type": "Synonym",
					"name": "M87o-transduced CD34+ PBSC"
				}
			],
			"definition": {
				"html": "Peripheral blood stem cells (PBSCs) transduced with the retroviral vector M87o encoding for the HIV-1-entry inhibitor peptide membrane-anchored antiviral peptide C46 (maC46). Expression of C46 by M87o-transduced CD34+ peripheral blood stem cells may prevent the fusion of viral and cellular membranes, thereby inhibiting HIV-1 entry. C46 is a membrane-anchored peptide encoding amino acids 628 to 673 of the HIV-1 entry inhibitory transmembrane glycoprotein gp41.",
				"text": "Peripheral blood stem cells (PBSCs) transduced with the retroviral vector M87o encoding for the HIV-1-entry inhibitor peptide membrane-anchored antiviral peptide C46 (maC46). Expression of C46 by M87o-transduced CD34+ peripheral blood stem cells may prevent the fusion of viral and cellular membranes, thereby inhibiting HIV-1 entry. C46 is a membrane-anchored peptide encoding amino acids 628 to 673 of the HIV-1 entry inhibitory transmembrane glycoprotein gp41."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C82351",
			"nciConceptName": "M87o-Transduced CD34+ Peripheral Blood Stem Cells",
			"termId": 639653,
			"name": "M87o-transduced CD34+ peripheral blood stem cells",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "m87o-transduced-cd34-peripheral-blood-stem-cells"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MaZiRenWan"
				},
				{
					"type": "Abbreviation",
					"name": "MZRW"
				},
				{
					"type": "Synonym",
					"name": "hemp seed formula"
				}
			],
			"definition": {
				"html": "A proprietary, traditional Chinese herbal (TCH) formula composed of six different herbs: Semen Cannabis Sativae (Huo Ma Ren, cannabis seed), Semen Pruni Armeniacae (Xing Ren, apricot seed), Radix Paeoniae Alba (Bai Shao, white peony root), Fructus Immaturus Citri Aurantii (Zhi Shi, immature bitter orange), Cortex Magnoliae Officinalis (Hou Po, magnolia bark and Radix et Rhizoma Rhei (Da Huang, rhubarb root and rhizome). Ma Zi Ren Wan (MZRW) may help with intestinal dryness and constipation by lubricating and moistening the intestines and the stool. MZRW may also stimulate intestinal movement. It is believed to drain heat, promote the movement of Qi and unblock the bowels.",
				"text": "A proprietary, traditional Chinese herbal (TCH) formula composed of six different herbs: Semen Cannabis Sativae (Huo Ma Ren, cannabis seed), Semen Pruni Armeniacae (Xing Ren, apricot seed), Radix Paeoniae Alba (Bai Shao, white peony root), Fructus Immaturus Citri Aurantii (Zhi Shi, immature bitter orange), Cortex Magnoliae Officinalis (Hou Po, magnolia bark and Radix et Rhizoma Rhei (Da Huang, rhubarb root and rhizome). Ma Zi Ren Wan (MZRW) may help with intestinal dryness and constipation by lubricating and moistening the intestines and the stool. MZRW may also stimulate intestinal movement. It is believed to drain heat, promote the movement of Qi and unblock the bowels."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C129581",
			"nciConceptName": "Ma Zi Ren Wan",
			"termId": 783794,
			"name": "Ma Zi Ren Wan",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "ma-zi-ren-wan"
		},
		{
			"preferredName": "magnesium hydroxide/aluminum hydroxide",
			"termId": 39600,
			"name": "Maalox",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "aluminum-hydroxide-magnesium-hydroxide"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "AEZS-130"
				},
				{
					"type": "CodeName",
					"name": "EP 1572"
				},
				{
					"type": "CodeName",
					"name": "JMV 1843"
				},
				{
					"type": "ChemicalStructureName",
					"name": "N-(2-Amino-2-Methylpropanoyl-N1-((1R)-1-Formamido-2-(1H-Indol-3-yl)Ethyl)-D-Tryptophanamide"
				},
				{
					"type": "ObsoleteName",
					"name": "Solorel"
				},
				{
					"type": "CASRegistryName",
					"name": "381231-18-1"
				}
			],
			"definition": {
				"html": "An orally available synthetic mimetic of the growth hormone (GH) secretagogue ghrelin with potential anti-cachexia activity. Upon oral administration, macimorelin mimics endogenous ghrelin by stimulating appetite and binds to the growth hormone secretagogue receptor GHSR in the central nervous system, thereby mimicking the GH-releasing effects of ghrelin from the pituitary gland. Stimulation of GH secretion increases insulin-like growth factor-I (IGF-I) levels which may further stimulate protein synthesis. In addition, ghrelin reduces the production of pro-inflammatory cytokines, which may play a direct role in cancer-related loss of appetite.",
				"text": "An orally available synthetic mimetic of the growth hormone (GH) secretagogue ghrelin with potential anti-cachexia activity. Upon oral administration, macimorelin mimics endogenous ghrelin by stimulating appetite and binds to the growth hormone secretagogue receptor GHSR in the central nervous system, thereby mimicking the GH-releasing effects of ghrelin from the pituitary gland. Stimulation of GH secretion increases insulin-like growth factor-I (IGF-I) levels which may further stimulate protein synthesis. In addition, ghrelin reduces the production of pro-inflammatory cytokines, which may play a direct role in cancer-related loss of appetite."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C95123",
			"nciConceptName": "Macimorelin",
			"termId": 735530,
			"name": "macimorelin",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "macimorelin"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "ACT-064992"
				},
				{
					"type": "ForeignBrandName",
					"name": "Actelion-1"
				},
				{
					"type": "ChemicalStructureName",
					"name": "N-[5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)-pyrimidin-4-yl]-N'-propylaminosulfonamide"
				}
			],
			"definition": {
				"html": "An orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity. Upon administration, macitentan and its metabolites block the binding of endothelin isoform 1 (ET-1) to type-A and type-B ETR on both the tumor cells and the endothelial cells in the tumor vasculature. This prevents ET-1 mediated signaling transduction which may decrease tumor cell proliferation, progression, and angiogenesis in tumor tissue. ET-1, a potent vasoconstrictor that plays an important role in inflammation and tissue repair, is, together with its receptors, overexpressed varyingly in many tumor cell types.",
				"text": "An orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity. Upon administration, macitentan and its metabolites block the binding of endothelin isoform 1 (ET-1) to type-A and type-B ETR on both the tumor cells and the endothelial cells in the tumor vasculature. This prevents ET-1 mediated signaling transduction which may decrease tumor cell proliferation, progression, and angiogenesis in tumor tissue. ET-1, a potent vasoconstrictor that plays an important role in inflammation and tissue repair, is, together with its receptors, overexpressed varyingly in many tumor cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C87728",
			"nciConceptName": "Macitentan",
			"termId": 721764,
			"name": "macitentan",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "macitentan"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "Sting agonist E7766"
				},
				{
					"type": "CodeName",
					"name": "E7766"
				},
				{
					"type": "CodeName",
					"name": "E-7766"
				},
				{
					"type": "CodeName",
					"name": "E 7766"
				},
				{
					"type": "CodeName",
					"name": "MBSA E7766"
				},
				{
					"type": "Synonym",
					"name": "stimulator of interferon genes agonist E7766"
				}
			],
			"definition": {
				"html": "An agonist of macrocycle-bridged stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon intravenous administration, macrocycle-bridged STING agonist (MBSA) E7766 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. Compared to conventional STING agonists, MBSA E7766 allows for conformational rigidity of the unique macrocycle bridge which enhances its stability and STING affinity, thereby increasing its efficacy.\n",
				"text": "An agonist of macrocycle-bridged stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon intravenous administration, macrocycle-bridged STING agonist (MBSA) E7766 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. Compared to conventional STING agonists, MBSA E7766 allows for conformational rigidity of the unique macrocycle bridge which enhances its stability and STING affinity, thereby increasing its efficacy.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C166141",
			"nciConceptName": "Macrocycle-bridged STING Agonist E7766",
			"termId": 799924,
			"name": "macrocycle-bridged STING agonist E7766",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "macrocycle-bridged-sting-agonist-e7766"
		},
		{
			"aliases": [
				{
					"type": "ForeignBrandName",
					"name": "Colonlytely"
				},
				{
					"type": "LexicalVariant",
					"name": "Macrogol 3350-Based Iso-Osmotic Laxative"
				}
			],
			"definition": {
				"html": "An  isotonic solution containing macrogol 3350 and electrolytes with laxative activity. Macrogol 3350-based oral osmotic laxative promotes the retention of water in the bowel, thereby increasing the water content of stool, which results in increased gastrointestinal motility and stool transit time and evacuation of colonic contents. Macrogol 3350 is also known as polyethylene glycol (PEG) 3350.",
				"text": "An  isotonic solution containing macrogol 3350 and electrolytes with laxative activity. Macrogol 3350-based oral osmotic laxative promotes the retention of water in the bowel, thereby increasing the water content of stool, which results in increased gastrointestinal motility and stool transit time and evacuation of colonic contents. Macrogol 3350 is also known as polyethylene glycol (PEG) 3350."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C29080",
			"nciConceptName": "Macrogol 3350-Based Iso-Osmotic Laxative",
			"termId": 615423,
			"name": "macrogol 3350-based oral osmotic laxative",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "macrogol-3350-based-iso-osmotic-laxative"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MMDT"
				},
				{
					"type": "Synonym",
					"name": "Ophiopogonis tuber/Pinelliae tuber/Glycyrrhizae radix/Zizyphi fructus/Ginseng radix/oryzae semen herbal formulation"
				},
				{
					"type": "Synonym",
					"name": "Maekgeuron granules"
				},
				{
					"type": "Synonym",
					"name": "Mai-men-dong-tang"
				},
				{
					"type": "Synonym",
					"name": "Bakumondo-to"
				},
				{
					"type": "Synonym",
					"name": "TJ-29"
				}
			],
			"definition": {
				"html": "A traditional East Asian herbal medicine composed of six herbs, including Ophiopogonis tuber, Pinelliae tuber, Glycyrrhizae radix, Zizyphi fructus, Ginseng radix, and oryzae semen, with potential anti-tussive activity. Maekmoondong-tang is traditionally prescribed for respiratory symptoms to direct the qi downwards and compensate for lung-yin deficiency or dry lung by tonifying yin and moistening the lung. Although the exact mechanisms through which Maekmoondong-tang exerts its effects have yet to be fully elucidated, this agent may, upon administration, improve the severity of chronic cough, reduce airway hyper-responsiveness possibly by reducing the cough reflex and bronchodilation, and airway inflammation possibly through anti-inflammatory and immunomodulatory effects.",
				"text": "A traditional East Asian herbal medicine composed of six herbs, including Ophiopogonis tuber, Pinelliae tuber, Glycyrrhizae radix, Zizyphi fructus, Ginseng radix, and oryzae semen, with potential anti-tussive activity. Maekmoondong-tang is traditionally prescribed for respiratory symptoms to direct the qi downwards and compensate for lung-yin deficiency or dry lung by tonifying yin and moistening the lung. Although the exact mechanisms through which Maekmoondong-tang exerts its effects have yet to be fully elucidated, this agent may, upon administration, improve the severity of chronic cough, reduce airway hyper-responsiveness possibly by reducing the cough reflex and bronchodilation, and airway inflammation possibly through anti-inflammatory and immunomodulatory effects."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C154567",
			"nciConceptName": "Maekmoondong-tang",
			"termId": 794323,
			"name": "Maekmoondong-tang",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "maekmoondong-tang"
		},
		{
			"aliases": [
				{
					"type": "INDCode",
					"name": "34353"
				},
				{
					"type": "NSCNumber",
					"name": "345842"
				},
				{
					"type": "CASRegistryName",
					"name": "88859-04-5"
				}
			],
			"definition": {
				"html": "A synthetic oxazaphosphorine derivative with antineoplastic properties.  Mafosfamide alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis.  Although closely related to cyclophosphamide, mafosfamide, unlike cyclophosphamide, does not require hepatic activation to generate its active metabolite 4-hydroxy-cyclophosphamide; accordingly, mafosfamide is potentially useful in the intrathecal treatment of neoplastic meningitis.",
				"text": "A synthetic oxazaphosphorine derivative with antineoplastic properties.  Mafosfamide alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis.  Although closely related to cyclophosphamide, mafosfamide, unlike cyclophosphamide, does not require hepatic activation to generate its active metabolite 4-hydroxy-cyclophosphamide; accordingly, mafosfamide is potentially useful in the intrathecal treatment of neoplastic meningitis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1150",
			"nciConceptName": "Mafosfamide",
			"termId": 41254,
			"name": "mafosfamide",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mafosfamide"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MAG-TN3 plus AS15 vaccine"
				},
				{
					"type": "Synonym",
					"name": "MAG-Tn3/AS15"
				}
			],
			"definition": {
				"html": "A vaccine containing synthetic multiple antigenic glycopeptide (MAG) composed of tri Tn glycotope (MAG-Tn3), which comprises a dendrimeric, nonimmunogenic lysine core linked to a tetravalent peptidic CD4+ T-cell epitope backbone and each attached to three Tn antigens (tri-Tn cluster), combined with the immunoadjuvant AS15, with potential antineoplastic activity. Upon administration of the MAG-Tn3/AS15 vaccine, MAG-Tn3 induces the production of tumor-specific anti-Tn glycosidic antibodies, which results in antibody-dependent cell cytotoxicity (ADCC) against Tn-expressing tumor cells. The Tn carbohydrate antigen, a tumor-associated antigen (TAA), is overexpressed in a number of tumor cell types. The tri-Tn clusters mimic carbohydrate structures found on tumor cells. The T-cell epitope stimulates effective T-cell responses. AS15, a potent adjuvant liposomal formulation that contains CpG 7909, monophosphoryl lipid (MPL), and QS-21, increases the immune response against the Tn antigens.",
				"text": "A vaccine containing synthetic multiple antigenic glycopeptide (MAG) composed of tri Tn glycotope (MAG-Tn3), which comprises a dendrimeric, nonimmunogenic lysine core linked to a tetravalent peptidic CD4+ T-cell epitope backbone and each attached to three Tn antigens (tri-Tn cluster), combined with the immunoadjuvant AS15, with potential antineoplastic activity. Upon administration of the MAG-Tn3/AS15 vaccine, MAG-Tn3 induces the production of tumor-specific anti-Tn glycosidic antibodies, which results in antibody-dependent cell cytotoxicity (ADCC) against Tn-expressing tumor cells. The Tn carbohydrate antigen, a tumor-associated antigen (TAA), is overexpressed in a number of tumor cell types. The tri-Tn clusters mimic carbohydrate structures found on tumor cells. The T-cell epitope stimulates effective T-cell responses. AS15, a potent adjuvant liposomal formulation that contains CpG 7909, monophosphoryl lipid (MPL), and QS-21, increases the immune response against the Tn antigens."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C120555",
			"nciConceptName": "MAG-Tn3/AS15 Vaccine",
			"termId": 769541,
			"name": "MAG-Tn3/AS15 vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mag-tn3-as15-vaccine"
		},
		{
			"aliases": [
				{
					"type": "LexicalVariant",
					"name": "MAGE10.A2"
				}
			],
			"definition": {
				"html": "A synthetic nonapeptide derived from a melanoma-associated antigen. Vaccination with MAGE-10.A2 may stimulate a host cytotoxic T-cell response against tumor cells that express the melanoma-associated antigen, resulting in tumor cell lysis.",
				"text": "A synthetic nonapeptide derived from a melanoma-associated antigen. Vaccination with MAGE-10.A2 may stimulate a host cytotoxic T-cell response against tumor cells that express the melanoma-associated antigen, resulting in tumor cell lysis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2681",
			"nciConceptName": "MAGE-10.A2",
			"termId": 38649,
			"name": "MAGE-10.A2",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mage-10a2"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MAGE-3.A1"
				},
				{
					"type": "Synonym",
					"name": "HLA-A1-restricted MAGE-3 peptide vaccine"
				}
			],
			"definition": {
				"html": "A synthetic peptide cancer vaccine consisting of human leukocyte antigen HLA-A1-restricted peptide derived from human melanoma antigen 3 (MAGE-3) with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-3.A1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-3, resulting in tumor cell lysis. MAGE-3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.",
				"text": "A synthetic peptide cancer vaccine consisting of human leukocyte antigen HLA-A1-restricted peptide derived from human melanoma antigen 3 (MAGE-3) with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-3.A1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-3, resulting in tumor cell lysis. MAGE-3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C48632",
			"nciConceptName": "MAGE-3.A1 Peptide Vaccine",
			"termId": 685200,
			"name": "MAGE-3.A1 peptide vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mage-3a1-peptide-vaccine"
		},
		{
			"aliases": [
				{
					"type": "LexicalVariant",
					"name": "MAGE-A1, Her-2/neu, FBP Peptides Cancer Vaccine"
				}
			],
			"definition": {
				"html": "A cancer vaccine containing multiple synthetic antigen peptides derived from MAGE-A1, Her-2/neu, and folate binding protein (FBP) with potential immunostimulating and antineoplastic properties.  MAGE-A1, Her-2/neu, FBP peptides cancer vaccine includes the antigen peptides MAGE-A1:161-169, FBP:191-199, Her-2/neu:369-377, MAGE-A1:96-104, and Her-2/neu:754-762. Upon administration, this cancer vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing  these antigen peptides, resulting in tumor cell lysis. MAGE-A1, Her-2/neu, and FBP proteins may be over-expressed in various cancer  cell types, such as epithelial ovarian cancer cells.\n\n\n",
				"text": "A cancer vaccine containing multiple synthetic antigen peptides derived from MAGE-A1, Her-2/neu, and folate binding protein (FBP) with potential immunostimulating and antineoplastic properties.  MAGE-A1, Her-2/neu, FBP peptides cancer vaccine includes the antigen peptides MAGE-A1:161-169, FBP:191-199, Her-2/neu:369-377, MAGE-A1:96-104, and Her-2/neu:754-762. Upon administration, this cancer vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing  these antigen peptides, resulting in tumor cell lysis. MAGE-A1, Her-2/neu, and FBP proteins may be over-expressed in various cancer  cell types, such as epithelial ovarian cancer cells.\n\n\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C62775",
			"nciConceptName": "MAGE-A1, Her-2/neu, FBP Peptides Cancer Vaccine",
			"termId": 506045,
			"name": "MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mage-a1-her-2-neu-fbp-peptides-cancer-vaccine"
		},
		{
			"aliases": [
				{
					"type": "LexicalVariant",
					"name": "MAGE-A1/MAGE-A3/NY-ESO-1 Peptides Vaccine"
				}
			],
			"definition": {
				"html": "A cancer vaccine comprised of synthetic peptides derived from human melanoma antigen A1 (MAGE-A1), human melanoma antigen A3 (MAGE-A3) and cancer-testis antigen NY-ESO-1 with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A1/MAGE-A3/NY-ESO-1 peptides vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A1, MAGE-A3 and NY-ESO-1, resulting in tumor cell lysis. The MAGE-A1, MAGE-A3, and NY-ESO-1 tumor-associated antigens (TAAS) are overexpressed by a variety of cancer cell types.",
				"text": "A cancer vaccine comprised of synthetic peptides derived from human melanoma antigen A1 (MAGE-A1), human melanoma antigen A3 (MAGE-A3) and cancer-testis antigen NY-ESO-1 with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A1/MAGE-A3/NY-ESO-1 peptides vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A1, MAGE-A3 and NY-ESO-1, resulting in tumor cell lysis. The MAGE-A1, MAGE-A3, and NY-ESO-1 tumor-associated antigens (TAAS) are overexpressed by a variety of cancer cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C84854",
			"nciConceptName": "MAGE-A1/MAGE-A3/NY-ESO-1 Peptides Vaccine",
			"termId": 651378,
			"name": "MAGE-A1, MAGE-A3, NY-ESO-1 peptides vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mage-a1-mage-a3-ny-eso-1-peptides-vaccine"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "GL-0817"
				},
				{
					"type": "Abbreviation",
					"name": "MAGE-A3"
				}
			],
			"definition": {
				"html": "A peptide cancer vaccine comprised of a peptide derived from the human melanoma antigen A3 (MAGE-A3), with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A3 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.",
				"text": "A peptide cancer vaccine comprised of a peptide derived from the human melanoma antigen A3 (MAGE-A3), with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A3 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C91710",
			"nciConceptName": "MAGE-A3 Peptide Vaccine",
			"termId": 391278,
			"name": "MAGE-A3 peptide vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mage-a3-peptide-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MAGE-A3 T cell receptor-transduced autologous T cells"
				},
				{
					"type": "Synonym",
					"name": "MAGE-A3 TCR-transduced autologous T cells"
				}
			],
			"definition": {
				"html": "Human autologous T-lymphocytes transduced with a retroviral vector encoding a T cell receptor (TCR) specific for the human melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the MAGE-A3 reactive TCR-transduced autologous T cells bind to tumor cells expressing MAGE-A3, which may halt the growth of MAGE-A3-expressing cancer cells; the TCR is specific for MAGE-A3:168-176.",
				"text": "Human autologous T-lymphocytes transduced with a retroviral vector encoding a T cell receptor (TCR) specific for the human melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the MAGE-A3 reactive TCR-transduced autologous T cells bind to tumor cells expressing MAGE-A3, which may halt the growth of MAGE-A3-expressing cancer cells; the TCR is specific for MAGE-A3:168-176."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C97035",
			"nciConceptName": "MAGE-A3 Reactive T Cell Receptor-transduced Autologous T Cells",
			"termId": 700454,
			"name": "MAGE-A3 reactive T cell receptor-transduced autologous T cells",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mage-a3-reactive-t-cell-receptor-transduced-autologous-t-cells"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "Ad-MAGE-A3"
				},
				{
					"type": "Abbreviation",
					"name": "AdMA3"
				},
				{
					"type": "Synonym",
					"name": "adenovirus/MAGE-A3"
				}
			],
			"definition": {
				"html": "An oncolytic adenoviral vaccine composed of a replication-defective, E1- and E3-deleted adenovirus serotype 5 (Ad5) with a transgene encoding the human melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. Upon administration, MAGE-A3-expressing adenovirus type 5 vaccine selectively replicates in cancer cells and expresses MAGE-A3. This induces an immune response against tumor cells expressing the MAGE-A3 antigen, which leads to tumor cell death. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types.",
				"text": "An oncolytic adenoviral vaccine composed of a replication-defective, E1- and E3-deleted adenovirus serotype 5 (Ad5) with a transgene encoding the human melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. Upon administration, MAGE-A3-expressing adenovirus type 5 vaccine selectively replicates in cancer cells and expresses MAGE-A3. This induces an immune response against tumor cells expressing the MAGE-A3 antigen, which leads to tumor cell death. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C119614",
			"nciConceptName": "MAGE-A3-expressing Adenovirus Type 5 Vaccine",
			"termId": 766624,
			"name": "MAGE-A3-expressing adenovirus type5 vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mage-a3-expressing-adenovirus-type-5-vaccine"
		},
		{
			"aliases": [
				{
					"type": "LexicalVariant",
					"name": "MAGE-A3 HPV-16 Peptide Vaccine"
				}
			],
			"definition": {
				"html": "A multi-epitope \"Trojan antigen\" (\"TA\") construct vaccine consisting of  human melanoma antigen A3 (MAGE-A3) and human papillomavirus (HPV) 16 peptide epitopes linked by the furin-sensitive linker peptide RVKR (arginine-serine-lysine-arginine) with immunostimulatory and antitumor activities. The TA construct enters the cytoplasm  of antigen-presenting cells (APC) and is processed by the endoplasmic reticulum (ER) and the trans-Golgi network (TGN),  where the endopeptidase furin releases the epitopes from the RVKR linker peptide and, together with various exopeptidases, generates MHC class I-binding peptides. Expressed on the cell surfaces of APC, these MHC class I-binding peptides stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that display the same peptide epitopes on their cell surfaces.",
				"text": "A multi-epitope \"Trojan antigen\" (\"TA\") construct vaccine consisting of  human melanoma antigen A3 (MAGE-A3) and human papillomavirus (HPV) 16 peptide epitopes linked by the furin-sensitive linker peptide RVKR (arginine-serine-lysine-arginine) with immunostimulatory and antitumor activities. The TA construct enters the cytoplasm  of antigen-presenting cells (APC) and is processed by the endoplasmic reticulum (ER) and the trans-Golgi network (TGN),  where the endopeptidase furin releases the epitopes from the RVKR linker peptide and, together with various exopeptidases, generates MHC class I-binding peptides. Expressed on the cell surfaces of APC, these MHC class I-binding peptides stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that display the same peptide epitopes on their cell surfaces."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C61088",
			"nciConceptName": "MAGE-A3/HPV 16 Peptide Vaccine",
			"termId": 478746,
			"name": "MAGE-A3/HPV 16 peptide vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mage-a3-hpv-16-peptide-vaccine"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "TBI-1201"
				}
			],
			"definition": {
				"html": "Autologous human T lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4), with potential immunostimulatory and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, MAGE-A4-specific TCR gene-transduced T lymphocytes TBI-1201 binds to tumor cells expressing MAGE-A4. This may result in both an inhibition of growth and increased cell death for MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4 is overexpressed by a variety of cancer cell types.",
				"text": "Autologous human T lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4), with potential immunostimulatory and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, MAGE-A4-specific TCR gene-transduced T lymphocytes TBI-1201 binds to tumor cells expressing MAGE-A4. This may result in both an inhibition of growth and increased cell death for MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4 is overexpressed by a variety of cancer cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C114978",
			"nciConceptName": "MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201",
			"termId": 759543,
			"name": "MAGE-A4-specific TCR gene-transduced T lymphocytes TBI-1201",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mage-a4-specific-tcr-gene-transduced-autologous-t-lymphocytes-tbi-1201"
		},
		{
			"aliases": [
				{
					"type": "ForeignBrandName",
					"name": "Citramag"
				},
				{
					"type": "Synonym",
					"name": "citrate of magnesia"
				},
				{
					"type": "USBrandName",
					"name": "Citroma"
				}
			],
			"definition": {
				"html": "The citrate salt of the element magnesium with cathartic activity. The cathartic action of magnesium cations appears to result, in part, from osmotically mediated water retention, which subsequently stimulates peristalsis. In addition, magnesium ions may also stimulate the activity of nitric oxide (NO) synthase and increase the biosynthesis of the phospholipid proinflammatory mediator platelet activating factor (PAF) in the gut. NO may stimulate intestinal secretion via prostglandin- and cyclic GMP-dependent mechanisms while PAF produces significant stimulation of colonic secretion and gastrointestinal motility.",
				"text": "The citrate salt of the element magnesium with cathartic activity. The cathartic action of magnesium cations appears to result, in part, from osmotically mediated water retention, which subsequently stimulates peristalsis. In addition, magnesium ions may also stimulate the activity of nitric oxide (NO) synthase and increase the biosynthesis of the phospholipid proinflammatory mediator platelet activating factor (PAF) in the gut. NO may stimulate intestinal secretion via prostglandin- and cyclic GMP-dependent mechanisms while PAF produces significant stimulation of colonic secretion and gastrointestinal motility."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C29241",
			"nciConceptName": "Magnesium Citrate",
			"termId": 480467,
			"name": "magnesium citrate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "magnesium-citrate"
		},
		{
			"aliases": [
				{
					"type": "CASRegistryName",
					"name": "14783-68-7"
				}
			],
			"definition": {
				"html": "An orally available magnesium salt of glycine. Magnesium activates over 600 enzymes and is essential for DNA and RNA synthesis, cellular repair, and maintaining the antioxidant status of the cell. Magnesium plays a key role in bone and muscle function and assists in the activation of vitamin D, which helps regulate calcium and phosphate homeostasis to influence the growth and maintenance of bones.",
				"text": "An orally available magnesium salt of glycine. Magnesium activates over 600 enzymes and is essential for DNA and RNA synthesis, cellular repair, and maintaining the antioxidant status of the cell. Magnesium plays a key role in bone and muscle function and assists in the activation of vitamin D, which helps regulate calcium and phosphate homeostasis to influence the growth and maintenance of bones."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C76082",
			"nciConceptName": "Magnesium Glycinate",
			"termId": 793899,
			"name": "magnesium glycinate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "magnesium-glycinate"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Milk of Magnesia"
				}
			],
			"definition": {
				"html": "A solution of magnesium hydroxide with antacid and laxative properties. Milk of magnesium exerts its antacid activity in low doses such that all hydroxide ions that enter the stomach are used to neutralize stomach acid. This agent exerts its laxative effect in higher doses so that hydroxide ions are able to move from the stomach to the intestines where they attract and retain water, thereby increasing intestinal movement (peristalsis) and inducing the urge to defecate.",
				"text": "A solution of magnesium hydroxide with antacid and laxative properties. Milk of magnesium exerts its antacid activity in low doses such that all hydroxide ions that enter the stomach are used to neutralize stomach acid. This agent exerts its laxative effect in higher doses so that hydroxide ions are able to move from the stomach to the intestines where they attract and retain water, thereby increasing intestinal movement (peristalsis) and inducing the urge to defecate."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C29262",
			"nciConceptName": "Magnesium Hydroxide",
			"termId": 537610,
			"name": "magnesium hydroxide",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "magnesium-hydroxide"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Maalox"
				},
				{
					"type": "Synonym",
					"name": "aluminum hydroxide/magnesium hydroxide"
				},
				{
					"type": "USBrandName",
					"name": "Mylanta"
				}
			],
			"definition": {
				"html": "An oral suspension containing magnesium hydroxide, aluminum hydroxide and simethicone with antacid activity. Both magnesium hydroxide and aluminum hydroxide react with excess acid in the stomach thereby neutralizing gastric acid. Simethicone, a mixture of polydimethylsiloxane and silica gel, reduces the surface tension of gas bubbles, promoting gas bubble coalescence and so intestinal gas transit and evacuation.",
				"text": "An oral suspension containing magnesium hydroxide, aluminum hydroxide and simethicone with antacid activity. Both magnesium hydroxide and aluminum hydroxide react with excess acid in the stomach thereby neutralizing gastric acid. Simethicone, a mixture of polydimethylsiloxane and silica gel, reduces the surface tension of gas bubbles, promoting gas bubble coalescence and so intestinal gas transit and evacuation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1149",
			"nciConceptName": "Aluminum Hydroxide/Magnesium Hydroxide",
			"termId": 39600,
			"name": "magnesium hydroxide/aluminum hydroxide",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "aluminum-hydroxide-magnesium-hydroxide"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "tianqingganmei"
				}
			],
			"definition": {
				"html": "The magnesium salt form of the saponin, isoglycyrrhizinate, a derivative of glycyrrhizic acid extracted from the roots of the plant Glycyrrhiza glabra, with potential anti-inflammatory, antioxidant and hepatoprotective activities. Although the exact mechanism of action remains to be fully elucidated, magnesium isoglycyrrhizinate may prevent or reduce hepatotoxicity through the scavenging of free radicals. This agent also modulates the activity of hepatic enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), superoxide dismutase (SOD) and glutathione peroxidase.",
				"text": "The magnesium salt form of the saponin, isoglycyrrhizinate, a derivative of glycyrrhizic acid extracted from the roots of the plant Glycyrrhiza glabra, with potential anti-inflammatory, antioxidant and hepatoprotective activities. Although the exact mechanism of action remains to be fully elucidated, magnesium isoglycyrrhizinate may prevent or reduce hepatotoxicity through the scavenging of free radicals. This agent also modulates the activity of hepatic enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), superoxide dismutase (SOD) and glutathione peroxidase."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C105617",
			"nciConceptName": "Magnesium Isoglycyrrhizinate",
			"termId": 747592,
			"name": "magnesium isoglycyrrhizinate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "magnesium-isoglycyrrhizinate"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "magnesium, bis((2R,3S)-2,3,4-trihydroxybutanoato-kappaO,kappaO')-, (T-4)-"
				},
				{
					"type": "CASRegistryName",
					"name": "778571-57-6"
				}
			],
			"definition": {
				"html": "A nutritional supplement containing the L-threonate form of magnesium (Mg) that can be used to normalize Mg levels in the body. Upon administration, Mg is utilized by the body for many biochemical functions and reactions including: bone and muscle function, protein and fatty acid formation, activation of B vitamins, blood clotting, insulin secretion, and ATP formation. Mg also serves as a catalyst for many enzymes throughout the body. In addition, magnesium improves the functioning of the immune system by enhancing the expression of natural killer activating receptor NKG2D in cytotoxic T-lymphocytes and natural killer (NK) cells. This increases their anti-viral and anti-tumor cytotoxic effects.",
				"text": "A nutritional supplement containing the L-threonate form of magnesium (Mg) that can be used to normalize Mg levels in the body. Upon administration, Mg is utilized by the body for many biochemical functions and reactions including: bone and muscle function, protein and fatty acid formation, activation of B vitamins, blood clotting, insulin secretion, and ATP formation. Mg also serves as a catalyst for many enzymes throughout the body. In addition, magnesium improves the functioning of the immune system by enhancing the expression of natural killer activating receptor NKG2D in cytotoxic T-lymphocytes and natural killer (NK) cells. This increases their anti-viral and anti-tumor cytotoxic effects."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C123781",
			"nciConceptName": "Magnesium L-threonate",
			"termId": 775593,
			"name": "magnesium L-threonate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "magnesium-l-threonate"
		},
		{
			"aliases": [
				{
					"type": "CASRegistryName",
					"name": "1309-48-4"
				}
			],
			"definition": {
				"html": "The oxide salt of magnesium with antacid, laxative and vascular smooth muscle relaxant activities. Magnesium combines with water to form magnesium hydroxide which reacts chemically to neutralize or buffer existing quantities of stomach acid;  stomach-content and intra-esophageal pH rise, resulting in a decrease in pepsin activity. This agent's laxative effect is the result, in part, of osmotically mediated water retention, which subsequently stimulates peristalsis. In addition, magnesium  ions may behave as calcium antagonists in vascular smooth muscle.",
				"text": "The oxide salt of magnesium with antacid, laxative and vascular smooth muscle relaxant activities. Magnesium combines with water to form magnesium hydroxide which reacts chemically to neutralize or buffer existing quantities of stomach acid;  stomach-content and intra-esophageal pH rise, resulting in a decrease in pepsin activity. This agent's laxative effect is the result, in part, of osmotically mediated water retention, which subsequently stimulates peristalsis. In addition, magnesium  ions may behave as calcium antagonists in vascular smooth muscle."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C29242",
			"nciConceptName": "Magnesium Oxide",
			"termId": 658594,
			"name": "magnesium oxide",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "magnesium-oxide"
		},
		{
			"aliases": null,
			"definition": {
				"html": "The magnesium salt of valproic acid (2-propylpentanoic acid) with antiepileptic and potential antineoplastic activities. Magnesium valproate dissociates in the gastrointestinal tract and is absorbed into the circulation as magnesium ions and valproic acid ions; valproic acid may inhibit histone deacetylases, inducing tumor cell differentiation, apoptosis, and growth arrest. In addition, valproic acid exerts an antiepileptic effect, likely by inhibiting enzymes that catabolize the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) catabolism and so increasing concentrations of GABA in the central nervous system (CNS). \nThe presence of the magnesium in this agent may contribute to its anticonvulsant activity and sedative properties.\n",
				"text": "The magnesium salt of valproic acid (2-propylpentanoic acid) with antiepileptic and potential antineoplastic activities. Magnesium valproate dissociates in the gastrointestinal tract and is absorbed into the circulation as magnesium ions and valproic acid ions; valproic acid may inhibit histone deacetylases, inducing tumor cell differentiation, apoptosis, and growth arrest. In addition, valproic acid exerts an antiepileptic effect, likely by inhibiting enzymes that catabolize the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) catabolism and so increasing concentrations of GABA in the central nervous system (CNS). \nThe presence of the magnesium in this agent may contribute to its anticonvulsant activity and sedative properties.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C71156",
			"nciConceptName": "Magnesium Valproate",
			"termId": 573418,
			"name": "magnesium valproate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "magnesium-valproate"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Osteocrete"
				},
				{
					"type": "Synonym",
					"name": "magnesium-based BVF"
				}
			],
			"definition": {
				"html": "An injectable magnesium oxide-based bone void filler (BVF) with potential osteoconductive properties. Upon injection into bony voids or defects, the magnesium-based BVF mimics cancellous bone and provides a supportive scaffold to facilitate the bone healing process. Magnesium contributes to the structural development of bone and may potentially increase proliferation of bone marrow stromal cells and improve attachment and growth of osteoblasts.\n",
				"text": "An injectable magnesium oxide-based bone void filler (BVF) with potential osteoconductive properties. Upon injection into bony voids or defects, the magnesium-based BVF mimics cancellous bone and provides a supportive scaffold to facilitate the bone healing process. Magnesium contributes to the structural development of bone and may potentially increase proliferation of bone marrow stromal cells and improve attachment and growth of osteoblasts.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": null,
			"nciConceptName": null,
			"termId": 794178,
			"name": "magnesium-based bone void filler",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "magnesium-based-bone-void-filler"
		},
		{
			"aliases": [
				{
					"type": "ForeignBrandName",
					"name": "Rozana"
				}
			],
			"definition": {
				"html": "Carbonated, iron-depleted mineral water from the French springs of Beauregard-Vendon (Rouzat) containing very high amounts of the mineral magnesium as well as sodium, calcium, potassium, bicarbonate, sulfate, chloride and nitrate, that can be used for supplemental purposes and can potentially be used to treat hypomagnesemia. Magnesium, an electrolyte, plays a key role as a cofactor in multiple enzymatic reactions and for muscle and nervous system functioning. Hypomagnesemia may manifest as asthenia, cramps, muscle weakness, fatigue, and mood disorders.\n",
				"text": "Carbonated, iron-depleted mineral water from the French springs of Beauregard-Vendon (Rouzat) containing very high amounts of the mineral magnesium as well as sodium, calcium, potassium, bicarbonate, sulfate, chloride and nitrate, that can be used for supplemental purposes and can potentially be used to treat hypomagnesemia. Magnesium, an electrolyte, plays a key role as a cofactor in multiple enzymatic reactions and for muscle and nervous system functioning. Hypomagnesemia may manifest as asthenia, cramps, muscle weakness, fatigue, and mood disorders.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C148542",
			"nciConceptName": "Magnesium-rich Mineral Water",
			"termId": 792733,
			"name": "magnesium-rich mineral water",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "magnesium-rich-mineral-water"
		},
		{
			"preferredName": "gadopentetate dimeglumine",
			"termId": 37987,
			"name": "Magnevist",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "gadopentetate-dimeglumine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "anti-CD47 monoclonal antibody Hu5F9-G4"
				},
				{
					"type": "CodeName",
					"name": "Hu5F9-G4"
				},
				{
					"type": "CodeName",
					"name": "ONO-7913"
				}
			],
			"definition": {
				"html": "A humanized monoclonal antibody targeting the human cell surface antigen CD47, with potential immunostimulating and antineoplastic activities. Upon administration, magrolimab selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with its ligand signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling, allows the activation of macrophages, through the induction of pro-phagocytic signaling mediated by calreticulin, which is specifically expressed on the surface of tumor cells, and results in specific tumor cell phagocytosis. In addition, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-mediated cell killing. CD47, a tumor associated antigen expressed on normal, healthy hematopoietic stem cells (HSC), is overexpressed on the surface of a variety of cancer cells. Expression of CD47, and interaction with SIRP-alpha, leads to inhibition of macrophages and protects cancer cells from phagocytosis thereby allowing cancer cells to proliferate. ",
				"text": "A humanized monoclonal antibody targeting the human cell surface antigen CD47, with potential immunostimulating and antineoplastic activities. Upon administration, magrolimab selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with its ligand signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling, allows the activation of macrophages, through the induction of pro-phagocytic signaling mediated by calreticulin, which is specifically expressed on the surface of tumor cells, and results in specific tumor cell phagocytosis. In addition, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-mediated cell killing. CD47, a tumor associated antigen expressed on normal, healthy hematopoietic stem cells (HSC), is overexpressed on the surface of a variety of cancer cells. Expression of CD47, and interaction with SIRP-alpha, leads to inhibition of macrophages and protects cancer cells from phagocytosis thereby allowing cancer cells to proliferate. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C117730",
			"nciConceptName": "Magrolimab",
			"termId": 763907,
			"name": "magrolimab",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "magrolimab"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "Maidong"
				},
				{
					"type": "Synonym",
					"name": "ophiopogon"
				},
				{
					"type": "Synonym",
					"name": "Radix Ophiopogonis"
				},
				{
					"type": "Synonym",
					"name": "Mai Men Dong"
				}
			],
			"definition": {
				"html": "The root of the perennial herbaceous plant Ophiopogon belonging to the Liliaceae family. Mai Dong is believed to tonify yin. This traditional Chinese medicine (TCM) may replenish fluids, moisten the intestines and thereby help relieve constipation. It may also have antipyretic and antitussive effects; it may be used as an expectorant and may moisten the lungs, throat and nose.",
				"text": "The root of the perennial herbaceous plant Ophiopogon belonging to the Liliaceae family. Mai Dong is believed to tonify yin. This traditional Chinese medicine (TCM) may replenish fluids, moisten the intestines and thereby help relieve constipation. It may also have antipyretic and antitussive effects; it may be used as an expectorant and may moisten the lungs, throat and nose."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C129584",
			"nciConceptName": "Mai Dong",
			"termId": 783797,
			"name": "Mai Dong",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mai-dong"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "Grifola frondosa extract"
				}
			],
			"definition": {
				"html": "An extract of the edible mushroom Maitaki, Grifola frondosa, rich in glucan polysaccharides, with potential immunostimulating activity. Upon oral ingestion, Maitaki mushroom extract may promote dendritic cell (DC) maturation, increase interferon gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) production, and may enhance natural killer (NK) cell activity, thereby amplifying both innate and T cell-mediated immune responses against cancer cells. In addition, this extract may stimulate the production of granulocyte colony stimulating factor (GCSF) and promote hematopoiesis, and may improve the neutrophil count.",
				"text": "An extract of the edible mushroom Maitaki, Grifola frondosa, rich in glucan polysaccharides, with potential immunostimulating activity. Upon oral ingestion, Maitaki mushroom extract may promote dendritic cell (DC) maturation, increase interferon gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) production, and may enhance natural killer (NK) cell activity, thereby amplifying both innate and T cell-mediated immune responses against cancer cells. In addition, this extract may stimulate the production of granulocyte colony stimulating factor (GCSF) and promote hematopoiesis, and may improve the neutrophil count."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C91082",
			"nciConceptName": "Maitake Mushroom Extract",
			"termId": 670889,
			"name": "Maitake mushroom extract",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "maitake-mushroom-extract"
		},
		{
			"preferredName": "diethylstilbestrol",
			"termId": 43081,
			"name": "Makarol",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "diethylstilbestrol"
		},
		{
			"preferredName": "maltodextrin",
			"termId": 751582,
			"name": "Maldex",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "maltodextrin"
		},
		{
			"preferredName": "maltodextrin",
			"termId": 751582,
			"name": "Maldrin",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "maltodextrin"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from malignant glioma cells with potential immunostimulatory and antineoplastic activities. Upon administration, malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine  exposes the immune system to  undefined malignant glioma tumor-associated antigens (TAAs), which may result in anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against glioma cells and glioma cell lysis.\n",
				"text": "A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from malignant glioma cells with potential immunostimulatory and antineoplastic activities. Upon administration, malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine  exposes the immune system to  undefined malignant glioma tumor-associated antigens (TAAs), which may result in anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against glioma cells and glioma cell lysis.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C74057",
			"nciConceptName": "Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine",
			"termId": 584589,
			"name": "malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "malignant-glioma-tumor-lysate-pulsed-autologous-dendritic-cell-vaccine"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "JNJ-67856633"
				},
				{
					"type": "CodeName",
					"name": "JNJ67856633"
				},
				{
					"type": "CodeName",
					"name": "JNJ 67856633"
				},
				{
					"type": "Synonym",
					"name": "mucosa-associated lymphoid tissue lymphoma translocation protein 1 inhibitor JNJ-67856633"
				}
			],
			"definition": {
				"html": "An orally bioavailable inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), with potential antineoplastic activity. Upon administration, MALT1 inhibitor JNJ-67856633 targets, binds to, and prevents the activity of MALT1. This inhibits MALT1-dependent signaling, reduces interleukin-10 (IL-10) and upregulates interferon (IFN). This results in the inhibition of Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling and nuclear factor kappa B (NF-kB) signaling, induces apoptosis, and inhibits tumor cell growth of MALT1-expressing tumor cells. MALT1 belongs to the caspase family of proteases and is the active component of the CARD11-BCL10-MALT1 (CBM) signaling complex. It plays an essential role in B- and T-lymphocyte activation and is over-activated in certain tumor cells.",
				"text": "An orally bioavailable inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), with potential antineoplastic activity. Upon administration, MALT1 inhibitor JNJ-67856633 targets, binds to, and prevents the activity of MALT1. This inhibits MALT1-dependent signaling, reduces interleukin-10 (IL-10) and upregulates interferon (IFN). This results in the inhibition of Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling and nuclear factor kappa B (NF-kB) signaling, induces apoptosis, and inhibits tumor cell growth of MALT1-expressing tumor cells. MALT1 belongs to the caspase family of proteases and is the active component of the CARD11-BCL10-MALT1 (CBM) signaling complex. It plays an essential role in B- and T-lymphocyte activation and is over-activated in certain tumor cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C160147",
			"nciConceptName": "MALT1 Inhibitor JNJ-67856633",
			"termId": 798315,
			"name": "MALT1 inhibitor JNJ-67856633",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "malt1-inhibitor-jnj-67856633"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Dextri-Maltose"
				},
				{
					"type": "USBrandName",
					"name": "Glucidex"
				},
				{
					"type": "USBrandName",
					"name": "Glucodry"
				},
				{
					"type": "USBrandName",
					"name": "Maldex"
				},
				{
					"type": "USBrandName",
					"name": "Maldrin"
				},
				{
					"type": "CASRegistryName",
					"name": "9050-36-6"
				}
			],
			"definition": {
				"html": "An oligosaccharide derived from starch that is used as a food additive and as a carbohydrate supplement.  As a supplement, maltodextrin is used to provide and sustain energy levels during endurance-oriented workouts or sports, to help build muscle mass and support weight gain.",
				"text": "An oligosaccharide derived from starch that is used as a food additive and as a carbohydrate supplement.  As a supplement, maltodextrin is used to provide and sustain energy levels during endurance-oriented workouts or sports, to help build muscle mass and support weight gain."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C68474",
			"nciConceptName": "Maltodextrin",
			"termId": 751582,
			"name": "maltodextrin",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "maltodextrin"
		},
		{
			"aliases": [
				{
					"type": "CASRegistryName",
					"name": "69-79-4"
				}
			],
			"definition": {
				"html": "A disaccharide consisting of two glucose units linked through an alpha-1,4 glycosidic bond.",
				"text": "A disaccharide consisting of two glucose units linked through an alpha-1,4 glycosidic bond."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C68478",
			"nciConceptName": "Maltose",
			"termId": 729924,
			"name": "maltose",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "maltose"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "M. sylvestris/A. digitata herbal compound"
				},
				{
					"type": "Synonym",
					"name": "traditional persian medicine preparation M. sylvestris/A. digitata"
				}
			],
			"definition": {
				"html": "A traditional Persian medicine composed of Malva sylvestris (M. sylvestris) and Alcea digitata (A. digitata; Boiss), with potential use for the treatment of radiation- and chemotherapy-induced xerostomia, and potential immunomodulating, anti-oxidant and antimicrobial activities. Upon administration to the mouth, M. sylvestris/A. digitata herbal compound may lubricate the mouth and throat, and may improve the symptoms of dry mouth, thereby preventing tooth decay and improving chewing, eating, tasting, swallowing, and speaking. M. sylvestris/A. digitata herbal compound may also improve mucositis by modulating the immune system, thereby preventing infection, reducing inflammation and promoting wound healing.",
				"text": "A traditional Persian medicine composed of Malva sylvestris (M. sylvestris) and Alcea digitata (A. digitata; Boiss), with potential use for the treatment of radiation- and chemotherapy-induced xerostomia, and potential immunomodulating, anti-oxidant and antimicrobial activities. Upon administration to the mouth, M. sylvestris/A. digitata herbal compound may lubricate the mouth and throat, and may improve the symptoms of dry mouth, thereby preventing tooth decay and improving chewing, eating, tasting, swallowing, and speaking. M. sylvestris/A. digitata herbal compound may also improve mucositis by modulating the immune system, thereby preventing infection, reducing inflammation and promoting wound healing."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C131822",
			"nciConceptName": "Malva sylvestris/Alcea digitata Herbal Compound",
			"termId": 786064,
			"name": "Malva sylvestris/Alcea digitata herbal compound",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "malva-sylvestris-alcea-digitata-herbal-compound"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "mam-A DNA vaccine"
				}
			],
			"definition": {
				"html": "A cancer vaccine containing a plasmid encoding the mammaglobin-A gene with potential immunostimulating and antineoplastic activities. Upon administration, mammaglobin-A DNA vaccine may induce both humoral and cytotoxic T lymphocyte (CTL) immune responses against tumor cells that express mammaglobin-A, which may result in decreased tumor growth. The 10 kiloDalton (kD) glycoprotein mammglobin-A is expressed in over 80% of human breast cancers.",
				"text": "A cancer vaccine containing a plasmid encoding the mammaglobin-A gene with potential immunostimulating and antineoplastic activities. Upon administration, mammaglobin-A DNA vaccine may induce both humoral and cytotoxic T lymphocyte (CTL) immune responses against tumor cells that express mammaglobin-A, which may result in decreased tumor growth. The 10 kiloDalton (kD) glycoprotein mammglobin-A is expressed in over 80% of human breast cancers."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C82675",
			"nciConceptName": "Mammaglobin-A DNA Vaccine",
			"termId": 632222,
			"name": "mammaglobin-A DNA vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mammaglobin-a-dna-vaccine"
		},
		{
			"aliases": null,
			"definition": {
				"html": "The trisodium salt of mangafodipir with potential antioxidant and chemoprotective activities. Consisting of manganese (II) ions chelated to fodipir (dipyridoxyl diphosphate or DPDP), mangafodipir scavenges oxygen free radicals such as superoxide anion, hydrogen peroxide, and hydroxyl radical, potentially preventing oxygen free radical damage to macromolecules such as DNA and minimizing oxygen free radical-related chemotoxicity in normal tissues. However, this agent may potentiate the chemotherapy-induced generation of oxygen free radicals in tumor cells, resulting in the potentiation of chemotherapy-induced cytotoxicity; tumor cells, with higher levels of reactive oxygen species than normal cells, possess a lower threshold for oxygen free radical-mediated cytotoxicity. Mangafodipir is traditionally used as an imaging agent  in magnetic resonance imaging (MRI).",
				"text": "The trisodium salt of mangafodipir with potential antioxidant and chemoprotective activities. Consisting of manganese (II) ions chelated to fodipir (dipyridoxyl diphosphate or DPDP), mangafodipir scavenges oxygen free radicals such as superoxide anion, hydrogen peroxide, and hydroxyl radical, potentially preventing oxygen free radical damage to macromolecules such as DNA and minimizing oxygen free radical-related chemotoxicity in normal tissues. However, this agent may potentiate the chemotherapy-induced generation of oxygen free radicals in tumor cells, resulting in the potentiation of chemotherapy-induced cytotoxicity; tumor cells, with higher levels of reactive oxygen species than normal cells, possess a lower threshold for oxygen free radical-mediated cytotoxicity. Mangafodipir is traditionally used as an imaging agent  in magnetic resonance imaging (MRI)."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C66053",
			"nciConceptName": "Mangafodipir Trisodium",
			"termId": 596487,
			"name": "mangafodipir trisodium",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mangafodipir-trisodium"
		},
		{
			"aliases": [
				{
					"type": "CASRegistryName",
					"name": "13446-34-9"
				},
				{
					"type": "Synonym",
					"name": "manganese chloride tetrahydrate"
				},
				{
					"type": "Synonym",
					"name": "manganum muriaticum"
				},
				{
					"type": "ChemicalStructureName",
					"name": "MnCl2"
				}
			],
			"definition": {
				"html": "The dichloridesalt ofmanganese, an essential trace element and a cofactor for many enzymes involved in a variety of biological activities in cells, with potential immunomodulating activity. Upon administration, manganese may act as an adjuvant and induce both humoral and cellular immune responses.\n",
				"text": "The dichloridesalt ofmanganese, an essential trace element and a cofactor for many enzymes involved in a variety of biological activities in cells, with potential immunomodulating activity. Upon administration, manganese may act as an adjuvant and induce both humoral and cellular immune responses.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C61823",
			"nciConceptName": "Manganese Chloride",
			"termId": 801788,
			"name": "manganese chloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "manganese-chloride"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Mangoral"
				},
				{
					"type": "CodeName",
					"name": "CMC001"
				},
				{
					"type": "CodeName",
					"name": "CMC 001"
				},
				{
					"type": "CodeName",
					"name": "CMC-001"
				},
				{
					"type": "Synonym",
					"name": "manganese-based contrast agent CMC 001"
				}
			],
			"definition": {
				"html": "An orally bioavailable contrast agent formulation composed of manganese chloride tetrahydrate (MnCl2 4H2O), and the absorption promoters L-alanine and vitamin D3, that can potentially be used as a contrast enhancement agent during hepatobiliary magnetic resonance imaging (MRI). Upon oral administration of the manganese/L-alanine/vitamin D3-containing contrast agent formulation, L-alanine and vitamin D3 enhance the absorption of the poorly absorbable contrast agent manganese mainly from the small intestines. Upon absorption, the trace element manganese is taken up by normal, healthy hepatocytes. Due to the retention of manganese in the hepatocytes and its paramagnetic properties, this contrast agent enhances the visualization of normal liver tissue during an MRI. As liver tumor cells and liver metastases do not accumulate manganese, these abnormalities will become clearly detectable against the enhanced liver tissue on the MR image. This enhances the visualization and detection of focal liver lesions, including liver metastases.",
				"text": "An orally bioavailable contrast agent formulation composed of manganese chloride tetrahydrate (MnCl2 4H2O), and the absorption promoters L-alanine and vitamin D3, that can potentially be used as a contrast enhancement agent during hepatobiliary magnetic resonance imaging (MRI). Upon oral administration of the manganese/L-alanine/vitamin D3-containing contrast agent formulation, L-alanine and vitamin D3 enhance the absorption of the poorly absorbable contrast agent manganese mainly from the small intestines. Upon absorption, the trace element manganese is taken up by normal, healthy hepatocytes. Due to the retention of manganese in the hepatocytes and its paramagnetic properties, this contrast agent enhances the visualization of normal liver tissue during an MRI. As liver tumor cells and liver metastases do not accumulate manganese, these abnormalities will become clearly detectable against the enhanced liver tissue on the MR image. This enhances the visualization and detection of focal liver lesions, including liver metastases."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C168527",
			"nciConceptName": "Manganese/L-alanine/Vitamin D3-containing Contrast Agent Formulation",
			"termId": 800686,
			"name": "manganese/L-alanine/vitamin D3-containing contrast agent formulation",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "manganese-l-alanine-vitamin-d3-containing-contrast-agent-formulation"
		},
		{
			"preferredName": "manganese/L-alanine/vitamin D3-containing contrast agent formulation",
			"termId": 800686,
			"name": "Mangoral",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "manganese-l-alanine-vitamin-d3-containing-contrast-agent-formulation"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Osmitrol"
				},
				{
					"type": "USBrandName",
					"name": "Resectisol"
				},
				{
					"type": "Synonym",
					"name": "D-mannitol"
				},
				{
					"type": "NSCNumber",
					"name": "407017"
				},
				{
					"type": "CASRegistryName",
					"name": "69-65-8"
				}
			],
			"definition": {
				"html": "A naturally occurring alcohol found in fruits and vegetables and used as an osmotic diuretic. Mannitol is freely filtered by the glomerulus and poorly reabsorbed from the renal tubule, thereby causing an increase in osmolarity of the glomerular filtrate. An increase in osmolarity limits tubular reabsorption of water and inhibits the renal tubular reabsorption of sodium, chloride, and other solutes, thereby promoting diuresis. In addition, mannitol elevates blood plasma osmolarity, resulting in enhanced flow of water from tissues into interstitial fluid and plasma.",
				"text": "A naturally occurring alcohol found in fruits and vegetables and used as an osmotic diuretic. Mannitol is freely filtered by the glomerulus and poorly reabsorbed from the renal tubule, thereby causing an increase in osmolarity of the glomerular filtrate. An increase in osmolarity limits tubular reabsorption of water and inhibits the renal tubular reabsorption of sodium, chloride, and other solutes, thereby promoting diuresis. In addition, mannitol elevates blood plasma osmolarity, resulting in enhanced flow of water from tissues into interstitial fluid and plasma."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C625",
			"nciConceptName": "Mannitol",
			"termId": 39493,
			"name": "mannitol",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mannitol"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Medihoney"
				}
			],
			"definition": {
				"html": "A monofloral honey with potential wound repair and antibacterial activities. Manuka honey is produced by bees fed on the flowers of the New Zealand Manuka bush (Leptospermum scoparium). Manuka honey contains  a significant higher concentration of the 1,2-dicarbonyl compound methylglyoxal, which may account for its antibacterial activity; this agent  may release small amounts of hydrogen peroxide which may also contribute to its antibacterial activity. Manuka honey has been reported to stimulate the formation of new blood capillaries and the growth of fibroblasts and epithelial cells when applied topically to wounds.",
				"text": "A monofloral honey with potential wound repair and antibacterial activities. Manuka honey is produced by bees fed on the flowers of the New Zealand Manuka bush (Leptospermum scoparium). Manuka honey contains  a significant higher concentration of the 1,2-dicarbonyl compound methylglyoxal, which may account for its antibacterial activity; this agent  may release small amounts of hydrogen peroxide which may also contribute to its antibacterial activity. Manuka honey has been reported to stimulate the formation of new blood capillaries and the growth of fibroblasts and epithelial cells when applied topically to wounds."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C74058",
			"nciConceptName": "Manuka Honey",
			"termId": 588952,
			"name": "Manuka honey",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "manuka-honey"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "HGS-ETR1"
				},
				{
					"type": "Abbreviation",
					"name": "TRM-1 mAb"
				},
				{
					"type": "Synonym",
					"name": "Anti-TRAIL R1-mAb"
				}
			],
			"definition": {
				"html": "A fully human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. TRAIL-R1 is a cell surface receptor expressed on many malignant cell types. Mapatumumab selectively binds to and activates the TRAIL cell receptor, thereby inducing apoptosis and reducing tumor growth.",
				"text": "A fully human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. TRAIL-R1 is a cell surface receptor expressed on many malignant cell types. Mapatumumab selectively binds to and activates the TRAIL cell receptor, thereby inducing apoptosis and reducing tumor growth."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C61502",
			"nciConceptName": "Mapatumumab",
			"termId": 486626,
			"name": "mapatumumab",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mapatumumab"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MG1-E6/E7"
				},
				{
					"type": "Synonym",
					"name": "MG1-E6E7"
				},
				{
					"type": "Synonym",
					"name": "oncolytic virus MG1-E6E7"
				},
				{
					"type": "Synonym",
					"name": "MG1-expressing mutant HPV E6/E7"
				},
				{
					"type": "Synonym",
					"name": "oncolytic MG1 virus-encoding E6E7"
				}
			],
			"definition": {
				"html": "A cancer vaccine comprised of a recombinant, attenuated form of the oncolytic rhabdovirus Maraba (MG1) encoding inactive, mutant forms of the human papillomavirus (HPV) transforming proteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration of MG1-E6E7, MG1 preferentially infects tumor cells and induces the expression of the E6 and E7 proteins. The MG1 virus exerts its oncolytic activity, thereby directly lysing tumor cells. Following the lysis of infected cells, the virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate the immune system to kill the infected tumor cells. The expressed E6 and E7 proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV E6 and E7, thereby further inducing tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.",
				"text": "A cancer vaccine comprised of a recombinant, attenuated form of the oncolytic rhabdovirus Maraba (MG1) encoding inactive, mutant forms of the human papillomavirus (HPV) transforming proteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration of MG1-E6E7, MG1 preferentially infects tumor cells and induces the expression of the E6 and E7 proteins. The MG1 virus exerts its oncolytic activity, thereby directly lysing tumor cells. Following the lysis of infected cells, the virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate the immune system to kill the infected tumor cells. The expressed E6 and E7 proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV E6 and E7, thereby further inducing tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C157776",
			"nciConceptName": "Maraba Oncolytic Virus Expressing Mutant HPV E6/E7",
			"termId": 797163,
			"name": "Maraba oncolytic virus expressing mutant HPV E6/E7",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "maraba-oncolytic-virus-expressing-mutant-hpv-e6-e7"
		},
		{
			"aliases": [
				{
					"type": "CASRegistryName",
					"name": "376348-65-1"
				},
				{
					"type": "USBrandName",
					"name": "Selzentry"
				},
				{
					"type": "ForeignBrandName",
					"name": "Celsentri"
				}
			],
			"definition": {
				"html": "A C-C chemokine receptor type 5 (CCR5) antagonist with activity against human immunodeficiency virus (HIV). Maraviroc inhibits HIV-1 entry via CCR5 coreceptor interaction.",
				"text": "A C-C chemokine receptor type 5 (CCR5) antagonist with activity against human immunodeficiency virus (HIV). Maraviroc inhibits HIV-1 entry via CCR5 coreceptor interaction."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C73144",
			"nciConceptName": "Maraviroc",
			"termId": 696304,
			"name": "maraviroc",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "maraviroc"
		},
		{
			"preferredName": "bupivacaine hydrochloride",
			"termId": 481366,
			"name": "Marcaine",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "bupivacaine-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "1-Naphthacenecarboxylic acid, 4-[[O-2,6-dideoxy-.alpha.-L-lyxo-hexopyranosyl-(1.fwdarw.4)-O-2, 6-dideoxy-.alpha.-L-lyxo-hexopyranosyl-(1.fwdarw.4)-2,3, 6-trideoxy-3-(dimethylamino)-.alpha.-L-lyxo-hexopyranosyl]oxy]-2-e thyl-1,2,3,4,6,11-hexahydro-2,5,7,10-tetrahydroxy-6,11-dioxo-, methyl ester, (1R-(1.alpha.,2.beta.,4.beta.))- (9CI)"
				},
				{
					"type": "Synonym",
					"name": "Rhodirubin E"
				},
				{
					"type": "NSCNumber",
					"name": "265211"
				},
				{
					"type": "CASRegistryName",
					"name": "63710-10-1"
				}
			],
			"definition": {
				"html": "An antineoplastic oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Actinosporangium bohemicum.  Marcellomycin intercalates into DNA and induces DNA crosslinks, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also induces differentiation in HL-60 promyelocytic leukemia cells by interfering with glycoprotein synthesis.",
				"text": "An antineoplastic oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Actinosporangium bohemicum.  Marcellomycin intercalates into DNA and induces DNA crosslinks, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also induces differentiation in HL-60 promyelocytic leukemia cells by interfering with glycoprotein synthesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1152",
			"nciConceptName": "Marcellomycin",
			"termId": 39758,
			"name": "marcellomycin",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "marcellomycin"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "anti-HER2 monoclonal antibody MGAH22"
				},
				{
					"type": "CodeName",
					"name": "MGAH22"
				},
				{
					"type": "Abbreviation",
					"name": "anti-HER2 mAb MGAH22"
				}
			],
			"definition": {
				"html": "A Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. After binding to HER2 on the tumor cell surface, margetuximab may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells overexpressing HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. Compared to other anti-HER2 monoclonal antibodies, the Fc domain of MGAH22 is optimized with increased binding to the activating Fcgamma receptor IIIA (CD16A), expressed on cells such as natural killer (NK) cells and macrophages, thereby mediating an enhanced ADCC; the Fc domain also shows decreased binding to the inhibitory Fcgamma receptor IIB (CD32B).",
				"text": "A Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. After binding to HER2 on the tumor cell surface, margetuximab may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells overexpressing HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. Compared to other anti-HER2 monoclonal antibodies, the Fc domain of MGAH22 is optimized with increased binding to the activating Fcgamma receptor IIIA (CD16A), expressed on cells such as natural killer (NK) cells and macrophages, thereby mediating an enhanced ADCC; the Fc domain also shows decreased binding to the inhibitory Fcgamma receptor IIB (CD32B)."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C91733",
			"nciConceptName": "Margetuximab",
			"termId": 681010,
			"name": "margetuximab",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "margetuximab"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "cannabis"
				},
				{
					"type": "NSCNumber",
					"name": "134452"
				}
			],
			"definition": {
				"html": "Any part of, or extract from, the female hemp plant Cannabis sativa.  Marijuana contains cannabinoids, substances with hallucinogenic, psychoactive, and addictive properties.  This agent has potential use for treating cancer pain and cachexia.",
				"text": "Any part of, or extract from, the female hemp plant Cannabis sativa.  Marijuana contains cannabinoids, substances with hallucinogenic, psychoactive, and addictive properties.  This agent has potential use for treating cancer pain and cachexia."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C26659",
			"nciConceptName": "Marijuana",
			"termId": 269131,
			"name": "marijuana",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "marijuana"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "BB-2516"
				},
				{
					"type": "ChemicalStructureName",
					"name": "(2S,3R)-3-(((1S)-2,2-dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic Acid"
				},
				{
					"type": "ChemicalStructureName",
					"name": "(2S,3R)-3-{(S)-[2,2-dimethyl-1-(methylcarbamoyl) propyl]carbamoyl}-2-hydroxy-5-methylhexanohydroxamic acid"
				},
				{
					"type": "LexicalVariant",
					"name": "Marimistat"
				},
				{
					"type": "CodeName",
					"name": "TA-2516"
				},
				{
					"type": "NSCNumber",
					"name": "689451"
				},
				{
					"type": "NSCNumber",
					"name": "719333"
				},
				{
					"type": "CASRegistryName",
					"name": "154039-60-8"
				}
			],
			"definition": {
				"html": "An orally-active synthetic hydroxamate with potential antineoplastic activity.  Marimastat covalently binds to the zinc(II) ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  This agent may also inhibit tumor necrosis factor-alpha converting enzyme (TACE), an enzyme involved in tumor necrosis factor alpha (TNF-alpha) production that may play a role in some malignancies as well as in the development of arthritis and sepsis.",
				"text": "An orally-active synthetic hydroxamate with potential antineoplastic activity.  Marimastat covalently binds to the zinc(II) ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  This agent may also inhibit tumor necrosis factor-alpha converting enzyme (TACE), an enzyme involved in tumor necrosis factor alpha (TNF-alpha) production that may play a role in some malignancies as well as in the development of arthritis and sepsis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1652",
			"nciConceptName": "Marimastat",
			"termId": 42443,
			"name": "marimastat",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "marimastat"
		},
		{
			"preferredName": "dronabinol",
			"termId": 39707,
			"name": "Marinol",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "dronabinol"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "NPI-0052"
				},
				{
					"type": "Synonym",
					"name": "salinosporamide A"
				},
				{
					"type": "Synonym",
					"name": "salinosporin A"
				}
			],
			"definition": {
				"html": "A naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues; inhibition of ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the  disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis. This agent more may more potent and selective than the proteasome inhibitor bortezomib.",
				"text": "A naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues; inhibition of ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the  disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis. This agent more may more potent and selective than the proteasome inhibitor bortezomib."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C64634",
			"nciConceptName": "Marizomib",
			"termId": 518316,
			"name": "marizomib",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "marizomib"
		},
		{
			"preferredName": "vincristine sulfate liposome",
			"termId": 38100,
			"name": "Marqibo",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "vincristine-sulfate-liposome"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "antigen LB39-AA"
				},
				{
					"type": "Synonym",
					"name": "antigen SK29-AA"
				},
				{
					"type": "Synonym",
					"name": "MART-1"
				},
				{
					"type": "Synonym",
					"name": "MART-1 tumor antigen"
				},
				{
					"type": "Synonym",
					"name": "MART1"
				},
				{
					"type": "Synonym",
					"name": "Melan A"
				},
				{
					"type": "Synonym",
					"name": "Melan-A"
				},
				{
					"type": "Synonym",
					"name": "Melan-A protein"
				},
				{
					"type": "Synonym",
					"name": "melanoma antigen recognized by T Cells 1"
				},
				{
					"type": "Synonym",
					"name": "MLANA"
				},
				{
					"type": "Synonym",
					"name": "MLANA protein"
				}
			],
			"definition": {
				"html": "A tumor-associated melanocytic differentiation antigen. Vaccination with MART-1 antigen may stimulate a host cytotoxic T-cell response against tumor cells expressing the melanocytic differentiation antigen, resulting in tumor cell lysis.",
				"text": "A tumor-associated melanocytic differentiation antigen. Vaccination with MART-1 antigen may stimulate a host cytotoxic T-cell response against tumor cells expressing the melanocytic differentiation antigen, resulting in tumor cell lysis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C28724",
			"nciConceptName": "MART-1 Antigen",
			"termId": 42205,
			"name": "MART-1 antigen",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mart-1-antigen"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MART-1 reactive CD8-positive T lymphocytes"
				},
				{
					"type": "Synonym",
					"name": "MART 1-reactive PBL"
				}
			],
			"definition": {
				"html": "Human CD8-positive T-lymphocytes that are engineered to recognize melanoma tumor-associated antigen MART-1 (Melanoma Antigen Recognized by T cells, also called Melan-A) in a human leukocyte antigen (HLA)-A2-restricted manner, with potential antineoplastic activity. Human peripheral blood lymphocytes (PBLs) are isolated from a melanoma patient, exposed to the MART-1:27-35(27L) peptide and MART-1 specific T-lymphocytes are isolated and expanded. Upon infusion, these lymphocytes recognize and exert a cytotoxic T-cell-mediated immune response against MART-1-expressing melanoma cells. The synthetic MART-1:27-35 HLA-A2-restricted peptide has an amino acid substitution, leucine to alanine at position 27, to increase its immunogenicity.",
				"text": "Human CD8-positive T-lymphocytes that are engineered to recognize melanoma tumor-associated antigen MART-1 (Melanoma Antigen Recognized by T cells, also called Melan-A) in a human leukocyte antigen (HLA)-A2-restricted manner, with potential antineoplastic activity. Human peripheral blood lymphocytes (PBLs) are isolated from a melanoma patient, exposed to the MART-1:27-35(27L) peptide and MART-1 specific T-lymphocytes are isolated and expanded. Upon infusion, these lymphocytes recognize and exert a cytotoxic T-cell-mediated immune response against MART-1-expressing melanoma cells. The synthetic MART-1:27-35 HLA-A2-restricted peptide has an amino acid substitution, leucine to alanine at position 27, to increase its immunogenicity."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C111683",
			"nciConceptName": "MART-1 Reactive CD8+ T-lymphocytes",
			"termId": 752696,
			"name": "MART-1 reactive CD8+ lymphocytes",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mart-1-reactive-cd8-t-lymphocytes"
		},
		{
			"aliases": [
				{
					"type": "ForeignBrandName",
					"name": "GeniusVac-Mel4"
				}
			],
			"definition": {
				"html": "Irradiated allogeneic, HLA-A*0201 positive, plasmacytoid dendritic cells (pDCs) loaded with 4 melanoma peptides derived from the tumor-associated antigens (TAAs) MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the irradiated allogeneic pDCs may trigger functional multi-specific T cells from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes, and activate the immune system to mount a cytotoxic T-lymphocyte response against HLA-A*0201-positive melanoma cancer cells expressing the TAAs MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3. These TAAs are upregulated in a variety of tumor cells. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses.\n",
				"text": "Irradiated allogeneic, HLA-A*0201 positive, plasmacytoid dendritic cells (pDCs) loaded with 4 melanoma peptides derived from the tumor-associated antigens (TAAs) MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the irradiated allogeneic pDCs may trigger functional multi-specific T cells from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes, and activate the immune system to mount a cytotoxic T-lymphocyte response against HLA-A*0201-positive melanoma cancer cells expressing the TAAs MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3. These TAAs are upregulated in a variety of tumor cells. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C107159",
			"nciConceptName": "MART-1/gp100/Tyrosinase/MAGE-A3 Peptides-loaded Irradiated Allogeneic Plasmacytoid Dendritic Cells",
			"termId": 750374,
			"name": "MART-1/gp100/Tyrosinase/MAGE-A3 peptides-loaded irradiated allogeneic plasmacytoid dendritic cells",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": ""
		},
		{
			"aliases": null,
			"definition": {
				"html": "A peptide-based cancer vaccine consisting of amino acid residues 26 through 35 of MART-1 (melanoma antigen recognized by T-cells-1) with a leucine substitution at amino acid position 27 to improve immunogenicity. Upon administration, MART-1:26-35(27L) peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against MART-1-expressing tumor cells, resulting in decreased tumor growth. The tumor-associated antigen (TAA) MART-1 may be overexpressed on melanoma cancer cells.",
				"text": "A peptide-based cancer vaccine consisting of amino acid residues 26 through 35 of MART-1 (melanoma antigen recognized by T-cells-1) with a leucine substitution at amino acid position 27 to improve immunogenicity. Upon administration, MART-1:26-35(27L) peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against MART-1-expressing tumor cells, resulting in decreased tumor growth. The tumor-associated antigen (TAA) MART-1 may be overexpressed on melanoma cancer cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2772",
			"nciConceptName": "MART-1:26-35(27L) Peptide Vaccine",
			"termId": 599670,
			"name": "MART-1:26-35(27L) peptide vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mart-126-3527l-peptide-vaccine"
		},
		{
			"aliases": [
				{
					"type": "INDCode",
					"name": "7474"
				},
				{
					"type": "INDCode",
					"name": "5909"
				},
				{
					"type": "INDCode",
					"name": "6123"
				},
				{
					"type": "NSCNumber",
					"name": "672643"
				}
			],
			"definition": {
				"html": "A natural or synthetic peptide cancer vaccine consisting of amino acid residues 27 through 35 of the melanoma-associated antigen MART-1 with potential antineoplastic activity. Vaccination with MART-1:27-35 peptide  may induce cytotoxic host immune responses against melanoma cells that express this peptide. ",
				"text": "A natural or synthetic peptide cancer vaccine consisting of amino acid residues 27 through 35 of the melanoma-associated antigen MART-1 with potential antineoplastic activity. Vaccination with MART-1:27-35 peptide  may induce cytotoxic host immune responses against melanoma cells that express this peptide. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2775",
			"nciConceptName": "MART-1:27-35 Peptide Vaccine",
			"termId": 476336,
			"name": "MART-1:27-35 peptide vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mart-127-35-peptide-vaccine"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "AB1010"
				},
				{
					"type": "ChemicalStructureName",
					"name": "4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)benzamide mesylate"
				}
			],
			"definition": {
				"html": "The orally bioavailable mesylate salt of masatinib, a multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity. Masitinib selectively binds to and inhibits both the wild-type and mutated forms of the stem cell factor receptor (c-Kit; SCFR); platelet-derived growth factor receptor (PDGFR); fibroblast growth factor receptor 3 (FGFR3); and, to a lesser extent, focal adhesion kinase (FAK). As a consequence, tumor cell proliferation may be inhibited in cancer cell types that overexpress these receptor tyrosine kinases (RTKs).",
				"text": "The orally bioavailable mesylate salt of masatinib, a multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity. Masitinib selectively binds to and inhibits both the wild-type and mutated forms of the stem cell factor receptor (c-Kit; SCFR); platelet-derived growth factor receptor (PDGFR); fibroblast growth factor receptor 3 (FGFR3); and, to a lesser extent, focal adhesion kinase (FAK). As a consequence, tumor cell proliferation may be inhibited in cancer cell types that overexpress these receptor tyrosine kinases (RTKs)."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C79831",
			"nciConceptName": "Masitinib Mesylate",
			"termId": 629109,
			"name": "masitinib mesylate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "masitinib-mesylate"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Actinex"
				},
				{
					"type": "Abbreviation",
					"name": "NDGA"
				},
				{
					"type": "Synonym",
					"name": "nordihydroguaiaretic acid"
				},
				{
					"type": "ChemicalStructureName",
					"name": "4,4'-(2,3-Dimethyl-1,4-butanediyl)bis[1,2-benzenediol]"
				},
				{
					"type": "NSCNumber",
					"name": "4291"
				},
				{
					"type": "CASRegistryName",
					"name": "500-38-9"
				}
			],
			"definition": {
				"html": "A naturally occurring antioxidant dicatechol originally derived from the creosote bush Larrea  divaricatta with antipromoter, anti-inflammatory, and antineoplastic activities. Masoprocol directly inhibits activation of two receptor tyrosine kinases (RTKs), the insulin-like growth factor receptor (IGF-1R) and the c-erbB2/HER2/neu receptor, resulting in decreased proliferation of susceptible tumor cell populations. This agent may induce apoptosis in susceptible tumor cell populations as a result of disruption of the actin cytoskeleton in association with the activation of stress activated protein kinases (SAPKs). In addition, NDGA inhibits arachidonic acid 5-lipoxygenase (5LOX), resulting in diminished  synthesis of inflammatory mediators such as prostaglandins and leukotrines; it may prevent leukocyte infiltration into tissues and the release of reactive oxygen species and, at higher concentrations, may  also inhibit cyclooxygenase. ",
				"text": "A naturally occurring antioxidant dicatechol originally derived from the creosote bush Larrea  divaricatta with antipromoter, anti-inflammatory, and antineoplastic activities. Masoprocol directly inhibits activation of two receptor tyrosine kinases (RTKs), the insulin-like growth factor receptor (IGF-1R) and the c-erbB2/HER2/neu receptor, resulting in decreased proliferation of susceptible tumor cell populations. This agent may induce apoptosis in susceptible tumor cell populations as a result of disruption of the actin cytoskeleton in association with the activation of stress activated protein kinases (SAPKs). In addition, NDGA inhibits arachidonic acid 5-lipoxygenase (5LOX), resulting in diminished  synthesis of inflammatory mediators such as prostaglandins and leukotrines; it may prevent leukocyte infiltration into tissues and the release of reactive oxygen species and, at higher concentrations, may  also inhibit cyclooxygenase. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C701",
			"nciConceptName": "Masoprocol",
			"termId": 479648,
			"name": "masoprocol",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "masoprocol"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A small molecule with mast cell stabilizing activity. Mast cell stabilizer TF002 inhibits the formation of lipid rafts of mast cell membranes that contain the signaling machinery which  triggers the release of mast cell allergic and inflammatory mediators.  Inhibition of lipid raft assembly by this agent results in mast cell stabilization, preventing mast cell degranulation and the release of the inflammatory mediators involved in type I allergic reactions (histamine, leukotrienes, prostaglandins, and cytokines). The assembly of the signaling machinery in mast cell lipid rafts, specialized membrane microdomains rich in cholesterol and sphingolipids, is initiated by IgE binding to its receptor on the mast cell surface; subsequently, allergens crosslink with the IgE/receptor complex and other proteins and lipids are recruited into the signaling machinery. \n",
				"text": "A small molecule with mast cell stabilizing activity. Mast cell stabilizer TF002 inhibits the formation of lipid rafts of mast cell membranes that contain the signaling machinery which  triggers the release of mast cell allergic and inflammatory mediators.  Inhibition of lipid raft assembly by this agent results in mast cell stabilization, preventing mast cell degranulation and the release of the inflammatory mediators involved in type I allergic reactions (histamine, leukotrienes, prostaglandins, and cytokines). The assembly of the signaling machinery in mast cell lipid rafts, specialized membrane microdomains rich in cholesterol and sphingolipids, is initiated by IgE binding to its receptor on the mast cell surface; subsequently, allergens crosslink with the IgE/receptor complex and other proteins and lipids are recruited into the signaling machinery. \n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C69146",
			"nciConceptName": "Mast Cell Stabilizer TF002",
			"termId": 547030,
			"name": "mast cell stabilizer TF002",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mast-cell-stabilizer-tf002"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "AG-270"
				},
				{
					"type": "CodeName",
					"name": "AG 270"
				},
				{
					"type": "CodeName",
					"name": "AG270"
				}
			],
			"definition": {
				"html": "An orally available small molecule inhibitor of methionine adenosyltransferase II alpha (MAT2A) with potential antineoplastic activity. Upon administration, AG-270 inhibits the activity of MAT2A, a metabolic enzyme responsible for the production of S-Adenosyl-L-methionine (SAM), a primary donor of methyl groups in cellular transmethylation reactions that regulate gene expression, cell growth, and differentiation. MAT2A activity is selectively essential in cancer cells deficient in methylthioadenosine phosphorylase (MTAP), a critical enzyme in the methionine salvage pathway, that is deleted in some human cancers. Inhibition of MAT2A may potentially inhibit tumor cell growth in MTAP-deleted cancers that rely heavily on SAM synthesis.",
				"text": "An orally available small molecule inhibitor of methionine adenosyltransferase II alpha (MAT2A) with potential antineoplastic activity. Upon administration, AG-270 inhibits the activity of MAT2A, a metabolic enzyme responsible for the production of S-Adenosyl-L-methionine (SAM), a primary donor of methyl groups in cellular transmethylation reactions that regulate gene expression, cell growth, and differentiation. MAT2A activity is selectively essential in cancer cells deficient in methylthioadenosine phosphorylase (MTAP), a critical enzyme in the methionine salvage pathway, that is deleted in some human cancers. Inhibition of MAT2A may potentially inhibit tumor cell growth in MTAP-deleted cancers that rely heavily on SAM synthesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C153180",
			"nciConceptName": "MAT2A Inhibitor AG-270",
			"termId": 793947,
			"name": "MAT2A inhibitor AG-270",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mat2a-inhibitor-ag-270"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "Chamomilla recutita gel"
				},
				{
					"type": "Synonym",
					"name": "German chamomile gel"
				},
				{
					"type": "Synonym",
					"name": "Matricaria chamomilla L. gel"
				}
			],
			"definition": {
				"html": "A gel-based formulation containing an extract of the herb Matricaria chamomilla  (M. recutita or German chamomile), which is native to eastern and southern Europe, belongs to the Asteraceae family and is high in flavonoids, with potential anti-inflammatory, skin protective, moisturizing, anti-bacterial, anti-oxidant and calming activities. M. recutita extract contains flavonoids, including apigenin, luteolin and quercetin, as well as coumarins, herniarin, umbelliferone, anthemic acid, anthemidine, tannin and matricarin. Upon topical application of the Matricaria recutita gel, the active ingredients in the chamomile may exert anti-inflammatory, calming and anti-oxidant effects on the skin and may protect the skin against radiotherapy-induced dermatitis.",
				"text": "A gel-based formulation containing an extract of the herb Matricaria chamomilla  (M. recutita or German chamomile), which is native to eastern and southern Europe, belongs to the Asteraceae family and is high in flavonoids, with potential anti-inflammatory, skin protective, moisturizing, anti-bacterial, anti-oxidant and calming activities. M. recutita extract contains flavonoids, including apigenin, luteolin and quercetin, as well as coumarins, herniarin, umbelliferone, anthemic acid, anthemidine, tannin and matricarin. Upon topical application of the Matricaria recutita gel, the active ingredients in the chamomile may exert anti-inflammatory, calming and anti-oxidant effects on the skin and may protect the skin against radiotherapy-induced dermatitis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C118448",
			"nciConceptName": "Matricaria recutita Gel",
			"termId": 765083,
			"name": "Matricaria recutita gel",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "matricaria-recutita-gel"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "Chamomilla recutita infuse"
				},
				{
					"type": "Synonym",
					"name": "German chamomile infuse"
				},
				{
					"type": "Synonym",
					"name": "Matricaria chamomilla L. topical infusion"
				}
			],
			"definition": {
				"html": "A gel-based formulation containing an extract of the herb Matricaria chamomilla  (M. recutita or German chamomile), which is native to eastern and southern Europe, belongs to the Asteraceae family and is high in flavonoids, with potential anti-inflammatory, skin protective, moisturizing, anti-bacterial, anti-oxidant and calming activities. M. recutita extract contains flavonoids, including apigenin, luteolin and quercetin, as well as coumarins, herniarin, umbelliferone, anthemic acid, anthemidine, tannin and matricarin. Upon topical application of the Matricaria recutita infusion, the active ingredients in the chamomile may exert anti-inflammatory, calming and anti-oxidant effects on the skin and may protect the skin against radiotherapy-induced dermatitis.",
				"text": "A gel-based formulation containing an extract of the herb Matricaria chamomilla  (M. recutita or German chamomile), which is native to eastern and southern Europe, belongs to the Asteraceae family and is high in flavonoids, with potential anti-inflammatory, skin protective, moisturizing, anti-bacterial, anti-oxidant and calming activities. M. recutita extract contains flavonoids, including apigenin, luteolin and quercetin, as well as coumarins, herniarin, umbelliferone, anthemic acid, anthemidine, tannin and matricarin. Upon topical application of the Matricaria recutita infusion, the active ingredients in the chamomile may exert anti-inflammatory, calming and anti-oxidant effects on the skin and may protect the skin against radiotherapy-induced dermatitis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C118449",
			"nciConceptName": "Matricaria recutita Topical Infusion",
			"termId": 765084,
			"name": "Matricaria recutita topical infusion",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "matricaria-recutita-topical-infusion"
		},
		{
			"preferredName": "procarbazine hydrochloride",
			"termId": 41607,
			"name": "Matulane",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "procarbazine-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "EMD 72000"
				},
				{
					"type": "CommonUsage",
					"name": "humanized anti-EGFR monoclonal antibody"
				}
			],
			"definition": {
				"html": "A humanized monoclonal antibody with antineoplastic activity. Matuzumab binds the epidermal growth factor receptor (EGFR) with high\naffinity, competitively blocking natural ligand binding and\nblocking receptor-mediated downstream signalling, resulting in impaired tumor cell proliferation.",
				"text": "A humanized monoclonal antibody with antineoplastic activity. Matuzumab binds the epidermal growth factor receptor (EGFR) with high\naffinity, competitively blocking natural ligand binding and\nblocking receptor-mediated downstream signalling, resulting in impaired tumor cell proliferation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2012",
			"nciConceptName": "Matuzumab",
			"termId": 350433,
			"name": "matuzumab",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "matuzumab"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "AMD-070"
				},
				{
					"type": "CodeName",
					"name": "AMD-11070"
				},
				{
					"type": "CodeName",
					"name": "X4P001"
				},
				{
					"type": "ChemicalStructureName",
					"name": "(S)-N1-((1H-benzo[d]imidazol-2-yl)methyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine"
				},
				{
					"type": "CodeName",
					"name": "X4P 001"
				},
				{
					"type": "CASRegistryName",
					"name": "558447-26-0"
				}
			],
			"definition": {
				"html": "An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration, mavorixafor selectively binds to CXCR4 and prevents the binding of CXCR4 to its ligand, stromal cell-derived factor 1 (SDF-1 or CXCL12). This inhibits receptor activation and results in decreased proliferation and migration of CXCR4-overexpressing tumor cells. In addition, inhibition of CXCR4 prevents the recruitment of regulatory T cells and myeloid-derived suppressor cells (MDSCs) to the tumor microenvironment, thereby abrogating CXCR4-mediated immunosuppression and enabling the activation of a cytotoxic T-lymphocyte-mediated immune response against cancer cells. The G protein-coupled receptor CXCR4, which is upregulated in several tumor cell types, induces the recruitment of immunosuppressive cells in the tumor microenvironment, suppresses immune surveillance, and promotes tumor angiogenesis and tumor cell proliferation. It is also a co-receptor for HIV entry into T cells.",
				"text": "An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration, mavorixafor selectively binds to CXCR4 and prevents the binding of CXCR4 to its ligand, stromal cell-derived factor 1 (SDF-1 or CXCL12). This inhibits receptor activation and results in decreased proliferation and migration of CXCR4-overexpressing tumor cells. In addition, inhibition of CXCR4 prevents the recruitment of regulatory T cells and myeloid-derived suppressor cells (MDSCs) to the tumor microenvironment, thereby abrogating CXCR4-mediated immunosuppression and enabling the activation of a cytotoxic T-lymphocyte-mediated immune response against cancer cells. The G protein-coupled receptor CXCR4, which is upregulated in several tumor cell types, induces the recruitment of immunosuppressive cells in the tumor microenvironment, suppresses immune surveillance, and promotes tumor angiogenesis and tumor cell proliferation. It is also a co-receptor for HIV entry into T cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C126660",
			"nciConceptName": "Mavorixafor",
			"termId": 780512,
			"name": "mavorixafor",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mavorixafor"
		},
		{
			"preferredName": "glecaprevir/pibrentasvir",
			"termId": 798328,
			"name": "Mavyret",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "glecaprevir-pibrentasvir"
		},
		{
			"preferredName": "rizatriptan benzoate",
			"termId": 779010,
			"name": "Maxalt",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "rizatriptan-benzoate"
		},
		{
			"preferredName": "cefepime hydrochloride",
			"termId": 38350,
			"name": "Maxipime",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "cefepime-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "maitansine"
				},
				{
					"type": "ChemicalStructureName",
					"name": "L-alanine, N-acetyl-N-methyl-, 11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03, 5]hexacosa-10,12,14(26),16,18-pentaen-6-yl ester, [1S-(1R*,2S*,3R*,5R*,6R*,16E,18E,20S*,21R*)]"
				},
				{
					"type": "Synonym",
					"name": "Maysanine"
				},
				{
					"type": "Synonym",
					"name": "Maytansin"
				},
				{
					"type": "ChemicalStructureName",
					"name": "alanine, N-acetyl-N-methyl-, 6-ester with 11-chloro-6, 21-dihydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-4,24-dioxa-9,22-diazatetracyclo[19.3.1.1(10,24).0(3,5)]hexacosa-10,12,14[26], 16,18-pentaene-8,23-dione"
				},
				{
					"type": "INDCode",
					"name": "11857"
				},
				{
					"type": "NSCNumber",
					"name": "153858"
				},
				{
					"type": "CASRegistryName",
					"name": "35846-53-8"
				}
			],
			"definition": {
				"html": "An ansamycin antibiotic originally isolated from the Ethiopian shrub Maytenus serrata. Maytansine binds to tubulin at the rhizoxin binding site, thereby inhibiting microtubule assembly, inducing microtubule disassembly, and disrupting mitosis.  Maytansine exhibits cytotoxicity against many tumor cell lines and may inhibit tumor growth in vivo.",
				"text": "An ansamycin antibiotic originally isolated from the Ethiopian shrub Maytenus serrata. Maytansine binds to tubulin at the rhizoxin binding site, thereby inhibiting microtubule assembly, inducing microtubule disassembly, and disrupting mitosis.  Maytansine exhibits cytotoxicity against many tumor cell lines and may inhibit tumor growth in vivo."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C626",
			"nciConceptName": "Maytansine",
			"termId": 39492,
			"name": "maytansine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "maytansine"
		},
		{
			"preferredName": "sizofiran",
			"termId": 752996,
			"name": "MC-Glucan",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "sizofiran"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "AMG 176"
				}
			],
			"definition": {
				"html": "An inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (myeloid cell leukemia-1), with potential pro-apoptotic and antineoplastic activities. Upon administration, AMG 176 binds to and inhibits the activity of MCL-1. This disrupts the formation of MCL-1/Bcl-2-like protein 11 (BCL2L11; BIM) complexes and induces apoptosis in tumor cells. MCL-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.",
				"text": "An inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (myeloid cell leukemia-1), with potential pro-apoptotic and antineoplastic activities. Upon administration, AMG 176 binds to and inhibits the activity of MCL-1. This disrupts the formation of MCL-1/Bcl-2-like protein 11 (BCL2L11; BIM) complexes and induces apoptosis in tumor cells. MCL-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C127817",
			"nciConceptName": "Tapotoclax",
			"termId": 781850,
			"name": "MCL-1 Inhibitor AMG 176",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "tapotoclax"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "AMG 397"
				},
				{
					"type": "CodeName",
					"name": "AMG397"
				},
				{
					"type": "CodeName",
					"name": "AMG-397"
				},
				{
					"type": "Synonym",
					"name": "myeloid cell leukemia 1 inhibitor AMG 397"
				}
			],
			"definition": {
				"html": "An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MCL-1 inhibitor AMG 397 targets and binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins. This promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the B-cell lymphoma 2 (Bcl-2) family of proteins, is upregulated in cancer cells and promotes tumor cell survival.",
				"text": "An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MCL-1 inhibitor AMG 397 targets and binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins. This promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the B-cell lymphoma 2 (Bcl-2) family of proteins, is upregulated in cancer cells and promotes tumor cell survival."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C156740",
			"nciConceptName": "Murizatoclax",
			"termId": 795697,
			"name": "MCL-1 inhibitor AMG 397",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "murizatoclax"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "AZD5991"
				},
				{
					"type": "CodeName",
					"name": "AZD-5991"
				},
				{
					"type": "Synonym",
					"name": "MCL1 inhibitor AZD5991"
				}
			],
			"definition": {
				"html": "An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, AZD5991 binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins, and promoting apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.",
				"text": "An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, AZD5991 binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins, and promoting apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C137989",
			"nciConceptName": "Mcl-1 Inhibitor AZD5991",
			"termId": 790242,
			"name": "Mcl-1 inhibitor AZD5991",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mcl-1-inhibitor-azd5991"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "MIK665"
				},
				{
					"type": "CodeName",
					"name": "MIK 665"
				},
				{
					"type": "CodeName",
					"name": "MIK-665"
				},
				{
					"type": "CodeName",
					"name": "S 64315"
				}
			],
			"definition": {
				"html": "An inhibitor of induced myeloid leukemia cell differentiation protein (Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MIK665 binds to and inhibits the activity of Mcl-1, which promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.",
				"text": "An inhibitor of induced myeloid leukemia cell differentiation protein (Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MIK665 binds to and inhibits the activity of Mcl-1, which promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C133174",
			"nciConceptName": "Mcl-1 Inhibitor MIK665",
			"termId": 788002,
			"name": "Mcl-1 inhibitor MIK665",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mcl-1-inhibitor-mik665"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MCPyV TAg-specific polyclonal autologous CD8-positive T cells"
				}
			],
			"definition": {
				"html": "A preparation of polyclonal autologous CD8 positive T-lymphocytes specific for the Merkel cell polyomavirus (MCPyV) T antigen (TAg) with potential antineoplastic activity. Peripheral blood lymphocytes from a Merkel cell carcinoma (MCC) patient were obtained and antigen-specific CD8+ T cells targeting a specific MCPyV TAg epitope were derived and expanded ex vivo. Upon infusion of the MCPyV TAg-specific polyclonal autologous CD8-positive T cell vaccine, the T cells recognize the MCPyV antigen and exert a cytotoxic T-lymphocyte response against the MCPyV TAg-expressing MCC cells. MCPyV is expressed in about 80% of MCC and is not expressed in normal, human tissue; the MCPyVTag oncoprotein plays a key role in MCC survival and tumor cell proliferation.",
				"text": "A preparation of polyclonal autologous CD8 positive T-lymphocytes specific for the Merkel cell polyomavirus (MCPyV) T antigen (TAg) with potential antineoplastic activity. Peripheral blood lymphocytes from a Merkel cell carcinoma (MCC) patient were obtained and antigen-specific CD8+ T cells targeting a specific MCPyV TAg epitope were derived and expanded ex vivo. Upon infusion of the MCPyV TAg-specific polyclonal autologous CD8-positive T cell vaccine, the T cells recognize the MCPyV antigen and exert a cytotoxic T-lymphocyte response against the MCPyV TAg-expressing MCC cells. MCPyV is expressed in about 80% of MCC and is not expressed in normal, human tissue; the MCPyVTag oncoprotein plays a key role in MCC survival and tumor cell proliferation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C104009",
			"nciConceptName": "MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells",
			"termId": 743909,
			"name": "MCPyV TAg-specific polyclonal autologous CD8-positive T cell vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mcpyv-tag-specific-polyclonal-autologous-cd8-positive-t-cells"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "medium chain triglyceride/long chain triglyceride lipid emulsion"
				},
				{
					"type": "ForeignBrandName",
					"name": "Lipofundin"
				},
				{
					"type": "LexicalVariant",
					"name": "MCT/LCT Lipid-Based Emulsion"
				}
			],
			"definition": {
				"html": "A nutritional lipid emulsion consisting of both coconut oil-derived medium chain triglycerides (MCTs) and soybean oil-derived long chain triglycerides (LCTs). The LCTs in the MCT/LCT lipid emulsion supply the body with essential omega-6 fatty acids, which are needed as components of phospholipids in cell membranes and as precursors of eicosanoids. The MCTs mainly provide calories for energy. In addition to LCTs and MCTs, this lipid emulsion contains egg yolk lecithin, glycerol, and the antioxidant alpha-tocopherol (vitamin E).",
				"text": "A nutritional lipid emulsion consisting of both coconut oil-derived medium chain triglycerides (MCTs) and soybean oil-derived long chain triglycerides (LCTs). The LCTs in the MCT/LCT lipid emulsion supply the body with essential omega-6 fatty acids, which are needed as components of phospholipids in cell membranes and as precursors of eicosanoids. The MCTs mainly provide calories for energy. In addition to LCTs and MCTs, this lipid emulsion contains egg yolk lecithin, glycerol, and the antioxidant alpha-tocopherol (vitamin E)."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C79837",
			"nciConceptName": "MCT/LCT Lipid Emulsion",
			"termId": 629935,
			"name": "MCT/LCT lipid emulsion",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mct-lct-lipid-emulsion"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "medium chain triglyceride/long chain triglyceride/ fish oil omega-3 fatty acid triglyceride lipid emulsion"
				},
				{
					"type": "ForeignBrandName",
					"name": "Lipoplus"
				}
			],
			"definition": {
				"html": "A nutritional lipid emulsion consisting of coconut oil-derived medium chain triglycerides (MCTs), soybean oil-derived long chain triglycerides (LCT), and the fish oil-derived polyunsaturated omega-3 fatty acids. This lipid emulsion supplies essential fatty acids and calories for energy. Omega-3 fatty acids may decrease the production of certain pro-inflammatory cytokines, including interleukin 1 (IL-1), Il-6 and tumor necrosis factor (TNF). The MCTs mainly provide calories for energy. In  addition to LCTs, MCTs, and omega-3 fatty acids, this lipid emulsion contains egg yolk lecithin, glycerol, and the antioxidant alpha-tocopherol (vitamin E).",
				"text": "A nutritional lipid emulsion consisting of coconut oil-derived medium chain triglycerides (MCTs), soybean oil-derived long chain triglycerides (LCT), and the fish oil-derived polyunsaturated omega-3 fatty acids. This lipid emulsion supplies essential fatty acids and calories for energy. Omega-3 fatty acids may decrease the production of certain pro-inflammatory cytokines, including interleukin 1 (IL-1), Il-6 and tumor necrosis factor (TNF). The MCTs mainly provide calories for energy. In  addition to LCTs, MCTs, and omega-3 fatty acids, this lipid emulsion contains egg yolk lecithin, glycerol, and the antioxidant alpha-tocopherol (vitamin E)."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C79839",
			"nciConceptName": "MCT/LCT/Fish Oil Omega-3 Fatty Acid Lipid Emulsion",
			"termId": 629937,
			"name": "MCT/LCT/fish oil omega-3 fatty triglyceride lipid emulsion",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mct-lct-fish-oil-omega-3-fatty-acid-lipid-emulsion"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MDM2 inhibitor ASTX295"
				},
				{
					"type": "CodeName",
					"name": "ASTX295"
				},
				{
					"type": "CodeName",
					"name": "ASTX 295"
				},
				{
					"type": "CodeName",
					"name": "ASTX-295"
				}
			],
			"definition": {
				"html": "An orally available, small molecule inhibitor of the human homolog of murine double minute 2 (MDM2; HDM2), with potential antineoplastic activity. Upon oral administration, MDM2 antagonist ASTX295 targets and binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. This prevents p53 proteasomal degradation and restores the transcriptional activity of p53. This leads to p53-mediated induction of apoptosis in cancers with a wild-type p53 gene. MDM2, an E3 ubiquitin ligase, regulates the level and activity of p53.",
				"text": "An orally available, small molecule inhibitor of the human homolog of murine double minute 2 (MDM2; HDM2), with potential antineoplastic activity. Upon oral administration, MDM2 antagonist ASTX295 targets and binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. This prevents p53 proteasomal degradation and restores the transcriptional activity of p53. This leads to p53-mediated induction of apoptosis in cancers with a wild-type p53 gene. MDM2, an E3 ubiquitin ligase, regulates the level and activity of p53."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C162749",
			"nciConceptName": "MDM2 Antagonist ASTX295",
			"termId": 798989,
			"name": "MDM2 antagonist ASTX295",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mdm2-antagonist-astx295"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "R7112"
				},
				{
					"type": "CodeName",
					"name": "RO5045337"
				}
			],
			"definition": {
				"html": "An MDM2 (human homolog of double minutes-2; HDM2) antagonist with potential antineoplastic activity. RO5045337 binds to MDM2, thereby preventing the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteosome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored, which may result in the restoration of p53 signaling and thus the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein, is a negative regulator of the p53 pathway; often overexpressed in cancer cells, it has been implicated in cancer cell proliferation and survival.",
				"text": "An MDM2 (human homolog of double minutes-2; HDM2) antagonist with potential antineoplastic activity. RO5045337 binds to MDM2, thereby preventing the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteosome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored, which may result in the restoration of p53 signaling and thus the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein, is a negative regulator of the p53 pathway; often overexpressed in cancer cells, it has been implicated in cancer cell proliferation and survival."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C91724",
			"nciConceptName": "MDM2 Antagonist RO5045337",
			"termId": 581121,
			"name": "MDM2 antagonist RO5045337",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mdm2-antagonist-ro5045337"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "RO6839921"
				}
			],
			"definition": {
				"html": "An MDM2 (human homolog of murine double minute-2; HDM2) antagonist with potential antineoplastic activity. Upon intravenous administration, RO6839921 binds to MDM2 and prevents the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling, followed by p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein, is a negative regulator of the p53 pathway and is often overexpressed in cancer cells; p53 inhibition has been implicated in cancer cell proliferation and survival.",
				"text": "An MDM2 (human homolog of murine double minute-2; HDM2) antagonist with potential antineoplastic activity. Upon intravenous administration, RO6839921 binds to MDM2 and prevents the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling, followed by p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein, is a negative regulator of the p53 pathway and is often overexpressed in cancer cells; p53 inhibition has been implicated in cancer cell proliferation and survival."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C114980",
			"nciConceptName": "MDM2 Antagonist RO6839921",
			"termId": 759578,
			"name": "MDM2 antagonist RO6839921",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mdm2-antagonist-ro6839921"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "BI 907828"
				},
				{
					"type": "CodeName",
					"name": "BI-907828"
				},
				{
					"type": "CodeName",
					"name": "BI907828"
				}
			],
			"definition": {
				"html": "An orally available inhibitor of murine double minute 2 (MDM2), with potential antineoplastic activity. Upon oral administration, BI 907828 binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. Compared to currently available MDM2 inhibitors, the pharmacokinetic properties of BI 907828 allow for more optimal dosing and dose schedules that may reduce myelosuppression, an on-target, dose-limiting toxicity for this class of inhibitors.",
				"text": "An orally available inhibitor of murine double minute 2 (MDM2), with potential antineoplastic activity. Upon oral administration, BI 907828 binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. Compared to currently available MDM2 inhibitors, the pharmacokinetic properties of BI 907828 allow for more optimal dosing and dose schedules that may reduce myelosuppression, an on-target, dose-limiting toxicity for this class of inhibitors."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C156709",
			"nciConceptName": "MDM2 Inhibitor BI 907828",
			"termId": 795735,
			"name": "MDM2 inhibitor BI 907828",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mdm2-inhibitor-bi-907828"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "KRT232"
				},
				{
					"type": "CodeName",
					"name": "AMG-232"
				},
				{
					"type": "Synonym",
					"name": "(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic acid"
				},
				{
					"type": "CodeName",
					"name": "AMG 232"
				},
				{
					"type": "CodeName",
					"name": "KRT 232"
				},
				{
					"type": "CASRegistryName",
					"name": "1352066-68-2"
				}
			],
			"definition": {
				"html": "An orally available inhibitor of MDM2 (murine double minute 2), with potential antineoplastic activity. Upon oral administration, MDM2 inhibitor KRT-232 binds to the MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival.",
				"text": "An orally available inhibitor of MDM2 (murine double minute 2), with potential antineoplastic activity. Upon oral administration, MDM2 inhibitor KRT-232 binds to the MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C116624",
			"nciConceptName": "MDM2 Inhibitor KRT-232",
			"termId": 742695,
			"name": "MDM2 inhibitor KRT-232",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mdm2-inhibitor-krt-232"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "KRT 232"
				},
				{
					"type": "CodeName",
					"name": "KRT-232"
				},
				{
					"type": "CodeName",
					"name": "KRT232"
				}
			],
			"definition": {
				"html": "An orally available inhibitor of MDM2 (murine double minute 2), with potential antineoplastic activity. Upon oral administration, MDM2 inhibitor KRT-232 binds to the MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival.",
				"text": "An orally available inhibitor of MDM2 (murine double minute 2), with potential antineoplastic activity. Upon oral administration, MDM2 inhibitor KRT-232 binds to the MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C156415",
			"nciConceptName": "MDM2 Inhibitor KRT-232",
			"termId": 795802,
			"name": "MDM2 inhibitor KRT-232",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mdm2-inhibitor-krt-232"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "ALRN-6924"
				}
			],
			"definition": {
				"html": "An orally available inhibitor of both murine double minute 2 (MDM2) and murine double minute X (MDMX), with potential antineoplastic activity. Upon oral administration, ALRN-6924 binds to both MDM2 and MDMX and interferes with their interaction with the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 and MDMX-p53 interactions, p53 activity is restored, which leads to p53-mediated induction of tumor cell apoptosis. MDM2 and MDMX, negative regulators of p53 function, are often overexpressed in cancer cells.",
				"text": "An orally available inhibitor of both murine double minute 2 (MDM2) and murine double minute X (MDMX), with potential antineoplastic activity. Upon oral administration, ALRN-6924 binds to both MDM2 and MDMX and interferes with their interaction with the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 and MDMX-p53 interactions, p53 activity is restored, which leads to p53-mediated induction of tumor cell apoptosis. MDM2 and MDMX, negative regulators of p53 function, are often overexpressed in cancer cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C118669",
			"nciConceptName": "MDM2/MDMX Inhibitor ALRN-6924",
			"termId": 765720,
			"name": "MDM2/MDMX inhibitor ALRN-6924",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mdm2-mdmx-inhibitor-alrn-6924"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "CBT-1"
				}
			],
			"definition": {
				"html": "A naturally-occurring,  orally bioavailable bisbenzylisoquinoline plant alkaloid with potential chemosensitization activity. MDR modulator CBT-1 binds to and inhibits the MDR efflux pump P-glycoprotein (P-gp), which may inhibit  the efflux of various chemotherapeutic agents from tumor cells and reverse P-gp-mediated tumor cell MDR. P-gp is a transmembrane ATP-binding cassette (ABC) transporter and is overexpressed by some multidrug resistant tumors.",
				"text": "A naturally-occurring,  orally bioavailable bisbenzylisoquinoline plant alkaloid with potential chemosensitization activity. MDR modulator CBT-1 binds to and inhibits the MDR efflux pump P-glycoprotein (P-gp), which may inhibit  the efflux of various chemotherapeutic agents from tumor cells and reverse P-gp-mediated tumor cell MDR. P-gp is a transmembrane ATP-binding cassette (ABC) transporter and is overexpressed by some multidrug resistant tumors."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C67042",
			"nciConceptName": "MDR Modulator CBT-1",
			"termId": 538747,
			"name": "MDR modulator CBT-1",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mdr-modulator-cbt-1"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "M-M-R II"
				},
				{
					"type": "Abbreviation",
					"name": "MMR vaccine"
				},
				{
					"type": "Synonym",
					"name": "measles mumps rubella vaccine"
				},
				{
					"type": "Synonym",
					"name": "measles, mumps and rubella virus vaccine, live"
				},
				{
					"type": "Synonym",
					"name": "measles, mumps, and rubella vaccine"
				}
			],
			"definition": {
				"html": "A trivalent vaccine containing live attenuated viruses that can cause measles, mumps and rubella.  It is an injection administered subcutaneously in two separate doses.",
				"text": "A trivalent vaccine containing live attenuated viruses that can cause measles, mumps and rubella.  It is an injection administered subcutaneously in two separate doses."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C96403",
			"nciConceptName": "Measles/Mumps/Rubella Vaccine",
			"termId": 702931,
			"name": "measles/mumps/rubella vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "measles-mumps-rubella-vaccine"
		},
		{
			"preferredName": "acetylsalicylic acid",
			"termId": 39152,
			"name": "Measurin",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "aspirin"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "(5-benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester"
				},
				{
					"type": "ChemicalStructureName",
					"name": "Methyl 5-benzoyl benzimidazole-2-carbamate"
				},
				{
					"type": "ForeignBrandName",
					"name": "Ovex"
				},
				{
					"type": "CodeName",
					"name": "R 17635"
				},
				{
					"type": "USBrandName",
					"name": "Vermox"
				},
				{
					"type": "NSCNumber",
					"name": "184849"
				},
				{
					"type": "CASRegistryName",
					"name": "31431-39-7"
				}
			],
			"definition": {
				"html": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually causes the helminths death.",
				"text": "A synthetic benzimidazole derivate and anthelmintic agent. Mebendazole interferes with the reproduction and survival of helminths by inhibiting the formation of their cytoplasmic microtubules, thereby selectively and irreversibly blocking glucose uptake. This results in a depletion of glycogen stores and leads to reduced formation of ATP required for survival and reproduction of the helminth. This eventually causes the helminths death."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C47595",
			"nciConceptName": "Mebendazole",
			"termId": 743306,
			"name": "mebendazole",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mebendazole"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "bis(2-chloroethyl)methylamine hydrochloride"
				},
				{
					"type": "ForeignBrandName",
					"name": "Caryolysine"
				},
				{
					"type": "Synonym",
					"name": "chlorethamine HCl"
				},
				{
					"type": "Synonym",
					"name": "chlorethamine hydrochloride"
				},
				{
					"type": "Synonym",
					"name": "chlorethazine hydrochloride"
				},
				{
					"type": "Synonym",
					"name": "chloromethine HCl"
				},
				{
					"type": "Synonym",
					"name": "chlormethine hydrochloride"
				},
				{
					"type": "ForeignBrandName",
					"name": "Cloramin"
				},
				{
					"type": "ForeignBrandName",
					"name": "Erasol"
				},
				{
					"type": "ChemicalStructureName",
					"name": "ethanamine,2-chloro-N-(2-chloroethyl)-N-methyl hydrochloride"
				},
				{
					"type": "Synonym",
					"name": "HN 2 hydrochloride"
				},
				{
					"type": "Synonym",
					"name": "mechlorethamine HCl"
				},
				{
					"type": "ChemicalStructureName",
					"name": "methylbis(beta-chloroethyl)amine hydrochloride"
				},
				{
					"type": "USBrandName",
					"name": "Mustargen"
				},
				{
					"type": "Synonym",
					"name": "mustargen HCl"
				},
				{
					"type": "Synonym",
					"name": "mustargen hydrochloride"
				},
				{
					"type": "Synonym",
					"name": "mustine"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mustine Hydrochloride"
				},
				{
					"type": "Synonym",
					"name": "N-Lost"
				},
				{
					"type": "ForeignBrandName",
					"name": "Onco-Cloramin"
				},
				{
					"type": "CodeName",
					"name": "WR-147650"
				},
				{
					"type": "NSCNumber",
					"name": "762"
				},
				{
					"type": "CASRegistryName",
					"name": "55-86-7"
				}
			],
			"definition": {
				"html": "The hydrochloride salt of mechlorethamine, a nitrogen mustard and an analogue of sulfur mustard, with antineoplastic and immunosuppressive activities. Mechlorethamine is metabolized to an unstable,  highly reactive ethyleniminium intemediate that alkylates DNA, particularly the 7 nitrogen of guanine residues,  resulting in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis. This agent also exhibits lympholytic properties.",
				"text": "The hydrochloride salt of mechlorethamine, a nitrogen mustard and an analogue of sulfur mustard, with antineoplastic and immunosuppressive activities. Mechlorethamine is metabolized to an unstable,  highly reactive ethyleniminium intemediate that alkylates DNA, particularly the 7 nitrogen of guanine residues,  resulting in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis. This agent also exhibits lympholytic properties."
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/mechlorethaminehydrochloride",
				"text": "Mechlorethamine Hydrochloride"
			},
			"nciConceptId": "C627",
			"nciConceptName": "Mechlorethamine Hydrochloride",
			"termId": 43434,
			"name": "mechlorethamine hydrochloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mechlorethamine-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Valchlor"
				},
				{
					"type": "Synonym",
					"name": "mechlorethamine HCl gel"
				}
			],
			"definition": {
				"html": "A gel formulation composed of the hydrochloride salt form of mechlorethamine, which is a nitrogen mustard alkylating agent and an analog of sulfur mustard, with antineoplastic and immunosuppressive activities. Upon topical application, mechlorethamine is metabolized to an unstable, highly reactive ethyleniminium intermediate that binds to and alkylates DNA, with a high affinity to the N7 nitrogen of guanine residues. This results in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis.",
				"text": "A gel formulation composed of the hydrochloride salt form of mechlorethamine, which is a nitrogen mustard alkylating agent and an analog of sulfur mustard, with antineoplastic and immunosuppressive activities. Upon topical application, mechlorethamine is metabolized to an unstable, highly reactive ethyleniminium intermediate that binds to and alkylates DNA, with a high affinity to the N7 nitrogen of guanine residues. This results in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C119736",
			"nciConceptName": "Mechlorethamine Hydrochloride Gel",
			"termId": 766986,
			"name": "mechlorethamine hydrochloride gel",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mechlorethamine-hydrochloride-gel"
		},
		{
			"preferredName": "meclocycline sulfosalicylate",
			"termId": 526788,
			"name": "Meclan",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "meclocycline-sulfosalicylate"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Meclan"
				},
				{
					"type": "Synonym",
					"name": "Mecloderm"
				},
				{
					"type": "ChemicalStructureName",
					"name": "(4S,4aR,5S,5aR,12aS)-7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide Mono(5-sulfosalicylate)(Salt)"
				},
				{
					"type": "CASRegistryName",
					"name": "73816-42-9"
				}
			],
			"definition": {
				"html": "The sulfosalicylate salt form of meclocycline, a tetracycline antibiotic with broad-spectrum antibacterial and antiprotozoal activity. Meclocycline sulfosalicylate is bacteriostatic and inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, thereby preventing the addition of amino acids to the growing peptide chain. This tetracycline is active against a wide range of gram-positive and gram-negative bacteria.",
				"text": "The sulfosalicylate salt form of meclocycline, a tetracycline antibiotic with broad-spectrum antibacterial and antiprotozoal activity. Meclocycline sulfosalicylate is bacteriostatic and inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, thereby preventing the addition of amino acids to the growing peptide chain. This tetracycline is active against a wide range of gram-positive and gram-negative bacteria."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C47596",
			"nciConceptName": "Meclocycline Sulfosalicylate",
			"termId": 526788,
			"name": "meclocycline sulfosalicylate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "meclocycline-sulfosalicylate"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "benzoic Acid, 2-((2,6-dichloro-3-methylphenyl)amino)-, monosodium salt"
				},
				{
					"type": "USBrandName",
					"name": "Meclomen"
				},
				{
					"type": "Synonym",
					"name": "meclonax"
				},
				{
					"type": "ChemicalStructureName",
					"name": "sodium 2-((2,6-dichloro-3-methylphenyl)amino)benzoate"
				},
				{
					"type": "CASRegistryName",
					"name": "6385-02-0"
				}
			],
			"definition": {
				"html": "The sodium salt form of meclofenamate, an anthranilic acid and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Meclofenamate sodium inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis, by prostaglandin synthase, is responsible for the therapeutic effects of meclofenamate sodium. Meclofenamate sodium also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.",
				"text": "The sodium salt form of meclofenamate, an anthranilic acid and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Meclofenamate sodium inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis, by prostaglandin synthase, is responsible for the therapeutic effects of meclofenamate sodium. Meclofenamate sodium also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C47597",
			"nciConceptName": "Meclofenamate Sodium",
			"termId": 772302,
			"name": "meclofenamate sodium",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "meclofenamate-sodium"
		},
		{
			"preferredName": "meclofenamate sodium",
			"termId": 772302,
			"name": "Meclomen",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "meclofenamate-sodium"
		},
		{
			"preferredName": "Manuka honey",
			"termId": 588952,
			"name": "Medihoney",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "manuka-honey"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Depo-Provera"
				},
				{
					"type": "Abbreviation",
					"name": "MPA"
				},
				{
					"type": "USBrandName",
					"name": "Provera"
				},
				{
					"type": "ChemicalStructureName",
					"name": "(6alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione"
				},
				{
					"type": "ChemicalStructureName",
					"name": "17alpha-acetoxy-6alpha-methylprogesterone"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6-alpha-methyl-17alpha-acetoxyprogesterone"
				},
				{
					"type": "ChemicalStructureName",
					"name": "17-(acetyloxy)-6alpha-methylpregn-4-ene-3,20-dione"
				},
				{
					"type": "ChemicalStructureName",
					"name": "17-hydroxy-6alpha-methylpregn-4-ene-3,20-dione acetate"
				},
				{
					"type": "USBrandName",
					"name": "Amen"
				},
				{
					"type": "ForeignBrandName",
					"name": "Aragest"
				},
				{
					"type": "ForeignBrandName",
					"name": "Ciclotal"
				},
				{
					"type": "ForeignBrandName",
					"name": "Clinofem"
				},
				{
					"type": "ForeignBrandName",
					"name": "Clinovir"
				},
				{
					"type": "ForeignBrandName",
					"name": "Depo-Clinovir"
				},
				{
					"type": "Synonym",
					"name": "depot-medroxyprogestereone acetate"
				},
				{
					"type": "ForeignBrandName",
					"name": "Farlutal"
				},
				{
					"type": "ForeignBrandName",
					"name": "G-Farlutal"
				},
				{
					"type": "ForeignBrandName",
					"name": "Gestapuran"
				},
				{
					"type": "ForeignBrandName",
					"name": "Hysron"
				},
				{
					"type": "ForeignBrandName",
					"name": "Lutoral"
				},
				{
					"type": "Synonym",
					"name": "metipregnone"
				},
				{
					"type": "ForeignBrandName",
					"name": "Perlutex"
				},
				{
					"type": "ForeignBrandName",
					"name": "Prodasone"
				},
				{
					"type": "ForeignBrandName",
					"name": "Sodelut G"
				},
				{
					"type": "ForeignBrandName",
					"name": "Veramix"
				},
				{
					"type": "NSCNumber",
					"name": "26386"
				},
				{
					"type": "NSCNumber",
					"name": "21171"
				},
				{
					"type": "CASRegistryName",
					"name": "71-58-9"
				}
			],
			"definition": {
				"html": "A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells.",
				"text": "A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1155",
			"nciConceptName": "Medroxyprogesterone Acetate",
			"termId": 39813,
			"name": "medroxyprogesterone acetate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "medroxyprogesterone-acetate"
		},
		{
			"aliases": [
				{
					"type": "CASRegistryName",
					"name": "53230-10-7"
				}
			],
			"definition": {
				"html": "A quinolinemethanol derivative with antimalarial, anti-inflammatory, and potential chemosensitization and radiosensitization activities. Although the exact mechanism remains to be elucidated, mefloquine, a weak base, preferentially accumulates in lysosomes and disrupts lysosomal function and integrity, thereby leading to host cell death. Similar to chloroquine, the chemosensitizing and radiosensitizing activities of this agent may be related to its inhibition of autophagocytosis, a cellular mechanism involving lysosomal degradation that minimizes the production of reactive oxygen species (ROS)related to tumor reoxygenation and tumor exposure to chemotherapeutic agents and radiation. Compared to chloroquine, mefloquine has better blood-brain-barrier (BBB) penetration.",
				"text": "A quinolinemethanol derivative with antimalarial, anti-inflammatory, and potential chemosensitization and radiosensitization activities. Although the exact mechanism remains to be elucidated, mefloquine, a weak base, preferentially accumulates in lysosomes and disrupts lysosomal function and integrity, thereby leading to host cell death. Similar to chloroquine, the chemosensitizing and radiosensitizing activities of this agent may be related to its inhibition of autophagocytosis, a cellular mechanism involving lysosomal degradation that minimizes the production of reactive oxygen species (ROS)related to tumor reoxygenation and tumor exposure to chemotherapeutic agents and radiation. Compared to chloroquine, mefloquine has better blood-brain-barrier (BBB) penetration."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C61827",
			"nciConceptName": "Mefloquine",
			"termId": 711805,
			"name": "mefloquine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mefloquine"
		},
		{
			"preferredName": "cefoxitin sodium",
			"termId": 787118,
			"name": "Mefoxin",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "cefoxitin-sodium"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "(9beta,10alpha)-17-(acetyloxy)-6-methylpregna-4,6-diene-3,20-dione"
				},
				{
					"type": "ChemicalStructureName",
					"name": "17 alpha-acetoxy-6-methylpregna-4,6-diene-3,20-dione"
				},
				{
					"type": "ChemicalStructureName",
					"name": "17-hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6-dehydro-6-methyl-17 alpha-acetoxyprogesterone"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6-dehydro-6-methyl-17.alpha.-acetoxyprogesterone"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6-methyl-6-dehydro-17.alpha.-acetoxyprogesterone"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6-methyl-delta-4,6-pregnadien-17 alpha-ol-3,20-dione acetate"
				},
				{
					"type": "CodeName",
					"name": "BDH 1298"
				},
				{
					"type": "CodeName",
					"name": "BDH-1298"
				},
				{
					"type": "ForeignBrandName",
					"name": "Maygace"
				},
				{
					"type": "ObsoleteName",
					"name": "Megace"
				},
				{
					"type": "ForeignBrandName",
					"name": "Megestat"
				},
				{
					"type": "ForeignBrandName",
					"name": "Megestil"
				},
				{
					"type": "ForeignBrandName",
					"name": "Niagestin"
				},
				{
					"type": "Synonym",
					"name": "ovaban"
				},
				{
					"type": "Synonym",
					"name": "pallace"
				},
				{
					"type": "CodeName",
					"name": "SC-10363"
				},
				{
					"type": "NSCNumber",
					"name": "71423"
				},
				{
					"type": "CASRegistryName",
					"name": "595-33-5"
				}
			],
			"definition": {
				"html": "The acetate salt of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone, with progestogenic, antiestrogenic, and antineoplastic activities. Mimicking the action of progesterone, megestrol binds to and activates nuclear progesterone receptors (PRs) in the reproductive system and pituitary; ligand-receptor complexes are translocated to the nucleus where they bind to progesterone response elements (PREs) located on target genes. Megestrols antineoplastic activity against estrogen-responsive tumors may be due, in part, to the suppression of pituitary gonadotrophin production and the resultant decrease in ovarian estrogen secretion; interference with the estrogen receptor complex in its interaction with genes and; as part of the progesterone receptor complex, direct interaction with the genome and downregulation of specific estrogen-responsive genes. This agent may also directly kill tumor cells.",
				"text": "The acetate salt of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone, with progestogenic, antiestrogenic, and antineoplastic activities. Mimicking the action of progesterone, megestrol binds to and activates nuclear progesterone receptors (PRs) in the reproductive system and pituitary; ligand-receptor complexes are translocated to the nucleus where they bind to progesterone response elements (PREs) located on target genes. Megestrols antineoplastic activity against estrogen-responsive tumors may be due, in part, to the suppression of pituitary gonadotrophin production and the resultant decrease in ovarian estrogen secretion; interference with the estrogen receptor complex in its interaction with genes and; as part of the progesterone receptor complex, direct interaction with the genome and downregulation of specific estrogen-responsive genes. This agent may also directly kill tumor cells."
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/megestrolacetate",
				"text": "Megestrol Acetate"
			},
			"nciConceptId": "C1156",
			"nciConceptName": "Megestrol Acetate",
			"termId": 43435,
			"name": "megestrol acetate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "megestrol-acetate"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "MSC2015103B"
				},
				{
					"type": "CodeName",
					"name": "AS703988"
				},
				{
					"type": "CodeName",
					"name": "AS703988/MSC2015103B"
				}
			],
			"definition": {
				"html": "An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) 1 and 2 with potential antineoplastic activity. MEK 1/2 inhibitor AS703988/MSC2015103B selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1 and MEK2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth and are often upregulated in a variety of tumor cell types.",
				"text": "An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) 1 and 2 with potential antineoplastic activity. MEK 1/2 inhibitor AS703988/MSC2015103B selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1 and MEK2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth and are often upregulated in a variety of tumor cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C98832",
			"nciConceptName": "MEK 1/2 Inhibitor AS703988/MSC2015103B",
			"termId": 714900,
			"name": "MEK 1/2 inhibitor AS703988/MSC2015103B",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mek-1-2-inhibitor-as703988-msc2015103b"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "FCN-159"
				},
				{
					"type": "CodeName",
					"name": "FCN159"
				},
				{
					"type": "CodeName",
					"name": "FCN 159"
				},
				{
					"type": "Synonym",
					"name": "MEK inhibitor FCN-159"
				}
			],
			"definition": {
				"html": "An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) 1 and 2, with potential antineoplastic activity. Upon administration, MEK 1/2 Inhibitor FCN-159 selectively binds to and inhibits the activity of MEK1 and MEK2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations.\n",
				"text": "An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) 1 and 2, with potential antineoplastic activity. Upon administration, MEK 1/2 Inhibitor FCN-159 selectively binds to and inhibits the activity of MEK1 and MEK2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C172382",
			"nciConceptName": "MEK 1/2 Inhibitor FCN-159",
			"termId": 801657,
			"name": "MEK 1/2 inhibitor FCN-159",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mek-1-2-inhibitor-fcn-159"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "ARRY-424704"
				}
			],
			"definition": {
				"html": "An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor AZD8330 specifically inhibits mitogen-activated protein kinase kinase 1 (MEK or MAP/ERK kinase1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers. \n ",
				"text": "An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor AZD8330 specifically inhibits mitogen-activated protein kinase kinase 1 (MEK or MAP/ERK kinase1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers. \n "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C69143",
			"nciConceptName": "MEK Inhibitor AZD8330",
			"termId": 543526,
			"name": "MEK inhibitor AZD8330",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mek-inhibitor-azd8330"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "CS3006"
				},
				{
					"type": "CodeName",
					"name": "CS-3006"
				},
				{
					"type": "CodeName",
					"name": "CS 3006"
				},
				{
					"type": "Synonym",
					"name": "MAPK kinase inhibitor CS3006"
				}
			],
			"definition": {
				"html": "An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPKK; MEK), with potential antineoplastic activity. Upon oral administration, MEK inhibitor CS3006 specifically targets, binds to and inhibits the catalytic activity of MEK, thereby inhibiting the activation of MEK-dependent effector proteins including extracellular signalregulated kinase (ERK) and inhibits the proliferation of tumor cells in which the RAS/RAF/MEK/ERK signaling pathway is overactivated. The threonine/tyrosine protein kinase MEK plays a key role in the  RAS/RAF/MEK/ERK signaling pathway, which is frequently upregulated in a variety of tumor cell types. The RAS/RAF/MEK/ERK pathway regulates key cellular activities including cell growth, proliferation, survival, differentiation and apoptosis.",
				"text": "An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPKK; MEK), with potential antineoplastic activity. Upon oral administration, MEK inhibitor CS3006 specifically targets, binds to and inhibits the catalytic activity of MEK, thereby inhibiting the activation of MEK-dependent effector proteins including extracellular signalregulated kinase (ERK) and inhibits the proliferation of tumor cells in which the RAS/RAF/MEK/ERK signaling pathway is overactivated. The threonine/tyrosine protein kinase MEK plays a key role in the  RAS/RAF/MEK/ERK signaling pathway, which is frequently upregulated in a variety of tumor cell types. The RAS/RAF/MEK/ERK pathway regulates key cellular activities including cell growth, proliferation, survival, differentiation and apoptosis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C155971",
			"nciConceptName": "MEK inhibitor CS3006",
			"termId": 795024,
			"name": "MEK inhibitor CS3006",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mek-inhibitor-cs3006"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "GDC-0623"
				}
			],
			"definition": {
				"html": "An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated protein kinase kinase (MEK or MAP/ERK kinase), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.",
				"text": "An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated protein kinase kinase (MEK or MAP/ERK kinase), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C95738",
			"nciConceptName": "MEK Inhibitor GDC-0623",
			"termId": 673612,
			"name": "MEK inhibitor GDC-0623",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mek-inhibitor-gdc-0623"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "HL-085"
				},
				{
					"type": "CodeName",
					"name": "HL 085"
				},
				{
					"type": "CodeName",
					"name": "HL085"
				}
			],
			"definition": {
				"html": "An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK), with potential antineoplastic activity. Upon administration, MEK inhibitor HL-085 selectively binds to and inhibits the activity of MEK, preventing the activation of MEK-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a threonine/tyrosine kinase, plays a key role in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations.\n",
				"text": "An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK), with potential antineoplastic activity. Upon administration, MEK inhibitor HL-085 selectively binds to and inhibits the activity of MEK, preventing the activation of MEK-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a threonine/tyrosine kinase, plays a key role in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C173437",
			"nciConceptName": "MEK Inhibitor HL-085",
			"termId": 801764,
			"name": "MEK inhibitor HL-085",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mek-inhibitor-hl-085"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "RO4987655"
				}
			],
			"definition": {
				"html": "An orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK inhibitor RO4987655 binds to and inhibits MEK, which may result in the inhibition of MEK-dependent cell signaling and the inhibition of tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.\n",
				"text": "An orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK inhibitor RO4987655 binds to and inhibits MEK, which may result in the inhibition of MEK-dependent cell signaling and the inhibition of tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C82696",
			"nciConceptName": "MEK Inhibitor RO4987655",
			"termId": 633506,
			"name": "MEK inhibitor RO4987655",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mek-inhibitor-ro4987655"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "SHR 7390"
				},
				{
					"type": "CodeName",
					"name": "SHR7390"
				},
				{
					"type": "Synonym",
					"name": "MAPK kinase inhibitor SHR 7390"
				},
				{
					"type": "CodeName",
					"name": "SHR-7390"
				},
				{
					"type": "Synonym",
					"name": "MAP2K inhibitor SHR 7390"
				},
				{
					"type": "Synonym",
					"name": "MEKi SHR 7390"
				}
			],
			"definition": {
				"html": "An orally available small molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK), with potential antineoplastic activity. Upon administration, MEK inhibitor SHR 7390 selectively binds to and inhibits the activity of MEK. This prevents the activation of MEK-dependent effector proteins, which results in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual-specificity threonine/tyrosine kinase family that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types.",
				"text": "An orally available small molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK), with potential antineoplastic activity. Upon administration, MEK inhibitor SHR 7390 selectively binds to and inhibits the activity of MEK. This prevents the activation of MEK-dependent effector proteins, which results in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual-specificity threonine/tyrosine kinase family that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C150680",
			"nciConceptName": "MEK Inhibitor SHR 7390",
			"termId": 793097,
			"name": "MEK inhibitor SHR 7390",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mek-inhibitor-shr-7390"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "TAK-733"
				}
			],
			"definition": {
				"html": "An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. MEK inhibitor TAK-733 selectively binds to and inhibits the activity of MEK1/2,  preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation.\nMEK1/2 (MAP2K1/K2) are  dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.",
				"text": "An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. MEK inhibitor TAK-733 selectively binds to and inhibits the activity of MEK1/2,  preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation.\nMEK1/2 (MAP2K1/K2) are  dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C84858",
			"nciConceptName": "MEK Inhibitor TAK-733",
			"termId": 651550,
			"name": "MEK inhibitor TAK-733",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mek-inhibitor-tak-733"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "WX-554"
				}
			],
			"definition": {
				"html": "An orally available small molecule mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) inhibitor, with potential antineoplastic activity. MEK inhibitor WX-554 selectively binds to and inhibits the activity of MEK, thereby preventing the activation of MEK-dependent effector proteins including some transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual-specificity threonine/tyrosine kinase that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types.",
				"text": "An orally available small molecule mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) inhibitor, with potential antineoplastic activity. MEK inhibitor WX-554 selectively binds to and inhibits the activity of MEK, thereby preventing the activation of MEK-dependent effector proteins including some transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual-specificity threonine/tyrosine kinase that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C101532",
			"nciConceptName": "MEK Inhibitor WX-554",
			"termId": 732484,
			"name": "MEK inhibitor WX-554",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mek-inhibitor-wx-554"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "E6201"
				}
			],
			"definition": {
				"html": "A synthetic,  fungal metabolite analogue inhibitor of mitogen-activated protein kinase kinase 1 (MEK-1) and mitogen-activated protein kinase kinase kinase 1 (MEKK-1) with potential antipsoriatic and antineoplastic activities. MEK-1/MEKK-1 inhibitor E6201 specifically binds to and inhibits the activities of MEK-1 and MEKK-1, which may result in the inhibition of tumor cell proliferation. MEK-1 and MEKK-1 are key components in the RAS/RAF/MEK/MAPK signaling pathway, which regulates cell proliferation and is frequently activated in human cancers.",
				"text": "A synthetic,  fungal metabolite analogue inhibitor of mitogen-activated protein kinase kinase 1 (MEK-1) and mitogen-activated protein kinase kinase kinase 1 (MEKK-1) with potential antipsoriatic and antineoplastic activities. MEK-1/MEKK-1 inhibitor E6201 specifically binds to and inhibits the activities of MEK-1 and MEKK-1, which may result in the inhibition of tumor cell proliferation. MEK-1 and MEKK-1 are key components in the RAS/RAF/MEK/MAPK signaling pathway, which regulates cell proliferation and is frequently activated in human cancers."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C79848",
			"nciConceptName": "MEK-1/MEKK-1 Inhibitor E6201",
			"termId": 629676,
			"name": "MEK-1/MEKK-1 inhibitor E6201",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mek-1-mekk-1-inhibitor-e6201"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "BI 847325"
				}
			],
			"definition": {
				"html": "An orally available dual inhibitor of mitogen-activated protein kinase kinase (MEK) and Aurora kinases, with potential antineoplastic activity. Upon oral administration, MEK/Aurora kinase inhibitor BI 847325 selectively binds to and inhibits the activity of MEK, which both prevents the activation of MEK-dependent effector proteins and inhibits growth factor-mediated cell signaling. BI 847325 also binds to and inhibits the activity of the Aurora kinases A, B and C which may disrupt the assembly of the mitotic spindle apparatus, prevent chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells.  Altogether, this leads to the inhibition of cell proliferation and tumor growth as well as the induction of tumor regression. MEK, a dual-specificity threonine/tyrosine kinase that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of cancer cell types.",
				"text": "An orally available dual inhibitor of mitogen-activated protein kinase kinase (MEK) and Aurora kinases, with potential antineoplastic activity. Upon oral administration, MEK/Aurora kinase inhibitor BI 847325 selectively binds to and inhibits the activity of MEK, which both prevents the activation of MEK-dependent effector proteins and inhibits growth factor-mediated cell signaling. BI 847325 also binds to and inhibits the activity of the Aurora kinases A, B and C which may disrupt the assembly of the mitotic spindle apparatus, prevent chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells.  Altogether, this leads to the inhibition of cell proliferation and tumor growth as well as the induction of tumor regression. MEK, a dual-specificity threonine/tyrosine kinase that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of cancer cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C106126",
			"nciConceptName": "MEK/Aurora Kinase Inhibitor BI 847325",
			"termId": 698315,
			"name": "MEK/Aurora kinase dual inhibitor BI 847325",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mek-aurora-kinase-inhibitor-bi-847325"
		},
		{
			"preferredName": "trametinib dimethyl sulfoxide",
			"termId": 599034,
			"name": "Mekinist",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "trametinib"
		},
		{
			"preferredName": "binimetinib",
			"termId": 653635,
			"name": "Mektovi",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "binimetinib"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A vaccine consisting of the melanocyte differentiation antigen Melan A (also called MART-1) encapsulated in noninfectious virus-like particles (VLPs) with potential immunostimulating and antineoplastic activities. Upon administration, Melan-A VLP vaccine may stimulate the immune system to exert a specific cytotoxic T lymphocyte (CTL) response against tumor cells expressing the Melan A antigen, resulting in tumor cell lysis. Melan A is upregulated in most melanomas. VLPs stimulate the immune system and promotes the CTL response.",
				"text": "A vaccine consisting of the melanocyte differentiation antigen Melan A (also called MART-1) encapsulated in noninfectious virus-like particles (VLPs) with potential immunostimulating and antineoplastic activities. Upon administration, Melan-A VLP vaccine may stimulate the immune system to exert a specific cytotoxic T lymphocyte (CTL) response against tumor cells expressing the Melan A antigen, resulting in tumor cell lysis. Melan A is upregulated in most melanomas. VLPs stimulate the immune system and promotes the CTL response."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C61495",
			"nciConceptName": "Melan-A VLP Vaccine",
			"termId": 506112,
			"name": "Melan-A VLP vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "melan-a-vlp-vaccine"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A cancer vaccine consisting of a peptide derived from the melanocyte differentiation antigen Melan-A (or MART-1) and the human leukocyte antigen HLA-DP4-restricted human melanoma antigen 3 (MAGE-3.DP4), with potential immunostimulating and antineoplastic activities. Upon administration, Melan-A/MAGE-3.DP4 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing Melan-A and MAGE-3, resulting in tumor cell lysis. The tumor associated antigens Melan-A and MAGE-3 are overexpressed in a variety of cancer cell types.",
				"text": "A cancer vaccine consisting of a peptide derived from the melanocyte differentiation antigen Melan-A (or MART-1) and the human leukocyte antigen HLA-DP4-restricted human melanoma antigen 3 (MAGE-3.DP4), with potential immunostimulating and antineoplastic activities. Upon administration, Melan-A/MAGE-3.DP4 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing Melan-A and MAGE-3, resulting in tumor cell lysis. The tumor associated antigens Melan-A and MAGE-3 are overexpressed in a variety of cancer cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": null,
			"nciConceptName": null,
			"termId": 697136,
			"name": "Melan-A/MAGE-3.DP4 peptide vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "melan-a-mage-3dp4-peptide-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MHP VAC"
				}
			],
			"definition": {
				"html": "A multivalent vaccine consisting of peptides derived from melanoma-associated antigens and an adjuvant peptide derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing melanoma-associated antigens, resulting in tumor cell lysis.",
				"text": "A multivalent vaccine consisting of peptides derived from melanoma-associated antigens and an adjuvant peptide derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing melanoma-associated antigens, resulting in tumor cell lysis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C38700",
			"nciConceptName": "Melanoma Helper Peptide Vaccine",
			"termId": 341633,
			"name": "melanoma helper peptide vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "melanoma-helper-peptide-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "human IgG1/murine IgG2a double-expression vector encoding TRP2 CTL epitope vaccine SCIB1"
				},
				{
					"type": "CodeName",
					"name": "SCIB1"
				}
			],
			"definition": {
				"html": "A proprietary DNA-based cancer vaccine that encodes a melanoma antigen tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope and a modified monoclonal antibody, a chimera of human IgG1/murine IgG2a with T cell mimotopes expressed within the complementarity-determining regions (CDR) of the antibodies, with potential immunostimulating and antineoplastic activities. Upon intramuscular injection and electroporation, melanoma TRP2 CTL epitope vaccine SCIB1 expresses the modified antibody. Subsequently, the Fc component of the engineered antibody targets and binds to the CD64 receptor on the dendritic cells (DCs); upon processing by DCs, the cellular immune system may be activated to induce helper T-cell and CTL immune responses against tumor cells expressing the TRP2 antigen.",
				"text": "A proprietary DNA-based cancer vaccine that encodes a melanoma antigen tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope and a modified monoclonal antibody, a chimera of human IgG1/murine IgG2a with T cell mimotopes expressed within the complementarity-determining regions (CDR) of the antibodies, with potential immunostimulating and antineoplastic activities. Upon intramuscular injection and electroporation, melanoma TRP2 CTL epitope vaccine SCIB1 expresses the modified antibody. Subsequently, the Fc component of the engineered antibody targets and binds to the CD64 receptor on the dendritic cells (DCs); upon processing by DCs, the cellular immune system may be activated to induce helper T-cell and CTL immune responses against tumor cells expressing the TRP2 antigen."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C91380",
			"nciConceptName": "Melanoma TRP2 CTL Epitope Vaccine SCIB1",
			"termId": 675320,
			"name": "melanoma TRP2 CTL epitope vaccine SCIB1",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "melanoma-trp2-ctl-epitope-vaccine-scib1"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "MELITAC 12.1"
				}
			],
			"definition": {
				"html": "A peptide cancer vaccine consisting of an emulsion of a mixture of 12 class I MHC-restricted melanoma peptides and a class II MHC-restricted tetanus toxoid helper peptide, with potential immunostimulating and antineoplastic activities. Upon administration, the MELITAC 12.1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T-cell response against tumor cells expressing the melanoma peptide antigens, resulting in tumor cell lysis. The melanoma peptides contained in the vaccine are upregulated in melanoma cancer cells.",
				"text": "A peptide cancer vaccine consisting of an emulsion of a mixture of 12 class I MHC-restricted melanoma peptides and a class II MHC-restricted tetanus toxoid helper peptide, with potential immunostimulating and antineoplastic activities. Upon administration, the MELITAC 12.1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T-cell response against tumor cells expressing the melanoma peptide antigens, resulting in tumor cell lysis. The melanoma peptides contained in the vaccine are upregulated in melanoma cancer cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C95741",
			"nciConceptName": "MELITAC 12.1 Peptide Vaccine",
			"termId": 691982,
			"name": "MELITAC 12.1 peptide vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "melitac-121-peptide-vaccine"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "OTS167"
				}
			],
			"definition": {
				"html": "An orally available inhibitor of maternal embryonic leucine zipper kinase (MELK) with potential antineoplastic activity. Upon administration, OTS167 binds to MELK, which prevents both MELK phosphorylation and activation; thus inhibiting the phosphorylation of downstream MELK substrates. This may lead to an inhibition of both cell proliferation and survival in MELK-expressing tumor cells. MELK, a serine/threonine kinase, is involved in cancer cell survival, invasiveness and cancer-stem cell formation and maintenance; it is highly upregulated in various types of cancer cells and absent in normal, healthy cells.",
				"text": "An orally available inhibitor of maternal embryonic leucine zipper kinase (MELK) with potential antineoplastic activity. Upon administration, OTS167 binds to MELK, which prevents both MELK phosphorylation and activation; thus inhibiting the phosphorylation of downstream MELK substrates. This may lead to an inhibition of both cell proliferation and survival in MELK-expressing tumor cells. MELK, a serine/threonine kinase, is involved in cancer cell survival, invasiveness and cancer-stem cell formation and maintenance; it is highly upregulated in various types of cancer cells and absent in normal, healthy cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C111569",
			"nciConceptName": "MELK Inhibitor OTS167",
			"termId": 751983,
			"name": "MELK inhibitor OTS167",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "melk-inhibitor-ots167"
		},
		{
			"preferredName": "thioridazine hydrochloride",
			"termId": 746026,
			"name": "Mellaril",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "thioridazine-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Mobicox"
				},
				{
					"type": "ChemicalStructureName",
					"name": "4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide"
				},
				{
					"type": "USBrandName",
					"name": "Mobec"
				},
				{
					"type": "USBrandName",
					"name": "Mobic"
				},
				{
					"type": "USBrandName",
					"name": "Movalis"
				},
				{
					"type": "USBrandName",
					"name": "Movatec"
				},
				{
					"type": "CASRegistryName",
					"name": "71125-38-7"
				}
			],
			"definition": {
				"html": "An oxicam derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Unlike traditional nonselective NSAIDs, meloxicam preferentially inhibits the activity of cyclo-oxygenase II (COX-II), resulting in a decreased conversion of arachidonic acid into prostaglandin precursors. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of meloxicam.",
				"text": "An oxicam derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Unlike traditional nonselective NSAIDs, meloxicam preferentially inhibits the activity of cyclo-oxygenase II (COX-II), resulting in a decreased conversion of arachidonic acid into prostaglandin precursors. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of meloxicam."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C61439",
			"nciConceptName": "Meloxicam",
			"termId": 472195,
			"name": "meloxicam",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "meloxicam"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "4-[bis(2-chloroethyl)amino]-L-phenylalanine"
				},
				{
					"type": "Synonym",
					"name": "alanine nitrogen mustard"
				},
				{
					"type": "USBrandName",
					"name": "Alkeran"
				},
				{
					"type": "CodeName",
					"name": "CB-3025"
				},
				{
					"type": "Abbreviation",
					"name": "L-PAM"
				},
				{
					"type": "Synonym",
					"name": "L-phenylalanine mustard"
				},
				{
					"type": "Synonym",
					"name": "L-sarcolysin"
				},
				{
					"type": "Synonym",
					"name": "L-sarcolysin phenylalanine mustard"
				},
				{
					"type": "Synonym",
					"name": "L-sarcolysine"
				},
				{
					"type": "ForeignBrandName",
					"name": "Melphalanum"
				},
				{
					"type": "ChemicalStructureName",
					"name": "p-di(chloroethyl)amino-L-phenylalanine"
				},
				{
					"type": "Synonym",
					"name": "phenylalanine mustard"
				},
				{
					"type": "Synonym",
					"name": "phenylalanine nitrogen mustard"
				},
				{
					"type": "Synonym",
					"name": "sarcoclorin"
				},
				{
					"type": "ForeignBrandName",
					"name": "Sarkolysin"
				},
				{
					"type": "CodeName",
					"name": "WR-19813"
				},
				{
					"type": "NSCNumber",
					"name": "241286"
				},
				{
					"type": "NSCNumber",
					"name": "8806"
				},
				{
					"type": "CASRegistryName",
					"name": "148-82-3"
				}
			],
			"definition": {
				"html": "A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.",
				"text": "A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells."
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/melphalan",
				"text": "Melphalan"
			},
			"nciConceptId": "C633",
			"nciConceptName": "Melphalan",
			"termId": 779085,
			"name": "melphalan",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "melphalan"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "3-(p-(bis(2-chloroethyl)amino)phenyl)-L-alanine, hydrochloride"
				},
				{
					"type": "ForeignBrandName",
					"name": "Alkerana"
				},
				{
					"type": "USBrandName",
					"name": "Evomela"
				},
				{
					"type": "ObsoleteName",
					"name": "Alkeran"
				},
				{
					"type": "NSCNumber",
					"name": "241286"
				},
				{
					"type": "CASRegistryName",
					"name": "3223-07-2"
				}
			],
			"definition": {
				"html": "A bifunctional alkylating agent and phenylalanine derivative of nitrogen mustard. Melphalan hydrochloride is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA. This agent also alkylates RNA and protein structures. As a result RNA transcription and protein synthesis are inhibited, ultimately leading to cell growth arrest and/or death.",
				"text": "A bifunctional alkylating agent and phenylalanine derivative of nitrogen mustard. Melphalan hydrochloride is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA. This agent also alkylates RNA and protein structures. As a result RNA transcription and protein synthesis are inhibited, ultimately leading to cell growth arrest and/or death."
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/melphalan-hydrochloride",
				"text": "Melphalan Hydrochloride"
			},
			"nciConceptId": "C48002",
			"nciConceptName": "Melphalan Hydrochloride",
			"termId": 42973,
			"name": "melphalan hydrochloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "melphalan-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Captisol-enabled Melphalan IV"
				}
			],
			"definition": {
				"html": "A propylene glycol-free intravenous formulation containing the hydrochloride salt of the nitrogen mustard phenylalanine derivative melphalan complexed with polyanionic sulfobutyl ether beta-cyclodextrin (SBE-CD) with potential antineoplastic activity. Upon administration, melphalan is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA; RNA and proteins may also be alkylated. Subsequently, RNA transcription and protein synthesis are inhibited, resulting in cell growth arrest. The addition of sulfobutyl ether beta-cyclodextrin to the formulation improves the solubility,  stability and ease of use of melphalan; cyclodextrins are cyclic dextrins derived from starch.",
				"text": "A propylene glycol-free intravenous formulation containing the hydrochloride salt of the nitrogen mustard phenylalanine derivative melphalan complexed with polyanionic sulfobutyl ether beta-cyclodextrin (SBE-CD) with potential antineoplastic activity. Upon administration, melphalan is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA; RNA and proteins may also be alkylated. Subsequently, RNA transcription and protein synthesis are inhibited, resulting in cell growth arrest. The addition of sulfobutyl ether beta-cyclodextrin to the formulation improves the solubility,  stability and ease of use of melphalan; cyclodextrins are cyclic dextrins derived from starch."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C84878",
			"nciConceptName": "Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex",
			"termId": 649061,
			"name": "melphalan hydrochloride/sulfobutyl ether beta-cyclodextrin complex",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "melphalan-hydrochloride-sulfobutyl-ether-beta-cyclodextrin-complex"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "melflufen"
				},
				{
					"type": "Synonym",
					"name": "mel-flufen"
				},
				{
					"type": "CodeName",
					"name": "J1"
				},
				{
					"type": "Synonym",
					"name": "L-melphalanyl-p-L-fluorophenylalanine ethyl ester"
				}
			],
			"definition": {
				"html": "A melphalan prodrug in which the alkylating agent melphalan is bound to flufenamide, with potential antineoplastic and anti-angiogenic activities. Upon administration, the dipeptide bond in the melphalan-flufenamide compound is hydrolyzed by peptidases, which are overexpressed by certain cancer cells. This results in the specific release and accumulation of the active metabolite melphalan in cancer cells. Melphalan alkylates DNA at the N7 position of guanine residues and induces DNA intra- and inter-strand cross-linkages. This results in the inhibition of DNA and RNA synthesis and the induction of apoptosis, thereby inhibiting tumor cell proliferation. The administration of the melphalan-flufenamide prodrug allows for enhanced efficacy and reduced toxicity compared to melphalan alone.",
				"text": "A melphalan prodrug in which the alkylating agent melphalan is bound to flufenamide, with potential antineoplastic and anti-angiogenic activities. Upon administration, the dipeptide bond in the melphalan-flufenamide compound is hydrolyzed by peptidases, which are overexpressed by certain cancer cells. This results in the specific release and accumulation of the active metabolite melphalan in cancer cells. Melphalan alkylates DNA at the N7 position of guanine residues and induces DNA intra- and inter-strand cross-linkages. This results in the inhibition of DNA and RNA synthesis and the induction of apoptosis, thereby inhibiting tumor cell proliferation. The administration of the melphalan-flufenamide prodrug allows for enhanced efficacy and reduced toxicity compared to melphalan alone."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C107680",
			"nciConceptName": "Melphalan Flufenamide",
			"termId": 751473,
			"name": "melphalan-flufenamide prodrug",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "melphalan-flufenamide"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "Ebixia"
				},
				{
					"type": "USBrandName",
					"name": "Namenda"
				},
				{
					"type": "ChemicalStructureName",
					"name": "1-amino-3,5-dimethyladamantane Hydrochloride"
				},
				{
					"type": "NSCNumber",
					"name": "102290"
				},
				{
					"type": "CASRegistryName",
					"name": "41100-52-1"
				}
			],
			"definition": {
				"html": "The hydrochloride salt of memantine, a low-affinity, voltage-dependent, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine binds to and inhibits cation channels of glutamanergic NMDA receptors located in the central nervous system (CNS), preventing the prolonged influx of calcium ions and the associated neuronal excitotoxicity, and thereby potentially enhancing cognitive function. Memantine is also a 5-hydroxytryptamine  type 3 (5HT3) receptor and  nicotinic receptor antagonist.",
				"text": "The hydrochloride salt of memantine, a low-affinity, voltage-dependent, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine binds to and inhibits cation channels of glutamanergic NMDA receptors located in the central nervous system (CNS), preventing the prolonged influx of calcium ions and the associated neuronal excitotoxicity, and thereby potentially enhancing cognitive function. Memantine is also a 5-hydroxytryptamine  type 3 (5HT3) receptor and  nicotinic receptor antagonist."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C47601",
			"nciConceptName": "Memantine Hydrochloride",
			"termId": 579596,
			"name": "memantine hydrochloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "memantine-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "(mbIL21)-expanded haploidentical NK Cells"
				},
				{
					"type": "Synonym",
					"name": "mbIL21-expanded haploidentical NK cells"
				}
			],
			"definition": {
				"html": "A preparation of human cytokine interleukin-21 (IL-21) primed, tumor-activated allogeneic human leukocyte antigen (HLA) haploidentical natural killer (NK) cells, with potential cytolytic and immunoregulatory activities. Allogeneic leukemia cells are genetically modified to express membrane-bound interleukin-21 (mbIL-21) on their cell surfaces. When human peripheral blood mononuclear cells (PBMCs) from an HLA-haploidentical donor are subsequently exposed to these cells, the donor PBMC differentiate into mature, highly cytotoxic NK cells, which are subsequently expanded in ex vivo culture.  Upon infusion of the mbIL-21-expanded haploidentical NK cells, the NK cells target, lyse and destroy tumor cells. mbIL-21 promotes sustained ex vivo proliferation of human NK cells and enhances its cytotoxic activity.\n",
				"text": "A preparation of human cytokine interleukin-21 (IL-21) primed, tumor-activated allogeneic human leukocyte antigen (HLA) haploidentical natural killer (NK) cells, with potential cytolytic and immunoregulatory activities. Allogeneic leukemia cells are genetically modified to express membrane-bound interleukin-21 (mbIL-21) on their cell surfaces. When human peripheral blood mononuclear cells (PBMCs) from an HLA-haploidentical donor are subsequently exposed to these cells, the donor PBMC differentiate into mature, highly cytotoxic NK cells, which are subsequently expanded in ex vivo culture.  Upon infusion of the mbIL-21-expanded haploidentical NK cells, the NK cells target, lyse and destroy tumor cells. mbIL-21 promotes sustained ex vivo proliferation of human NK cells and enhances its cytotoxic activity.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C131901",
			"nciConceptName": "Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells",
			"termId": 786203,
			"name": "membrane-bound interleukin-21-expanded haploidentical natural killer cells",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "membrane-bound-interleukin-21-expanded-haploidentical-natural-killer-cells"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MDP EP-100"
				},
				{
					"type": "CodeName",
					"name": "EP-100"
				}
			],
			"definition": {
				"html": "A water-soluble, positively charged fusion protein consisting of  a luteinizing hormone releasing hormone (LHRH) receptor-targeting ligand conjugated to the membrane-disrupting peptide CLIP 71 with membrane-disrupting and potential antineoplastic activities. The LHRH ligand moiety of membrane-disrupting peptide EP-100 specifically binds to LHRH receptors, which are upregulated on a variety of human cancer cell types. Subsequently, the positively charged CLIP 71 moiety of this agent interacts with the negatively charged membrane on the cancer cell surface, which may result in cell membrane disruption and  cell lysis.",
				"text": "A water-soluble, positively charged fusion protein consisting of  a luteinizing hormone releasing hormone (LHRH) receptor-targeting ligand conjugated to the membrane-disrupting peptide CLIP 71 with membrane-disrupting and potential antineoplastic activities. The LHRH ligand moiety of membrane-disrupting peptide EP-100 specifically binds to LHRH receptors, which are upregulated on a variety of human cancer cell types. Subsequently, the positively charged CLIP 71 moiety of this agent interacts with the negatively charged membrane on the cancer cell surface, which may result in cell membrane disruption and  cell lysis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C84860",
			"nciConceptName": "Membrane-Disrupting Peptide EP-100",
			"termId": 652192,
			"name": "membrane-disrupting peptide EP-100",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "membrane-disrupting-peptide-ep-100"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A topical lotion containing the small organic molecule protein tyrosine phosphatase (PTP) inhibitor menadione (vitamin K3) with potential EGFR-  and ErbB2/HER2-activating  activities. Upon topical administration, menadione binds to and inhibits the activity of PTPs that dephosphorylate and  inactivate EGFR and ErbB2 in human keratinocytes; local reversal of   EGFR and ErbB2 inhibition associated with the systemic administration of EGFR inhibitors may help alleviate EGFR inhibitor-mediated skin toxicity. EGFR  (epidermal growth factor receptor) and ErbB2/HER2 (erythroblastic leukemia viral oncogene homolog 2/ human epidermal growth factor receptor 2) are cell surface receptors that are  upregulated in a number of cancer cells types and play  important roles in the growth and maintenance of normal epithelial tissues.",
				"text": "A topical lotion containing the small organic molecule protein tyrosine phosphatase (PTP) inhibitor menadione (vitamin K3) with potential EGFR-  and ErbB2/HER2-activating  activities. Upon topical administration, menadione binds to and inhibits the activity of PTPs that dephosphorylate and  inactivate EGFR and ErbB2 in human keratinocytes; local reversal of   EGFR and ErbB2 inhibition associated with the systemic administration of EGFR inhibitors may help alleviate EGFR inhibitor-mediated skin toxicity. EGFR  (epidermal growth factor receptor) and ErbB2/HER2 (erythroblastic leukemia viral oncogene homolog 2/ human epidermal growth factor receptor 2) are cell surface receptors that are  upregulated in a number of cancer cells types and play  important roles in the growth and maintenance of normal epithelial tissues."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C84863",
			"nciConceptName": "Menadione Topical Lotion",
			"termId": 652615,
			"name": "menadione topical lotion",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "menadione-topical-lotion"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "E0167"
				}
			],
			"definition": {
				"html": "A menaquinone compound and form of vitamin K2 with potential antineoplastic activity. Menatetrenone may act by modulating the signalling of certain tyrosine kinases, thereby affecting several transcription factors including c-myc and c-fos. This agent inhibits tumor cell growth by inducing apoptosis and cell cycle arrest.",
				"text": "A menaquinone compound and form of vitamin K2 with potential antineoplastic activity. Menatetrenone may act by modulating the signalling of certain tyrosine kinases, thereby affecting several transcription factors including c-myc and c-fos. This agent inhibits tumor cell growth by inducing apoptosis and cell cycle arrest."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C52194",
			"nciConceptName": "Menatetrenone",
			"termId": 459755,
			"name": "menatetrenone",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "menatetrenone"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "KO 539"
				},
				{
					"type": "Synonym",
					"name": "menin-KMT2A inhibitor KO 539"
				},
				{
					"type": "CodeName",
					"name": "KO-539"
				},
				{
					"type": "CodeName",
					"name": "KO539"
				},
				{
					"type": "Synonym",
					"name": "menin-mixed lineage leukemia protein-protein interaction inhibitor KO 539"
				},
				{
					"type": "Synonym",
					"name": "menin-MLL inhibitor KO-539"
				}
			],
			"definition": {
				"html": "An orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, with potential antineoplastic activity. Upon oral administration, menin-MLL interaction inhibitor KO 539 prevents the interaction between the two proteins menin and MLL, and thus the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth and proliferation of certain kinds of leukemia cells.\n",
				"text": "An orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, with potential antineoplastic activity. Upon oral administration, menin-MLL interaction inhibitor KO 539 prevents the interaction between the two proteins menin and MLL, and thus the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth and proliferation of certain kinds of leukemia cells.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C164227",
			"nciConceptName": "Menin-MLL Interaction Inhibitor KO 539",
			"termId": 799439,
			"name": "menin-MLL interaction inhibitor KO 539",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "menin-mll-interaction-inhibitor-ko-539"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "menin-mixed lineage leukemia protein-protein interaction inhibitor SNDX-5613"
				},
				{
					"type": "Synonym",
					"name": "menin-MLL inhibitor SNDX-5613"
				},
				{
					"type": "CodeName",
					"name": "SNDX-5613"
				},
				{
					"type": "CodeName",
					"name": "SNDX5613"
				},
				{
					"type": "CodeName",
					"name": "SNDX 5613"
				}
			],
			"definition": {
				"html": "An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, menin-MLL interaction inhibitor SNDX-5613 targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.",
				"text": "An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, menin-MLL interaction inhibitor SNDX-5613 targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C165776",
			"nciConceptName": "Menin-MLL Interaction Inhibitor SNDX-5613",
			"termId": 800199,
			"name": "menin-MLL interaction inhibitor SNDX-5613",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "menin-mll-interaction-inhibitor-sndx-5613"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "7-OMEN"
				},
				{
					"type": "ChemicalStructureName",
					"name": "7-con-O-methylnorgarol"
				},
				{
					"type": "Abbreviation",
					"name": "MEN"
				},
				{
					"type": "ChemicalStructureName",
					"name": "7-(R)-O-methylnogarol"
				},
				{
					"type": "ChemicalStructureName",
					"name": "7-con-O-methylnogarol"
				},
				{
					"type": "USBrandName",
					"name": "Menogarol"
				},
				{
					"type": "Abbreviation",
					"name": "TUT-7"
				},
				{
					"type": "CodeName",
					"name": "U-52047"
				},
				{
					"type": "ChemicalStructureName",
					"name": "[2R-(2alpha,3beta,4alpha,5beta,6alpha,11alpha,13alpha)]-4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-2,6-epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione"
				},
				{
					"type": "INDCode",
					"name": "22519"
				},
				{
					"type": "NSCNumber",
					"name": "269148"
				},
				{
					"type": "NSCNumber",
					"name": "8806"
				},
				{
					"type": "CASRegistryName",
					"name": "71628-96-1"
				}
			],
			"definition": {
				"html": "A semisynthetic derivative of the anthracycline antineoplastic antibiotic nogalamycin.  Menogaril intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin.",
				"text": "A semisynthetic derivative of the anthracycline antineoplastic antibiotic nogalamycin.  Menogaril intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1389",
			"nciConceptName": "Menogaril",
			"termId": 40153,
			"name": "menogaril",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "menogaril"
		},
		{
			"preferredName": "menogaril",
			"termId": 40153,
			"name": "Menogarol",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "menogaril"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "meperidine"
				},
				{
					"type": "USBrandName",
					"name": "Demerol"
				}
			],
			"definition": {
				"html": "The hydrochloride salt of a synthetic piperidine ester with opioid analgesic activity. Meperidine mimics the actions of endogenous neuropeptides via opioid receptors such as the mu-opiiod receptor, thereby producing characteristic morphine-like effects  including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence.",
				"text": "The hydrochloride salt of a synthetic piperidine ester with opioid analgesic activity. Meperidine mimics the actions of endogenous neuropeptides via opioid receptors such as the mu-opiiod receptor, thereby producing characteristic morphine-like effects  including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C635",
			"nciConceptName": "Meperidine Hydrochloride",
			"termId": 39278,
			"name": "meperidine hydrochloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "meperidine-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Carbocaine"
				},
				{
					"type": "USBrandName",
					"name": "Polocaine"
				},
				{
					"type": "ChemicalStructureName",
					"name": "1-methyl-2',6'-pipecoloxylidide hydrochloride (SY), (1-methyl-DL-piperidine-2-carboxylic acid)-2,6-dimethylanilide hydrochloride"
				},
				{
					"type": "CASRegistryName",
					"name": "96-88-8"
				}
			],
			"definition": {
				"html": "The hydrochloride salt form of mepivacaine, an amide-type local anesthetic agent.  At the injection site, mepivacaine binds to specific voltage-gated sodium ion channels in neuronal cell membranes, which inhibits both sodium influx and membrane depolarization. This leads to a blockage of nerve impulse initiation and conduction and results in a reversible loss of sensation. Compared to other local anesthetics, this agent has a more rapid onset and moderate duration of action.",
				"text": "The hydrochloride salt form of mepivacaine, an amide-type local anesthetic agent.  At the injection site, mepivacaine binds to specific voltage-gated sodium ion channels in neuronal cell membranes, which inhibits both sodium influx and membrane depolarization. This leads to a blockage of nerve impulse initiation and conduction and results in a reversible loss of sensation. Compared to other local anesthetics, this agent has a more rapid onset and moderate duration of action."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C47602",
			"nciConceptName": "Mepivacaine Hydrochloride",
			"termId": 751573,
			"name": "mepivacaine hydrochloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mepivacaine-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Nucala"
				},
				{
					"type": "ForeignBrandName",
					"name": "Bosatria"
				},
				{
					"type": "CodeName",
					"name": "SB-240563"
				},
				{
					"type": "CodeName",
					"name": "SB 240563"
				},
				{
					"type": "CodeName",
					"name": "SB240563"
				}
			],
			"definition": {
				"html": "A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. Upon administration, mepolizumab selectively binds to IL-5, preventing it from associating with interleukin-5 receptor subunit alpha (IL5RA) on the surface of eosinophils and their progenitors. IL-5 plays a role in the regulation of eosinophil development from hematopoietic progenitors as well as eosinophil maturation, differentiation, mobilization, activation, and survival. IL-5 also play a role in the pathogenesis of some phenotypes of hypereosinophilic syndrome (HES).",
				"text": "A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. Upon administration, mepolizumab selectively binds to IL-5, preventing it from associating with interleukin-5 receptor subunit alpha (IL5RA) on the surface of eosinophils and their progenitors. IL-5 plays a role in the regulation of eosinophil development from hematopoietic progenitors as well as eosinophil maturation, differentiation, mobilization, activation, and survival. IL-5 also play a role in the pathogenesis of some phenotypes of hypereosinophilic syndrome (HES)."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C157376",
			"nciConceptName": "Mepolizumab",
			"termId": 796922,
			"name": "mepolizumab",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mepolizumab"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "6-MP"
				},
				{
					"type": "Synonym",
					"name": "6-mercaptopurine"
				},
				{
					"type": "LexicalVariant",
					"name": "6MP"
				},
				{
					"type": "ForeignBrandName",
					"name": "Leukerin"
				},
				{
					"type": "Abbreviation",
					"name": "MP"
				},
				{
					"type": "USBrandName",
					"name": "Purinethol"
				},
				{
					"type": "ChemicalStructureName",
					"name": "1,7 dihydro-6H-purine-6-thione monohydrate"
				},
				{
					"type": "ChemicalStructureName",
					"name": "1,7-Dihydro-6H-purine-6-thione"
				},
				{
					"type": "ChemicalStructureName",
					"name": "3H purine-6-thiol"
				},
				{
					"type": "Synonym",
					"name": "6 thiohypoxanthine"
				},
				{
					"type": "Synonym",
					"name": "6 thiopurine"
				},
				{
					"type": "Synonym",
					"name": "6-mercaptopurine monohydrate"
				},
				{
					"type": "Synonym",
					"name": "6-purinethiol"
				},
				{
					"type": "Synonym",
					"name": "6-thiopurine"
				},
				{
					"type": "Synonym",
					"name": "6-thioxopurine"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6H-purine-6-thione, 1,7-dihydro- (9CI)"
				},
				{
					"type": "ChemicalStructureName",
					"name": "7-mercapto-1,3,4,6-tetrazaindene"
				},
				{
					"type": "ForeignBrandName",
					"name": "Alti-Mercaptopurine"
				},
				{
					"type": "Synonym",
					"name": "Azathiopurine"
				},
				{
					"type": "CodeName",
					"name": "BW 57-323H"
				},
				{
					"type": "ForeignBrandName",
					"name": "Flocofil"
				},
				{
					"type": "ForeignBrandName",
					"name": "Ismipur"
				},
				{
					"type": "Synonym",
					"name": "Leupurin"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mercaleukim"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mercaptina"
				},
				{
					"type": "ChemicalStructureName",
					"name": "Mercapto-6-purine"
				},
				{
					"type": "ObsoleteName",
					"name": "Mercaptopurinum"
				},
				{
					"type": "Synonym",
					"name": "Mercapurin"
				},
				{
					"type": "Synonym",
					"name": "Mern"
				},
				{
					"type": "ForeignBrandName",
					"name": "Puri-Nethol"
				},
				{
					"type": "Synonym",
					"name": "Purimethol"
				},
				{
					"type": "ChemicalStructureName",
					"name": "purine-6-thiol (8CI)"
				},
				{
					"type": "ChemicalStructureName",
					"name": "purine-6-thiol Monohydrate"
				},
				{
					"type": "ChemicalStructureName",
					"name": "purine-6-thiol, monohydrate"
				},
				{
					"type": "ForeignBrandName",
					"name": "Purinethiol"
				},
				{
					"type": "CodeName",
					"name": "U-4748"
				},
				{
					"type": "CodeName",
					"name": "WR-2785"
				},
				{
					"type": "INDCode",
					"name": "24850"
				},
				{
					"type": "INDCode",
					"name": "1226"
				},
				{
					"type": "NSCNumber",
					"name": "755"
				},
				{
					"type": "CASRegistryName",
					"name": "50-44-2"
				},
				{
					"type": "CASRegistryName",
					"name": "6112-76-1 (monohydrate)"
				},
				{
					"type": "ForeignBrandName",
					"name": "Xaluprine"
				},
				{
					"type": "USBrandName",
					"name": "Purixan"
				}
			],
			"definition": {
				"html": "A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis.",
				"text": "A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis."
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/mercaptopurine",
				"text": "Mercaptopurine"
			},
			"nciConceptId": "C195",
			"nciConceptName": "Mercaptopurine",
			"termId": 43436,
			"name": "mercaptopurine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mercaptopurine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "6-MP oral suspension"
				},
				{
					"type": "USBrandName",
					"name": "Purixan"
				},
				{
					"type": "ForeignBrandName",
					"name": "Xaluprine"
				}
			],
			"definition": {
				"html": "An oral suspension containing the thiopurine-derivative antimetabolite 6-mercaptopurine, with potential antineoplastic activity. Upon oral administration, mercaptopurine is metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) to its active metabolite 6-thioinosine monophosphate (TIMP); TIMP inhibits nucleotide interconversions and de novo purine ribonucleotide synthesis, which both blocks the formation of purine nucleotides and inhibits DNA synthesis. This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. By blocking DNA synthesis and replication, cancer cells are unable to proliferate. Compared to the tablet formulation, the liquid is easier to swallow and offers more flexibility and accuracy in dosing, which is beneficial for use in pediatric patients.",
				"text": "An oral suspension containing the thiopurine-derivative antimetabolite 6-mercaptopurine, with potential antineoplastic activity. Upon oral administration, mercaptopurine is metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) to its active metabolite 6-thioinosine monophosphate (TIMP); TIMP inhibits nucleotide interconversions and de novo purine ribonucleotide synthesis, which both blocks the formation of purine nucleotides and inhibits DNA synthesis. This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. By blocking DNA synthesis and replication, cancer cells are unable to proliferate. Compared to the tablet formulation, the liquid is easier to swallow and offers more flexibility and accuracy in dosing, which is beneficial for use in pediatric patients."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C111757",
			"nciConceptName": "Mercaptopurine Oral Suspension",
			"termId": 752956,
			"name": "mercaptopurine oral suspension",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mercaptopurine-oral-suspension"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "mercaptopurine anhydrous"
				},
				{
					"type": "CASRegistryName",
					"name": "50-44-2"
				},
				{
					"type": "ForeignBrandName",
					"name": "Puri-Nethol"
				},
				{
					"type": "ForeignBrandName",
					"name": "Purinethol"
				}
			],
			"definition": {
				"html": "The anhydrous form of mercaptopurine, a thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities. Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis. This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis.",
				"text": "The anhydrous form of mercaptopurine, a thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities. Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis. This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C64832",
			"nciConceptName": "Specific Gravity",
			"termId": 760529,
			"name": "mercaptopurine tablet",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "specific-gravity"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "c-Met inhibitor LY2801653"
				},
				{
					"type": "CodeName",
					"name": "LY2801653"
				},
				{
					"type": "ChemicalStructureName",
					"name": "3-pyridinecarboxamide, N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-1,2-dihydro-6-methyl-2-oxo-"
				}
			],
			"definition": {
				"html": "An orally available, small molecule inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. Merestinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.",
				"text": "An orally available, small molecule inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. Merestinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C95729",
			"nciConceptName": "Merestinib",
			"termId": 694732,
			"name": "merestinib",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "merestinib"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "SM-7338"
				},
				{
					"type": "Synonym",
					"name": "meropenem trihydrate"
				},
				{
					"type": "USBrandName",
					"name": "Merrem I.V."
				},
				{
					"type": "CASRegistryName",
					"name": "119478-56-7"
				}
			],
			"definition": {
				"html": "A broad-spectrum carbapenem with antibacterial properties, synthetic Meropenem inhibits cell wall synthesis in gram-positive and gram-negative bacteria. It penetrates cell walls and binds to penicillin-binding protein targets. Meropenem acts against aerobes and anaerobes including Klebsiella, E. coli, Enterococcus, Clostridium sp..",
				"text": "A broad-spectrum carbapenem with antibacterial properties, synthetic Meropenem inhibits cell wall synthesis in gram-positive and gram-negative bacteria. It penetrates cell walls and binds to penicillin-binding protein targets. Meropenem acts against aerobes and anaerobes including Klebsiella, E. coli, Enterococcus, Clostridium sp.."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1160",
			"nciConceptName": "Meropenem",
			"termId": 41899,
			"name": "meropenem",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "meropenem"
		},
		{
			"preferredName": "meropenem",
			"termId": 41899,
			"name": "Merrem I.V.",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "meropenem"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "5-ASA"
				},
				{
					"type": "ChemicalStructureName",
					"name": "5-amino-2-hydroxybenzoic acid"
				},
				{
					"type": "ChemicalStructureName",
					"name": "5-aminosalicylic acid"
				},
				{
					"type": "USBrandName",
					"name": "Apriso"
				},
				{
					"type": "USBrandName",
					"name": "Asacol"
				},
				{
					"type": "USBrandName",
					"name": "Lialda"
				},
				{
					"type": "Synonym",
					"name": "mesalazine"
				},
				{
					"type": "USBrandName",
					"name": "Pentasa"
				},
				{
					"type": "USBrandName",
					"name": "Rowasa"
				},
				{
					"type": "CASRegistryName",
					"name": "89-57-6"
				}
			],
			"definition": {
				"html": "An agent derived from sulfasalazine, an antiinflammatory agent.  Mesalamine may reduce inflammation through inhibition of cyclooxygenase and prostaglandin production. Following rectal or oral administration, only a small amount of mesalamine is absorbed; the remainder, acting topically, reduces bowel inflammation, diarrhea, rectal bleeding and stomach pain.",
				"text": "An agent derived from sulfasalazine, an antiinflammatory agent.  Mesalamine may reduce inflammation through inhibition of cyclooxygenase and prostaglandin production. Following rectal or oral administration, only a small amount of mesalamine is absorbed; the remainder, acting topically, reduces bowel inflammation, diarrhea, rectal bleeding and stomach pain."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": null,
			"nciConceptName": null,
			"termId": 732182,
			"name": "mesalamine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mesalamine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MSC-derived exosomes with KrasG12D siRNA"
				},
				{
					"type": "Synonym",
					"name": "KrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes"
				}
			],
			"definition": {
				"html": "Exosomes derived from mesenchymal stromal cells (MSCs) that have been engineered to carry short interfering RNA (siRNA) specific to the KRAS G12D mutation subtype. Upon administration, the KRAS G12D siRNA-loaded exosomes deliver siRNA to tumor cells expressing the mutant form of KRAS, potentially silencing its activity. The KRAS G12D mutation is thought to drive tumorigenesis and progression in some cancers.",
				"text": "Exosomes derived from mesenchymal stromal cells (MSCs) that have been engineered to carry short interfering RNA (siRNA) specific to the KRAS G12D mutation subtype. Upon administration, the KRAS G12D siRNA-loaded exosomes deliver siRNA to tumor cells expressing the mutant form of KRAS, potentially silencing its activity. The KRAS G12D mutation is thought to drive tumorigenesis and progression in some cancers."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C153214",
			"nciConceptName": "Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA",
			"termId": 794048,
			"name": "mesenchymal stromal cells-derived exosomes with KRAS G12D siRNA",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mesenchymal-stromal-cells-derived-exosomes-with-kras-g12d-sirna"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MSA"
				},
				{
					"type": "USBrandName",
					"name": "Mesnex"
				},
				{
					"type": "Synonym",
					"name": "mercaptoethane sulfonate"
				},
				{
					"type": "LexicalVariant",
					"name": "mercaptoethanesulfonate"
				},
				{
					"type": "ChemicalStructureName",
					"name": "2-mercaptoethanesulfonic acid, sodium salt"
				},
				{
					"type": "ForeignBrandName",
					"name": "Ausobronc"
				},
				{
					"type": "CodeName",
					"name": "D-7093"
				},
				{
					"type": "ForeignBrandName",
					"name": "Filesna"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mesnil"
				},
				{
					"type": "Synonym",
					"name": "Mesnum"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mexan"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mistabron"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mistabronco"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mitexan"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mucofluid"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mucolene"
				},
				{
					"type": "ChemicalStructureName",
					"name": "sodium 2-mercaptoethane sulfonate"
				},
				{
					"type": "LexicalVariant",
					"name": "Sodium 2-Mercaptoethanesulphonate"
				},
				{
					"type": "CodeName",
					"name": "UCB 3983"
				},
				{
					"type": "ForeignBrandName",
					"name": "Uromitexan"
				},
				{
					"type": "ForeignBrandName",
					"name": "Ziken"
				},
				{
					"type": "INDCode",
					"name": "25232"
				},
				{
					"type": "NSCNumber",
					"name": "113891"
				},
				{
					"type": "CASRegistryName",
					"name": "19767-45-4"
				}
			],
			"definition": {
				"html": "A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.  Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion.",
				"text": "A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.  Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion."
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/mesna",
				"text": "Mesna"
			},
			"nciConceptId": "C192",
			"nciConceptName": "Mesna",
			"termId": 39759,
			"name": "mesna",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mesna"
		},
		{
			"preferredName": "mesna",
			"termId": 39759,
			"name": "Mesnex",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "mesna"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "mesothelin-specific CAR-engineered PBLs"
				},
				{
					"type": "Synonym",
					"name": "anti-mesothelin CAR PBL"
				}
			],
			"definition": {
				"html": "A preparation of peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding a T cell chimeric antigen receptor (CAR) specific for mesothelin with potential immunostimulatory and antineoplastic activities. After transduction, expansion in culture, and reintroduction into the patient, the mesothelin-specific chimeric antigen receptor-engineered PBLs bind to tumor cells expressing mesothelin. This may stimulate the secretion of cytokines and result in cell lysis of mesothelin-expressing cancer cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in many epithelial-derived cancers.",
				"text": "A preparation of peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding a T cell chimeric antigen receptor (CAR) specific for mesothelin with potential immunostimulatory and antineoplastic activities. After transduction, expansion in culture, and reintroduction into the patient, the mesothelin-specific chimeric antigen receptor-engineered PBLs bind to tumor cells expressing mesothelin. This may stimulate the secretion of cytokines and result in cell lysis of mesothelin-expressing cancer cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in many epithelial-derived cancers."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C101773",
			"nciConceptName": "Mesothelin-specific Chimeric Antigen Receptor-engineered Peripheral Blood Lymphocytes",
			"termId": 732671,
			"name": "mesothelin-specific chimeric antigen receptor-engineered peripheral blood lymphocytes",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": ""
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "TriTAC HPN536"
				},
				{
					"type": "Synonym",
					"name": "mesothelin/CD3e-specific TriTAC HPN536"
				},
				{
					"type": "CodeName",
					"name": "HPN536"
				},
				{
					"type": "CodeName",
					"name": "HPN 536"
				},
				{
					"type": "CodeName",
					"name": "HPN-536"
				},
				{
					"type": "CodeName",
					"name": "MSLN-specific TriTAC HPN536"
				},
				{
					"type": "Synonym",
					"name": "mesothelin-targeting T-cell engager HPN536"
				},
				{
					"type": "Synonym",
					"name": "MSLN/CD3e TriTAC HPN536"
				}
			],
			"definition": {
				"html": "A recombinant antibody derivative composed of a tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) mesothelin (MSLN) and the epsilon domain of CD3 antigen (CD3e) found on T lymphocytes which are both linked to either side of an anti-albumin single domain antibody, with potential immunostimulating and antineoplastic activities. Upon administration of the MSLN/CD3e TriTAC HPN536, the anti-MSLN single antibody domain targets and binds MSLN on tumor cells and the anti-CD3e single-chain variable fragment (scFv) targets and binds to CD3e on cytotoxic T lymphocytes (CTLs), thereby bringing MSLN-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of MSLN-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of HPN536. MSLN is overexpressed on the surface of certain tumor cell types. Overexpression of MSLN is often associated with poor prognosis.\n",
				"text": "A recombinant antibody derivative composed of a tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) mesothelin (MSLN) and the epsilon domain of CD3 antigen (CD3e) found on T lymphocytes which are both linked to either side of an anti-albumin single domain antibody, with potential immunostimulating and antineoplastic activities. Upon administration of the MSLN/CD3e TriTAC HPN536, the anti-MSLN single antibody domain targets and binds MSLN on tumor cells and the anti-CD3e single-chain variable fragment (scFv) targets and binds to CD3e on cytotoxic T lymphocytes (CTLs), thereby bringing MSLN-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of MSLN-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of HPN536. MSLN is overexpressed on the surface of certain tumor cell types. Overexpression of MSLN is often associated with poor prognosis.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C162935",
			"nciConceptName": "Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536",
			"termId": 799094,
			"name": "mesothelin/CD3e tri-specific T-cell activating construct HPN536",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mesothelin-cd3e-tri-specific-t-cell-activating-construct-hpn536"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A cell-based cancer vaccine consisting of autologous dendritic cells (DCs) pulsed with mesothelioma tumor lysate with potential immunostimulating and antineoplastic activities. Upon administration, mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount a specific cytotoxic T lymphocyte (CTL) response against mesothelioma tumor cells, resulting in tumor cell lysis.",
				"text": "A cell-based cancer vaccine consisting of autologous dendritic cells (DCs) pulsed with mesothelioma tumor lysate with potential immunostimulating and antineoplastic activities. Upon administration, mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount a specific cytotoxic T lymphocyte (CTL) response against mesothelioma tumor cells, resulting in tumor cell lysis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C78448",
			"nciConceptName": "Mesothelioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine",
			"termId": 599454,
			"name": "mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mesothelioma-tumor-lysate-pulsed-autologous-dendritic-cell-vaccine"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "OMO-1"
				},
				{
					"type": "CodeName",
					"name": "JNJ-38877618"
				},
				{
					"type": "CodeName",
					"name": "OMO1"
				}
			],
			"definition": {
				"html": "An inhibitor of the proto-oncogene and receptor tyrosine kinase (RTK) hepatocyte growth factor receptor (c-Met; HGFR; MET) with potential antineoplastic activity. Upon administration, OMO-1 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.",
				"text": "An inhibitor of the proto-oncogene and receptor tyrosine kinase (RTK) hepatocyte growth factor receptor (c-Met; HGFR; MET) with potential antineoplastic activity. Upon administration, OMO-1 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C148537",
			"nciConceptName": "MET Kinase Inhibitor OMO-1",
			"termId": 792712,
			"name": "MET kinase inhibitor OMO-1",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "met-kinase-inhibitor-omo-1"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "SGX523"
				},
				{
					"type": "LexicalVariant",
					"name": "MET Tyrosine Kinase Inhibitor SGX523"
				}
			],
			"definition": {
				"html": "An orally bioavailable small molecule, belonging to the class of c-Met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors, with potential antineoplastic activity. MET receptor tyrosine kinase inhibitor SGX523 specifically binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway; this agent may induce cell death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis.",
				"text": "An orally bioavailable small molecule, belonging to the class of c-Met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors, with potential antineoplastic activity. MET receptor tyrosine kinase inhibitor SGX523 specifically binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway; this agent may induce cell death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C74062",
			"nciConceptName": "MET Tyrosine Kinase Inhibitor SGX523",
			"termId": 588972,
			"name": "MET receptor tyrosine kinase inhibitor SGX523",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "met-tyrosine-kinase-inhibitor-sgx523"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "BMS-777607"
				},
				{
					"type": "CodeName",
					"name": "ASLAN002"
				}
			],
			"definition": {
				"html": "An inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibitor BMS-777607 binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway; this agent may induce cell death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis.",
				"text": "An inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibitor BMS-777607 binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway; this agent may induce cell death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C74060",
			"nciConceptName": "MET Tyrosine Kinase Inhibitor BMS-777607",
			"termId": 587999,
			"name": "Met tyrosine kinase inhibitor BMS-777607",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "met-tyrosine-kinase-inhibitor-bms-777607"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "EMD 1204831"
				}
			],
			"definition": {
				"html": "An inhibitor of the receptor tyrosine kinase MET (hepatocyte growth factor receptor) with potential antineoplastic activity. MET inhibitor EMD 1204831 selectively binds to MET tyrosine kinase, thereby disrupting MET-mediated signal transduction pathways. This may induce cell death in tumor cells overexpressing this kinase. MET is overexpressed or mutated in many tumor cell types, and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.",
				"text": "An inhibitor of the receptor tyrosine kinase MET (hepatocyte growth factor receptor) with potential antineoplastic activity. MET inhibitor EMD 1204831 selectively binds to MET tyrosine kinase, thereby disrupting MET-mediated signal transduction pathways. This may induce cell death in tumor cells overexpressing this kinase. MET is overexpressed or mutated in many tumor cell types, and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C91097",
			"nciConceptName": "MET Tyrosine Kinase Inhibitor EMD 1204831",
			"termId": 672542,
			"name": "MET tyrosine kinase inhibitor EMD 1204831",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "met-tyrosine-kinase-inhibitor-emd-1204831"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "PF-04217903"
				}
			],
			"definition": {
				"html": "An orally bioavailabe, small-molecule tyrosine kinase inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. c-Met inhibitor PF-04217903 selectively binds to and inhibits c-Met, disrupting the c-Met signaling pathway, which may result in the inhibition of tumor cell growth, migration and invasion of tumor cells, and the induction of death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.",
				"text": "An orally bioavailabe, small-molecule tyrosine kinase inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. c-Met inhibitor PF-04217903 selectively binds to and inhibits c-Met, disrupting the c-Met signaling pathway, which may result in the inhibition of tumor cell growth, migration and invasion of tumor cells, and the induction of death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C78483",
			"nciConceptName": "MET Tyrosine Kinase Inhibitor PF-04217903",
			"termId": 601032,
			"name": "MET tyrosine kinase inhibitor PF-04217903",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "met-tyrosine-kinase-inhibitor-pf-04217903"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "SAR125844"
				}
			],
			"definition": {
				"html": "An inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. Upon intravenous administration, c-Met inhibitor SAR125844 binds to c-Met, thereby disrupting c-Met-mediated signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in a variety of cancers, plays an important role in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.",
				"text": "An inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. Upon intravenous administration, c-Met inhibitor SAR125844 binds to c-Met, thereby disrupting c-Met-mediated signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in a variety of cancers, plays an important role in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C97511",
			"nciConceptName": "MET Tyrosine Kinase Inhibitor SAR125844",
			"termId": 703771,
			"name": "MET tyrosine kinase inhibitor SAR125844",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "met-tyrosine-kinase-inhibitor-sar125844"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "REGN5093"
				},
				{
					"type": "CodeName",
					"name": "REGN 5093"
				},
				{
					"type": "CodeName",
					"name": "REGN-5093"
				},
				{
					"type": "Synonym",
					"name": "anti-c-Met bispecific antibody REGN5093"
				},
				{
					"type": "Synonym",
					"name": "METxMET antibody REGN5093"
				},
				{
					"type": "Synonym",
					"name": "METxMET bispecific antibody REGN5093"
				}
			],
			"definition": {
				"html": "A bispecific monoclonal antibody that targets two different epitopes of the human tumor-associated antigen (TAA) MET (c-MET; hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon administration, MET x MET bispecific antibody REGN5093 targets and binds to two different, non-overlapping epitopes on MET expressed on the tumor cell surface, thereby forming unique REGN5093-MET complexes. The binding of REGN5093 to the MET epitopes and the unique complex formation causes MET internalization and degradation. This prevents MET-mediated signaling and inhibits growth of MET-driven tumor cells. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types where it is involved in epithelial-mesenchymal transition; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.",
				"text": "A bispecific monoclonal antibody that targets two different epitopes of the human tumor-associated antigen (TAA) MET (c-MET; hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon administration, MET x MET bispecific antibody REGN5093 targets and binds to two different, non-overlapping epitopes on MET expressed on the tumor cell surface, thereby forming unique REGN5093-MET complexes. The binding of REGN5093 to the MET epitopes and the unique complex formation causes MET internalization and degradation. This prevents MET-mediated signaling and inhibits growth of MET-driven tumor cells. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types where it is involved in epithelial-mesenchymal transition; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C167188",
			"nciConceptName": "MET x MET Bispecific Antibody REGN5093",
			"termId": 800420,
			"name": "MET x MET bispecific antibody REGN5093",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "met-x-met-bispecific-antibody-regn5093"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "meta-[(18)F]-fluorobenzylguanidine"
				},
				{
					"type": "Abbreviation",
					"name": "18F-MFBG"
				},
				{
					"type": "Abbreviation",
					"name": "[(18)F]-MFBG"
				}
			],
			"definition": {
				"html": "A radioconjugate composed of the positron-emitting radioisotope fluorine F 18-labeled benzylguanidine, a synthetic analogue of the adrenergic neurotransmitter norepinephrine (NE), with potential use in the diagnostic imaging of human norepinephrine transporter (hNET)-expressing cells by either positron emitting tomography (PET) or computed tomography (CT). Upon administration, meta-fluorine F 18 fluorobenzylguanidine (MFBG) is taken up by and accumulates in both the granules of adrenal medullary chromaffin cells and the pre-synaptic granules of adrenergic neurons in a manner almost identical to that of NE. In turn, hNET-expressing tumor cells can be imaged by PET or CT. hNET, a transmembrane protein and regulator of catecholamine uptake normally restricted to the central and peripheral sympathetic nervous system, is overexpressed in certain tumor cell types.",
				"text": "A radioconjugate composed of the positron-emitting radioisotope fluorine F 18-labeled benzylguanidine, a synthetic analogue of the adrenergic neurotransmitter norepinephrine (NE), with potential use in the diagnostic imaging of human norepinephrine transporter (hNET)-expressing cells by either positron emitting tomography (PET) or computed tomography (CT). Upon administration, meta-fluorine F 18 fluorobenzylguanidine (MFBG) is taken up by and accumulates in both the granules of adrenal medullary chromaffin cells and the pre-synaptic granules of adrenergic neurons in a manner almost identical to that of NE. In turn, hNET-expressing tumor cells can be imaged by PET or CT. hNET, a transmembrane protein and regulator of catecholamine uptake normally restricted to the central and peripheral sympathetic nervous system, is overexpressed in certain tumor cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C120311",
			"nciConceptName": "meta-Fluorine F 18 Fluorobenzylguanidine",
			"termId": 768769,
			"name": "meta-fluorine F 18 fluorobenzylguanidine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "meta-fluorine-f-18-fluorobenzylguanidine"
		},
		{
			"aliases": [
				{
					"type": "CASRegistryName",
					"name": "565-33-3"
				}
			],
			"definition": {
				"html": "A long-acting, first-generation, cyclohexyl sulfonylurea with antihyperglycemic activity. Metahexamide has greater potency than chlorpropamide and tolbutamide. This agent may cause jaundice.",
				"text": "A long-acting, first-generation, cyclohexyl sulfonylurea with antihyperglycemic activity. Metahexamide has greater potency than chlorpropamide and tolbutamide. This agent may cause jaundice."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C91022",
			"nciConceptName": "Metahexamide",
			"termId": 775351,
			"name": "metahexamide",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "metahexamide"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "APL-1202"
				},
				{
					"type": "CodeName",
					"name": "APL1202"
				},
				{
					"type": "CodeName",
					"name": "APL 1202"
				},
				{
					"type": "Synonym",
					"name": "methionine aminopeptidase type II inhibitor APL-1202"
				}
			],
			"definition": {
				"html": "An orally available inhibitor of methionine aminopeptidase II type (MetAP2) with potential antiangiogenic and antineoplastic activities. Upon administration, APL-1202 binds to and reversibly inhibits MetAP2, thereby preventing MetAP2-mediated signal transduction pathways. This may suppress endothelial cell growth and inhibit tumor angiogenesis, resulting in tumor cell death. MetAP2, a member of the dimetallohydrolase family, is upregulated in certain tumor cell types and plays a key role in angiogenesis, proliferation and survival.",
				"text": "An orally available inhibitor of methionine aminopeptidase II type (MetAP2) with potential antiangiogenic and antineoplastic activities. Upon administration, APL-1202 binds to and reversibly inhibits MetAP2, thereby preventing MetAP2-mediated signal transduction pathways. This may suppress endothelial cell growth and inhibit tumor angiogenesis, resulting in tumor cell death. MetAP2, a member of the dimetallohydrolase family, is upregulated in certain tumor cell types and plays a key role in angiogenesis, proliferation and survival."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C162480",
			"nciConceptName": "MetAP2 Inhibitor APL-1202",
			"termId": 798664,
			"name": "MetAP2 inhibitor APL-1202",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "metap2-inhibitor-apl-1202"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "SDX-7320"
				},
				{
					"type": "Synonym",
					"name": "methionine aminopeptidase type II inhibitor SDX-7320"
				}
			],
			"definition": {
				"html": "A synthetic copolymer-drug conjugate of a fumagillin-derived methionine aminopeptidase 2 (MetAP2) inhibitor conjugated to the bio-compatible polymer poly(N-(hydroxypropyl)methacrylamide) (HPMA), with potential antineoplastic activity. Upon administration of SDX-7320, the active moiety SDX7539 is released inside the tumor cells. SDX7539 binds to and inhibits MetAP2, which prevents MetAP2-mediated signal transduction pathways and results in tumor cell death. MetAP2, a member of the dimetallohydrolase family upregulated in certain tumor cell types, plays a key role in angiogenesis, proliferation and survival. Polymer conjugation reduces systemic drug exposure and increases this agents efficacy as compared to non-polymer conjugates.",
				"text": "A synthetic copolymer-drug conjugate of a fumagillin-derived methionine aminopeptidase 2 (MetAP2) inhibitor conjugated to the bio-compatible polymer poly(N-(hydroxypropyl)methacrylamide) (HPMA), with potential antineoplastic activity. Upon administration of SDX-7320, the active moiety SDX7539 is released inside the tumor cells. SDX7539 binds to and inhibits MetAP2, which prevents MetAP2-mediated signal transduction pathways and results in tumor cell death. MetAP2, a member of the dimetallohydrolase family upregulated in certain tumor cell types, plays a key role in angiogenesis, proliferation and survival. Polymer conjugation reduces systemic drug exposure and increases this agents efficacy as compared to non-polymer conjugates."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C128030",
			"nciConceptName": "MetAP2 Inhibitor SDX-7320",
			"termId": 781275,
			"name": "MetAP2 inhibitor SDX-7320",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "metap2-inhibitor-sdx-7320"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "ML-246"
				},
				{
					"type": "CodeName",
					"name": "ML246"
				},
				{
					"type": "CodeName",
					"name": "ML 246"
				},
				{
					"type": "ChemicalStructureName",
					"name": "trans-4-(7-benzyl-4-imino-5,6-diphenylpyrrolo[2,3-d]pyrimidin-3-yl)cyclohexan-1-ol"
				}
			],
			"definition": {
				"html": "An orally available small molecule inhibitor of perinucleolar compartment (PNC), with potential antineoplastic activities. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon oral administration, metarrestin disrupts the structure of PNC and inhibits RNA polymerase (Pol) I transcription. This leads to the reduction in the prevalence of PNC in cancer cells and decrease in tumor growth and spread. PNC is a subnuclear structure and a phenotypic marker of metastatic cancer cells. A high PNC prevalence has been associated with disease progression and poor patient outcomes.\n",
				"text": "An orally available small molecule inhibitor of perinucleolar compartment (PNC), with potential antineoplastic activities. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon oral administration, metarrestin disrupts the structure of PNC and inhibits RNA polymerase (Pol) I transcription. This leads to the reduction in the prevalence of PNC in cancer cells and decrease in tumor growth and spread. PNC is a subnuclear structure and a phenotypic marker of metastatic cancer cells. A high PNC prevalence has been associated with disease progression and poor patient outcomes.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C168544",
			"nciConceptName": "Metarrestin",
			"termId": 800687,
			"name": "metarrestin",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "metarrestin"
		},
		{
			"preferredName": "incyclinide",
			"termId": 42884,
			"name": "Metastat",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "incyclinide"
		},
		{
			"preferredName": "strontium chloride Sr 89",
			"termId": 41810,
			"name": "Metastron",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "strontium-chloride-sr-89"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "BL001"
				},
				{
					"type": "Synonym",
					"name": "BCR-ABL tyrosine kinase inhibitor BL001"
				},
				{
					"type": "Synonym",
					"name": "metatinib"
				}
			],
			"definition": {
				"html": "An orally bioavailable tyrosine kinase inhibitor of the BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, metatinib tromethamine may inhibit the BCL-ABL protein, which may lead to decreased proliferation and enhanced apoptosis in tumor cells. BCR-ABL oncoprotein is generated by a reciprocal translocation between chromosome 9 and 22 specifically t(9;22)(q34;q11). The resulting fusion gene produces proteins with constitutively active tyrosine kinase activity, which stimulate both abnormal cell division and increased cellular proliferation. This fusion is associated with both chronic myeloid leukemia and acute lymphoblastic leukemia.",
				"text": "An orally bioavailable tyrosine kinase inhibitor of the BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, metatinib tromethamine may inhibit the BCL-ABL protein, which may lead to decreased proliferation and enhanced apoptosis in tumor cells. BCR-ABL oncoprotein is generated by a reciprocal translocation between chromosome 9 and 22 specifically t(9;22)(q34;q11). The resulting fusion gene produces proteins with constitutively active tyrosine kinase activity, which stimulate both abnormal cell division and increased cellular proliferation. This fusion is associated with both chronic myeloid leukemia and acute lymphoblastic leukemia."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C113294",
			"nciConceptName": "Metatinib Tromethamine",
			"termId": 755994,
			"name": "metatinib tromethamine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "metatinib-tromethamine"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "ACTOplus Met XR"
				},
				{
					"type": "Synonym",
					"name": "metformide HCl/pioglitazone HCl ER tablet"
				}
			],
			"definition": {
				"html": "An extended-release (ER) tablet composed of the hydrochloride salt form of the biguanide metformin and the hydrochloride salt form of the thiazolidinedione pioglitazone, with antihyperglycemic activity. Upon oral administration and although the exact mechanism of action has yet to be fully elucidated, metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain and increases the cellular AMP to ATP ratio leading to activation of AMP-activated protein kinase (AMPK). This modulates AMPK-mediated transcription of target genes, which prevents hepatic gluconeogenesis, decreases intestinal absorption of glucose, enhances insulin sensitivity and fatty acid oxidation, and increases glucose uptake and utilization in target tissues. Pioglitazone binds to and activates the transcription factor peroxisome proliferator-activated receptor gamma (PPAR-gamma), thereby increasing the transcription of insulin-responsive genes. This enhances insulin sensitivity of insulin-dependent tissues, decreases insulin resistance, enhances peripheral glucose utilization, and decreases hepatic glucose output. Altogether, this lowers blood glucose levels.",
				"text": "An extended-release (ER) tablet composed of the hydrochloride salt form of the biguanide metformin and the hydrochloride salt form of the thiazolidinedione pioglitazone, with antihyperglycemic activity. Upon oral administration and although the exact mechanism of action has yet to be fully elucidated, metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain and increases the cellular AMP to ATP ratio leading to activation of AMP-activated protein kinase (AMPK). This modulates AMPK-mediated transcription of target genes, which prevents hepatic gluconeogenesis, decreases intestinal absorption of glucose, enhances insulin sensitivity and fatty acid oxidation, and increases glucose uptake and utilization in target tissues. Pioglitazone binds to and activates the transcription factor peroxisome proliferator-activated receptor gamma (PPAR-gamma), thereby increasing the transcription of insulin-responsive genes. This enhances insulin sensitivity of insulin-dependent tissues, decreases insulin resistance, enhances peripheral glucose utilization, and decreases hepatic glucose output. Altogether, this lowers blood glucose levels."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C129316",
			"nciConceptName": "Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet",
			"termId": 784561,
			"name": "metformide hydrochloride/pioglitazone hydrochloride extended-release tablet",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "metformide-hydrochloride-pioglitazone-hydrochloride-extended-release-tablet"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Glucophage"
				},
				{
					"type": "ForeignBrandName",
					"name": "Glifage"
				},
				{
					"type": "ForeignBrandName",
					"name": "Dimefor"
				},
				{
					"type": "ForeignBrandName",
					"name": "Glucoformin"
				},
				{
					"type": "ChemicalStructureName",
					"name": "N,N-dimethylimidodicarbonimidic diamide monohydrochloride"
				},
				{
					"type": "ChemicalStructureName",
					"name": "1,1-dimethylbiguanide hydrochloride"
				},
				{
					"type": "Synonym",
					"name": "Metformin HCl"
				},
				{
					"type": "CASRegistryName",
					"name": "657-24-9"
				},
				{
					"type": "USBrandName",
					"name": "Glumetza"
				},
				{
					"type": "USBrandName",
					"name": "Fortamet"
				},
				{
					"type": "ForeignBrandName",
					"name": "Siofor"
				},
				{
					"type": "USBrandName",
					"name": "Riomet"
				},
				{
					"type": "USBrandName",
					"name": "Glucophage XR"
				},
				{
					"type": "ForeignBrandName",
					"name": "Cidophage"
				}
			],
			"definition": {
				"html": "The hydrochloride salt of the biguanide metformin with antihyperglycemic and potential antineoplastic activities. Metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain, thereby increasing the cellular AMP to ATP ratio and leading to activation of AMP-activated protein kinase (AMPK) and regulating AMPK-mediated transcription of target genes. This eventually prevents hepatic gluconeogenesis, enhances insulin sensitivity and fatty acid oxidation and ultimately leads to a decrease in glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation.",
				"text": "The hydrochloride salt of the biguanide metformin with antihyperglycemic and potential antineoplastic activities. Metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain, thereby increasing the cellular AMP to ATP ratio and leading to activation of AMP-activated protein kinase (AMPK) and regulating AMPK-mediated transcription of target genes. This eventually prevents hepatic gluconeogenesis, enhances insulin sensitivity and fatty acid oxidation and ultimately leads to a decrease in glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C29251",
			"nciConceptName": "Metformin Hydrochloride",
			"termId": 593641,
			"name": "metformin hydrochloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "metformin-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Adanon"
				},
				{
					"type": "USBrandName",
					"name": "Althose"
				},
				{
					"type": "USBrandName",
					"name": "Dolophine"
				},
				{
					"type": "USBrandName",
					"name": "Methadose"
				}
			],
			"definition": {
				"html": "The hydrochloride salt of methadone, a synthetic opioid with analgesic activity. Similar to morphine and other morphine-like agents, methadone mimics the actions of endogenous peptides at CNS opioid receptors, primarily the mu-receptor, resulting in characteristic morphine-like effects including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence. Because of the prolonged half-life of merthadone compared to other morphine-like agents such as heroin, the onset of opiate withdrawal symptoms is slower, the duration of opiate withdrawal is prolonged, and opiate wihdrawal symptoms are less severe.",
				"text": "The hydrochloride salt of methadone, a synthetic opioid with analgesic activity. Similar to morphine and other morphine-like agents, methadone mimics the actions of endogenous peptides at CNS opioid receptors, primarily the mu-receptor, resulting in characteristic morphine-like effects including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence. Because of the prolonged half-life of merthadone compared to other morphine-like agents such as heroin, the onset of opiate withdrawal symptoms is slower, the duration of opiate withdrawal is prolonged, and opiate wihdrawal symptoms are less severe."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C638",
			"nciConceptName": "Methadone Hydrochloride",
			"termId": 39498,
			"name": "methadone hydrochloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methadone-hydrochloride"
		},
		{
			"preferredName": "methadone hydrochloride",
			"termId": 39498,
			"name": "Methadose",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "methadone-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "Acronym",
					"name": "MER"
				},
				{
					"type": "Acronym",
					"name": "MER-BCG"
				},
				{
					"type": "Synonym",
					"name": "MER of BCG"
				},
				{
					"type": "Synonym",
					"name": "methanol extraction residue of bacillus Calmette-Guerin"
				},
				{
					"type": "INDCode",
					"name": "642"
				},
				{
					"type": "NSCNumber",
					"name": "143769"
				}
			],
			"definition": {
				"html": "A cell wall fraction of bacillus Calmette-Guerin (BCG) obtained by menthol extraction with immunomodulating properties and potential use in cancer immunotherapy.",
				"text": "A cell wall fraction of bacillus Calmette-Guerin (BCG) obtained by menthol extraction with immunomodulating properties and potential use in cancer immunotherapy."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1159",
			"nciConceptName": "Methanol Extraction Residue of BCG",
			"termId": 39495,
			"name": "methanol extraction residue of BCG",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methanol-extraction-residue-of-bcg"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Neptazane"
				}
			],
			"definition": {
				"html": "A sulfonamide derivate and carbonic anhydrase inhibitor with potential antineoplastic activity. Methazolamide inhibits tumor-associated carbonic anhydrase IX (CAIX), which may result in increased cell death in hypoxic tumors. As a hypoxia-inducible transmembrane glycoprotein, CAIX catalyzes the rapid interconversion of carbon dioxide and water into carbonic acid, protons, and bicarbonate ions, helping to maintain acidification of the tumor microenvironment and enhance  resistance to cytotoxic therapy in some hypoxic tumors. \n",
				"text": "A sulfonamide derivate and carbonic anhydrase inhibitor with potential antineoplastic activity. Methazolamide inhibits tumor-associated carbonic anhydrase IX (CAIX), which may result in increased cell death in hypoxic tumors. As a hypoxia-inducible transmembrane glycoprotein, CAIX catalyzes the rapid interconversion of carbon dioxide and water into carbonic acid, protons, and bicarbonate ions, helping to maintain acidification of the tumor microenvironment and enhance  resistance to cytotoxic therapy in some hypoxic tumors. \n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C61318",
			"nciConceptName": "Methazolamide",
			"termId": 484587,
			"name": "methazolamide",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methazolamide"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MetAP2 inhibitor M8891"
				},
				{
					"type": "CodeName",
					"name": "M8891"
				}
			],
			"definition": {
				"html": "A proprietary orally available inhibitor of methionine aminopeptidase 2 (MetAP2), which cleaves the amino-terminal methionine residue from nascent proteins, with potential antiangiogenic and antineoplastic activities. Upon administration, MetAP2 inhibitor M8891 inhibits MetAP2 aminopeptidase activity and impairs protein synthesis, which may lead to a decrease in endothelial cell proliferation. Decreased proliferation of endothelial cells results in reductions of both angiogenesis and the growth and spread of solid tumors that are dependent on new blood vessel formation. MetAP2, a metallopeptidase, is involved in promoting protein synthesis and endothelial cell proliferation.",
				"text": "A proprietary orally available inhibitor of methionine aminopeptidase 2 (MetAP2), which cleaves the amino-terminal methionine residue from nascent proteins, with potential antiangiogenic and antineoplastic activities. Upon administration, MetAP2 inhibitor M8891 inhibits MetAP2 aminopeptidase activity and impairs protein synthesis, which may lead to a decrease in endothelial cell proliferation. Decreased proliferation of endothelial cells results in reductions of both angiogenesis and the growth and spread of solid tumors that are dependent on new blood vessel formation. MetAP2, a metallopeptidase, is involved in promoting protein synthesis and endothelial cell proliferation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C142831",
			"nciConceptName": "Methionine Aminopeptidase 2 Inhibitor M8891",
			"termId": 791701,
			"name": "methionine aminopeptidase 2 inhibitor M8891",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methionine-aminopeptidase-2-inhibitor-m8891"
		},
		{
			"aliases": [
				{
					"type": "LexicalVariant",
					"name": "methionine C11"
				},
				{
					"type": "Synonym",
					"name": "11C-methionine"
				},
				{
					"type": "Abbreviation",
					"name": "11C-MET"
				}
			],
			"definition": {
				"html": "A synthetic amino acid radiolabeled with carbon-11. Acting as a methyl donor, methionine C 11 is incorporated into macromolecules, where it serves as a positron emission tomography (PET) imaging agent for detecting tumors with high rates of protein synthesis.",
				"text": "A synthetic amino acid radiolabeled with carbon-11. Acting as a methyl donor, methionine C 11 is incorporated into macromolecules, where it serves as a positron emission tomography (PET) imaging agent for detecting tumors with high rates of protein synthesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1534",
			"nciConceptName": "Methionine C 11",
			"termId": 42650,
			"name": "methionine C 11",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methionine-c-11"
		},
		{
			"preferredName": "calusterone",
			"termId": 41710,
			"name": "Methosarb",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "calusterone"
		},
		{
			"aliases": [
				{
					"type": "ObsoleteName",
					"name": "Folex"
				},
				{
					"type": "Abbreviation",
					"name": "MTX"
				},
				{
					"type": "ObsoleteName",
					"name": "Mexate"
				},
				{
					"type": "Synonym",
					"name": "amethopterin"
				},
				{
					"type": "Synonym",
					"name": "methylaminopterin"
				},
				{
					"type": "ChemicalStructureName",
					"name": "4-amino-10-methylfolic acid"
				},
				{
					"type": "ChemicalStructureName",
					"name": "4-amino-4-deoxy-10-methylpteroyl-L-glutamic acid"
				},
				{
					"type": "ObsoleteName",
					"name": "Abitrexate"
				},
				{
					"type": "Synonym",
					"name": "alpha-methopterin"
				},
				{
					"type": "ForeignBrandName",
					"name": "Brimexate"
				},
				{
					"type": "CodeName",
					"name": "CL-14377"
				},
				{
					"type": "ForeignBrandName",
					"name": "Emtexate"
				},
				{
					"type": "ForeignBrandName",
					"name": "Emthexat"
				},
				{
					"type": "ForeignBrandName",
					"name": "Emthexate"
				},
				{
					"type": "ForeignBrandName",
					"name": "Farmitrexat"
				},
				{
					"type": "ForeignBrandName",
					"name": "Fauldexato"
				},
				{
					"type": "ObsoleteName",
					"name": "Folex PFS"
				},
				{
					"type": "ForeignBrandName",
					"name": "Lantarel"
				},
				{
					"type": "ForeignBrandName",
					"name": "Ledertrexate"
				},
				{
					"type": "ForeignBrandName",
					"name": "Lumexon"
				},
				{
					"type": "ForeignBrandName",
					"name": "Maxtrex"
				},
				{
					"type": "ForeignBrandName",
					"name": "Medsatrexate"
				},
				{
					"type": "ForeignBrandName",
					"name": "Metex"
				},
				{
					"type": "ForeignBrandName",
					"name": "Methoblastin"
				},
				{
					"type": "ObsoleteName",
					"name": "Methotrexate LPF"
				},
				{
					"type": "Synonym",
					"name": "methotrexate methylaminopterin"
				},
				{
					"type": "Synonym",
					"name": "Methotrexatum"
				},
				{
					"type": "Synonym",
					"name": "Metotrexato"
				},
				{
					"type": "ForeignBrandName",
					"name": "Metrotex"
				},
				{
					"type": "ObsoleteName",
					"name": "Mexate-AQ"
				},
				{
					"type": "ChemicalStructureName",
					"name": "N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid"
				},
				{
					"type": "ForeignBrandName",
					"name": "Novatrex"
				},
				{
					"type": "USBrandName",
					"name": "Rheumatrex"
				},
				{
					"type": "ForeignBrandName",
					"name": "Texate"
				},
				{
					"type": "ForeignBrandName",
					"name": "Tremetex"
				},
				{
					"type": "USBrandName",
					"name": "Trexall"
				},
				{
					"type": "ForeignBrandName",
					"name": "Trexeron"
				},
				{
					"type": "ForeignBrandName",
					"name": "Trixilem"
				},
				{
					"type": "CodeName",
					"name": "WR-19039"
				},
				{
					"type": "INDCode",
					"name": "7723"
				},
				{
					"type": "INDCode",
					"name": "4291"
				},
				{
					"type": "NSCNumber",
					"name": "740"
				},
				{
					"type": "CASRegistryName",
					"name": "59-05-2"
				}
			],
			"definition": {
				"html": "An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities.  Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.",
				"text": "An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities.  Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear."
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/methotrexate",
				"text": "Methotrexate"
			},
			"nciConceptId": "C642",
			"nciConceptName": "Methotrexate",
			"termId": 41719,
			"name": "methotrexate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methotrexate"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MTX-e TI"
				},
				{
					"type": "Synonym",
					"name": "MTX/epi gel"
				},
				{
					"type": "Synonym",
					"name": "methotrexate-epinephrine therapeutic implant"
				},
				{
					"type": "Synonym",
					"name": "methotrexate/epi"
				}
			],
			"definition": {
				"html": "An injectable collagen matrix gel containing the antimetabolite methotrexate and the sympathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of methotrexate into the tumor tissue and reduce dispersion to the surrounding tissues thereby enhancing the local concentration of methotrexate and increasing its anti-tumor activity. Intratumoral injection of methotrexate combined with epinephrine may potentially increase chemotherapeutic efficacy compared to systemic administration and reduce systemic toxicity and side effects.",
				"text": "An injectable collagen matrix gel containing the antimetabolite methotrexate and the sympathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of methotrexate into the tumor tissue and reduce dispersion to the surrounding tissues thereby enhancing the local concentration of methotrexate and increasing its anti-tumor activity. Intratumoral injection of methotrexate combined with epinephrine may potentially increase chemotherapeutic efficacy compared to systemic administration and reduce systemic toxicity and side effects."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C17876",
			"nciConceptName": "Methotrexate-E Therapeutic Implant",
			"termId": 41858,
			"name": "methotrexate-e therapeutic implant",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methotrexate-e-therapeutic-implant"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MTX-ATMP"
				}
			],
			"definition": {
				"html": "A suspension of autologous tumor-derived microparticles (ATMP), that are harvested from a patient with malignant pleural effusion, encapsulating the antimetabolic drug methotrexate (MTX), with potential anticancer activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration of MTX-ATMP, the MTX moiety is released and internalized by tumor cells. It then binds to and inhibits the enzyme dihydrofolate reductase. This results in the inhibition of purine nucleotide synthesis and leads to decreased synthesis of both DNA and RNA, which induces cell death. Presumably, the encapsulation of MTX by the ATMP improves its bioavailability and decreases its toxicity.",
				"text": "A suspension of autologous tumor-derived microparticles (ATMP), that are harvested from a patient with malignant pleural effusion, encapsulating the antimetabolic drug methotrexate (MTX), with potential anticancer activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration of MTX-ATMP, the MTX moiety is released and internalized by tumor cells. It then binds to and inhibits the enzyme dihydrofolate reductase. This results in the inhibition of purine nucleotide synthesis and leads to decreased synthesis of both DNA and RNA, which induces cell death. Presumably, the encapsulation of MTX by the ATMP improves its bioavailability and decreases its toxicity."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C125656",
			"nciConceptName": "Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles",
			"termId": 778520,
			"name": "methotrexate-encapsulating autologous tumor-derived microparticles",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methotrexate-encapsulating-autologous-tumor-derived-microparticles"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "8-MOP"
				},
				{
					"type": "Synonym",
					"name": "8-methoxypsoralen"
				},
				{
					"type": "USBrandName",
					"name": "Oxsoralen"
				},
				{
					"type": "ChemicalStructureName",
					"name": "9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one"
				},
				{
					"type": "USBrandName",
					"name": "Ammoidin"
				},
				{
					"type": "ForeignBrandName",
					"name": "Deltasoralen"
				},
				{
					"type": "ForeignBrandName",
					"name": "Dermox"
				},
				{
					"type": "ForeignBrandName",
					"name": "Geralen"
				},
				{
					"type": "ForeignBrandName",
					"name": "Geroxalen"
				},
				{
					"type": "ForeignBrandName",
					"name": "Meladinina"
				},
				{
					"type": "ForeignBrandName",
					"name": "Meladinine"
				},
				{
					"type": "Synonym",
					"name": "Methoxypsoralen"
				},
				{
					"type": "ForeignBrandName",
					"name": "Metoxaleno"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mopsoralen"
				},
				{
					"type": "USBrandName",
					"name": "Oxsoralen-Ultra"
				},
				{
					"type": "ForeignBrandName",
					"name": "Puvasoralen"
				},
				{
					"type": "ForeignBrandName",
					"name": "Ultramop"
				},
				{
					"type": "USBrandName",
					"name": "Uvadex"
				},
				{
					"type": "USBrandName",
					"name": "Xanthotoxin"
				},
				{
					"type": "NSCNumber",
					"name": "45923"
				},
				{
					"type": "CASRegistryName",
					"name": "298-81-7"
				}
			],
			"definition": {
				"html": "A naturally occurring substance isolated from the seeds of the plant Ammi majus with photoactivating properties.  As a member of the family of compounds known as psoralens or furocoumarins, methoxsalen's exact mechanism of action is unknown; upon photoactivation, methoxsalen has been observed to bind covalently to and crosslink DNA.",
				"text": "A naturally occurring substance isolated from the seeds of the plant Ammi majus with photoactivating properties.  As a member of the family of compounds known as psoralens or furocoumarins, methoxsalen's exact mechanism of action is unknown; upon photoactivation, methoxsalen has been observed to bind covalently to and crosslink DNA."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C643",
			"nciConceptName": "Methoxsalen",
			"termId": 39499,
			"name": "methoxsalen",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methoxsalen"
		},
		{
			"aliases": [
				{
					"type": "LexicalVariant",
					"name": "Methoxypolyethylene Glycol Epoetin Beta"
				},
				{
					"type": "CodeName",
					"name": "Ro 50-3821"
				},
				{
					"type": "USBrandName",
					"name": "Mircera"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mircera"
				}
			],
			"definition": {
				"html": "A pegylated form of recombinant human erythropoietin, a glycosylated protein naturally produced in the kidney that stimulates erythrocyte production in the bone marrow. Methoxypolyethylene glycol epoetin beta may reverse anemias induced by cancer therapy.",
				"text": "A pegylated form of recombinant human erythropoietin, a glycosylated protein naturally produced in the kidney that stimulates erythrocyte production in the bone marrow. Methoxypolyethylene glycol epoetin beta may reverse anemias induced by cancer therapy."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C38687",
			"nciConceptName": "Methoxy Polyethylene Glycol-Epoetin beta",
			"termId": 339378,
			"name": "methoxy polyethylene glycol epoetin beta",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methoxy-polyethylene-glycol-epoetin-beta"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "TRC102"
				}
			],
			"definition": {
				"html": "An orally bioavailable small molecule inhibitor with potential adjuvant activity. Methoxyamine covalently binds to apurinic/apyrimidinic (AP) DNA damage sites and inhibits base excision repair (BER), which may result in an increase in DNA strand breaks and apoptosis. This agent may potentiate the anti-tumor activity of alkylating agents.",
				"text": "An orally bioavailable small molecule inhibitor with potential adjuvant activity. Methoxyamine covalently binds to apurinic/apyrimidinic (AP) DNA damage sites and inhibits base excision repair (BER), which may result in an increase in DNA strand breaks and apoptosis. This agent may potentiate the anti-tumor activity of alkylating agents."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C78084",
			"nciConceptName": "Methoxyamine",
			"termId": 599836,
			"name": "methoxyamine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methoxyamine"
		},
		{
			"aliases": [
				{
					"type": "ForeignBrandName",
					"name": "Penthrox"
				},
				{
					"type": "ChemicalStructureName",
					"name": "2,2-dichloro-1,1-difluoro-1-methoxyethane"
				},
				{
					"type": "Synonym",
					"name": "analgizer"
				},
				{
					"type": "Synonym",
					"name": "methoflurane"
				},
				{
					"type": "NSCNumber",
					"name": "110432"
				},
				{
					"type": "CASRegistryName",
					"name": "76-38-0"
				}
			],
			"definition": {
				"html": "A fluorinated isopropyl ether with anesthetic and muscle relaxant activities. Although the mechanism of action has not been fully elucidated, upon inhalation, methoxyflurane acts through multiple mechanisms of action. This agent interferes with the release and re-uptake of neurotransmitters at post-synaptic terminals, and/or alters ionic conductance following receptor activation by a neurotransmitter, thereby disrupting neuronal transmission. In addition, this agent activates the inhibitory receptor gamma-aminobutyric acid (GABA). Altogether, this results in a general anesthetic effect and induces analgesia.",
				"text": "A fluorinated isopropyl ether with anesthetic and muscle relaxant activities. Although the mechanism of action has not been fully elucidated, upon inhalation, methoxyflurane acts through multiple mechanisms of action. This agent interferes with the release and re-uptake of neurotransmitters at post-synaptic terminals, and/or alters ionic conductance following receptor activation by a neurotransmitter, thereby disrupting neuronal transmission. In addition, this agent activates the inhibitory receptor gamma-aminobutyric acid (GABA). Altogether, this results in a general anesthetic effect and induces analgesia."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C75098",
			"nciConceptName": "Methoxyflurane",
			"termId": 777390,
			"name": "methoxyflurane",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methoxyflurane"
		},
		{
			"aliases": [
				{
					"type": "ForeignBrandName",
					"name": "Metvix cream"
				},
				{
					"type": "ForeignBrandName",
					"name": "Metvixia cream"
				},
				{
					"type": "USBrandName",
					"name": "Metvixia cream"
				},
				{
					"type": "Abbreviation",
					"name": "MAL cream"
				}
			],
			"definition": {
				"html": "A topical cream formulation containing the hydrochloride salt of methyl-5-aminolevulinate, a lipophilic methyl ester of 5-aminolevulinic acid, with photosensitizer prodrug activity. Upon topical administration, methyl-5-aminolevulinate in the cream is selectively absorbed by tumor cells where it  is converted to the photosensitizer protoporphyrin IX (PpIX). Upon photoirradiation, PpIX is activated and transfers energy to oxygen, generating singlet oxygen and  superoxide and hydroxyl radicals, which may result in free-radical-mediated DNA damage and cell death.",
				"text": "A topical cream formulation containing the hydrochloride salt of methyl-5-aminolevulinate, a lipophilic methyl ester of 5-aminolevulinic acid, with photosensitizer prodrug activity. Upon topical administration, methyl-5-aminolevulinate in the cream is selectively absorbed by tumor cells where it  is converted to the photosensitizer protoporphyrin IX (PpIX). Upon photoirradiation, PpIX is activated and transfers energy to oxygen, generating singlet oxygen and  superoxide and hydroxyl radicals, which may result in free-radical-mediated DNA damage and cell death."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2647",
			"nciConceptName": "Methyl-5-Aminolevulinate Hydrochloride Cream",
			"termId": 38410,
			"name": "methyl-5-aminolevulinate hydrochloride cream",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methyl-5-aminolevulinate-hydrochloride-cream"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "N-methylcantharidimide"
				},
				{
					"type": "Abbreviation",
					"name": "NMC"
				}
			],
			"definition": {
				"html": "An orally bioavailable derivative of the terpenoid cantharidin, which is a natural toxin extracted from blister beetles, with potential antineoplastic activity. Although the exact mechanism of action through which methylcantharidimide exerts its effect has yet to be fully elucidated, this agent, upon oral administration, may exert a direct tumor cell killing effect in susceptible tumor cells.\n",
				"text": "An orally bioavailable derivative of the terpenoid cantharidin, which is a natural toxin extracted from blister beetles, with potential antineoplastic activity. Although the exact mechanism of action through which methylcantharidimide exerts its effect has yet to be fully elucidated, this agent, upon oral administration, may exert a direct tumor cell killing effect in susceptible tumor cells.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C173446",
			"nciConceptName": "Methylcantharidimide",
			"termId": 801753,
			"name": "methylcantharidimide",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methylcantharidimide"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MB"
				},
				{
					"type": "Acronym",
					"name": "MB"
				},
				{
					"type": "ForeignBrandName",
					"name": "Azul Metile"
				},
				{
					"type": "Synonym",
					"name": "Azul de Metileno"
				},
				{
					"type": "Synonym",
					"name": "Blu di Metilene"
				},
				{
					"type": "Synonym",
					"name": "CI Basic Blue 9"
				},
				{
					"type": "CodeName",
					"name": "CI-52015"
				},
				{
					"type": "ForeignBrandName",
					"name": "Collubleu"
				},
				{
					"type": "Synonym",
					"name": "Colour Index No. 52015"
				},
				{
					"type": "ForeignBrandName",
					"name": "Desmoidpillen"
				},
				{
					"type": "Synonym",
					"name": "Methylenum Caeruleum"
				},
				{
					"type": "Synonym",
					"name": "Methylthioninii Chloridum"
				},
				{
					"type": "Synonym",
					"name": "Methylthioninium Chloride"
				},
				{
					"type": "Synonym",
					"name": "Schultz No. 1038"
				},
				{
					"type": "Synonym",
					"name": "Tetramethylthionine Chloride Trihydrate"
				},
				{
					"type": "USBrandName",
					"name": "Urolene Blue"
				},
				{
					"type": "ForeignBrandName",
					"name": "Vitableu"
				},
				{
					"type": "NSCNumber",
					"name": "617593"
				},
				{
					"type": "CASRegistryName",
					"name": "61-73-4"
				}
			],
			"definition": {
				"html": "A synthetic basic dye. Methylene blue stains to negatively charged cell components like nucleic acids; when administered in the lymphatic bed of a tumor during oncologic surgery, methylene blue may stain lymph nodes draining from the tumor, thereby aiding in the visual localization of tumor sentinel lymph nodes. When administered intravenously in low doses, this agent may convert methemoglobin to hemoglobin.",
				"text": "A synthetic basic dye. Methylene blue stains to negatively charged cell components like nucleic acids; when administered in the lymphatic bed of a tumor during oncologic surgery, methylene blue may stain lymph nodes draining from the tumor, thereby aiding in the visual localization of tumor sentinel lymph nodes. When administered intravenously in low doses, this agent may convert methemoglobin to hemoglobin."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C644",
			"nciConceptName": "Methylene Blue",
			"termId": 41780,
			"name": "methylene blue",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methylene-blue"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MDMS"
				}
			],
			"definition": {
				"html": "A member of the homologous series of dimethane sulphonic acid esters with alkylating properties. Methylene dimethane sulfonate alkylates DNA, resulting in interstrand DNA crosslinking, inhibition of DNA replication, disruption of the cell cycle, and cell death. ",
				"text": "A member of the homologous series of dimethane sulphonic acid esters with alkylating properties. Methylene dimethane sulfonate alkylates DNA, resulting in interstrand DNA crosslinking, inhibition of DNA replication, disruption of the cell cycle, and cell death. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1162",
			"nciConceptName": "Methylene Dimethane Sulfonate",
			"termId": 40293,
			"name": "methylene dimethane sulfonate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methylene-dimethane-sulfonate"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MMPR"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6-(methylmercapto)purine ribonucleoside"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6-(methylthio) inosine"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6-(methylthio)purine ribonucleoside"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6-(methylthio)purine riboside"
				},
				{
					"type": "Abbreviation",
					"name": "6-MMPR"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6-methyl MP riboside"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6-methylmercaptopurine riboside"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6-methylthioinosine"
				},
				{
					"type": "ChemicalStructureName",
					"name": "9H-purine, 6-(methylthio)-9-beta-D-ribofuranosyl- (8CI 9CI)"
				},
				{
					"type": "ChemicalStructureName",
					"name": "9H-purine, 6-(methylthio)-9-beta-D-ribofuranosyl-, dihydrate"
				},
				{
					"type": "ChemicalStructureName",
					"name": "9H-purine, 6-(methylthio)-9beta-D-ribofuranosyl"
				},
				{
					"type": "CodeName",
					"name": "NCI-C04784"
				},
				{
					"type": "CodeName",
					"name": "SQ 21977"
				},
				{
					"type": "ChemicalStructureName",
					"name": "beta-D-ribosyl-6-methylthiopurine"
				},
				{
					"type": "Synonym",
					"name": "methylthioinosine"
				},
				{
					"type": "ChemicalStructureName",
					"name": "purine-6-thiol,6-methyl-9-ribofuranosyl"
				},
				{
					"type": "INDCode",
					"name": "19524"
				},
				{
					"type": "INDCode",
					"name": "924"
				},
				{
					"type": "INDCode",
					"name": "2818"
				},
				{
					"type": "NSCNumber",
					"name": "40774"
				},
				{
					"type": "CASRegistryName",
					"name": "342-69-8"
				}
			],
			"definition": {
				"html": "A purine derivative with antineoplastic and anti-angiogenic properties.  6-methylmercaptopurine riboside (6-MMPR) inhibits amidophosphoribosyltransferase, the first committed step in de novo purine synthesis, and inhibits fibroblast growth factor-2 (FGF2)-induced cell proliferation.",
				"text": "A purine derivative with antineoplastic and anti-angiogenic properties.  6-methylmercaptopurine riboside (6-MMPR) inhibits amidophosphoribosyltransferase, the first committed step in de novo purine synthesis, and inhibits fibroblast growth factor-2 (FGF2)-induced cell proliferation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2352",
			"nciConceptName": "Methylmercaptopurine Riboside",
			"termId": 39497,
			"name": "methylmercaptopurine riboside",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methylmercaptopurine-riboside"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MNTX"
				},
				{
					"type": "Synonym",
					"name": "N-methylnaltrexone bromide"
				},
				{
					"type": "ChemicalStructureName",
					"name": "17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium"
				}
			],
			"definition": {
				"html": "A methyl derivative of noroxymorphone with selective, opioid-receptor antagonistic activity. Methylnaltrexone displaces opioids from peripheral opioid receptors in the gastrointestinal tract, the bladder, and the skin, resulting in decreases in opioid-related constipation, urinary retention, and pruritis, respectively. Methylnaltrexone does not cross the blood-brain barrier and does not affect the centrally-mediated analgesic effect of opioids.",
				"text": "A methyl derivative of noroxymorphone with selective, opioid-receptor antagonistic activity. Methylnaltrexone displaces opioids from peripheral opioid receptors in the gastrointestinal tract, the bladder, and the skin, resulting in decreases in opioid-related constipation, urinary retention, and pruritis, respectively. Methylnaltrexone does not cross the blood-brain barrier and does not affect the centrally-mediated analgesic effect of opioids."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C48403",
			"nciConceptName": "Methylnaltrexone",
			"termId": 437863,
			"name": "methylnaltrexone",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methylnaltrexone"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Relistor"
				},
				{
					"type": "CASRegistryName",
					"name": "73232-52-7"
				}
			],
			"definition": {
				"html": "The bromide salt form of methylnaltrexone, a methyl derivative of noroxymorphone with selective, peripherally-acting mu-opioid receptor antagonistic activity. Methylnaltrexone displaces opioids from peripheral opioid receptors in the gastrointestinal tract, the bladder, and the skin, thereby reversing the opioid-related peripheral side-effects, such as constipation, urinary retention, and pruritis, respectively. Unlike naltrexone and due to the presence of a positively charged nitrogen atom in methylnaltrexone, this agent does not cross the blood-brain barrier and does not affect the centrally-mediated analgesic effect of opioids.",
				"text": "The bromide salt form of methylnaltrexone, a methyl derivative of noroxymorphone with selective, peripherally-acting mu-opioid receptor antagonistic activity. Methylnaltrexone displaces opioids from peripheral opioid receptors in the gastrointestinal tract, the bladder, and the skin, thereby reversing the opioid-related peripheral side-effects, such as constipation, urinary retention, and pruritis, respectively. Unlike naltrexone and due to the presence of a positively charged nitrogen atom in methylnaltrexone, this agent does not cross the blood-brain barrier and does not affect the centrally-mediated analgesic effect of opioids."
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/methylnaltrexonebromide",
				"text": "Methylnaltrexone Bromide"
			},
			"nciConceptId": "C80569",
			"nciConceptName": "Methylnaltrexone Bromide",
			"termId": 786490,
			"name": "methylnaltrexone bromide",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methylnaltrexone-bromide"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Ritalin"
				},
				{
					"type": "USBrandName",
					"name": "Quillivant XR"
				},
				{
					"type": "Synonym",
					"name": "d-methylphenidate"
				},
				{
					"type": "USBrandName",
					"name": "Concerta"
				},
				{
					"type": "ChemicalStructureName",
					"name": "alpha-phenyl-2-piperidineacetic acid methyl ester hydrochloride"
				},
				{
					"type": "CASRegistryName",
					"name": "298-59-9"
				},
				{
					"type": "NSCNumber",
					"name": "169868"
				}
			],
			"definition": {
				"html": "The hydrochloride salt of the  synthetic central nervous system stimulant methylphenidate. Methylphenidate appears to activate the brain stem arousal system and cortex to produce its stimulant effect and, in some clinical settings, may improve cognitive function.",
				"text": "The hydrochloride salt of the  synthetic central nervous system stimulant methylphenidate. Methylphenidate appears to activate the brain stem arousal system and cortex to produce its stimulant effect and, in some clinical settings, may improve cognitive function."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C646",
			"nciConceptName": "Methylphenidate Hydrochloride",
			"termId": 41225,
			"name": "methylphenidate hydrochloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methylphenidate-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 21-acetate"
				},
				{
					"type": "ForeignBrandName",
					"name": "D-Med"
				},
				{
					"type": "Synonym",
					"name": "D-Med"
				},
				{
					"type": "ForeignBrandName",
					"name": "Depo-Medrate"
				},
				{
					"type": "USBrandName",
					"name": "Depo-Medrol"
				},
				{
					"type": "ForeignBrandName",
					"name": "Depo-Medrone"
				},
				{
					"type": "Synonym",
					"name": "Depo-Medrone"
				},
				{
					"type": "NSCNumber",
					"name": "48985"
				},
				{
					"type": "CASRegistryName",
					"name": "53-36-1"
				}
			],
			"definition": {
				"html": "The acetate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and antiinflammatory effects. Methylprednisolone acetate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.",
				"text": "The acetate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and antiinflammatory effects. Methylprednisolone acetate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C48003",
			"nciConceptName": "Methylprednisolone Acetate",
			"termId": 41528,
			"name": "methylprednisolone acetate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methylprednisolone-acetate"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "3-(methylseleno)-l-alanine"
				},
				{
					"type": "Synonym",
					"name": "l-se-methylselenocysteine"
				},
				{
					"type": "Abbreviation",
					"name": "MSC"
				},
				{
					"type": "LexicalVariant",
					"name": "Se-Methyl-seleno-L-cysteine"
				},
				{
					"type": "Synonym",
					"name": "selenium-methylselenocystine"
				},
				{
					"type": "Abbreviation",
					"name": "SeMSC"
				},
				{
					"type": "CASRegistryName",
					"name": "26046-90-2"
				}
			],
			"definition": {
				"html": "A naturally occurring organoselenium compound found in many plants, including garlic, onions, and broccoli, with potential antioxidant and chemopreventive activities. Se-Methyl-seleno-L-cysteine (MSC) is an amino acid analogue of cysteine in which a methylselenium moiety replaces the sulphur atom of cysteine. This agent acts as an antioxidant when incorporated into glutathione peroxidase and has been shown to exhibit potent chemopreventive activity in animal models.\n",
				"text": "A naturally occurring organoselenium compound found in many plants, including garlic, onions, and broccoli, with potential antioxidant and chemopreventive activities. Se-Methyl-seleno-L-cysteine (MSC) is an amino acid analogue of cysteine in which a methylselenium moiety replaces the sulphur atom of cysteine. This agent acts as an antioxidant when incorporated into glutathione peroxidase and has been shown to exhibit potent chemopreventive activity in animal models.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C63678",
			"nciConceptName": "Methylselenocysteine",
			"termId": 554706,
			"name": "methylselenocysteine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "methylselenocysteine"
		},
		{
			"preferredName": "prednisolone",
			"termId": 43296,
			"name": "Meti-derm",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "prednisolone"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Reglan"
				},
				{
					"type": "CASRegistryName",
					"name": "7232-21-5"
				},
				{
					"type": "NSCNumber",
					"name": "354467"
				}
			],
			"definition": {
				"html": "The hydrochloride salt of the substituted benzamide metoclopramide, a  para-aminobenzoic acid (PABA) derivative that is structurally related to procainamide, with gastroprokinetic and antiemetic activities. Metoclopramide binds to dopamine 2 (D2) receptors in the peripheral nervous system (PNS), antagonizing dopamine-mediated relaxation of gastrointestinal smooth muscle and promoting gastroprokinesis;  the pyloric sphincter and the duodenal bulb are relaxed, peristalsis of the duodenum and jejunum increase, and  gastric emptying and intestinal transit accelerate. This agent may also increase the resting tone of the lower esophagus sphincter (LES), preventing acid reflux. In the central nervous system (CNS), metoclopramide antagonizes D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) of the medulla, thereby preventing nausea and vomiting.",
				"text": "The hydrochloride salt of the substituted benzamide metoclopramide, a  para-aminobenzoic acid (PABA) derivative that is structurally related to procainamide, with gastroprokinetic and antiemetic activities. Metoclopramide binds to dopamine 2 (D2) receptors in the peripheral nervous system (PNS), antagonizing dopamine-mediated relaxation of gastrointestinal smooth muscle and promoting gastroprokinesis;  the pyloric sphincter and the duodenal bulb are relaxed, peristalsis of the duodenum and jejunum increase, and  gastric emptying and intestinal transit accelerate. This agent may also increase the resting tone of the lower esophagus sphincter (LES), preventing acid reflux. In the central nervous system (CNS), metoclopramide antagonizes D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) of the medulla, thereby preventing nausea and vomiting."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C649",
			"nciConceptName": "Metoclopramide Hydrochloride",
			"termId": 39502,
			"name": "metoclopramide hydrochloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "metoclopramide-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "DDMP"
				},
				{
					"type": "CodeName",
					"name": "BW 197U"
				},
				{
					"type": "NSCNumber",
					"name": "19494"
				},
				{
					"type": "NSCNumber",
					"name": "7364"
				},
				{
					"type": "CASRegistryName",
					"name": "7761-45-7"
				}
			],
			"definition": {
				"html": "A diaminopyrimidine folate antagonist with potential antineoplastic activity.  Metoprine inhibits dihydrofolate reductase, resulting in decreased cellular folate metabolism and cell growth; it also inhibits histamine-N-methyltransferase, resulting in decreased histamine catabolism. Lipid-soluble metoprine is capable of crossing the blood-brain barrier.",
				"text": "A diaminopyrimidine folate antagonist with potential antineoplastic activity.  Metoprine inhibits dihydrofolate reductase, resulting in decreased cellular folate metabolism and cell growth; it also inhibits histamine-N-methyltransferase, resulting in decreased histamine catabolism. Lipid-soluble metoprine is capable of crossing the blood-brain barrier."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1161",
			"nciConceptName": "Metoprine",
			"termId": 39206,
			"name": "metoprine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "metoprine"
		},
		{
			"aliases": [
				{
					"type": "CASRegistryName",
					"name": "37350-58-6"
				}
			],
			"definition": {
				"html": "A cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction leading to a reduction in cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thereby preventing vasoconstriction and aldosterone secretion.",
				"text": "A cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction leading to a reduction in cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thereby preventing vasoconstriction and aldosterone secretion."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C61845",
			"nciConceptName": "Metoprolol",
			"termId": 694582,
			"name": "metoprolol",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "metoprolol"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Flagyl"
				},
				{
					"type": "CodeName",
					"name": "SC 32642"
				},
				{
					"type": "USBrandName",
					"name": "Satric"
				},
				{
					"type": "CASRegistryName",
					"name": "69198-10-3"
				}
			],
			"definition": {
				"html": "The hydrochloride salt of a synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities. Although its mechanism of action is not fully elucidated, un-ionized metronidazole is readily taken up by obligate anaerobic organisms and is subsequently reduced by low-redox potential electron-transport proteins to an active, intermediate product. Reduced metronidazole causes DNA strand breaks, thereby inhibiting DNA synthesis and bacterial cell growth. ",
				"text": "The hydrochloride salt of a synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities. Although its mechanism of action is not fully elucidated, un-ionized metronidazole is readily taken up by obligate anaerobic organisms and is subsequently reduced by low-redox potential electron-transport proteins to an active, intermediate product. Reduced metronidazole causes DNA strand breaks, thereby inhibiting DNA synthesis and bacterial cell growth. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C48005",
			"nciConceptName": "Metronidazole Hydrochloride",
			"termId": 39503,
			"name": "metronidazole hydrochloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "metronidazole-hydrochloride"
		},
		{
			"preferredName": "methyl-5-aminolevulinate hydrochloride cream",
			"termId": 38410,
			"name": "Metvixia cream",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "methyl-5-aminolevulinate-hydrochloride-cream"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "DEMSER"
				},
				{
					"type": "Synonym",
					"name": "methyl-tyrosine"
				},
				{
					"type": "Synonym",
					"name": "Alpha-methyl-p-tyrosine"
				},
				{
					"type": "CodeName",
					"name": "L-588357-0"
				},
				{
					"type": "CodeName",
					"name": "MK-781"
				},
				{
					"type": "Synonym",
					"name": "Metirosine"
				},
				{
					"type": "CASRegistryName",
					"name": "672-87-7"
				}
			],
			"definition": {
				"html": "A methylated tyrosine, a catecholamine synthesis antagonist with antihypertensive property. Metyrosine competitively inhibits tyrosine 3-monooxygenase, an enzyme that activates molecular oxygen to catalyze the hydroxylation of tyrosine to dihydroxyphenylalanine (Dopa), an intermediate to catecholamine (dopamine, norepinephrine, and epinephrine) production. This agent reduces the elevated levels of catecholamines associated with pheochromocytoma, thereby preventing hypertension.",
				"text": "A methylated tyrosine, a catecholamine synthesis antagonist with antihypertensive property. Metyrosine competitively inhibits tyrosine 3-monooxygenase, an enzyme that activates molecular oxygen to catalyze the hydroxylation of tyrosine to dihydroxyphenylalanine (Dopa), an intermediate to catecholamine (dopamine, norepinephrine, and epinephrine) production. This agent reduces the elevated levels of catecholamines associated with pheochromocytoma, thereby preventing hypertension."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C998",
			"nciConceptName": "Metyrosine",
			"termId": 39501,
			"name": "metyrosine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "metyrosine"
		},
		{
			"preferredName": "lovastatin",
			"termId": 41658,
			"name": "Mevacor",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "lovastatin"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MG-98 oligonucleotide"
				},
				{
					"type": "LexicalVariant",
					"name": "MG98"
				},
				{
					"type": "LexicalVariant",
					"name": "MG-98"
				}
			],
			"definition": {
				"html": "A second-generation, mixed-backbone, phosphorothioate antisense oligonucleotide (ODN) with potential antitumor activity. MG 98 is a highly specific inhibitor of translation of the mRNA for human DNA (cytosine-5-)-methyltransferase 1 (DNMT1), hybridizing to the 3' un-translated region of DNMT1 mRNA. The silencing of DNMT1 translation by MG 98 may result in the prevention or reversal of abnormal methylation of tumor suppressor genes and ultimately in tumor growth inhibition or tumor regression. ",
				"text": "A second-generation, mixed-backbone, phosphorothioate antisense oligonucleotide (ODN) with potential antitumor activity. MG 98 is a highly specific inhibitor of translation of the mRNA for human DNA (cytosine-5-)-methyltransferase 1 (DNMT1), hybridizing to the 3' un-translated region of DNMT1 mRNA. The silencing of DNMT1 translation by MG 98 may result in the prevention or reversal of abnormal methylation of tumor suppressor genes and ultimately in tumor growth inhibition or tumor regression. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2530",
			"nciConceptName": "DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98",
			"termId": 43475,
			"name": "MG 98",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "dnmt1-mixed-backbone-antisense-oligonucleotide-mg-98"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "FK463"
				},
				{
					"type": "Synonym",
					"name": "FK463"
				}
			],
			"definition": {
				"html": "A semi-synthetic echinocandin derived from a natural product of the fungus Coleophama empedri with potent antifungal activity. Micafungin, like other cyclic lipopeptides, noncompetitively inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, an enzyme essential for fungal cell wall synthesis. Inhibition of this enzyme weakens of the cell wall, thereby leading to osmotic lysis and eventually, fungal cell death.",
				"text": "A semi-synthetic echinocandin derived from a natural product of the fungus Coleophama empedri with potent antifungal activity. Micafungin, like other cyclic lipopeptides, noncompetitively inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, an enzyme essential for fungal cell wall synthesis. Inhibition of this enzyme weakens of the cell wall, thereby leading to osmotic lysis and eventually, fungal cell death."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1850",
			"nciConceptName": "Micafungin",
			"termId": 43552,
			"name": "Micafungin",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "micafungin"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "NC-6004"
				},
				{
					"type": "ForeignBrandName",
					"name": "Nanoplatin"
				}
			],
			"definition": {
				"html": "A nanoparticle-based prodrug formulation consisting of polymeric micelles incorporating the inorganic platinum agent cisplatin with potential antineoplastic activity.  In micellar nanoparticle-encapsulated cisplatin NC-6004, cisplatin forms a polymer-metal complex with hydrophilic polyethylene glycol poly(glutamic acid) block copolymers by attaching to the micelle inner core consisting of the hydrophobic polymer polyamino acid. Upon cell entry and release from the polymer-metal complex, cisplatin forms highly reactive, charged platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-linking, DNA-protein cross-linking and, subsequently, tumor cell apoptosis and growth inhibition. Due to the hydrophilic nature of polyethylene glycol, this formulation increases the water-solubility of cisplatin and decreases the nephrotoxicity and neurotoxicity associated with the administration of cisplatin alone.",
				"text": "A nanoparticle-based prodrug formulation consisting of polymeric micelles incorporating the inorganic platinum agent cisplatin with potential antineoplastic activity.  In micellar nanoparticle-encapsulated cisplatin NC-6004, cisplatin forms a polymer-metal complex with hydrophilic polyethylene glycol poly(glutamic acid) block copolymers by attaching to the micelle inner core consisting of the hydrophobic polymer polyamino acid. Upon cell entry and release from the polymer-metal complex, cisplatin forms highly reactive, charged platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-linking, DNA-protein cross-linking and, subsequently, tumor cell apoptosis and growth inhibition. Due to the hydrophilic nature of polyethylene glycol, this formulation increases the water-solubility of cisplatin and decreases the nephrotoxicity and neurotoxicity associated with the administration of cisplatin alone."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C85476",
			"nciConceptName": "Demplatin Pegraglumer",
			"termId": 647541,
			"name": "micellar nanoparticle-encapsulated cisplatin NC-6004",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "demplatin-pegraglumer"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "epirubicin-conjugated polymer micelles"
				},
				{
					"type": "CodeName",
					"name": "NC-6300"
				},
				{
					"type": "CodeName",
					"name": "K-912"
				},
				{
					"type": "Synonym",
					"name": "epirubicin-incorporating micelle"
				},
				{
					"type": "Synonym",
					"name": "nanoparticle epirubicin"
				}
			],
			"definition": {
				"html": "A nanoparticle-based prodrug formulation consisting of polymeric micelles encapsulating the anthracycline epirubicin, with potential antineoplastic activity. Epirubicin is covalently bound to polyethylene glycol (PEG) polyaspartate block copolymers through an acid-labile hydrazone bond and, upon suspension in an aqueous solution, a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic epirubicin is formed. Upon administration of the micellar nanoparticle-encapsulated epirubicin, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, epirubicin is released in the tumor milieu; it then intercalates into DNA and inhibits topoisomerase II, which inhibits DNA replication and interferes with synthesis of both RNA and protein. Compared to the administration of epirubicin alone, this formulation increases the water-solubility of epirubicin and increases its therapeutic effect while decreasing its cardiotoxicity.",
				"text": "A nanoparticle-based prodrug formulation consisting of polymeric micelles encapsulating the anthracycline epirubicin, with potential antineoplastic activity. Epirubicin is covalently bound to polyethylene glycol (PEG) polyaspartate block copolymers through an acid-labile hydrazone bond and, upon suspension in an aqueous solution, a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic epirubicin is formed. Upon administration of the micellar nanoparticle-encapsulated epirubicin, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, epirubicin is released in the tumor milieu; it then intercalates into DNA and inhibits topoisomerase II, which inhibits DNA replication and interferes with synthesis of both RNA and protein. Compared to the administration of epirubicin alone, this formulation increases the water-solubility of epirubicin and increases its therapeutic effect while decreasing its cardiotoxicity."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C139003",
			"nciConceptName": "Micellar Nanoparticle-encapsulated Epirubicin",
			"termId": 790960,
			"name": "micellar nanoparticle-encapsulated epirubicin",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "micellar-nanoparticle-encapsulated-epirubicin"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MA leaf oil"
				}
			],
			"definition": {
				"html": "A steam distilled essential oil composed of the oil from the leaves of the Michelia alba (MA) plant belonging to the Magnolia family, with potential anti-anxiety activity. Upon administration of drops of the MA leaf oil on the inside of an oxygen face mask, the aroma from the leaf oil, containing high amounts of the terpene alcohol component linalool, may improve anxiety and may help sedate, relax and soothe the patient.",
				"text": "A steam distilled essential oil composed of the oil from the leaves of the Michelia alba (MA) plant belonging to the Magnolia family, with potential anti-anxiety activity. Upon administration of drops of the MA leaf oil on the inside of an oxygen face mask, the aroma from the leaf oil, containing high amounts of the terpene alcohol component linalool, may improve anxiety and may help sedate, relax and soothe the patient."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C159489",
			"nciConceptName": "Michelia alba Leaf Oil",
			"termId": 797813,
			"name": "Michelia alba leaf oil",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "michelia-alba-leaf-oil"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MNA-D"
				},
				{
					"type": "Synonym",
					"name": "MNA-doxorubicin"
				},
				{
					"type": "Synonym",
					"name": "microneedle array doxorubicin"
				},
				{
					"type": "Synonym",
					"name": "micro-needle array doxorubicin"
				},
				{
					"type": "Synonym",
					"name": "microneedle applicator-doxorubicin"
				},
				{
					"type": "Synonym",
					"name": "doxorubicin-coated patches"
				},
				{
					"type": "Synonym",
					"name": "doxorubicin-loaded patches"
				},
				{
					"type": "Synonym",
					"name": "MNA-D patches"
				}
			],
			"definition": {
				"html": "A formulation composed of dissolvable small, adhesive-like patches composed of a biocompatible material which is coated with the anthracycline antibiotic doxorubicin, with potential antineoplastic and immunomodulating activities. Upon cutaneous administration of the microneedle-array-doxorubicin, the microneedles degrade once inserted into the skin and doxorubicin is released from the dissolvable microneedle array delivery device directly into the tumor microenvironment (TME). Doxorubicin is taken up by tumor cells and intercalates into DNA and interferes with topoisomerase II activity. This inhibits DNA replication and RNA synthesis, leading to tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. In addition, doxorubicin induces innate, adaptive, and tumor-specific effector and memory immune responses, thereby further killing the tumor cells. Delivery of doxorubicin using the microneedle array delivery system allows direct and specific administration of doxorubicin to the TME which may improve drug concentration into tumor cells and may reduce systemic toxicity, compared to the administration of systemic doxorubicin alone.\n",
				"text": "A formulation composed of dissolvable small, adhesive-like patches composed of a biocompatible material which is coated with the anthracycline antibiotic doxorubicin, with potential antineoplastic and immunomodulating activities. Upon cutaneous administration of the microneedle-array-doxorubicin, the microneedles degrade once inserted into the skin and doxorubicin is released from the dissolvable microneedle array delivery device directly into the tumor microenvironment (TME). Doxorubicin is taken up by tumor cells and intercalates into DNA and interferes with topoisomerase II activity. This inhibits DNA replication and RNA synthesis, leading to tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. In addition, doxorubicin induces innate, adaptive, and tumor-specific effector and memory immune responses, thereby further killing the tumor cells. Delivery of doxorubicin using the microneedle array delivery system allows direct and specific administration of doxorubicin to the TME which may improve drug concentration into tumor cells and may reduce systemic toxicity, compared to the administration of systemic doxorubicin alone.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C156665",
			"nciConceptName": "Micro Needle Array-Doxorubicin",
			"termId": 795832,
			"name": "micro needle array-doxorubicin",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "micro-needle-array-doxorubicin"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "MET-4"
				},
				{
					"type": "CodeName",
					"name": "MET4"
				},
				{
					"type": "CodeName",
					"name": "MET 4"
				}
			],
			"definition": {
				"html": "An orally available formulation consisting of a well-defined mixture of over thirty intestinal bacteria isolated from a healthy donor stool sample with potential immunomodulatory effects. Upon administration, the bacteria in microbial ecosystem therapeutics-4 (MET4) may help maintain adequate colonization of the gastrointestinal (GI) tract and modulate the composition of the normal microflora. Upon colonization of the GI tract, the probiotic bacteria form a protective barrier that helps maintain the integrity of the epithelial barrier. This will interfere with the attachment of pathogenic bacteria and other harmful substances, prevent inflammation and improve GI function. Additionally, increased gut microbiota diversity and the presence of certain bacterial genera present in MET4 may improve outcomes following immunotherapy, potentially via certain mucosal and systemic immune responses induced by the microbiome across the gut barrier.",
				"text": "An orally available formulation consisting of a well-defined mixture of over thirty intestinal bacteria isolated from a healthy donor stool sample with potential immunomodulatory effects. Upon administration, the bacteria in microbial ecosystem therapeutics-4 (MET4) may help maintain adequate colonization of the gastrointestinal (GI) tract and modulate the composition of the normal microflora. Upon colonization of the GI tract, the probiotic bacteria form a protective barrier that helps maintain the integrity of the epithelial barrier. This will interfere with the attachment of pathogenic bacteria and other harmful substances, prevent inflammation and improve GI function. Additionally, increased gut microbiota diversity and the presence of certain bacterial genera present in MET4 may improve outcomes following immunotherapy, potentially via certain mucosal and systemic immune responses induced by the microbiome across the gut barrier."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C162187",
			"nciConceptName": "Microbial Ecosystem Therapeutics-4",
			"termId": 798423,
			"name": "microbial ecosystem therapeutics-4",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "microbial-ecosystem-therapeutics-4"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "GEN-001"
				},
				{
					"type": "CodeName",
					"name": "GEN 001"
				},
				{
					"type": "CodeName",
					"name": "GEN001"
				},
				{
					"type": "Synonym",
					"name": "microbiome-based therapeutic GEN-001"
				}
			],
			"definition": {
				"html": "A microbiome therapeutic composed of a single-strain bacterium, isolated from the gut of healthy donors, with potential anti-tumor and immunomodulating activities. Upon oral administration, the metabolites of GEN-001 may activate dendritic cells and macrophages in the gut and increase the expression of the cytokines interleukin-7 (IL-7) and interleukin-15 (IL-15), which stimulates the proliferation of natural killer (NK) cells and memory CD8+ T cells. The memory T cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. GEN-001 may improve therapeutic responses to other therapies, such as anti-PD-1 therapy.",
				"text": "A microbiome therapeutic composed of a single-strain bacterium, isolated from the gut of healthy donors, with potential anti-tumor and immunomodulating activities. Upon oral administration, the metabolites of GEN-001 may activate dendritic cells and macrophages in the gut and increase the expression of the cytokines interleukin-7 (IL-7) and interleukin-15 (IL-15), which stimulates the proliferation of natural killer (NK) cells and memory CD8+ T cells. The memory T cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. GEN-001 may improve therapeutic responses to other therapies, such as anti-PD-1 therapy."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C171422",
			"nciConceptName": "Microbiome GEN-001",
			"termId": 801465,
			"name": "microbiome GEN-001",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "microbiome-gen-001"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "SER-401"
				},
				{
					"type": "CodeName",
					"name": "SER 401"
				},
				{
					"type": "CodeName",
					"name": "SER401"
				},
				{
					"type": "Synonym",
					"name": "microbiome-based therapeutic SER-401"
				}
			],
			"definition": {
				"html": "A donor-derived microbiome therapeutic composed of a combination of as of yet not disclosed microbes that were specifically selected to incorporate the bacterial signature found in melanoma patients who have a robust response to immunotherapy, with potential immunomodulating activity. Upon administration, SER-401 may restore the unhealthy, altered gut microbiome, enhance the microbial diversity and function in the gastrointestinal (GI) tact and may re-establish a healthy microbiome in the GI tract. This may enhance a patient's immunological activity and improve a patient's response to immunotherapy.",
				"text": "A donor-derived microbiome therapeutic composed of a combination of as of yet not disclosed microbes that were specifically selected to incorporate the bacterial signature found in melanoma patients who have a robust response to immunotherapy, with potential immunomodulating activity. Upon administration, SER-401 may restore the unhealthy, altered gut microbiome, enhance the microbial diversity and function in the gastrointestinal (GI) tact and may re-establish a healthy microbiome in the GI tract. This may enhance a patient's immunological activity and improve a patient's response to immunotherapy."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C165519",
			"nciConceptName": "Microbiome SER-401",
			"termId": 799975,
			"name": "microbiome SER-401",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "microbiome-ser-401"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "EO2401"
				},
				{
					"type": "CodeName",
					"name": "EO 2401"
				},
				{
					"type": "CodeName",
					"name": "EO-2401"
				},
				{
					"type": "Synonym",
					"name": "cancer vaccine EO2401"
				},
				{
					"type": "Synonym",
					"name": "microbiome-derived therapeutic cancer vaccine EO2401"
				},
				{
					"type": "Synonym",
					"name": "microbial-derived peptide vaccine EO2401"
				}
			],
			"definition": {
				"html": "A donor-derived, off-the-shelf, microbiome therapeutic cancer peptide vaccine composed of three bacterial onco-mimics, immunogenic microbiome-derived peptides that are highly homologous to tumor-associated antigens (TAAs), that are obtained and selected from the human gut microbiome and are specific for brain tumors, including glioblastoma, with potential immunomodulating and antineoplastic activities. The three microbiome-derived bacterial antigens in EO2401 mimic three TAAs that are highly expressed by brain tumors. Upon administration of microbiome-derived peptide vaccine EO2401, the peptides are taken up by and presented on dendritic cells (DCs) to T cells. As the presented antigens display molecular mimicry with selected TAAs on brain cancer cells, a memory T-cell- and cytotoxic T-lymphocyte (CTL)-mediated immune response may be mounted against the TAAs expressed on the brain cancer cells, thereby eradicating the brain cancer cells.\n",
				"text": "A donor-derived, off-the-shelf, microbiome therapeutic cancer peptide vaccine composed of three bacterial onco-mimics, immunogenic microbiome-derived peptides that are highly homologous to tumor-associated antigens (TAAs), that are obtained and selected from the human gut microbiome and are specific for brain tumors, including glioblastoma, with potential immunomodulating and antineoplastic activities. The three microbiome-derived bacterial antigens in EO2401 mimic three TAAs that are highly expressed by brain tumors. Upon administration of microbiome-derived peptide vaccine EO2401, the peptides are taken up by and presented on dendritic cells (DCs) to T cells. As the presented antigens display molecular mimicry with selected TAAs on brain cancer cells, a memory T-cell- and cytotoxic T-lymphocyte (CTL)-mediated immune response may be mounted against the TAAs expressed on the brain cancer cells, thereby eradicating the brain cancer cells.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C165646",
			"nciConceptName": "Microbiome-derived Peptide Vaccine EO2401",
			"termId": 799761,
			"name": "microbiome-derived peptide vaccine EO2401",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "microbiome-derived-peptide-vaccine-eo2401"
		},
		{
			"preferredName": "ethinyl estradiol/levonorgestrel",
			"termId": 781019,
			"name": "Microgynon",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "ethinyl-estradiol-levonorgestrel"
		},
		{
			"preferredName": "glyburide",
			"termId": 772960,
			"name": "Micronase",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "glyburide"
		},
		{
			"aliases": null,
			"definition": {
				"html": "An micronutrient-fortified fermented dairy product with potential positive immunomodulatory activity. Micronutrient-fortified probiotic yogurt contains various micronutrients in addition to beneficial microorganisms, such as strains of Lactobacillus. Probiotic Lactobacillus strains have been shown to protect against gastrointestinal and urogenital infections, to moderate diarrheal episodes, and to increase CD4 T-lymphocyte counts. In immunocompromised subjects, micronutrient supplementation may also increase CD4 T-lymphocyte counts. \n",
				"text": "An micronutrient-fortified fermented dairy product with potential positive immunomodulatory activity. Micronutrient-fortified probiotic yogurt contains various micronutrients in addition to beneficial microorganisms, such as strains of Lactobacillus. Probiotic Lactobacillus strains have been shown to protect against gastrointestinal and urogenital infections, to moderate diarrheal episodes, and to increase CD4 T-lymphocyte counts. In immunocompromised subjects, micronutrient supplementation may also increase CD4 T-lymphocyte counts. \n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C70677",
			"nciConceptName": "Micronutrient-Fortified Probiotic Yogurt",
			"termId": 570688,
			"name": "micronutrient-fortified probiotic yogurt",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "micronutrient-fortified-probiotic-yogurt"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "SCB01A"
				},
				{
					"type": "CodeName",
					"name": "SCB-01A"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6-methoxy-3-(3',4',5'-trimethoxybenzoyl) Indole"
				},
				{
					"type": "CodeName",
					"name": "SB 01"
				},
				{
					"type": "CodeName",
					"name": "BPR 0L075"
				},
				{
					"type": "CodeName",
					"name": "DBPR104"
				},
				{
					"type": "CodeName",
					"name": "SB01"
				},
				{
					"type": "CodeName",
					"name": "SCB 01A"
				}
			],
			"definition": {
				"html": "An aroylindole derivative and tubulin polymerization inhibitor, with potential tubulin-inhibiting, vascular-disrupting and antineoplastic activities. Upon administration, tubulin polymerization inhibitor SCB01A binds at the colchicine binding site of tubulin and prevents its polymerization in tumor blood vessel endothelial cells and in tumor cells. This blocks the formation of the mitotic spindle and leads to both cell cycle arrest at the G2/M phase and tumor cell apoptosis. Also, this agent's effect on the tumor blood vessel endothelial cells leads to a disruption of the tumor vasculature and tumor blood flow, which deprives tumor cells of nutrients and induces tumor cell apoptosis.",
				"text": "An aroylindole derivative and tubulin polymerization inhibitor, with potential tubulin-inhibiting, vascular-disrupting and antineoplastic activities. Upon administration, tubulin polymerization inhibitor SCB01A binds at the colchicine binding site of tubulin and prevents its polymerization in tumor blood vessel endothelial cells and in tumor cells. This blocks the formation of the mitotic spindle and leads to both cell cycle arrest at the G2/M phase and tumor cell apoptosis. Also, this agent's effect on the tumor blood vessel endothelial cells leads to a disruption of the tumor vasculature and tumor blood flow, which deprives tumor cells of nutrients and induces tumor cell apoptosis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C143158",
			"nciConceptName": "Microtubule Inhibitor SCB01A",
			"termId": 791849,
			"name": "microtubule inhibitor SCB01A",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "microtubule-inhibitor-scb01a"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "BAL101553"
				}
			],
			"definition": {
				"html": "An orally available, highly water-soluble lysine prodrug of the synthetic small molecule BAL27862 with potential antitumor activity. Upon administration of BAL101553 and conversion into the active form BAL27862, this agent binds to tubulin at a site distinct from the vinca-alkaloid-binding site, and prevents tubulin polymerization and destabilizes microtubules, ultimately leading to cell cycle arrest, blockage of cell division and an induction of cell death in cancer cells.",
				"text": "An orally available, highly water-soluble lysine prodrug of the synthetic small molecule BAL27862 with potential antitumor activity. Upon administration of BAL101553 and conversion into the active form BAL27862, this agent binds to tubulin at a site distinct from the vinca-alkaloid-binding site, and prevents tubulin polymerization and destabilizes microtubules, ultimately leading to cell cycle arrest, blockage of cell division and an induction of cell death in cancer cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C97664",
			"nciConceptName": "Lisavanbulin",
			"termId": 706747,
			"name": "microtubule-targeted agent BAL101553",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "lisavanbulin"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "8-Chloro-6-(2-fluorophenyl)-1-Methyl- 4H- Imidazo(1,5a)(1,4)Benzodiazepine"
				},
				{
					"type": "Synonym",
					"name": "midazolam"
				},
				{
					"type": "USBrandName",
					"name": "Versed"
				}
			],
			"definition": {
				"html": "The hydrochloride salt of a short-acting benzodiazepine derivative with an imidazole structure and anxiolytic, amnestic, hypnotic, anticonvulsant and sedative properties. Midazolam binds to the benzodiazepine receptor at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS), resulting in increases in the opening of chloride channels, membrane hyperpolarization, and the inhibitory effect of GABA. This agent may also interfere with the reuptake of GABA, thereby causing accumulation of GABA in the synaptic cleft. ",
				"text": "The hydrochloride salt of a short-acting benzodiazepine derivative with an imidazole structure and anxiolytic, amnestic, hypnotic, anticonvulsant and sedative properties. Midazolam binds to the benzodiazepine receptor at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS), resulting in increases in the opening of chloride channels, membrane hyperpolarization, and the inhibitory effect of GABA. This agent may also interfere with the reuptake of GABA, thereby causing accumulation of GABA in the synaptic cleft. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C654",
			"nciConceptName": "Midazolam Hydrochloride",
			"termId": 41056,
			"name": "midazolam hydrochloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "midazolam-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "ForeignBrandName",
					"name": "Epistatus"
				},
				{
					"type": "Synonym",
					"name": "midazolam maleate buccal liquid"
				},
				{
					"type": "Synonym",
					"name": "midazolam maleate oromucosal solution"
				}
			],
			"definition": {
				"html": "An oromucosal solution containing the maleate salt form of midazolam, a short-acting benzodiazepine derivative, with anxiolytic, hypnotic, anticonvulsant and sedative activities. Upon administration of the solution into the buccal cavity, midazolam exerts its effect by binding to the benzodiazepine receptor at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS). This leads to an increase in the permeability of chloride channels, membrane hyperpolarization and enhances the inhibitory effect of GABA in the CNS. Midazolam may also interfere with the reuptake of GABA, thereby causing accumulation of GABA in the synaptic cleft. The oromucosal formulation facilitates administration to patients that are unable to swallow. The ethanol in this formulation improves the buccal absorption of midazolam.\n",
				"text": "An oromucosal solution containing the maleate salt form of midazolam, a short-acting benzodiazepine derivative, with anxiolytic, hypnotic, anticonvulsant and sedative activities. Upon administration of the solution into the buccal cavity, midazolam exerts its effect by binding to the benzodiazepine receptor at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS). This leads to an increase in the permeability of chloride channels, membrane hyperpolarization and enhances the inhibitory effect of GABA in the CNS. Midazolam may also interfere with the reuptake of GABA, thereby causing accumulation of GABA in the synaptic cleft. The oromucosal formulation facilitates administration to patients that are unable to swallow. The ethanol in this formulation improves the buccal absorption of midazolam.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C113654",
			"nciConceptName": "Midazolam-containing Buccal Liquid",
			"termId": 756929,
			"name": "midazolam-containing buccal liquid",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "midazolam-containing-buccal-liquid"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "PKC412"
				},
				{
					"type": "CodeName",
					"name": "PKC 412"
				},
				{
					"type": "CodeName",
					"name": "CGP41251"
				},
				{
					"type": "CodeName",
					"name": "CGP 41251"
				},
				{
					"type": "Synonym",
					"name": "N-benzoyl-staurosporine"
				},
				{
					"type": "Synonym",
					"name": "N-benzoylstaurosporine"
				},
				{
					"type": "USBrandName",
					"name": "Rydapt"
				}
			],
			"definition": {
				"html": "A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.",
				"text": "A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors."
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/midostaurin",
				"text": "Midostaurin"
			},
			"nciConceptId": "C1872",
			"nciConceptName": "Midostaurin",
			"termId": 462346,
			"name": "midostaurin",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "midostaurin"
		},
		{
			"aliases": [
				{
					"type": "ForeignBrandName",
					"name": "MEPACT"
				},
				{
					"type": "USBrandName",
					"name": "JUNOVAN"
				},
				{
					"type": "Synonym",
					"name": "muramyl tripeptide phosphatidylethanolamine liposome"
				},
				{
					"type": "Abbreviation",
					"name": "L-MTP-PE"
				},
				{
					"type": "Synonym",
					"name": "CGP 19835A Lipid"
				},
				{
					"type": "Abbreviation",
					"name": "MTP-PE Liposome"
				}
			],
			"definition": {
				"html": "A liposomal formulation containing a muramyl dipeptide (MDP) analogue with potential immunomodulatory and antineoplastic activities.. Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a derivative of the mycobacterial cell wall component MDP, activates both monocytes and macrophages. Activated macrophages secrete cytokines and induce the recruitment and activation of other immune cells, which may result in indirect tumoricidal effects. Liposomal encapsulation of MTP-PE prolongs its  half-life and enhances tissue targeting. ",
				"text": "A liposomal formulation containing a muramyl dipeptide (MDP) analogue with potential immunomodulatory and antineoplastic activities.. Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a derivative of the mycobacterial cell wall component MDP, activates both monocytes and macrophages. Activated macrophages secrete cytokines and induce the recruitment and activation of other immune cells, which may result in indirect tumoricidal effects. Liposomal encapsulation of MTP-PE prolongs its  half-life and enhances tissue targeting. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1394",
			"nciConceptName": "Mifamurtide",
			"termId": 41541,
			"name": "mifamurtide",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mifamurtide"
		},
		{
			"preferredName": "mifepristone",
			"termId": 40888,
			"name": "Mifeprex",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "mifepristone"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "RU-38486"
				},
				{
					"type": "USBrandName",
					"name": "Mifeprex"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mifegyne"
				},
				{
					"type": "ChemicalStructureName",
					"name": "11-((4-dimethylamino) phenyl)-17-Hydroxy-17-(1-propynyl) estra-4,9- dien-3-one"
				},
				{
					"type": "ChemicalStructureName",
					"name": "11 beta-[4-(N,N-dimethylamino)phenyl]-17alpha-(propyl-1-ynyl)-delta-4,9-estradiene-17 beta-ol-3-one"
				},
				{
					"type": "ChemicalStructureName",
					"name": "(aa Beta, 17 beta)-11-[4-(dimethylamino)-phenyl]-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one"
				},
				{
					"type": "CodeName",
					"name": "RU 486"
				},
				{
					"type": "LexicalVariant",
					"name": "RU-486"
				},
				{
					"type": "LexicalVariant",
					"name": "RU486"
				},
				{
					"type": "NSCNumber",
					"name": "652104"
				},
				{
					"type": "CASRegistryName",
					"name": "84371-65-3"
				}
			],
			"definition": {
				"html": "A derivative of the synthetic progestin norethindrone with antiprogesterone activity.  Mifepristone competitively binds to the progesterone receptor, resulting in inhibition of the effects of endogenous or exogenous progesterone. This agent also exhibits antiglucocorticoid and weak antiandrogenic activities.",
				"text": "A derivative of the synthetic progestin norethindrone with antiprogesterone activity.  Mifepristone competitively binds to the progesterone receptor, resulting in inhibition of the effects of endogenous or exogenous progesterone. This agent also exhibits antiglucocorticoid and weak antiandrogenic activities."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C655",
			"nciConceptName": "Mifepristone",
			"termId": 40888,
			"name": "mifepristone",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mifepristone"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Glyset"
				},
				{
					"type": "CASRegistryName",
					"name": "72432-03-2"
				}
			],
			"definition": {
				"html": "A desoxynojirimycin derivative and inhibitor of alpha-glucosidase with antihyperglycemic activity. Miglitol binds to and inhibits alpha-glucosidase, an enteric enzyme found in the brush border of the small intestines that hydrolyzes oligosaccharides and disaccharides into glucose and other monosaccharides. This prevents the breakdown of larger carbohydrates into glucose and decreases the rise in postprandial blood glucose levels. Compared to acarbose, miglitol is systemically absorbed.",
				"text": "A desoxynojirimycin derivative and inhibitor of alpha-glucosidase with antihyperglycemic activity. Miglitol binds to and inhibits alpha-glucosidase, an enteric enzyme found in the brush border of the small intestines that hydrolyzes oligosaccharides and disaccharides into glucose and other monosaccharides. This prevents the breakdown of larger carbohydrates into glucose and decreases the rise in postprandial blood glucose levels. Compared to acarbose, miglitol is systemically absorbed."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C61847",
			"nciConceptName": "Miglitol",
			"termId": 775336,
			"name": "miglitol",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "miglitol"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MiHA-loaded PD-L-silenced DC vaccine"
				}
			],
			"definition": {
				"html": "A dendritic cell (DC)-based vaccine composed of program death ligands 1 and 2 (PDL1/L2)-silenced DCs and loaded with the recipients minor histocompatibility antigens (MiHA), with potential use for graft-versus-tumor (GVT) induction following allogeneic stem cell transplantation (allo-SCT). Donor DCs are electroporated ex vivo with MiHA mRNA and small interfering RNAs (siRNAs) designed to silence the expression of PD L1/L2. After allo-SCT and upon intravenous administration of the MiHA-loaded PD-L1/L2-silenced DC vaccine, the DCs induce the expansion and activation of MiHA-specific CD8-positive T-cells. These tumor antigen-reactive T-cells exert their GVT effect by killing MiHA-positive tumor cells. PD-L1/L2, co-inhibitory ligands expressed on DCs, play key roles in preventing MiHA-specific CD8-positive T-cell expansion; silencing enhances MiHA-specific CD8-positive T-cell expansion and activity and improves the GVT effect. The MiHA are human leukocyte antigen (HLA)-bound peptides and are exclusively expressed by the recipients hematopoietic tumor cells.",
				"text": "A dendritic cell (DC)-based vaccine composed of program death ligands 1 and 2 (PDL1/L2)-silenced DCs and loaded with the recipients minor histocompatibility antigens (MiHA), with potential use for graft-versus-tumor (GVT) induction following allogeneic stem cell transplantation (allo-SCT). Donor DCs are electroporated ex vivo with MiHA mRNA and small interfering RNAs (siRNAs) designed to silence the expression of PD L1/L2. After allo-SCT and upon intravenous administration of the MiHA-loaded PD-L1/L2-silenced DC vaccine, the DCs induce the expansion and activation of MiHA-specific CD8-positive T-cells. These tumor antigen-reactive T-cells exert their GVT effect by killing MiHA-positive tumor cells. PD-L1/L2, co-inhibitory ligands expressed on DCs, play key roles in preventing MiHA-specific CD8-positive T-cell expansion; silencing enhances MiHA-specific CD8-positive T-cell expansion and activity and improves the GVT effect. The MiHA are human leukocyte antigen (HLA)-bound peptides and are exclusively expressed by the recipients hematopoietic tumor cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C123921",
			"nciConceptName": "MiHA-loaded PD-L1/L2-silenced Dendritic Cell Vaccine",
			"termId": 775894,
			"name": "MiHA-loaded PD-L1/L2-silenced dendritic cell vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "miha-loaded-pd-l1-l2-silenced-dendritic-cell-vaccine"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "DS-3032b"
				},
				{
					"type": "Synonym",
					"name": "HDM2 inhibitor DS-3032b"
				},
				{
					"type": "Synonym",
					"name": "MDM2 inhibitor DS-3032b"
				}
			],
			"definition": {
				"html": "An orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, milademetan tosylate binds to, and prevents the binding of MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteosome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This results in the restoration of p53 signaling and leads to the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it has been implicated in cancer cell proliferation and survival.\n",
				"text": "An orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, milademetan tosylate binds to, and prevents the binding of MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteosome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This results in the restoration of p53 signaling and leads to the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it has been implicated in cancer cell proliferation and survival.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C107384",
			"nciConceptName": "Milademetan Tosylate",
			"termId": 750863,
			"name": "milademetan tosylate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "milademetan-tosylate"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "hLL1"
				},
				{
					"type": "Synonym",
					"name": "humanized anti-CD74 monoclonal antibody hLL1"
				}
			],
			"definition": {
				"html": "A humanized monoclonal antibody directed against human CD74 with potential antineoplastic activity. Milatuzumab specifically binds to CD74 on CD74-positive cells. Although the exact mechanism through which this agent induces apoptosis is unknown, it may involve antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated cytotoxicity (CMC). Alternatively, as CD74 is the cellular receptor for the cytokine migration-inhibitory factor (MIF), the cytotoxicity of this agent may be related to inhibition of CD74 activation by MIF. CD74, an integral membrane protein that functions as an MHC class II chaperone, may also be an accessory-signaling molecule; activation of CD74 may initiate cell survival mechanisms involving induction of a signaling cascade resulting in NFkB activation, entry of stimulated cells into the S phase of the cell cycle, elevation of DNA synthesis, cell division, and augmented expression of Bcl-xL.",
				"text": "A humanized monoclonal antibody directed against human CD74 with potential antineoplastic activity. Milatuzumab specifically binds to CD74 on CD74-positive cells. Although the exact mechanism through which this agent induces apoptosis is unknown, it may involve antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated cytotoxicity (CMC). Alternatively, as CD74 is the cellular receptor for the cytokine migration-inhibitory factor (MIF), the cytotoxicity of this agent may be related to inhibition of CD74 activation by MIF. CD74, an integral membrane protein that functions as an MHC class II chaperone, may also be an accessory-signaling molecule; activation of CD74 may initiate cell survival mechanisms involving induction of a signaling cascade resulting in NFkB activation, entry of stimulated cells into the S phase of the cell cycle, elevation of DNA synthesis, cell division, and augmented expression of Bcl-xL."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C66983",
			"nciConceptName": "Milatuzumab",
			"termId": 534127,
			"name": "milatuzumab",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "milatuzumab"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "hLL1-DOX"
				},
				{
					"type": "CodeName",
					"name": "IMMU-110"
				}
			],
			"definition": {
				"html": "An immunoconjugate consisting of milatuzumab, a humanized monoclonal antibody against CD74, conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. The milatuzumab moiety of this antibody-drug conjugate (ADC) selectively binds to CD74 on tumor cell surfaces; upon internalization, the doxorubicin moiety is released, where it intercalates between base pairs in the DNA helix and inhibits topoisomerase II, thereby preventing DNA replication and increasing double-strand breakage. As a result, this agent may inhibit the proliferation of cancer cells that overexpress CD74. CD74, an integral membrane protein and tumor associated antigen (TAA), is overexpressed in certain cancer cells and promotes survival in rapidly proliferating tumor cells.",
				"text": "An immunoconjugate consisting of milatuzumab, a humanized monoclonal antibody against CD74, conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. The milatuzumab moiety of this antibody-drug conjugate (ADC) selectively binds to CD74 on tumor cell surfaces; upon internalization, the doxorubicin moiety is released, where it intercalates between base pairs in the DNA helix and inhibits topoisomerase II, thereby preventing DNA replication and increasing double-strand breakage. As a result, this agent may inhibit the proliferation of cancer cells that overexpress CD74. CD74, an integral membrane protein and tumor associated antigen (TAA), is overexpressed in certain cancer cells and promotes survival in rapidly proliferating tumor cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C91086",
			"nciConceptName": "Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110",
			"termId": 671813,
			"name": "milatuzumab-doxorubicin antibody-drug conjugate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "milatuzumab-doxorubicin-antibody-drug-conjugate-immu-110"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "PHA-848125 AC"
				},
				{
					"type": "ChemicalStructureName",
					"name": "N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide"
				},
				{
					"type": "Synonym",
					"name": "CDK2/TRKA inhibitor PHA-848125 AC"
				}
			],
			"definition": {
				"html": "An orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. Milciclib maleate potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA  is mutated in a variety of cancer cell types.",
				"text": "An orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. Milciclib maleate potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA  is mutated in a variety of cancer cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C88312",
			"nciConceptName": "Milciclib Maleate",
			"termId": 660138,
			"name": "milciclib maleate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "milciclib-maleate"
		},
		{
			"preferredName": "diethylstilbestrol",
			"termId": 43081,
			"name": "Milestrol",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "diethylstilbestrol"
		},
		{
			"preferredName": "magnesium hydroxide",
			"termId": 537610,
			"name": "Milk of Magnesia",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "magnesium-hydroxide"
		},
		{
			"aliases": [
				{
					"type": "ForeignBrandName",
					"name": "Fresubin Protein Energy Drink"
				}
			],
			"definition": {
				"html": "An oral milk protein-based nutritional supplement. Milk protein-based energy drink is a flavored liquid that consists of milk protein, rapeseed and sunflower oils, carbohydrates, vitamins, minerals and trace-elements, providing 1.5kcal and 10 mg of protein per ml.",
				"text": "An oral milk protein-based nutritional supplement. Milk protein-based energy drink is a flavored liquid that consists of milk protein, rapeseed and sunflower oils, carbohydrates, vitamins, minerals and trace-elements, providing 1.5kcal and 10 mg of protein per ml."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C77871",
			"nciConceptName": "Milk Protein-Based Energy Drink",
			"termId": 598301,
			"name": "milk protein-based energy drink",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "milk-protein-based-energy-drink"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A substance derived from any of several Old World coarse prickly-leaved shrubs and subshrubs including the plant Silybum marianum.  Milk thistle's active chemical component is silymarin, which is a combination of flavonoids such as silibinin, dehydrosilibinin, silychristin and silydianin.  These compounds are antioxidants and may alter the membrane structure of the liver cell, thereby blocking the absorption of toxins; they may also stimulate the production of new liver cells. In addition, milk thistle may increase cellular adenosine triphosphate (ATP) levels, exhibiting dose-dependent cardiac myocyte cytoprotection against doxorubicin.  The silibinin component of milk thistle has been shown to inhibit growth factor receptor-mediated mitogenic and cell survival signaling, thereby inhibiting tumor growth. (NCI04)",
				"text": "A substance derived from any of several Old World coarse prickly-leaved shrubs and subshrubs including the plant Silybum marianum.  Milk thistle's active chemical component is silymarin, which is a combination of flavonoids such as silibinin, dehydrosilibinin, silychristin and silydianin.  These compounds are antioxidants and may alter the membrane structure of the liver cell, thereby blocking the absorption of toxins; they may also stimulate the production of new liver cells. In addition, milk thistle may increase cellular adenosine triphosphate (ATP) levels, exhibiting dose-dependent cardiac myocyte cytoprotection against doxorubicin.  The silibinin component of milk thistle has been shown to inhibit growth factor receptor-mediated mitogenic and cell survival signaling, thereby inhibiting tumor growth. (NCI04)"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C29261",
			"nciConceptName": "Milk Thistle",
			"termId": 459958,
			"name": "milk thistle",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "milk-thistle"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "milled flax/sesame/pumpkin seed mix"
				},
				{
					"type": "Synonym",
					"name": "milled mix of flax/sesame/pumpkin seeds in sour milk"
				},
				{
					"type": "Synonym",
					"name": "milled sesame/pumpkin/flax seed mixture"
				}
			],
			"definition": {
				"html": "A nutritional supplement composed of a milled seed mixture, including milled flax, sesame and pumpkin seeds, in sour milk, with potential anti-inflammatory and lipid-regulating activities. The seeds contain high levels of fatty acids, including omega-3 and omega-6 polyunsaturated fatty acids (PUFAs), such as dihomo-gamma-linolenic acid (DGLA), alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA). Upon administration of the milled seed mix, the intake of PUFAs improves PUFA levels and may favorably change the n-6/n-3 PUFA ratio, decrease triglyceride (TG) levels, and improve body weight. In addition, the active ingredients in the milled seed mix may change the expression of inflammatory markers, such as C-reactive protein (CRP) and pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-a), thereby decreasing inflammation. The milled seed mix may also prevent oxidative stress and affect glycemic control. Tumors cause inflammatory states and unfavorably affect lipid and fatty acid metabolism.",
				"text": "A nutritional supplement composed of a milled seed mixture, including milled flax, sesame and pumpkin seeds, in sour milk, with potential anti-inflammatory and lipid-regulating activities. The seeds contain high levels of fatty acids, including omega-3 and omega-6 polyunsaturated fatty acids (PUFAs), such as dihomo-gamma-linolenic acid (DGLA), alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA). Upon administration of the milled seed mix, the intake of PUFAs improves PUFA levels and may favorably change the n-6/n-3 PUFA ratio, decrease triglyceride (TG) levels, and improve body weight. In addition, the active ingredients in the milled seed mix may change the expression of inflammatory markers, such as C-reactive protein (CRP) and pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-a), thereby decreasing inflammation. The milled seed mix may also prevent oxidative stress and affect glycemic control. Tumors cause inflammatory states and unfavorably affect lipid and fatty acid metabolism."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C153380",
			"nciConceptName": "Milled Seed Mix",
			"termId": 793931,
			"name": "milled seed mix",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "milled-seed-mix"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "PIXY321"
				},
				{
					"type": "Synonym",
					"name": "pixykine"
				},
				{
					"type": "Synonym",
					"name": "GM-CSF/IL-3 Fusion Protein"
				},
				{
					"type": "Synonym",
					"name": "GM-CSF/IL3 Fusion Protein"
				},
				{
					"type": "Synonym",
					"name": "Granulocyte-Macrophage Colony Stimulating Factor/Interleukin-3 Fusion Protein"
				},
				{
					"type": "INDCode",
					"name": "4341"
				},
				{
					"type": "NSCNumber",
					"name": "645014"
				}
			],
			"definition": {
				"html": "A recombinant fusion protein derived from the coding sequences of two growth factors, interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF).  Milodistim exhibits greater receptor binding affinity and colony stimulating activity than its parent cytokines.  This agent stimulates proliferation of immature hematopoietic cells and allows the stimulation and expansion of multi-lineage hematopoiesis from immature bone marrow progenitor cells.",
				"text": "A recombinant fusion protein derived from the coding sequences of two growth factors, interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF).  Milodistim exhibits greater receptor binding affinity and colony stimulating activity than its parent cytokines.  This agent stimulates proliferation of immature hematopoietic cells and allows the stimulation and expansion of multi-lineage hematopoiesis from immature bone marrow progenitor cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1477",
			"nciConceptName": "Milodistim",
			"termId": 41615,
			"name": "milodistim",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "milodistim"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "HDPC"
				},
				{
					"type": "Synonym",
					"name": "hexadecylphosphocholine"
				},
				{
					"type": "ChemicalStructureName",
					"name": "2-[[(Hexadecycloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethylethanaminium Inner Salt"
				},
				{
					"type": "Synonym",
					"name": "Choline Phosphate Hexadecyl Ester, Hydroxide, Inner Salt"
				},
				{
					"type": "CodeName",
					"name": "D-18506"
				},
				{
					"type": "ChemicalStructureName",
					"name": "Hexadecyl 2-(N,N,N-trimethylamino)ethyl Phosphate"
				},
				{
					"type": "Synonym",
					"name": "Miltefosin"
				},
				{
					"type": "Synonym",
					"name": "Miltefosina"
				},
				{
					"type": "Synonym",
					"name": "Miltefosinum"
				},
				{
					"type": "ForeignBrandName",
					"name": "Miltex"
				},
				{
					"type": "ChemicalStructureName",
					"name": "n-Hexadecylphosphorylcholine"
				},
				{
					"type": "CASRegistryName",
					"name": "58066-85-6"
				}
			],
			"definition": {
				"html": "An orally- and topically-active alkyl-phosphocholine compound with potential antineoplastic activity.  Miltefosine targets cellular membranes, modulating cell membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  As an immunomodulator, miltefosine stimulates T-cells, macrophages and the expression of interleukin 3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF), and interferon gamma (INF-gamma).",
				"text": "An orally- and topically-active alkyl-phosphocholine compound with potential antineoplastic activity.  Miltefosine targets cellular membranes, modulating cell membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  As an immunomodulator, miltefosine stimulates T-cells, macrophages and the expression of interleukin 3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF), and interferon gamma (INF-gamma)."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1170",
			"nciConceptName": "Miltefosine",
			"termId": 41212,
			"name": "miltefosine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "miltefosine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "P10s-PADRE Vaccine"
				},
				{
					"type": "Synonym",
					"name": "P10s-PADRE"
				}
			],
			"definition": {
				"html": "A peptide-based vaccine containing a carbohydrate mimetic peptide (CMP) P10s fused to the pan HLA DR-binding epitope (PADRE) peptide, with immunomoadjuvant activity and potential antineoplastic activity. Upon injection of the mimotope-P10s-PADRE peptide vaccine, the P10s peptide, which mimics gangliosides and other tumor-associated carbohydrate antigens (TACA), both stimulates a cytotoxic T-lymphocyte (CTL) response towards cells expressing TACAs and induces the production of antibodies that are reactive with a broad set of TACAs. Additionally, the anti-TACA antibodies may interfere with cellular pathways involved in tumor cell survival and may induce antibody-dependent cellular cytotoxicity (ADCC) toward cells expressing TACAs. PADRE is a helper T-cell epitope that is able to increase the magnitude and duration of the CTL response. ",
				"text": "A peptide-based vaccine containing a carbohydrate mimetic peptide (CMP) P10s fused to the pan HLA DR-binding epitope (PADRE) peptide, with immunomoadjuvant activity and potential antineoplastic activity. Upon injection of the mimotope-P10s-PADRE peptide vaccine, the P10s peptide, which mimics gangliosides and other tumor-associated carbohydrate antigens (TACA), both stimulates a cytotoxic T-lymphocyte (CTL) response towards cells expressing TACAs and induces the production of antibodies that are reactive with a broad set of TACAs. Additionally, the anti-TACA antibodies may interfere with cellular pathways involved in tumor cell survival and may induce antibody-dependent cellular cytotoxicity (ADCC) toward cells expressing TACAs. PADRE is a helper T-cell epitope that is able to increase the magnitude and duration of the CTL response. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C123381",
			"nciConceptName": "Mimotope-P10s-PADRE Peptide Vaccine",
			"termId": 703623,
			"name": "mimotope-P10s-PADRE peptide vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mimotope-p10s-padre-peptide-vaccine"
		},
		{
			"preferredName": "triptolide analogue",
			"termId": 753195,
			"name": "Minnelide",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "triptolide-analog"
		},
		{
			"preferredName": "minocycline hydrochloride",
			"termId": 552699,
			"name": "Minocin",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "minocycline-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide Monohydrochloride"
				},
				{
					"type": "USBrandName",
					"name": "Dynacin"
				},
				{
					"type": "Synonym",
					"name": "Minomycin"
				},
				{
					"type": "USBrandName",
					"name": "Minocin"
				},
				{
					"type": "Synonym",
					"name": "Minomax"
				},
				{
					"type": "USBrandName",
					"name": "Vectrin"
				},
				{
					"type": "Synonym",
					"name": "Tri-minocycline"
				},
				{
					"type": "CASRegistryName",
					"name": "13614-98-7"
				}
			],
			"definition": {
				"html": "The hydrochloride salt of minocycline, a broad spectrum long-acting derivative of the antibiotic tetracycline, with antibacterial and anti-inflammatory activities. Minocycline binds to the bacterial 30S ribosomal subunit and interferes with the binding of tRNA to the ribosomal complex, thereby inhibiting protein translation in bacteria. In addition, minocycline  inhibits the inflammatory enzyme 5-lipoxygenase (5LOX) and may impede T cell-microglia interactions; both activities may contribute to minocycline's neuroprotective effects. 5LOX catalyzes the synthesis of inflammatory mediators such as prostaglandins and leukotrienes. ",
				"text": "The hydrochloride salt of minocycline, a broad spectrum long-acting derivative of the antibiotic tetracycline, with antibacterial and anti-inflammatory activities. Minocycline binds to the bacterial 30S ribosomal subunit and interferes with the binding of tRNA to the ribosomal complex, thereby inhibiting protein translation in bacteria. In addition, minocycline  inhibits the inflammatory enzyme 5-lipoxygenase (5LOX) and may impede T cell-microglia interactions; both activities may contribute to minocycline's neuroprotective effects. 5LOX catalyzes the synthesis of inflammatory mediators such as prostaglandins and leukotrienes. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C47622",
			"nciConceptName": "Minocycline Hydrochloride",
			"termId": 552699,
			"name": "minocycline hydrochloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "minocycline-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "M-EDTA"
				}
			],
			"definition": {
				"html": "A combination preparation containing  the broad-spectrum, semi-synthetic tetracycline antibiotic minocycline and the chelator ethylenediaminetetraacetate (EDTA) with antimicrobial and antibiofilm activities. Minocycline exhibits bacteriostatic activity by binding to the bacterial 30S ribosomal subunit and preventing binding of aminoacyl-tRNA to the mRNA-ribosome complex during protein translation; this results in an inhibition of bacterial protein synthesis and, consequently, an inhibition of bacterial cell growth. EDTA may cause the dispersal and killing of biofilms by  chelating metal ions important to the stabilization of  biofilm structure.  The two agents in this combination may act synergistically to eradicate bacteria embedded in biofilms.",
				"text": "A combination preparation containing  the broad-spectrum, semi-synthetic tetracycline antibiotic minocycline and the chelator ethylenediaminetetraacetate (EDTA) with antimicrobial and antibiofilm activities. Minocycline exhibits bacteriostatic activity by binding to the bacterial 30S ribosomal subunit and preventing binding of aminoacyl-tRNA to the mRNA-ribosome complex during protein translation; this results in an inhibition of bacterial protein synthesis and, consequently, an inhibition of bacterial cell growth. EDTA may cause the dispersal and killing of biofilms by  chelating metal ions important to the stabilization of  biofilm structure.  The two agents in this combination may act synergistically to eradicate bacteria embedded in biofilms."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C63545",
			"nciConceptName": "Minocycline-EDTA",
			"termId": 509172,
			"name": "minocycline-EDTA",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "minocycline-edta"
		},
		{
			"preferredName": "thiabendazole",
			"termId": 39713,
			"name": "Mintezol",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "thiabendazole"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "thapsigargin prodrug G-202"
				},
				{
					"type": "CodeName",
					"name": "G-202"
				},
				{
					"type": "CASRegistryName",
					"name": "1245732-48-2"
				}
			],
			"definition": {
				"html": "A soluble, thapsigargin prodrug containing the cytotoxic analog of thapsigargin, 8-O-(12Aminododecanoyl)-8-O debutanoylthapsigargin (12-ADT) linked, via a carboxyl group, to the targeting peptide containing aspartic acid with potential antineoplastic activity. Upon intravenous administration, the non-toxic prodrug targets prostate specific membrane antigen (PSMA), a type II membrane carboxypeptidase, which is overexpressed in prostate cancer cells and in the neovasculature of most solid tumors but not in normal blood vessels. Mipsagargin is subsequently converted, through hydrolysis, into the active cytotoxic analog of thapsigargin 12-ADT-Asp. 12-ADT binds to and blocks the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) pump, thereby increasing the concentration of cytosolic calcium which leads to an induction of apoptosis. By preventing nutrient supply to tumor cells, mipsagargin may be able to inhibit tumor growth. Compared to thapsigargin alone, mipsagargin is able to achieve higher concentrations of the active agents at the tumor site while avoiding systemic toxicity.",
				"text": "A soluble, thapsigargin prodrug containing the cytotoxic analog of thapsigargin, 8-O-(12Aminododecanoyl)-8-O debutanoylthapsigargin (12-ADT) linked, via a carboxyl group, to the targeting peptide containing aspartic acid with potential antineoplastic activity. Upon intravenous administration, the non-toxic prodrug targets prostate specific membrane antigen (PSMA), a type II membrane carboxypeptidase, which is overexpressed in prostate cancer cells and in the neovasculature of most solid tumors but not in normal blood vessels. Mipsagargin is subsequently converted, through hydrolysis, into the active cytotoxic analog of thapsigargin 12-ADT-Asp. 12-ADT binds to and blocks the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) pump, thereby increasing the concentration of cytosolic calcium which leads to an induction of apoptosis. By preventing nutrient supply to tumor cells, mipsagargin may be able to inhibit tumor growth. Compared to thapsigargin alone, mipsagargin is able to achieve higher concentrations of the active agents at the tumor site while avoiding systemic toxicity."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C90554",
			"nciConceptName": "Mipsagargin",
			"termId": 666090,
			"name": "mipsagargin",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mipsagargin"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "2-(2-aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl] acetamide"
				},
				{
					"type": "CodeName",
					"name": "YM 178"
				},
				{
					"type": "CodeName",
					"name": "YM178"
				},
				{
					"type": "ChemicalStructureName",
					"name": "4-thiazoleacetamide, 2-amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)"
				},
				{
					"type": "USBrandName",
					"name": "Myrbetriq"
				},
				{
					"type": "ForeignBrandName",
					"name": "Betanis"
				},
				{
					"type": "CASRegistryName",
					"name": "223673-61-8"
				}
			],
			"definition": {
				"html": "An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic activities.  Upon oral administration, mirabegron binds to and activates ADRB3, which leads to smooth muscle relaxation. Mirabegron also restores sympathetic stimulation in mesenchymal stem cell (MSC) niches, inhibits JAK2-mutated hematopoietic stem cell (HSC) expansion and blocks the progression of myeloproliferative neoplasms (MPNs). Lack of sympathetic stimulation of the MSC and HSC niches is associated with the development of MPNs.",
				"text": "An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic activities.  Upon oral administration, mirabegron binds to and activates ADRB3, which leads to smooth muscle relaxation. Mirabegron also restores sympathetic stimulation in mesenchymal stem cell (MSC) niches, inhibits JAK2-mutated hematopoietic stem cell (HSC) expansion and blocks the progression of myeloproliferative neoplasms (MPNs). Lack of sympathetic stimulation of the MSC and HSC niches is associated with the development of MPNs."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C90633",
			"nciConceptName": "Mirabegron",
			"termId": 767328,
			"name": "mirabegron",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mirabegron"
		},
		{
			"preferredName": "Tc 99m sestamibi",
			"termId": 37878,
			"name": "Miraluma",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "technetium-tc-99m-sestamibi"
		},
		{
			"preferredName": "pramipexole dihydrochloride",
			"termId": 779012,
			"name": "Mirapex",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "pramipexole-dihydrochloride"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "allogeneic Mirasol platelets"
				},
				{
					"type": "Synonym",
					"name": "allogeneic MIR PLTs"
				},
				{
					"type": "Synonym",
					"name": "allogeneic Mirasol PRT-treated platelets"
				}
			],
			"definition": {
				"html": "A preparation of allogeneic platelets that have been treated with Mirasol, a proprietary pathogen reduction technology (PRT) system, and can potentially be used to improve symptoms associated with thrombocytopenia. Upon apheresis, platelets are treated with the patented PRT system, which includes treatment of the platelets with riboflavin (vitamin B2) and broad-spectrum ultraviolet (UV) light. The treatment causes irreversible changes to the RNA and DNA of a broad range of pathogens, including viruses, bacteria, parasites and white blood cells (WBCs), which prevents them from replicating and causing disease. After ex vivo treatment and upon transfusion, the Mirasol-treated allogeneic platelets may reduce thrombocytopenia and prevent bleeding. By preventing the replication of contaminating pathogens, Mirasol treatment improves transfusion safety. Inactivation of WBCs may reduce transfusion reactions and immunological complications in patients.",
				"text": "A preparation of allogeneic platelets that have been treated with Mirasol, a proprietary pathogen reduction technology (PRT) system, and can potentially be used to improve symptoms associated with thrombocytopenia. Upon apheresis, platelets are treated with the patented PRT system, which includes treatment of the platelets with riboflavin (vitamin B2) and broad-spectrum ultraviolet (UV) light. The treatment causes irreversible changes to the RNA and DNA of a broad range of pathogens, including viruses, bacteria, parasites and white blood cells (WBCs), which prevents them from replicating and causing disease. After ex vivo treatment and upon transfusion, the Mirasol-treated allogeneic platelets may reduce thrombocytopenia and prevent bleeding. By preventing the replication of contaminating pathogens, Mirasol treatment improves transfusion safety. Inactivation of WBCs may reduce transfusion reactions and immunological complications in patients."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C134620",
			"nciConceptName": "Mirasol-treated Allogeneic Platelets",
			"termId": 788856,
			"name": "Mirasol-treated allogeneic platelets",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mirasol-treated-allogeneic-platelets"
		},
		{
			"preferredName": "methoxy polyethylene glycol epoetin beta",
			"termId": 339378,
			"name": "Mircera",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "methoxy-polyethylene-glycol-epoetin-beta"
		},
		{
			"preferredName": "levonorgestrel-releasing intrauterine system",
			"termId": 459975,
			"name": "Mirena",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "levonorgestrel-releasing-intrauterine-system"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "GSK2315698"
				},
				{
					"type": "CodeName",
					"name": "GSK 2315698"
				},
				{
					"type": "CodeName",
					"name": "GSK-2315698"
				},
				{
					"type": "CodeName",
					"name": "CPHPC"
				},
				{
					"type": "Abbreviation",
					"name": "CPHPC"
				},
				{
					"type": "ChemicalStructureName",
					"name": "(2R)-1-[6-[(2R)-2-carboxypyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylic acid"
				}
			],
			"definition": {
				"html": "A small molecule compound that depletes serum amyloid P component (SAP), with potential anti-amyloid activity. Upon injection, miridesap binds to circulating SAP, forming complexes that are rapidly cleared in the liver. SAP bound to amyloid deposits is in equilibrium with plasma SAP, and depletion of the latter should lead to the eventual removal of SAP from amyloid deposits as well. SAP is a universal component of amyloid deposits and contributes to the pathogenesis of amyloidosis.",
				"text": "A small molecule compound that depletes serum amyloid P component (SAP), with potential anti-amyloid activity. Upon injection, miridesap binds to circulating SAP, forming complexes that are rapidly cleared in the liver. SAP bound to amyloid deposits is in equilibrium with plasma SAP, and depletion of the latter should lead to the eventual removal of SAP from amyloid deposits as well. SAP is a universal component of amyloid deposits and contributes to the pathogenesis of amyloidosis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C153209",
			"nciConceptName": "Miridesap",
			"termId": 794046,
			"name": "miridesap",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "miridesap"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Remeron"
				},
				{
					"type": "CASRegistryName",
					"name": "61337-67-5"
				}
			],
			"definition": {
				"html": "A synthetic tetracyclic derivative of the piperazino-azepines with antidepressant activity. Although its mechanism of action is unknown, mirtazapine enhances central adrenergic and serotonergic transmission, possibly by acting as an antagonist at central presynaptic alpha 2 adrenergic inhibitory autoreceptors and  heteroreceptors. This agent is a potent antagonist of 5-hydroxytryptamine type 2 (5-HT2), 5-HT3, and histamine 1 (H1) receptors, and a moderate anatgonist of peripheral alpha 1 adrenergic and muscarinic receptors. ",
				"text": "A synthetic tetracyclic derivative of the piperazino-azepines with antidepressant activity. Although its mechanism of action is unknown, mirtazapine enhances central adrenergic and serotonergic transmission, possibly by acting as an antagonist at central presynaptic alpha 2 adrenergic inhibitory autoreceptors and  heteroreceptors. This agent is a potent antagonist of 5-hydroxytryptamine type 2 (5-HT2), 5-HT3, and histamine 1 (H1) receptors, and a moderate anatgonist of peripheral alpha 1 adrenergic and muscarinic receptors. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C29265",
			"nciConceptName": "Mirtazapine",
			"termId": 559298,
			"name": "mirtazapine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mirtazapine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "anti-FOLR1 monoclonal antibody-maytansinoid conjugate IMGN853"
				},
				{
					"type": "CodeName",
					"name": "IMGN853"
				},
				{
					"type": "Synonym",
					"name": "M9346A-sulfo-SPDB-DM4"
				},
				{
					"type": "CASRegistryName",
					"name": "1453084-37-1"
				}
			],
			"definition": {
				"html": "An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agents efficacy in multidrug resistant tumor cells.",
				"text": "An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agents efficacy in multidrug resistant tumor cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C102566",
			"nciConceptName": "Mirvetuximab Soravtansine",
			"termId": 734941,
			"name": "mirvetuximab soravtansine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mirvetuximab-soravtansine"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "Ro-07-0582"
				},
				{
					"type": "ChemicalStructureName",
					"name": "1-(alpha-methoxymethyl ethanol)-2-Nitroimidazole"
				},
				{
					"type": "INDCode",
					"name": "13462"
				},
				{
					"type": "INDCode",
					"name": "16288"
				},
				{
					"type": "NSCNumber",
					"name": "261037"
				},
				{
					"type": "CASRegistryName",
					"name": "13551-87-6"
				}
			],
			"definition": {
				"html": "A nitroimidazole with radiosensitizing and antineoplastic properties. Exhibiting high electron affinity, misonidazole induces the formation of free radicals and depletes radioprotective thiols, thereby sensitizing hypoxic cells to the cytotoxic effects of ionizing radiation. This single-strand breaks in DNA induced by this agent result in the inhibition of DNA synthesis.",
				"text": "A nitroimidazole with radiosensitizing and antineoplastic properties. Exhibiting high electron affinity, misonidazole induces the formation of free radicals and depletes radioprotective thiols, thereby sensitizing hypoxic cells to the cytotoxic effects of ionizing radiation. This single-strand breaks in DNA induced by this agent result in the inhibition of DNA synthesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C657",
			"nciConceptName": "Misonidazole",
			"termId": 39504,
			"name": "misonidazole",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "misonidazole"
		},
		{
			"aliases": [
				{
					"type": "ForeignBrandName",
					"name": "Iscador"
				},
				{
					"type": "Synonym",
					"name": "Viscum"
				},
				{
					"type": "ForeignBrandName",
					"name": "Eurixor"
				},
				{
					"type": "ForeignBrandName",
					"name": "Helixor"
				},
				{
					"type": "ForeignBrandName",
					"name": "Isorel"
				},
				{
					"type": "ForeignBrandName",
					"name": "Vysorel"
				},
				{
					"type": "Synonym",
					"name": "Viscum album Loranthacea"
				},
				{
					"type": "USBrandName",
					"name": "Iscar"
				},
				{
					"type": "ForeignBrandName",
					"name": "Apotheker Bauer's Misteltinktur"
				},
				{
					"type": "ForeignBrandName",
					"name": "Cefalektin"
				},
				{
					"type": "ForeignBrandName",
					"name": "Isugran"
				},
				{
					"type": "ForeignBrandName",
					"name": "Lektinol"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mistel Curarina"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mistel- Krautertabletten"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mistelol-Kapseln"
				},
				{
					"type": "ForeignBrandName",
					"name": "Plenosol N"
				},
				{
					"type": "ForeignBrandName",
					"name": "Viscysat"
				},
				{
					"type": "ForeignBrandName",
					"name": "ABNOBAviscum"
				},
				{
					"type": "CASRegistryName",
					"name": "75882-01-8 (Helixor)"
				},
				{
					"type": "CASRegistryName",
					"name": "53986-31-5 (Iscador)"
				}
			],
			"definition": {
				"html": "An extract of the whole plant Viscum album (mistletoe) with potential biological response modifier (BRM) activity. Mistletoe extract may both stimulate the antitumoral functions of the immune system and have a direct toxic effect on tumor cells.",
				"text": "An extract of the whole plant Viscum album (mistletoe) with potential biological response modifier (BRM) activity. Mistletoe extract may both stimulate the antitumoral functions of the immune system and have a direct toxic effect on tumor cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2703",
			"nciConceptName": "Mistletoe Extract",
			"termId": 41724,
			"name": "mistletoe extract",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mistletoe-extract"
		},
		{
			"preferredName": "plicamycin",
			"termId": 41738,
			"name": "Mithracin",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "plicamycin"
		},
		{
			"preferredName": "sustained-release mitomycin C hydrogel formulation UGN-101",
			"termId": 779705,
			"name": "MitoGel",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "sustained-release-mitomycin-c-hydrogel-formulation-ugn-101"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MGBG"
				},
				{
					"type": "Abbreviation",
					"name": "MGGH"
				},
				{
					"type": "Abbreviation",
					"name": "MeGAG"
				},
				{
					"type": "LexicalVariant",
					"name": "methyl GAG"
				},
				{
					"type": "Abbreviation",
					"name": "methyl-G"
				},
				{
					"type": "Abbreviation",
					"name": "methyl-GAG"
				},
				{
					"type": "ChemicalStructureName",
					"name": "1,1'-[(methylethanediylidene)dinitrilo)diguanidine"
				},
				{
					"type": "ChemicalStructureName",
					"name": "2,2\"-(methyl-1,2-ethanediylidene)bis[hydrazinecarboximidamide]"
				},
				{
					"type": "CodeName",
					"name": "DRG-0223"
				},
				{
					"type": "Synonym",
					"name": "methylglyoxal bisguanylhydrazone"
				},
				{
					"type": "ChemicalStructureName",
					"name": "methylglyoxal bis(amidinohydrazone)"
				},
				{
					"type": "Synonym",
					"name": "mitoguazone dihydrochloride"
				},
				{
					"type": "CodeName",
					"name": "NSC 32946"
				},
				{
					"type": "ForeignBrandName",
					"name": "Zyrkamine"
				},
				{
					"type": "Synonym",
					"name": "pyruvaldehyde bis(amidinohydrazone)"
				},
				{
					"type": "INDCode",
					"name": "927"
				},
				{
					"type": "NSCNumber",
					"name": "32946"
				},
				{
					"type": "CASRegistryName",
					"name": "459-86-9"
				}
			],
			"definition": {
				"html": "A guanylhydrazone with potential antineoplastic activity. Mitoguazone competitively inhibits S-adenosyl-L-methionine decarboxylase (SAMD), an enzyme involved in the synthesis of polyamines, resulting in decreased proliferation of tumor cells, antimitochondrial effects, and p53-independent apoptosis. Polyamines, specifically spermine and spermidine, are essential for thymidine kinase production, DNA synthesis, and cell proliferation.",
				"text": "A guanylhydrazone with potential antineoplastic activity. Mitoguazone competitively inhibits S-adenosyl-L-methionine decarboxylase (SAMD), an enzyme involved in the synthesis of polyamines, resulting in decreased proliferation of tumor cells, antimitochondrial effects, and p53-independent apoptosis. Polyamines, specifically spermine and spermidine, are essential for thymidine kinase production, DNA synthesis, and cell proliferation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C661",
			"nciConceptName": "Mitoguazone",
			"termId": 39500,
			"name": "mitoguazone",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mitoguazone"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "6-dibromodideoxydulcitol"
				},
				{
					"type": "ChemicalStructureName",
					"name": "6-dibromodulcitol"
				},
				{
					"type": "Abbreviation",
					"name": "DBD"
				},
				{
					"type": "Synonym",
					"name": "Dibromdicil"
				},
				{
					"type": "ForeignBrandName",
					"name": "Elobromol"
				},
				{
					"type": "Synonym",
					"name": "dibromodulcitol"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mitolac"
				},
				{
					"type": "INDCode",
					"name": "5217"
				},
				{
					"type": "NSCNumber",
					"name": "104800"
				},
				{
					"type": "CASRegistryName",
					"name": "10318-26-0"
				}
			],
			"definition": {
				"html": "A synthetic derivative of hexitol with antineoplastic and radiosensitizing properties.  Mitolactol alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA and RNA synthesis.",
				"text": "A synthetic derivative of hexitol with antineoplastic and radiosensitizing properties.  Mitolactol alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA and RNA synthesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C662",
			"nciConceptName": "Mitolactol",
			"termId": 39216,
			"name": "mitolactol",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mitolactol"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MITC"
				},
				{
					"type": "Abbreviation",
					"name": "MITO"
				},
				{
					"type": "Abbreviation",
					"name": "MITO-C"
				},
				{
					"type": "Abbreviation",
					"name": "MTC"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mitocin-C"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mito-Medac"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mitolem"
				},
				{
					"type": "ForeignBrandName",
					"name": "Ametycine"
				},
				{
					"type": "ChemicalStructureName",
					"name": "[1aS-(1a alpha,8beta,8a alpha,8b alpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione"
				},
				{
					"type": "ObsoleteName",
					"name": "Mitozytrex"
				},
				{
					"type": "Synonym",
					"name": "mitomycin-X"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mutamycine"
				},
				{
					"type": "ChemicalStructureName",
					"name": "(1aS,8S,8aR,8bS)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione"
				},
				{
					"type": "Synonym",
					"name": "mitomycine C"
				},
				{
					"type": "ObsoleteName",
					"name": "Mutamycin"
				},
				{
					"type": "LexicalVariant",
					"name": "mitomycin-C"
				},
				{
					"type": "CodeName",
					"name": "NCI-C04706"
				},
				{
					"type": "Synonym",
					"name": "mitomycin C"
				},
				{
					"type": "USBrandName",
					"name": "Jelmyto"
				}
			],
			"definition": {
				"html": "A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species. Bioreduced mitomycin generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. ",
				"text": "A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species. Bioreduced mitomycin generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. "
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/mitomycinc",
				"text": "Mitomycin"
			},
			"nciConceptId": "C1820",
			"nciConceptName": "Mitomycin",
			"termId": 42674,
			"name": "mitomycin",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mitomycin"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "T 1101 tosylate"
				},
				{
					"type": "Synonym",
					"name": "T1101 tosylate"
				}
			],
			"definition": {
				"html": "The tosylate salt form of T-1101, an inhibitor of mitosis, with potential antineoplastic activity. Upon oral administration, T-1101 inhibits mitosis, through an as of yet not elucidated mechanism of action, which leads to decreased tumor cell proliferation.",
				"text": "The tosylate salt form of T-1101, an inhibitor of mitosis, with potential antineoplastic activity. Upon oral administration, T-1101 inhibits mitosis, through an as of yet not elucidated mechanism of action, which leads to decreased tumor cell proliferation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C151933",
			"nciConceptName": "Mitosis Inhibitor T 1101 Tosylate",
			"termId": 793127,
			"name": "mitosis inhibitor T 1101 tosylate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mitosis-inhibitor-t-1101-tosylate"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "R1530"
				},
				{
					"type": "Abbreviation",
					"name": "MAI R1530"
				}
			],
			"definition": {
				"html": "A pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. Mitosis-angiogenesis inhibitor (MAI) R1530 inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2. In addition, this agents exhibits anti-proliferative activity by initiating mitotic arrest and inducing apoptosis.",
				"text": "A pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. Mitosis-angiogenesis inhibitor (MAI) R1530 inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2. In addition, this agents exhibits anti-proliferative activity by initiating mitotic arrest and inducing apoptosis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C71710",
			"nciConceptName": "Receptor Tyrosine Kinase Inhibitor R1530",
			"termId": 560180,
			"name": "mitosis-angiogenesis inhibitor R1530",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "receptor-tyrosine-kinase-inhibitor-r1530"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "DDD"
				},
				{
					"type": "USBrandName",
					"name": "Lysodren"
				},
				{
					"type": "Synonym",
					"name": "o,p'-DDD"
				},
				{
					"type": "Abbreviation",
					"name": "o,p'-DDD"
				},
				{
					"type": "ChemicalStructureName",
					"name": "1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane"
				},
				{
					"type": "ChemicalStructureName",
					"name": "1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene"
				},
				{
					"type": "ChemicalStructureName",
					"name": "2,2-bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane"
				},
				{
					"type": "ChemicalStructureName",
					"name": "2,4'-dichlorodiphenyldichloroethane"
				},
				{
					"type": "ChemicalStructureName",
					"name": "2-(2-chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane"
				},
				{
					"type": "CodeName",
					"name": "CB-313"
				},
				{
					"type": "Synonym",
					"name": "Chloditan"
				},
				{
					"type": "Synonym",
					"name": "Chlodithane"
				},
				{
					"type": "Synonym",
					"name": "Khloditan"
				},
				{
					"type": "ForeignBrandName",
					"name": "Lisodren"
				},
				{
					"type": "Synonym",
					"name": "Mytotan"
				},
				{
					"type": "Synonym",
					"name": "Ortho,para-DDD"
				},
				{
					"type": "CodeName",
					"name": "WR-13045"
				},
				{
					"type": "Abbreviation",
					"name": "o,p' - DDD"
				},
				{
					"type": "NSCNumber",
					"name": "38721"
				},
				{
					"type": "CASRegistryName",
					"name": "53-19-0"
				}
			],
			"definition": {
				"html": "A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production.",
				"text": "A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C664",
			"nciConceptName": "Mitotane",
			"termId": 39506,
			"name": "mitotane",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mitotane"
		},
		{
			"aliases": [
				{
					"type": "LexicalVariant",
					"name": "CL 232,315"
				},
				{
					"type": "CodeName",
					"name": "CL 232315"
				},
				{
					"type": "Abbreviation",
					"name": "DHAD"
				},
				{
					"type": "Abbreviation",
					"name": "DHAQ"
				},
				{
					"type": "ObsoleteName",
					"name": "Novantrone"
				},
				{
					"type": "Synonym",
					"name": "dihydroxyanthracenedione"
				},
				{
					"type": "ChemicalStructureName",
					"name": "dihydroxyanthracenedione"
				},
				{
					"type": "Synonym",
					"name": "mitoxantrone HCl"
				},
				{
					"type": "Synonym",
					"name": "mitoxantrone dihydrochloride"
				},
				{
					"type": "ChemicalStructureName",
					"name": "1,3-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthracenedione"
				},
				{
					"type": "ChemicalStructureName",
					"name": "1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthroquinone"
				},
				{
					"type": "Synonym",
					"name": "dihydroxyanthracenedione dihydrochloride"
				},
				{
					"type": "Synonym",
					"name": "mitozantrone"
				},
				{
					"type": "ForeignBrandName",
					"name": "Mitroxone"
				},
				{
					"type": "ForeignBrandName",
					"name": "Neotalem"
				},
				{
					"type": "ForeignBrandName",
					"name": "Onkotrone"
				},
				{
					"type": "ForeignBrandName",
					"name": "Pralifan"
				},
				{
					"type": "INDCode",
					"name": "16802"
				},
				{
					"type": "NSCNumber",
					"name": "301739"
				},
				{
					"type": "NSCNumber",
					"name": "279836"
				},
				{
					"type": "CASRegistryName",
					"name": "65271-80-9"
				}
			],
			"definition": {
				"html": "The hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.",
				"text": "The hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin."
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/mitoxantronehydrochloride",
				"text": "Mitoxantrone Hydrochloride"
			},
			"nciConceptId": "C665",
			"nciConceptName": "Mitoxantrone Hydrochloride",
			"termId": 39219,
			"name": "mitoxantrone hydrochloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mitoxantrone-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "CI-980"
				}
			],
			"definition": {
				"html": "The isethionate salt of mivobulin, a synthetic colchicine analogue with potential antineoplastic activity. Mivobulin isethionate binds to tubulin, thereby inhibiting microtubule polymerization and mitosis. ",
				"text": "The isethionate salt of mivobulin, a synthetic colchicine analogue with potential antineoplastic activity. Mivobulin isethionate binds to tubulin, thereby inhibiting microtubule polymerization and mitosis. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1357",
			"nciConceptName": "Mivobulin Isethionate",
			"termId": 41656,
			"name": "mivobulin isethionate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mivobulin-isethionate"
		},
		{
			"aliases": [
				{
					"type": "Acronym",
					"name": "MBV"
				},
				{
					"type": "Synonym",
					"name": "Coley's toxins"
				}
			],
			"definition": {
				"html": "A cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coleys toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes; the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12).",
				"text": "A cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coleys toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes; the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12)."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C74063",
			"nciConceptName": "Mixed Bacteria Vaccine",
			"termId": 590146,
			"name": "mixed bacteria vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mixed-bacteria-vaccine"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A synthetic small molecule with potential antineoplastic activity. MK0731 selectively inhibits kinesin spindle protein (KSP), which may result in the inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and apoptosis in tumor cells that overexpress KSP.",
				"text": "A synthetic small molecule with potential antineoplastic activity. MK0731 selectively inhibits kinesin spindle protein (KSP), which may result in the inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and apoptosis in tumor cells that overexpress KSP."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C49174",
			"nciConceptName": "MK0731",
			"termId": 446551,
			"name": "MK0731",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mk0731"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "Ro 31-7453"
				},
				{
					"type": "CodeName",
					"name": "R440"
				}
			],
			"definition": {
				"html": "An orally bioavailable, small-molecule,  bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites inhibit tubulin polymerization, blocking the formation of the mitotic spindle, which may result in cell cycle arrest at the G2/M phase and apoptosis. In addition, this agent has been shown to inhibit the activities of the oncogenic kinase Akt, the mTOR pathway, and importin-beta, a protein essential to the transport of other proteins from the cytosol into the nucleus.",
				"text": "An orally bioavailable, small-molecule,  bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites inhibit tubulin polymerization, blocking the formation of the mitotic spindle, which may result in cell cycle arrest at the G2/M phase and apoptosis. In addition, this agent has been shown to inhibit the activities of the oncogenic kinase Akt, the mTOR pathway, and importin-beta, a protein essential to the transport of other proteins from the cytosol into the nucleus."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2507",
			"nciConceptName": "MKC-1",
			"termId": 486351,
			"name": "MKC-1",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mkc-1"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "BAY 1143269"
				}
			],
			"definition": {
				"html": "An orally bioavailable inhibitor of mitogen-activated protein kinase interacting serine/threonine-protein kinase 1 (MKNK1), with potential antineoplastic activity. Upon oral administration, MKNK1 inhibitor BAY 1143269 binds to MKNK1, thereby preventing its activation and the downstream MKNK1-mediated phosphorylation and activation of eukaryotic translation initiation factor 4E (eIF4E). As eIF4E enhances the synthesis of oncogenic proteins, preventing eIF4E activity inhibits the synthesis of tumor angiogenic factors and leads to both the inhibition of cellular proliferation and apoptosis in susceptible tumor cells. eIF4E, overexpressed in a variety of cancer cells, plays a key role in tumor cell proliferation and survival.",
				"text": "An orally bioavailable inhibitor of mitogen-activated protein kinase interacting serine/threonine-protein kinase 1 (MKNK1), with potential antineoplastic activity. Upon oral administration, MKNK1 inhibitor BAY 1143269 binds to MKNK1, thereby preventing its activation and the downstream MKNK1-mediated phosphorylation and activation of eukaryotic translation initiation factor 4E (eIF4E). As eIF4E enhances the synthesis of oncogenic proteins, preventing eIF4E activity inhibits the synthesis of tumor angiogenic factors and leads to both the inhibition of cellular proliferation and apoptosis in susceptible tumor cells. eIF4E, overexpressed in a variety of cancer cells, plays a key role in tumor cell proliferation and survival."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C121956",
			"nciConceptName": "MKNK1 Inhibitor BAY 1143269",
			"termId": 772160,
			"name": "MKNK1 inhibitor BAY 1143269",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mknk1-inhibitor-bay-1143269"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "MLN591DM1"
				},
				{
					"type": "Synonym",
					"name": "DM1-conjugated monoclonal antibody MLN591"
				},
				{
					"type": "Synonym",
					"name": "maytansinoid -1 conjugated with MLN591 monoclonal antibody"
				}
			],
			"definition": {
				"html": "An immunoconjugate that consists of a humanized monoclonal antibody (MLN591), directed against prostate-specific membrane antigen linked to a maytansinoid (DM1). The monoclonal antibody moiety of MLN2704 binds to tumor cells expressing prostate-specific membrane antigen; MLN274 is then internalized into the tumor cell where the DM1 maytansinoid moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, resulting in a disruption of microtubule activity and cell division, and cell death.",
				"text": "An immunoconjugate that consists of a humanized monoclonal antibody (MLN591), directed against prostate-specific membrane antigen linked to a maytansinoid (DM1). The monoclonal antibody moiety of MLN2704 binds to tumor cells expressing prostate-specific membrane antigen; MLN274 is then internalized into the tumor cell where the DM1 maytansinoid moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, resulting in a disruption of microtubule activity and cell division, and cell death."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C26660",
			"nciConceptName": "Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704",
			"termId": 299464,
			"name": "MLN2704",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "anti-psma-monoclonal-antibody-mln591-dm1-immunoconjugate-mln2704"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "ETC-1907206"
				},
				{
					"type": "CodeName",
					"name": "ETC 1907206"
				},
				{
					"type": "CodeName",
					"name": "ETC1907206"
				},
				{
					"type": "CodeName",
					"name": "ETC-206"
				},
				{
					"type": "CodeName",
					"name": "ETC 206"
				},
				{
					"type": "CodeName",
					"name": "ETC206"
				}
			],
			"definition": {
				"html": "A selective mitogen-activated protein kinase (MAPK)-interacting protein kinase (MNK) types 1/2 inhibitor with potential antineoplastic activity. Upon administration, MNK1/2 inhibitor ETC-1907206 may inhibit MNK1/2-dependent phosphorylation of eukaryotic initiation factor 4E (eIF4E) and interfere with its role in mRNA translation. eIF4E is an oncoprotein that must be phosphorylated before it can promote the proliferation and progression of tumor cells. MNKs are a family of serine/threonine kinases that have been implicated in oncogenic transformation and tumor progression.",
				"text": "A selective mitogen-activated protein kinase (MAPK)-interacting protein kinase (MNK) types 1/2 inhibitor with potential antineoplastic activity. Upon administration, MNK1/2 inhibitor ETC-1907206 may inhibit MNK1/2-dependent phosphorylation of eukaryotic initiation factor 4E (eIF4E) and interfere with its role in mRNA translation. eIF4E is an oncoprotein that must be phosphorylated before it can promote the proliferation and progression of tumor cells. MNKs are a family of serine/threonine kinases that have been implicated in oncogenic transformation and tumor progression."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C153262",
			"nciConceptName": "MNK1/2 Inhibitor ETC-1907206",
			"termId": 794054,
			"name": "MNK1/2 inhibitor ETC-1907206",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mnk1-2-inhibitor-etc-1907206"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "manganese (III) ortho N-butoxyethylpyridylporphyrin"
				},
				{
					"type": "ChemicalStructureName",
					"name": "manganese(5+), ((2,2',2'',2'''-(21H,23H-porphine-5,10,15,20-tetrayl-kappaN21,kappaN22,kappaN23,kappaN24)tetrakis(1-(2-butoxyethyl)pyridiniumato))(2-))-, chloride (1:5), (sp-4-1)-"
				},
				{
					"type": "ChemicalStructureName",
					"name": "manganese butoxyethyl pyridyl porphyrin; Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin (SY); MnTnBuOE-3-PyP 5+"
				},
				{
					"type": "Synonym",
					"name": "mitochondrial manganese superoxide dismutatse mimetic BMX-001"
				},
				{
					"type": "CodeName",
					"name": "BMX-001"
				},
				{
					"type": "CASRegistryName",
					"name": "1379783-91-1"
				}
			],
			"definition": {
				"html": "A third generation, cationic, lipophilic, manganese (Mn) and porphyrin-based mimetic of the human mitochondrial manganese superoxide dismutase (MnSOD), with antioxidant and potential chemoprotective activities. Upon administration, MnSOD mimetic BMX-001 is internalized by cells and mimics the activity of MnSOD by scavenging reactive oxygen species (ROS), such as superoxide anion, hydrogen peroxide, and hydroxyl radical. This prevents oxidative damage to macromolecules such as DNA and minimizes oxygen free radical-related chemotoxicity in normal tissues. This agent was designed to be more lipophilic and less toxic than first and second generation Mn-porphyrin mimetics.",
				"text": "A third generation, cationic, lipophilic, manganese (Mn) and porphyrin-based mimetic of the human mitochondrial manganese superoxide dismutase (MnSOD), with antioxidant and potential chemoprotective activities. Upon administration, MnSOD mimetic BMX-001 is internalized by cells and mimics the activity of MnSOD by scavenging reactive oxygen species (ROS), such as superoxide anion, hydrogen peroxide, and hydroxyl radical. This prevents oxidative damage to macromolecules such as DNA and minimizes oxygen free radical-related chemotoxicity in normal tissues. This agent was designed to be more lipophilic and less toxic than first and second generation Mn-porphyrin mimetics."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C125666",
			"nciConceptName": "MnSOD Mimetic BMX-001",
			"termId": 778525,
			"name": "MnSOD mimetic BMX-001",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mnsod-mimetic-bmx-001"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MnSOD-PL"
				},
				{
					"type": "Synonym",
					"name": "manganese superoxide dismutase plasmid liposomes"
				}
			],
			"definition": {
				"html": "A plasmid DNA encoding human manganese superoxide dismutase (MnSOD) and liposomally encapsulated with potential chemoprotective activity. When administered orally and localizing in the esophagus, MnSOD-plasmid liposomes express MnSOD, which scavenges reactive oxygen species (ROS); MnSOD scavenging of ROS may result in a  reduction in ROS-mediated lipid peroxidation, apoptosis, and micro-ulceration in the epithelial lining of the esophagus.",
				"text": "A plasmid DNA encoding human manganese superoxide dismutase (MnSOD) and liposomally encapsulated with potential chemoprotective activity. When administered orally and localizing in the esophagus, MnSOD-plasmid liposomes express MnSOD, which scavenges reactive oxygen species (ROS); MnSOD scavenging of ROS may result in a  reduction in ROS-mediated lipid peroxidation, apoptosis, and micro-ulceration in the epithelial lining of the esophagus."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C74054",
			"nciConceptName": "Liposomal MnSOD Plasmid",
			"termId": 589811,
			"name": "MnSOD-plasmid liposomes",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "liposomal-mnsod-plasmid"
		},
		{
			"preferredName": "meloxicam",
			"termId": 472195,
			"name": "Mobec",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "meloxicam"
		},
		{
			"preferredName": "meloxicam",
			"termId": 472195,
			"name": "Mobic",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "meloxicam"
		},
		{
			"preferredName": "meloxicam",
			"termId": 472195,
			"name": "Mobicox",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "meloxicam"
		},
		{
			"preferredName": "adenovirus-expressing TLR5/TLR5 agonist nanoformulation M-VM3",
			"termId": 786108,
			"name": "Mobilan",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "adenovirus-expressing-tlr5-tlr5-agonist-nanoformulation-m-vm3"
		},
		{
			"preferredName": "recombinant flt3 ligand",
			"termId": 42928,
			"name": "Mobista",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "recombinant-flt3-ligand"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "MGCD0103"
				},
				{
					"type": "ChemicalStructureName",
					"name": "benzamide, N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]-"
				},
				{
					"type": "ChemicalStructureName",
					"name": "N-(2-aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide"
				}
			],
			"definition": {
				"html": "A rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activity.  Mocetinostat binds to and inhibits Class 1 isoforms of HDAC, specifically HDAC 1, 2 and 3, which may result in epigenetic changes in tumor cells and  so tumor cell death; although the exact mechanism has yet to be defined, tumor cell death may occur through  the induction of apoptosis, differentiation, cell cycle arrest, inhibition of DNA repair, upregulation of tumor suppressors, down regulation of growth factors, oxidative stress, and autophagy, among others. Overexpression of Class I HDACs 1, 2 and 3 has been found in many tumors and has been correlated with a poor prognosis.",
				"text": "A rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activity.  Mocetinostat binds to and inhibits Class 1 isoforms of HDAC, specifically HDAC 1, 2 and 3, which may result in epigenetic changes in tumor cells and  so tumor cell death; although the exact mechanism has yet to be defined, tumor cell death may occur through  the induction of apoptosis, differentiation, cell cycle arrest, inhibition of DNA repair, upregulation of tumor suppressors, down regulation of growth factors, oxidative stress, and autophagy, among others. Overexpression of Class I HDACs 1, 2 and 3 has been found in many tumors and has been correlated with a poor prognosis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C62521",
			"nciConceptName": "Mocetinostat",
			"termId": 486941,
			"name": "mocetinostat",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mocetinostat"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Provigil"
				}
			],
			"definition": {
				"html": "A synthetic central nervous system stimulant with wakefulness-promoting activity. Modafinil appears to inhibit dopamine reuptake, resulting in an increase in extracellular dopamine.  This agent exhibits pronounced wakefulness-promoting activity (without sympathomimetic activity) and may improve cognitive function in certain clinical settings.",
				"text": "A synthetic central nervous system stimulant with wakefulness-promoting activity. Modafinil appears to inhibit dopamine reuptake, resulting in an increase in extracellular dopamine.  This agent exhibits pronounced wakefulness-promoting activity (without sympathomimetic activity) and may improve cognitive function in certain clinical settings."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C26661",
			"nciConceptName": "Modafinil",
			"termId": 256449,
			"name": "modafinil",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "modafinil"
		},
		{
			"preferredName": "ethinyl estradiol/norethindrone",
			"termId": 759182,
			"name": "Modicon",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "ethinyl-estradiol-norethindrone"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "PectaSol-C"
				}
			],
			"definition": {
				"html": "A dietary supplement containing the modified citrus pectin (MCP) derived from the soluble fiber of citrus fruit peels and a galectin-3 inhibitor with potential antioxidant, hypocholesterolemic, immunostimulatory, metal chelating, and anti-metastatic activities. MCP is a low molecular weight version of pectin composed of short, slightly-branched carbohydrate chains and is modified for enhanced absorbability. The bioactive fragments, most likely the galactan-containing portion, of pectin binds to galectin-3, a carbohydrate-binding protein involved in imflammation, heart disease and is upregulated on the surface of certain types of tumor cells. Binding of MCP may result in the suppression of cancer cell aggregation, adhesion, proliferation and metastasis. In addition, MCP decreases prostate specific antigen (PSA) levels and may remove heavy metals. Also, unsaturated oligogalacturonic acids in MCP may stimulate the immune system through the activation of natural killer cells, cytotoxic T-cells, and B-cells.",
				"text": "A dietary supplement containing the modified citrus pectin (MCP) derived from the soluble fiber of citrus fruit peels and a galectin-3 inhibitor with potential antioxidant, hypocholesterolemic, immunostimulatory, metal chelating, and anti-metastatic activities. MCP is a low molecular weight version of pectin composed of short, slightly-branched carbohydrate chains and is modified for enhanced absorbability. The bioactive fragments, most likely the galactan-containing portion, of pectin binds to galectin-3, a carbohydrate-binding protein involved in imflammation, heart disease and is upregulated on the surface of certain types of tumor cells. Binding of MCP may result in the suppression of cancer cell aggregation, adhesion, proliferation and metastasis. In addition, MCP decreases prostate specific antigen (PSA) levels and may remove heavy metals. Also, unsaturated oligogalacturonic acids in MCP may stimulate the immune system through the activation of natural killer cells, cytotoxic T-cells, and B-cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C103178",
			"nciConceptName": "Modified Citrus Pectin Supplement",
			"termId": 740207,
			"name": "modified citrus pectin supplement",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "modified-citrus-pectin-supplement"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MVA-BN-HER2 vaccine"
				},
				{
					"type": "ForeignBrandName",
					"name": "MVA-BN Breast"
				}
			],
			"definition": {
				"html": "A cancer vaccine consisting of a  proprietary, recombinant modified vaccinia Ankara (MVA) viral vector encoding an epitope of human epidermal growth factor receptor 2 (HER2) with potential antineoplastic activity. Upon administration, modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine may stimulate the host immune system to mount  humoral and cytotoxic T lymphocyte responses against HER2-expressing tumor cells, resulting in tumor cell lysis. HER2, also known as ErbB-2, is a  tyrosine kinase growth factor receptor and a member of the epidermal growth factor receptor family; it plays a significant role in the pathogenesis of some breast cancers.",
				"text": "A cancer vaccine consisting of a  proprietary, recombinant modified vaccinia Ankara (MVA) viral vector encoding an epitope of human epidermal growth factor receptor 2 (HER2) with potential antineoplastic activity. Upon administration, modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine may stimulate the host immune system to mount  humoral and cytotoxic T lymphocyte responses against HER2-expressing tumor cells, resulting in tumor cell lysis. HER2, also known as ErbB-2, is a  tyrosine kinase growth factor receptor and a member of the epidermal growth factor receptor family; it plays a significant role in the pathogenesis of some breast cancers."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C71758",
			"nciConceptName": "Modified Vaccinia Ankara (Bavarian Nordic)-HER2 Vaccine",
			"termId": 558806,
			"name": "modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "modified-vaccinia-ankara-bavarian-nordic-her2-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MVAp53 vaccine"
				},
				{
					"type": "Abbreviation",
					"name": "MVA-p53 vaccine"
				},
				{
					"type": "Synonym",
					"name": "p53MVA"
				},
				{
					"type": "Synonym",
					"name": "p53MVA vaccine"
				},
				{
					"type": "Synonym",
					"name": "MVAp53"
				}
			],
			"definition": {
				"html": "A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the wild-type form of the tumor protein p53 (wt p53), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with MVA vaccine expressing p53, the expressed p53 may stimulate the host immune system to mount a p53-specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing p53, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain and is incapable of virion assembly. The p53 gene, a tumor suppressor gene, is mutated in many cancer cell types.",
				"text": "A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the wild-type form of the tumor protein p53 (wt p53), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with MVA vaccine expressing p53, the expressed p53 may stimulate the host immune system to mount a p53-specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing p53, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain and is incapable of virion assembly. The p53 gene, a tumor suppressor gene, is mutated in many cancer cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C116868",
			"nciConceptName": "Modified Vaccinia Virus Ankara Vaccine Expressing p53",
			"termId": 683738,
			"name": "modified vaccinia virus ankara vaccine expressing p53",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "modified-vaccinia-virus-ankara-vaccine-expressing-p53"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "EF-022"
				},
				{
					"type": "Synonym",
					"name": "MVDP-macrophage activator"
				},
				{
					"type": "Synonym",
					"name": "modified VDBP-macrophage activator EF-022"
				}
			],
			"definition": {
				"html": "A modified version of vitamin D binding protein (VDBP; Gc protein) macrophage activator, with potential antineoplastic and anti-angiogenic activities. Upon administration, modified VDBP-macrophage activator EF-022, acting in a similar manner as VDBP-macrophage activating factor (GcMAF), is able to activate tumoricidal macrophages, thereby enhancing the killing and eradication of cancer cells. In addition, EF-022 may inhibit tumor cell proliferation, migration and angiogenesis. VDBP is a glycoprotein and precursor for macrophage activating factor (MAF), which promotes macrophage activation; however VDBP can be deglycosylated by serum alpha-N-acetylgalactosaminidase, which is secreted from cancerous cells, and cannot be converted to MAF. Thus, the macrophage activation cascade is often impaired in tumor cells and plays a key role in tumor immunosuppression. Modification of VDBP stabilizes MAF.",
				"text": "A modified version of vitamin D binding protein (VDBP; Gc protein) macrophage activator, with potential antineoplastic and anti-angiogenic activities. Upon administration, modified VDBP-macrophage activator EF-022, acting in a similar manner as VDBP-macrophage activating factor (GcMAF), is able to activate tumoricidal macrophages, thereby enhancing the killing and eradication of cancer cells. In addition, EF-022 may inhibit tumor cell proliferation, migration and angiogenesis. VDBP is a glycoprotein and precursor for macrophage activating factor (MAF), which promotes macrophage activation; however VDBP can be deglycosylated by serum alpha-N-acetylgalactosaminidase, which is secreted from cancerous cells, and cannot be converted to MAF. Thus, the macrophage activation cascade is often impaired in tumor cells and plays a key role in tumor immunosuppression. Modification of VDBP stabilizes MAF."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C131824",
			"nciConceptName": "Modified Vitamin D Binding Protein Macrophage Activator EF-022",
			"termId": 786093,
			"name": "modified vitamin D binding protein macrophage activator EF-022",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "modified-vitamin-d-binding-protein-macrophage-activator-ef-022"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "CTAP101"
				},
				{
					"type": "USBrandName",
					"name": "Rayaldee"
				}
			],
			"definition": {
				"html": "An orally available, modified-release formulation containing the calcitriol prohormone, calcifediol (25-hydroxyvitamin D), which can potentially be used for vitamin D supplementation. Upon oral administration of the modified-release calcifediol capsule, calcifediol is slowly and gradually released in the gastrointestinal tract. Then it is taken up by the body and converted, in the kidneys, to the active form calcitriol (1,25-dihydroxyvitamin D or 1,25 D). This form increases and normalizes vitamin D plasma levels, which, in turn, regulates calcium plasma levels, and normalizes elevated parathyroid hormone (PTH) levels by suppressing both PTH synthesis, and secretion. This formulation appears to have fewer side effects than supplementation with formulations containing active 1,25 D and does not stimulate the upregulation of vitamin D 24-hydroxylase (CYP24), a cytochrome P-450 family enzyme that inactivates vitamin D.",
				"text": "An orally available, modified-release formulation containing the calcitriol prohormone, calcifediol (25-hydroxyvitamin D), which can potentially be used for vitamin D supplementation. Upon oral administration of the modified-release calcifediol capsule, calcifediol is slowly and gradually released in the gastrointestinal tract. Then it is taken up by the body and converted, in the kidneys, to the active form calcitriol (1,25-dihydroxyvitamin D or 1,25 D). This form increases and normalizes vitamin D plasma levels, which, in turn, regulates calcium plasma levels, and normalizes elevated parathyroid hormone (PTH) levels by suppressing both PTH synthesis, and secretion. This formulation appears to have fewer side effects than supplementation with formulations containing active 1,25 D and does not stimulate the upregulation of vitamin D 24-hydroxylase (CYP24), a cytochrome P-450 family enzyme that inactivates vitamin D."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C118789",
			"nciConceptName": "Modified-release Calcifediol Capsule",
			"termId": 766479,
			"name": "modified-release calcifediol capsule",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "modified-release-calcifediol-capsule"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "zatuximab"
				},
				{
					"type": "CodeName",
					"name": "1024 DS"
				},
				{
					"type": "CodeName",
					"name": "1024-DS"
				},
				{
					"type": "CASRegistryName",
					"name": "1310460-86-6"
				}
			],
			"definition": {
				"html": "A recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, modotuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibition EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, often is overexpressed on the cell surfaces of various solid tumor cell types.",
				"text": "A recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, modotuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibition EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, often is overexpressed on the cell surfaces of various solid tumor cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C152075",
			"nciConceptName": "Modotuximab",
			"termId": 793840,
			"name": "modotuximab",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "modotuximab"
		},
		{
			"preferredName": "trilostane",
			"termId": 39812,
			"name": "Modrastane",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "trilostane"
		},
		{
			"preferredName": "arfolitixorin",
			"termId": 796585,
			"name": "Modufolin",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "arfolitixorin"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "RiMO-301"
				}
			],
			"definition": {
				"html": "A nanoparticle-based metal-organic framework (MOF) compound composed of proprietary X-ray-absorbing metals, with potential radiosensitizing properties. Upon intratumoral administration and subsequent irradiation of the tumor site, RiMO-301 absorbs the X-ray photons and produces reactive oxygen species (ROS), such as hydroxyl radicals and singlet oxygen, which induces ROS-mediated DNA damage in the irradiated cancer cells leading to tumor cell lysis. In addition, RiMO-301 may also contain an as of yet unidentified immunomodulating agent loaded into the channels/pores of the construct that may induce an immune response against the tumor-associated antigens (TAAs) released by the lysed tumor cells, thereby locally killing additional tumor and non-tumor cells. MOFs, porous crystalline materials composed of metal clusters and organic linkers, generate ROS at much lower X-ray dosages than used in standard radiotherapy, which results in reduced radiation exposure and X-ray damage to normal, healthy cells.",
				"text": "A nanoparticle-based metal-organic framework (MOF) compound composed of proprietary X-ray-absorbing metals, with potential radiosensitizing properties. Upon intratumoral administration and subsequent irradiation of the tumor site, RiMO-301 absorbs the X-ray photons and produces reactive oxygen species (ROS), such as hydroxyl radicals and singlet oxygen, which induces ROS-mediated DNA damage in the irradiated cancer cells leading to tumor cell lysis. In addition, RiMO-301 may also contain an as of yet unidentified immunomodulating agent loaded into the channels/pores of the construct that may induce an immune response against the tumor-associated antigens (TAAs) released by the lysed tumor cells, thereby locally killing additional tumor and non-tumor cells. MOFs, porous crystalline materials composed of metal clusters and organic linkers, generate ROS at much lower X-ray dosages than used in standard radiotherapy, which results in reduced radiation exposure and X-ray damage to normal, healthy cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C148280",
			"nciConceptName": "MOF Compound RiMO-301",
			"termId": 795715,
			"name": "MOF compound RiMO-301",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mof-compound-rimo-301"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "mogamulizumab"
				},
				{
					"type": "USBrandName",
					"name": "Poteligeo"
				},
				{
					"type": "Synonym",
					"name": "Anti-CCR4 monoclonal antibody KW-0761"
				},
				{
					"type": "CodeName",
					"name": "KW-0761"
				}
			],
			"definition": {
				"html": "A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for   C-C chemokines  such MIP-1, RANTES, TARC and MCP-1, is  expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194,  may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.",
				"text": "A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for   C-C chemokines  such MIP-1, RANTES, TARC and MCP-1, is  expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194,  may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells."
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/mogamulizumabkpkc",
				"text": "Mogamulizumab-kpkc"
			},
			"nciConceptId": "C62510",
			"nciConceptName": "Mogamulizumab",
			"termId": 500479,
			"name": "mogamulizumab-kpkc",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mogamulizumab"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "WO2085"
				},
				{
					"type": "CodeName",
					"name": "WO 2085"
				},
				{
					"type": "CodeName",
					"name": "WO-2085"
				}
			],
			"definition": {
				"html": "A vaginal moisturizing cream that may be used to relieve vulvovaginal dryness. Upon intravaginal administration of the moisturizing cream WO2085, the as of yet not specified ingredients in the cream may help moisturize vaginal tissue and relieve the discomfort that is associated with vaginal dryness.\n",
				"text": "A vaginal moisturizing cream that may be used to relieve vulvovaginal dryness. Upon intravaginal administration of the moisturizing cream WO2085, the as of yet not specified ingredients in the cream may help moisturize vaginal tissue and relieve the discomfort that is associated with vaginal dryness.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C165544",
			"nciConceptName": "Moisturizing Cream WO2085",
			"termId": 799500,
			"name": "moisturizing cream WO2085",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "moisturizing-cream-wo2085"
		},
		{
			"aliases": [
				{
					"type": "CASRegistryName",
					"name": "1895049-20-3"
				},
				{
					"type": "ChemicalStructureName",
					"name": "2-((4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepin-4-yl)-N-ethylacetamide monobenzenesulfonate salt"
				},
				{
					"type": "CodeName",
					"name": "GSK525762C"
				}
			],
			"definition": {
				"html": "The besylate salt of molibresib, a small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, molibresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, comprising of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.",
				"text": "The besylate salt of molibresib, a small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, molibresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, comprising of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C159943",
			"nciConceptName": "Molibresib Besylate",
			"termId": 801626,
			"name": "molibresib besylate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "molibresib-besylate"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "Mo"
				},
				{
					"type": "CASRegistryName",
					"name": "7439-98-7"
				}
			],
			"definition": {
				"html": "An element with atomic symbol Mo, atomic number 42, and atomic weight 95.94.",
				"text": "An element with atomic symbol Mo, atomic number 42, and atomic weight 95.94."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C666",
			"nciConceptName": "Molybdenum",
			"termId": 38724,
			"name": "molybdenum",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "molybdenum"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "CYT387"
				},
				{
					"type": "Synonym",
					"name": "JAK1/2 inhibitor CYT387"
				},
				{
					"type": "CodeName",
					"name": "GS-0387"
				}
			],
			"definition": {
				"html": "An orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity. Momelotinib competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction  of apoptosis and a reduction of  tumor cell proliferation in JAK1/2-expressing tumor cells. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.\n",
				"text": "An orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity. Momelotinib competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction  of apoptosis and a reduction of  tumor cell proliferation in JAK1/2-expressing tumor cells. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C88311",
			"nciConceptName": "Momelotinib",
			"termId": 660135,
			"name": "momelotinib",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "momelotinib"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Elocon"
				},
				{
					"type": "ChemicalStructureName",
					"name": "(11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione"
				}
			],
			"definition": {
				"html": "The furoate salt form of mometasone, a synthetic topical glucocorticosteroid receptor agonist with anti-inflammatory, anti-pruritic and vasoconstrictive properties. Mometasone furoate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.. Specifically, mometasone furoate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from phospholipid membrane by phospholipase A2. ",
				"text": "The furoate salt form of mometasone, a synthetic topical glucocorticosteroid receptor agonist with anti-inflammatory, anti-pruritic and vasoconstrictive properties. Mometasone furoate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.. Specifically, mometasone furoate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from phospholipid membrane by phospholipase A2. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C29268",
			"nciConceptName": "Mometasone Furoate",
			"termId": 531049,
			"name": "mometasone furoate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mometasone-furoate"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "anti-NKG2A monoclonal antibody IPH2201"
				},
				{
					"type": "CodeName",
					"name": "IPH2201"
				}
			],
			"definition": {
				"html": "A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis.",
				"text": "A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C120208",
			"nciConceptName": "Monalizumab",
			"termId": 768226,
			"name": "monalizumab",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monalizumab"
		},
		{
			"preferredName": "tafasitamab-cxix",
			"termId": 682091,
			"name": "Monjuvi",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "tafasitamab"
		},
		{
			"preferredName": "salsalate",
			"termId": 801902,
			"name": "Mono-Gesic",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "salsalate"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MBEH"
				},
				{
					"type": "Synonym",
					"name": "monobenzyl ether of hydroquinone"
				},
				{
					"type": "USBrandName",
					"name": "Benoquin"
				},
				{
					"type": "NSCNumber",
					"name": "33918"
				},
				{
					"type": "CASRegistryName",
					"name": "103-16-2"
				}
			],
			"definition": {
				"html": "A monobenzyl ether of hydroquinone with topical depigmentation activity. Although the exact mechanism of action of depigmentation is unknown, the metabolites of monobenzone appear to have a cytotoxic effect on melanocytes. Furthermore, the depigmentation effect might be mediated through the inhibition of tyrosinase, which is essential in the synthesis of melanin pigments, thereby causing permanent depigmentation of the skin.",
				"text": "A monobenzyl ether of hydroquinone with topical depigmentation activity. Although the exact mechanism of action of depigmentation is unknown, the metabolites of monobenzone appear to have a cytotoxic effect on melanocytes. Furthermore, the depigmentation effect might be mediated through the inhibition of tyrosinase, which is essential in the synthesis of melanin pigments, thereby causing permanent depigmentation of the skin."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C992",
			"nciConceptName": "Monobenzone",
			"termId": 39494,
			"name": "monobenzone",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monobenzone"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "AZD3965"
				},
				{
					"type": "Synonym",
					"name": "MCT1 inhibitor AZD3965"
				}
			],
			"definition": {
				"html": "An orally available inhibitor of monocarboxylate transporter 1 (MCT1), with potential antineoplastic activity. Upon oral administration, MCT1 inhibitor AZD3965 binds to MCT1 and prevents the transport of lactate into and out of the cell. This leads to an accumulation of lactate, intracellular acidification, and eventually cancer cell death. MCT1, a protein overexpressed on tumor cells, is responsible for the transport of monocarboxylates across the cell membrane and plays a key role in cell metabolism.",
				"text": "An orally available inhibitor of monocarboxylate transporter 1 (MCT1), with potential antineoplastic activity. Upon oral administration, MCT1 inhibitor AZD3965 binds to MCT1 and prevents the transport of lactate into and out of the cell. This leads to an accumulation of lactate, intracellular acidification, and eventually cancer cell death. MCT1, a protein overexpressed on tumor cells, is responsible for the transport of monocarboxylates across the cell membrane and plays a key role in cell metabolism."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C105399",
			"nciConceptName": "Monocarboxylate Transporter 1 Inhibitor AZD3965",
			"termId": 746809,
			"name": "monocarboxylate transporter 1 inhibitor AZD3965",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monocarboxylate-transporter-1-inhibitor-azd3965"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "105AD7"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB 105AD7"
				}
			],
			"definition": {
				"html": "A cancer vaccine consisting of a humanized monoclonal antibody that mimics a tumor-associated antigen 791Tgp72 (also known as CD55). Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing CD55, resulting in tumor cell lysis.",
				"text": "A cancer vaccine consisting of a humanized monoclonal antibody that mimics a tumor-associated antigen 791Tgp72 (also known as CD55). Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing CD55, resulting in tumor cell lysis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2648",
			"nciConceptName": "Monoclonal Antibody 105AD7 Anti-idiotype Vaccine",
			"termId": 38413,
			"name": "monoclonal antibody 105AD7 anti-idiotype vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-105ad7-anti-idiotype-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "11D10 anti-idiotype vaccine"
				},
				{
					"type": "LexicalVariant",
					"name": "11D10 anti-idiotype vaccine, monoclonal antibody"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB 11D10 VAC"
				},
				{
					"type": "USBrandName",
					"name": "TriAb"
				},
				{
					"type": "Synonym",
					"name": "vaccine, MOAB 11D10 anti-idiotype"
				},
				{
					"type": "Synonym",
					"name": "TriAb anti-idiotype antibody"
				}
			],
			"definition": {
				"html": "A vaccine consisting of a monoclonal antibody (MoAB) directed against an idiotype that mimics a human milk fat globule (HMFG) membrane epitope.  Vaccination with monoclonal antibody 11D10 anti-idiotype vaccine induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope.",
				"text": "A vaccine consisting of a monoclonal antibody (MoAB) directed against an idiotype that mimics a human milk fat globule (HMFG) membrane epitope.  Vaccination with monoclonal antibody 11D10 anti-idiotype vaccine induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2606",
			"nciConceptName": "Monoclonal Antibody 11D10 Anti-Idiotype Vaccine",
			"termId": 38135,
			"name": "monoclonal antibody 11D10 anti-idiotype vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-11d10-anti-idiotype-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "14G2A"
				},
				{
					"type": "Synonym",
					"name": "14G2A, monoclonal antibody"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB 14G2A"
				},
				{
					"type": "Synonym",
					"name": "antibody 14G2A, monoclonal"
				},
				{
					"type": "INDCode",
					"name": "3204"
				},
				{
					"type": "NSCNumber",
					"name": "624345"
				}
			],
			"definition": {
				"html": "A murine monoclonal antibody directed against the ganglioside GD2 with potential antineoplastic activity. Monoclonal antibody 14G2A binds to the ganglioside GD2 and induces antibody-dependent cell mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.",
				"text": "A murine monoclonal antibody directed against the ganglioside GD2 with potential antineoplastic activity. Monoclonal antibody 14G2A binds to the ganglioside GD2 and induces antibody-dependent cell mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2368",
			"nciConceptName": "Monoclonal Antibody 14G2A",
			"termId": 41244,
			"name": "monoclonal antibody 14G2A",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-14g2a"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "3F8"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB 3F8"
				},
				{
					"type": "LexicalVariant",
					"name": "3F8 Monoclonal Antibody"
				},
				{
					"type": "Synonym",
					"name": "anti-Ganglioside (GD2) Monoclonal Antibody 3F8"
				}
			],
			"definition": {
				"html": "A murine monoclonal antibody directed against the cell-surface, tumor-associated antigen ganglioside GD2. Vaccination with monoclonal antibody 3F8 may stimulate a host cytotoxic immune response against tumors that express ganglioside GD2.",
				"text": "A murine monoclonal antibody directed against the cell-surface, tumor-associated antigen ganglioside GD2. Vaccination with monoclonal antibody 3F8 may stimulate a host cytotoxic immune response against tumors that express ganglioside GD2."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2370",
			"nciConceptName": "Monoclonal Antibody 3F8",
			"termId": 41259,
			"name": "monoclonal antibody 3F8",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-3f8"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "3H1 anti-idiotype vaccine"
				},
				{
					"type": "USBrandName",
					"name": "CeaVac"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB 3H1"
				},
				{
					"type": "Synonym",
					"name": "MOAB 3H1 anti-idiotype vaccine"
				},
				{
					"type": "Synonym",
					"name": "CEA-Vac"
				},
				{
					"type": "NSCNumber",
					"name": "720063"
				}
			],
			"definition": {
				"html": "A recombinant monoclonal antibody in which the heavy and light chain variable domains mimic a specific epitope of the tumor-associated protein carcinoembryonic antigen (CEA).  This agent is used as a cancer vaccine against tumors that express CEA.",
				"text": "A recombinant monoclonal antibody in which the heavy and light chain variable domains mimic a specific epitope of the tumor-associated protein carcinoembryonic antigen (CEA).  This agent is used as a cancer vaccine against tumors that express CEA."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2424",
			"nciConceptName": "Monoclonal Antibody 3H1 Anti-Idiotype Vaccine",
			"termId": 42652,
			"name": "monoclonal antibody 3H1 anti-idiotype vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-3h1-anti-idiotype-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "4B5 monoclonal antibody anti-idiotype vaccine"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB 4B5"
				},
				{
					"type": "Synonym",
					"name": "MOAB 4B5 anti-idiotype vaccine"
				}
			],
			"definition": {
				"html": "A humanized anti-idiotypic (anti-Id) monoclonal antibody (MoAb) that mimics the disialoganglioside GD2 with potential immunostimulating and antineoplastic activities.  Upon administration, monoclonal antibody 4B5 anti-idiotype vaccine may elicit both cellular and humoral immune responses against GD2- expressing tumor cells. GD2 is a  glycosphingolipid (ceramide and oligosaccharide) that may be highly expressed by melanomas and other neuroectodermal tumors, while only minimally expressed by normal tissues. ",
				"text": "A humanized anti-idiotypic (anti-Id) monoclonal antibody (MoAb) that mimics the disialoganglioside GD2 with potential immunostimulating and antineoplastic activities.  Upon administration, monoclonal antibody 4B5 anti-idiotype vaccine may elicit both cellular and humoral immune responses against GD2- expressing tumor cells. GD2 is a  glycosphingolipid (ceramide and oligosaccharide) that may be highly expressed by melanomas and other neuroectodermal tumors, while only minimally expressed by normal tissues. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2227",
			"nciConceptName": "Monoclonal Antibody 4B5 Anti-Idiotype Vaccine",
			"termId": 37797,
			"name": "monoclonal antibody 4B5 anti-idiotype vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-4b5-anti-idiotype-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "A27.15"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB A27.15"
				},
				{
					"type": "Synonym",
					"name": "ANTI-TRANSFERRIN MOAB 27.15"
				},
				{
					"type": "INDCode",
					"name": "7237"
				},
				{
					"type": "NSCNumber",
					"name": "644261"
				}
			],
			"definition": {
				"html": "A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody A27.15 binds to the Tf receptor, blocking the binding of transferrin to the receptor and resulting in decreased tumor cell growth.",
				"text": "A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody A27.15 binds to the Tf receptor, blocking the binding of transferrin to the receptor and resulting in decreased tumor cell growth."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2447",
			"nciConceptName": "Monoclonal Antibody A27.15",
			"termId": 42834,
			"name": "monoclonal antibody A27.15",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-a2715"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "A33 monoclonal antibody"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB A33"
				},
				{
					"type": "Synonym",
					"name": "A33"
				}
			],
			"definition": {
				"html": "A humanized monoclonal antibody directed against the human A33 antigen.  Monoclonal antibody A33 recognizes the human A33 antigen, a 43 KDa transmembrane glycoprotein of the immunoglobulin superfamily, which is highly and homogenously expressed in 95% of colorectal cancer metastases with only restricted expression in normal colonic mucosa. ",
				"text": "A humanized monoclonal antibody directed against the human A33 antigen.  Monoclonal antibody A33 recognizes the human A33 antigen, a 43 KDa transmembrane glycoprotein of the immunoglobulin superfamily, which is highly and homogenously expressed in 95% of colorectal cancer metastases with only restricted expression in normal colonic mucosa. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2410",
			"nciConceptName": "Monoclonal Antibody A33",
			"termId": 42527,
			"name": "monoclonal antibody A33",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-a33"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "AbGn-7"
				}
			],
			"definition": {
				"html": "A chimeric monoclonal antibody against a Lewis-A-like glycotope (AbGn-7 antigen) with potential immunomodulating and antineoplastic activities. Monoclonal antibody AbGn-7 targets and binds to the carbohydrate AbGn-7 antigen on the cell surface of tumor cells and may induce complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), thereby killing AbGn-7-epitope positive tumor cells. AbGn-7 antigen is expressed on a variety of tumor cell types, including human colorectal, pancreatic and gastric tumor cells.",
				"text": "A chimeric monoclonal antibody against a Lewis-A-like glycotope (AbGn-7 antigen) with potential immunomodulating and antineoplastic activities. Monoclonal antibody AbGn-7 targets and binds to the carbohydrate AbGn-7 antigen on the cell surface of tumor cells and may induce complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), thereby killing AbGn-7-epitope positive tumor cells. AbGn-7 antigen is expressed on a variety of tumor cell types, including human colorectal, pancreatic and gastric tumor cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C99162",
			"nciConceptName": "Monoclonal Antibody AbGn-7",
			"termId": 717457,
			"name": "monoclonal antibody AbGn-7",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-abgn-7"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "AK002"
				},
				{
					"type": "CodeName",
					"name": "AK 002"
				},
				{
					"type": "Synonym",
					"name": "monoclonal antibody AK 002"
				}
			],
			"definition": {
				"html": "A therapeutic monoclonal antibody against an as-of-yet unidentified target expressed on mast cells and eosinophils. Upon administration, AK002 targets and binds to a receptor expressed on the surface of mast cells and eosinophils. This may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against cells overexpressing the undisclosed receptor. This may reduce abnormal proliferation of mast cells and eosinophils, which play a key role in allergic and inflammatory responses.",
				"text": "A therapeutic monoclonal antibody against an as-of-yet unidentified target expressed on mast cells and eosinophils. Upon administration, AK002 targets and binds to a receptor expressed on the surface of mast cells and eosinophils. This may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against cells overexpressing the undisclosed receptor. This may reduce abnormal proliferation of mast cells and eosinophils, which play a key role in allergic and inflammatory responses."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C129591",
			"nciConceptName": "Monoclonal Antibody AK002",
			"termId": 783857,
			"name": "monoclonal antibody AK002",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-ak002"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "ASP1948"
				},
				{
					"type": "CodeName",
					"name": "ASP 1948"
				},
				{
					"type": "CodeName",
					"name": "ASP-1948"
				},
				{
					"type": "CodeName",
					"name": "PTZ-329"
				},
				{
					"type": "CodeName",
					"name": "PTZ329"
				},
				{
					"type": "CodeName",
					"name": "PTZ 329"
				}
			],
			"definition": {
				"html": "A monoclonal antibody targeting a not yet disclosed immunomodulatory receptor, with potential antineoplastic activities. Upon intravenous administration, monoclonal antibody ASP1948 binds to its not yet disclosed target, which may stimulate an immune-mediated response against tumor cells.",
				"text": "A monoclonal antibody targeting a not yet disclosed immunomodulatory receptor, with potential antineoplastic activities. Upon intravenous administration, monoclonal antibody ASP1948 binds to its not yet disclosed target, which may stimulate an immune-mediated response against tumor cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C156402",
			"nciConceptName": "Monoclonal Antibody ASP1948",
			"termId": 795699,
			"name": "monoclonal antibody ASP1948",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-asp1948"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "CAL"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB CAL"
				}
			],
			"definition": {
				"html": "A humanized monoclonal antibody directed against parathyroid hormone-related protein (PTH-rP). As a poly-hormone with diverse biological roles, PTH-rP is expressed by normal tissues, acting in local tissue environments in a variety of ways; it is commonly overexpressed by breast, prostate, and other cancers, acting systemically by promoting bone resorption, inhibiting calcium excretion from the kidney, inducing hypercalcemia, and possibly playing a role in the formation of bony metastases. By blocking the effects of PTH-rP on calcium metabolism, monoclonal antibody CAL may inhibit cancer-related hypercalcemia.",
				"text": "A humanized monoclonal antibody directed against parathyroid hormone-related protein (PTH-rP). As a poly-hormone with diverse biological roles, PTH-rP is expressed by normal tissues, acting in local tissue environments in a variety of ways; it is commonly overexpressed by breast, prostate, and other cancers, acting systemically by promoting bone resorption, inhibiting calcium excretion from the kidney, inducing hypercalcemia, and possibly playing a role in the formation of bony metastases. By blocking the effects of PTH-rP on calcium metabolism, monoclonal antibody CAL may inhibit cancer-related hypercalcemia."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2659",
			"nciConceptName": "Monoclonal Antibody CAL",
			"termId": 38505,
			"name": "monoclonal antibody CAL",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-cal"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "CC49"
				},
				{
					"type": "LexicalVariant",
					"name": "CC49 monoclonal antibody"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB CC49"
				},
				{
					"type": "Synonym",
					"name": "antibody CC49, monoclonal"
				},
				{
					"type": "Synonym",
					"name": "monoclonal antibody CC-49"
				},
				{
					"type": "Synonym",
					"name": "CC-49 Monoclonal Antibody"
				},
				{
					"type": "Abbreviation",
					"name": "MAb CC49"
				},
				{
					"type": "Synonym",
					"name": "MOAB CC-49/TAG72 (DW)"
				},
				{
					"type": "INDCode",
					"name": "3006"
				},
				{
					"type": "INDCode",
					"name": "6218"
				},
				{
					"type": "INDCode",
					"name": "4427"
				},
				{
					"type": "INDCode",
					"name": "3088"
				},
				{
					"type": "INDCode",
					"name": "3496"
				},
				{
					"type": "NSCNumber",
					"name": "620537"
				}
			],
			"definition": {
				"html": "A second-generation murine monoclonal antibody based on the antibody B72.3 that is directed against tumor-associated glycoprotein 72 (TAG72).  TAG72 is expressed by gastric, breast, pancreatic, colorectal, and ovarian carcinoma cells.",
				"text": "A second-generation murine monoclonal antibody based on the antibody B72.3 that is directed against tumor-associated glycoprotein 72 (TAG72).  TAG72 is expressed by gastric, breast, pancreatic, colorectal, and ovarian carcinoma cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2567",
			"nciConceptName": "Minretumomab",
			"termId": 41760,
			"name": "monoclonal antibody CC49",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "minretumomab"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MOAB CC49-deltaCH2"
				},
				{
					"type": "Synonym",
					"name": "MOAB HCC49DCH2"
				},
				{
					"type": "Synonym",
					"name": "MoAb HuCC49DeltaCH2"
				},
				{
					"type": "Synonym",
					"name": "Monoclonal Antibody HCC49DCH2"
				},
				{
					"type": "INDCode",
					"name": "9260"
				},
				{
					"type": "NSCNumber",
					"name": "696081"
				}
			],
			"definition": {
				"html": "A humanized CH2 domain-deleted second-generation monoclonal antibody based on the antibody B72.3 that is directed against tumor-associated glycoprotein 72 (TAG72).  TAG72 is expressed by gastric, breast, pancreatic, colorectal, and ovarian carcinoma cells.",
				"text": "A humanized CH2 domain-deleted second-generation monoclonal antibody based on the antibody B72.3 that is directed against tumor-associated glycoprotein 72 (TAG72).  TAG72 is expressed by gastric, breast, pancreatic, colorectal, and ovarian carcinoma cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2698",
			"nciConceptName": "Monoclonal Antibody CC49-delta CH2",
			"termId": 38456,
			"name": "monoclonal antibody CC49-delta CH2",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-cc49-delta-ch2"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "CEP-37250/KHK2804"
				}
			],
			"definition": {
				"html": "A humanized monoclonal antibody targeting glycolipids, with potential immunomodulating and antineoplastic activity. Upon administration, monoclonal antibody CEP-37250/KHK2804 targets and binds to a specific tumor antigen, thereby stimulating the immune system to exert an antibody-dependent cellular cytotoxicity (ADCC) against the tumor associated antigen (TAA)-expressing cancer cells. This agent has shown to be active in both wild-type and mutant K-RAS-expressing colorectal cancer cells.",
				"text": "A humanized monoclonal antibody targeting glycolipids, with potential immunomodulating and antineoplastic activity. Upon administration, monoclonal antibody CEP-37250/KHK2804 targets and binds to a specific tumor antigen, thereby stimulating the immune system to exert an antibody-dependent cellular cytotoxicity (ADCC) against the tumor associated antigen (TAA)-expressing cancer cells. This agent has shown to be active in both wild-type and mutant K-RAS-expressing colorectal cancer cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C98296",
			"nciConceptName": "Monoclonal Antibody CEP-37250/KHK2804",
			"termId": 714212,
			"name": "monoclonal antibody CEP-37250/KHK2804",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-cep-37250-khk2804"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "E2.3"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB E2.3"
				},
				{
					"type": "Synonym",
					"name": "Anti-Transferrin MOAB E2.3"
				},
				{
					"type": "INDCode",
					"name": "7237"
				},
				{
					"type": "NSCNumber",
					"name": "644262"
				}
			],
			"definition": {
				"html": "A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody E2.3 binds to the Tf receptor, blocking the binding of transferrin to the receptor and resulting in decreased tumor cell growth.",
				"text": "A murine IgG1 monoclonal antibody directed against the human transferrin (Tf) receptor. Monoclonal antibody E2.3 binds to the Tf receptor, blocking the binding of transferrin to the receptor and resulting in decreased tumor cell growth."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2448",
			"nciConceptName": "Monoclonal Antibody E2.3",
			"termId": 42835,
			"name": "monoclonal antibody E2.3",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-e23"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A class of vaccines that consist of anti-idiotype monoclonal antibodies against the tumor-associated antigen disialoganglioside GD2 with potential antineoplastic activity.  Vaccination with a monoclonal antibody GD2 anti-idiotype vaccine produces an immunoglobulin response against GD2 with subsequent destruction of GD2 positive tumor cells via antibody-dependent cellular cytotoxicity (ADCC).  GD2 is overexpressed in melanoma, neuroblastoma, soft tissue sarcoma, and small cell carcinoma of the lung.",
				"text": "A class of vaccines that consist of anti-idiotype monoclonal antibodies against the tumor-associated antigen disialoganglioside GD2 with potential antineoplastic activity.  Vaccination with a monoclonal antibody GD2 anti-idiotype vaccine produces an immunoglobulin response against GD2 with subsequent destruction of GD2 positive tumor cells via antibody-dependent cellular cytotoxicity (ADCC).  GD2 is overexpressed in melanoma, neuroblastoma, soft tissue sarcoma, and small cell carcinoma of the lung."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C26450",
			"nciConceptName": "Monoclonal Antibody GD2 Anti-Idiotype Vaccine",
			"termId": 257174,
			"name": "monoclonal antibody GD2 anti-idiotype vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-gd2-anti-idiotype-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MOAB HeFi-1"
				},
				{
					"type": "Synonym",
					"name": "HeFi-1"
				},
				{
					"type": "INDCode",
					"name": "2400"
				},
				{
					"type": "INDCode",
					"name": "9848"
				},
				{
					"type": "NSCNumber",
					"name": "603573"
				}
			],
			"definition": {
				"html": "A murine monoclonal antibody with potential antineoplastic activity. Monoclonal antibody HeFi-1 binds to CD30, a cell surface antigen found on mitogen-activated B-cells and T-cells, and Reed-Sternberg cells.  Monoclonal antibody HeFi-1 has been shown to arrest tumor growth and prevent metastasis in animal models.",
				"text": "A murine monoclonal antibody with potential antineoplastic activity. Monoclonal antibody HeFi-1 binds to CD30, a cell surface antigen found on mitogen-activated B-cells and T-cells, and Reed-Sternberg cells.  Monoclonal antibody HeFi-1 has been shown to arrest tumor growth and prevent metastasis in animal models."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2505",
			"nciConceptName": "Monoclonal Antibody HeFi-1",
			"termId": 43332,
			"name": "monoclonal antibody HeFi-1",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-hefi-1"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "Hu3S193"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB Hu3S193"
				}
			],
			"definition": {
				"html": "A humanized monoclonal antibody directed against the Lewis Y antigen, a tumor-associated epithelial antigen, with potential antineoplastic activity. Following binding, monoclonal antibody Hu3S193 triggers an antibody-dependent cell-mediated cytotoxicity in cells expressing Lewis Y antigen. ",
				"text": "A humanized monoclonal antibody directed against the Lewis Y antigen, a tumor-associated epithelial antigen, with potential antineoplastic activity. Following binding, monoclonal antibody Hu3S193 triggers an antibody-dependent cell-mediated cytotoxicity in cells expressing Lewis Y antigen. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2547",
			"nciConceptName": "Monoclonal Antibody Hu3S193",
			"termId": 38031,
			"name": "monoclonal antibody Hu3S193",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-hu3s193"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MOAB HuAFP31"
				},
				{
					"type": "LexicalVariant",
					"name": "Monoclonal Antibody HuAPF31"
				}
			],
			"definition": {
				"html": "A humanized monoclonal antibody directed against alpha fetoprotein with potential antineoplastic activity. Upon administration, monoclonal antibody HuAFP31 (mAb HuAFP31)  binds to and stimulates a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein.",
				"text": "A humanized monoclonal antibody directed against alpha fetoprotein with potential antineoplastic activity. Upon administration, monoclonal antibody HuAFP31 (mAb HuAFP31)  binds to and stimulates a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C48407",
			"nciConceptName": "Monoclonal Antibody HuAFP31",
			"termId": 425344,
			"name": "monoclonal antibody HuAFP31",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-huafp31"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "AS1402"
				},
				{
					"type": "Synonym",
					"name": "humanized human milk fat globule-1 monoclonal antibody"
				},
				{
					"type": "ForeignBrandName",
					"name": "Therex"
				},
				{
					"type": "CodeName",
					"name": "R1550"
				},
				{
					"type": "Synonym",
					"name": "humanized IgG1 monoclonal antibody HMFG-1"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB HuHMFG1"
				},
				{
					"type": "Abbreviation",
					"name": "HuHMFG1"
				}
			],
			"definition": {
				"html": "A humanized monoclonal antibody directed against MUC1, a mucin glycoprotein overexpressed in breast and other carcinomas.  Monoclonal antibody HuHMFG1 stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing MUC1, resulting in a decrease in tumor burden.",
				"text": "A humanized monoclonal antibody directed against MUC1, a mucin glycoprotein overexpressed in breast and other carcinomas.  Monoclonal antibody HuHMFG1 stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing MUC1, resulting in a decrease in tumor burden."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C38697",
			"nciConceptName": "Monoclonal Antibody HuHMFG1",
			"termId": 322247,
			"name": "monoclonal antibody HuHMFG1",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-huhmfg1"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MOAB HuPAM4"
				}
			],
			"definition": {
				"html": "A humanized monoclonal antibody directed against the pancreatic cancer antigen MUC1 with potential antineoplastic activity. Monoclonal antibody HuPAM4 (mAb HuPAM4) binds to cells expressing MUC1 antigen; mAb HuPAM4 may be useful as a carrier for radioisotopes and other antineoplastic therapeutic agents. ",
				"text": "A humanized monoclonal antibody directed against the pancreatic cancer antigen MUC1 with potential antineoplastic activity. Monoclonal antibody HuPAM4 (mAb HuPAM4) binds to cells expressing MUC1 antigen; mAb HuPAM4 may be useful as a carrier for radioisotopes and other antineoplastic therapeutic agents. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C48408",
			"nciConceptName": "Monoclonal Antibody HuPAM4",
			"termId": 425351,
			"name": "monoclonal antibody HuPAM4",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-hupam4"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "L6"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB L6"
				},
				{
					"type": "INDCode",
					"name": "2990"
				}
			],
			"definition": {
				"html": "A murine IgG2a monoclonal antibody with potential antineoplastic activity. Monoclonal antibody L6 binds to the L6 antigen, a cell surface glycoprotein overexpressed in many carcinomas, and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against L6-expressing tumor cells.  This agent may be conjugated with various toxins in order to target their cytotoxic activity to tumor cells expressing the L6 antigen.",
				"text": "A murine IgG2a monoclonal antibody with potential antineoplastic activity. Monoclonal antibody L6 binds to the L6 antigen, a cell surface glycoprotein overexpressed in many carcinomas, and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against L6-expressing tumor cells.  This agent may be conjugated with various toxins in order to target their cytotoxic activity to tumor cells expressing the L6 antigen."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2372",
			"nciConceptName": "Monoclonal Antibody L6",
			"termId": 41472,
			"name": "monoclonal antibody L6",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-l6"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "IgG2a murine monoclonal antibody Lym-1"
				},
				{
					"type": "Synonym",
					"name": "Lym-1"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB Lym-1"
				},
				{
					"type": "Synonym",
					"name": "monoclonal antibody Lym-1, IgG2a murine"
				},
				{
					"type": "INDCode",
					"name": "3097"
				},
				{
					"type": "NSCNumber",
					"name": "620858"
				}
			],
			"definition": {
				"html": "A murine IgG2a monoclonal antibody directed against the HLA-Dr10 protein, a cell surface marker present on over eighty percent of lymphoma cells.  When conjugated with a radioactive isotope, Lym-1 monoclonal antibody selectively transports the cytotoxic radioisotope to HLA-Dr10-expressing tumor cells, thereby sparing healthy B-cells and normal tissues.  This agent also mediates antibody-dependent cytotoxicity thereby promoting Raji B-lymphoid cell lysis by human neutrophils.",
				"text": "A murine IgG2a monoclonal antibody directed against the HLA-Dr10 protein, a cell surface marker present on over eighty percent of lymphoma cells.  When conjugated with a radioactive isotope, Lym-1 monoclonal antibody selectively transports the cytotoxic radioisotope to HLA-Dr10-expressing tumor cells, thereby sparing healthy B-cells and normal tissues.  This agent also mediates antibody-dependent cytotoxicity thereby promoting Raji B-lymphoid cell lysis by human neutrophils."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1561",
			"nciConceptName": "Monoclonal Antibody Lym-1",
			"termId": 41126,
			"name": "monoclonal antibody Lym-1",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-lym-1"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A panadenocarcinoma murine monoclonal antibody with potential antineoplastic activity.  Monoclonal antibody m170 may be conjugated with a radioactive element and used in radioimmunotherapy (RIT), a procedure that uses a tumor-specific monoclonal antibody to target radiation to cancer cells.",
				"text": "A panadenocarcinoma murine monoclonal antibody with potential antineoplastic activity.  Monoclonal antibody m170 may be conjugated with a radioactive element and used in radioimmunotherapy (RIT), a procedure that uses a tumor-specific monoclonal antibody to target radiation to cancer cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2610",
			"nciConceptName": "Monoclonal Antibody M170",
			"termId": 38169,
			"name": "monoclonal antibody m170",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-m170"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MOAB Me1-14 F(ab')2"
				},
				{
					"type": "Synonym",
					"name": "Me1-14 F(ab')2"
				},
				{
					"type": "LexicalVariant",
					"name": "Me1-14 F(ab')2 monoclonal antibody"
				}
			],
			"definition": {
				"html": "The F(ab)2 fragment of Me1-14, a murine IgG2a monoclonal antibody directed against proteoglycan chondroitin sulfate-associated protein expressed by gliomas and melanomas.  By binding to proteoglycan chondroitin sulfate-associated protein, monoclonal antibody Me1-14 F(ab')2 conjugated to a radioisotope may localize gliomas and melanomas when used as a tracer in radioimaging applications; in radioimmunotherapeutic applications, this agent conjugated to a radioisotope may be used to deliver targeted radiotoxicity to these tumors.",
				"text": "The F(ab)2 fragment of Me1-14, a murine IgG2a monoclonal antibody directed against proteoglycan chondroitin sulfate-associated protein expressed by gliomas and melanomas.  By binding to proteoglycan chondroitin sulfate-associated protein, monoclonal antibody Me1-14 F(ab')2 conjugated to a radioisotope may localize gliomas and melanomas when used as a tracer in radioimaging applications; in radioimmunotherapeutic applications, this agent conjugated to a radioisotope may be used to deliver targeted radiotoxicity to these tumors."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2409",
			"nciConceptName": "Monoclonal Antibody Me1-14 F(ab')2",
			"termId": 42523,
			"name": "monoclonal antibody Me1-14 F(ab')2",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-me1-14-fab2"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MOAB Mik-beta-1"
				}
			],
			"definition": {
				"html": "A murine monoclonal antibody directed against the beta subunit of the interleukin-2 receptor (IL-2R), expressed on resting T-lymphocytes, natural killer (NK) cells, and some leukemic cell types.  Monoclonal antibody Mik-beta-1 prevents the binding of IL-2 to IL-2R beta, thereby inhibiting the IL-2-mediated proliferation and activation of T-cells.",
				"text": "A murine monoclonal antibody directed against the beta subunit of the interleukin-2 receptor (IL-2R), expressed on resting T-lymphocytes, natural killer (NK) cells, and some leukemic cell types.  Monoclonal antibody Mik-beta-1 prevents the binding of IL-2 to IL-2R beta, thereby inhibiting the IL-2-mediated proliferation and activation of T-cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2669",
			"nciConceptName": "Monoclonal Antibody Mik-Beta-1",
			"termId": 38589,
			"name": "monoclonal antibody Mik-beta-1",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-mik-beta-1"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "NEO-201"
				},
				{
					"type": "CodeName",
					"name": "NEO 201"
				},
				{
					"type": "CodeName",
					"name": "NEO201"
				},
				{
					"type": "Synonym",
					"name": "neoantigen-targeting antibody NEO-201"
				},
				{
					"type": "Synonym",
					"name": "h16C3"
				},
				{
					"type": "Synonym",
					"name": "h16C3 antibody"
				}
			],
			"definition": {
				"html": "A humanized immunoglobulin G1 (IgG1) monoclonal antibody derived from an immunogenic preparation of tumor-associated antigens (TAAs) from pooled allogeneic colon cancer tissue extracts, with potential antineoplastic and immunomodulatory activities. Upon intravenous administration, monoclonal antibody NEO-201 targets and binds to malignant tissues with tumor-specific mutations in the membrane-anchored proteins, carcinoembryonic antigen-related cell adhesion molecules 5 and 6 (CEACAM5 and CEACAM6). This prevents the interaction between tumor cell CEACAM 5 and natural killer (NK) cell CEACAM1, and reverses CEACAM1-dependent inhibition of NK cytotoxicity. This may result in the activation of NKs and results in NK-mediated tumor cell killing. Additionally, monoclonal antibody NEO-201 may activate innate immune responses against tumor cells such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CEACAM 5, and 6 are members of the CEA family of proteins. These membrane proteins are over expressed in a variety of cancer cell types and play a key role in cell migration, invasion, and adhesion.",
				"text": "A humanized immunoglobulin G1 (IgG1) monoclonal antibody derived from an immunogenic preparation of tumor-associated antigens (TAAs) from pooled allogeneic colon cancer tissue extracts, with potential antineoplastic and immunomodulatory activities. Upon intravenous administration, monoclonal antibody NEO-201 targets and binds to malignant tissues with tumor-specific mutations in the membrane-anchored proteins, carcinoembryonic antigen-related cell adhesion molecules 5 and 6 (CEACAM5 and CEACAM6). This prevents the interaction between tumor cell CEACAM 5 and natural killer (NK) cell CEACAM1, and reverses CEACAM1-dependent inhibition of NK cytotoxicity. This may result in the activation of NKs and results in NK-mediated tumor cell killing. Additionally, monoclonal antibody NEO-201 may activate innate immune responses against tumor cells such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CEACAM 5, and 6 are members of the CEA family of proteins. These membrane proteins are over expressed in a variety of cancer cell types and play a key role in cell migration, invasion, and adhesion."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C156398",
			"nciConceptName": "Monoclonal Antibody NEO-201",
			"termId": 795513,
			"name": "monoclonal antibody NEO-201",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-neo-201"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MOAB R24"
				},
				{
					"type": "Synonym",
					"name": "R24"
				},
				{
					"type": "INDCode",
					"name": "2380"
				},
				{
					"type": "INDCode",
					"name": "3802"
				},
				{
					"type": "NSCNumber",
					"name": "608918"
				},
				{
					"type": "NSCNumber",
					"name": "733504"
				}
			],
			"definition": {
				"html": "An IgG murine monoclonal antibody directed against the ganglioside GD3 glycolipid, located in the cell membranes of some tumor cells.  Monoclonal antibody R24 binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells.",
				"text": "An IgG murine monoclonal antibody directed against the ganglioside GD3 glycolipid, located in the cell membranes of some tumor cells.  Monoclonal antibody R24 binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2349",
			"nciConceptName": "Monoclonal Antibody R24",
			"termId": 39362,
			"name": "monoclonal antibody R24",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-r24"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "RAV12"
				},
				{
					"type": "Synonym",
					"name": "anti-RAAG12 monoclonal antibody"
				},
				{
					"type": "Abbreviation",
					"name": "anti-RAAG12 MOAB"
				}
			],
			"definition": {
				"html": "A chimeric monoclonal antibody directed against a primate-restricted N-linked carbohydrate epitope (glycotope) expressed on various human carcinomas with potential antineoplastic activity. Following binding, monoclonal antibody RAV12 disrupts sodium channels of tumor cells expressing this glycotope, resulting in cell and organelle swelling, loss of membrane integrity, and cell death.",
				"text": "A chimeric monoclonal antibody directed against a primate-restricted N-linked carbohydrate epitope (glycotope) expressed on various human carcinomas with potential antineoplastic activity. Following binding, monoclonal antibody RAV12 disrupts sodium channels of tumor cells expressing this glycotope, resulting in cell and organelle swelling, loss of membrane integrity, and cell death."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C48409",
			"nciConceptName": "Monoclonal Antibody RAV12",
			"termId": 415732,
			"name": "monoclonal antibody RAV12",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-rav12"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "SGN-30"
				}
			],
			"definition": {
				"html": "A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Monoclonal antibody SGN-30 specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations.",
				"text": "A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Monoclonal antibody SGN-30 specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2007",
			"nciConceptName": "Brentuximab",
			"termId": 357600,
			"name": "monoclonal antibody SGN-30",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "brentuximab"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "TRK-950"
				},
				{
					"type": "CodeName",
					"name": "TRK 950"
				}
			],
			"definition": {
				"html": "A proprietary monoclonal antibody targeting an as of yet undisclosed tumor-associated antigen (TAA), with potential antineoplastic activity. Although the mechanism of action has not been elucidated presumably monoclonal antibody TRK-950 binds to a specific TAA on the cell surface of tumor cells and may induce complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This may lead to the death of tumor cells expressing the TAA.",
				"text": "A proprietary monoclonal antibody targeting an as of yet undisclosed tumor-associated antigen (TAA), with potential antineoplastic activity. Although the mechanism of action has not been elucidated presumably monoclonal antibody TRK-950 binds to a specific TAA on the cell surface of tumor cells and may induce complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This may lead to the death of tumor cells expressing the TAA."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C142826",
			"nciConceptName": "Monoclonal Antibody TRK-950",
			"termId": 791700,
			"name": "monoclonal antibody TRK-950",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-antibody-trk-950"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "EDP1503"
				},
				{
					"type": "CodeName",
					"name": "EDP 1503"
				},
				{
					"type": "CodeName",
					"name": "EDP-1503"
				}
			],
			"definition": {
				"html": "An orally available preparation derived from a single clone of Bifidobacterium spp. with potential immunomodulatory and antineoplastic activities. Upon oral administration, monoclonal microbial EDP1503 colonizes the gut and may, through a not yet fully elucidated mechanism, promote the activation of dendritic cells (DCs), and enhance the induction and infiltration of cytotoxic T-lymphocytes (CTLs) in the tumor microenvironment (TME). Bifidobacterium is a genus of anaerobic, Gram-positive bacteria, with some species being a commensal part of the human gastrointestinal tract and vaginal flora. \n",
				"text": "An orally available preparation derived from a single clone of Bifidobacterium spp. with potential immunomodulatory and antineoplastic activities. Upon oral administration, monoclonal microbial EDP1503 colonizes the gut and may, through a not yet fully elucidated mechanism, promote the activation of dendritic cells (DCs), and enhance the induction and infiltration of cytotoxic T-lymphocytes (CTLs) in the tumor microenvironment (TME). Bifidobacterium is a genus of anaerobic, Gram-positive bacteria, with some species being a commensal part of the human gastrointestinal tract and vaginal flora. \n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C155907",
			"nciConceptName": "Monoclonal Microbial EDP1503",
			"termId": 795263,
			"name": "monoclonal microbial EDP1503",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-microbial-edp1503"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "IMCgp100"
				},
				{
					"type": "Synonym",
					"name": "ImmTAC-gp100"
				}
			],
			"definition": {
				"html": "A fusion protein containing a modified form of human T-cell receptor (TCR) specific for the gp100 antigen and fused to an anti-CD3 single-chain antibody fragment, with potential antineoplastic activity. Upon direct intratumoral administration of IMCgp100 into the melanoma lesion, the TCR moiety of this agent targets and binds to the tumor associated antigen (TAA) gp100 presented on the melanoma tumor cell; the anti-CD3 fragment moiety binds to CD3- expressing T lymphocytes, thereby selectively cross-linking tumor cells and T-lymphocytes. This may lead to the recruitment of cytotoxic T lymphocytes (CTL) to the T lymphocyte/tumor cell aggregates and result in CTL-mediated death of gp100-expressing melanoma cancer cells.",
				"text": "A fusion protein containing a modified form of human T-cell receptor (TCR) specific for the gp100 antigen and fused to an anti-CD3 single-chain antibody fragment, with potential antineoplastic activity. Upon direct intratumoral administration of IMCgp100 into the melanoma lesion, the TCR moiety of this agent targets and binds to the tumor associated antigen (TAA) gp100 presented on the melanoma tumor cell; the anti-CD3 fragment moiety binds to CD3- expressing T lymphocytes, thereby selectively cross-linking tumor cells and T-lymphocytes. This may lead to the recruitment of cytotoxic T lymphocytes (CTL) to the T lymphocyte/tumor cell aggregates and result in CTL-mediated death of gp100-expressing melanoma cancer cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C94208",
			"nciConceptName": "Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100",
			"termId": 686537,
			"name": "monoclonal T-cell receptor anti-CD3 scFv fusion protein IMCgp100",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monoclonal-t-cell-receptor-anti-cd3-scfv-fusion-protein-imcgp100"
		},
		{
			"preferredName": "iron isomaltoside 1000",
			"termId": 680696,
			"name": "Monofer",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "iron-isomaltoside-1000"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "3-deacylated monophosphoryl lipid A"
				},
				{
					"type": "ChemicalStructureName",
					"name": "3-O-desacyl-4'-monophosphoryl lipid A"
				},
				{
					"type": "Abbreviation",
					"name": "MPL"
				},
				{
					"type": "Abbreviation",
					"name": "MPLA"
				}
			],
			"definition": {
				"html": "A modified form of lipid A, the biologically active part of Gram-negative bacterial lipopolysaccharide (LPS) endotoxin, and a Toll-like receptor 4 (TL=\nR4) agonist, with potential immunostimulatory activity. As a vaccine adjuvant, monophosphoryl lipid A (MPLA) stimulates both cellular and humoral responses to the vaccine antigen. Compared to LPS, MPLA exerts a similar immunostimulatory activity but with reduced toxicity.",
				"text": "A modified form of lipid A, the biologically active part of Gram-negative bacterial lipopolysaccharide (LPS) endotoxin, and a Toll-like receptor 4 (TL=\nR4) agonist, with potential immunostimulatory activity. As a vaccine adjuvant, monophosphoryl lipid A (MPLA) stimulates both cellular and humoral responses to the vaccine antigen. Compared to LPS, MPLA exerts a similar immunostimulatory activity but with reduced toxicity."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": null,
			"nciConceptName": null,
			"termId": 732707,
			"name": "monophosphoryl lipid A",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monophosphoryl-lipid-a"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "GM1"
				},
				{
					"type": "Abbreviation",
					"name": "GM-1"
				},
				{
					"type": "Synonym",
					"name": "ganglioside GM1"
				},
				{
					"type": "Synonym",
					"name": "monosialoanglioside GM1"
				}
			],
			"definition": {
				"html": "A glycosphingolipid containing a sialic acid residue found in neuronal cell membranes, with potential neuroprotective and neuroregenerative activities. Upon administration, monosialotetrahexosylganglioside, also called GM-1, is able to both prevent neurologic damage and induce regeneration of damaged neurons through neurotrophic repair mechanisms, enhancement of the production of neutrophins, and augmenting neurite outgrowth. In addition, GM-1 exerts anti-excitotoxic activity, prevents necrosis, and improves neuronal recovery and function.",
				"text": "A glycosphingolipid containing a sialic acid residue found in neuronal cell membranes, with potential neuroprotective and neuroregenerative activities. Upon administration, monosialotetrahexosylganglioside, also called GM-1, is able to both prevent neurologic damage and induce regeneration of damaged neurons through neurotrophic repair mechanisms, enhancement of the production of neutrophins, and augmenting neurite outgrowth. In addition, GM-1 exerts anti-excitotoxic activity, prevents necrosis, and improves neuronal recovery and function."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C107389",
			"nciConceptName": "Monosialotetrahexosylganglioside",
			"termId": 751157,
			"name": "monosialotetrahexosylganglioside",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "monosialotetrahexosylganglioside"
		},
		{
			"aliases": null,
			"definition": {
				"html": "An water-in-oil (w/o) emulsion with immunomoadjuvant activity. Montanide ISA 51 VG appears to act by enhancing the immune systems cytotoxic T-lymphocyte (CTL) response against antigen(s) in vaccines. The surfactant mannide monooleate in Montanide ISA 51 VG contains vegetable-grade (VG) oleic acid derived from olive oil.\n",
				"text": "An water-in-oil (w/o) emulsion with immunomoadjuvant activity. Montanide ISA 51 VG appears to act by enhancing the immune systems cytotoxic T-lymphocyte (CTL) response against antigen(s) in vaccines. The surfactant mannide monooleate in Montanide ISA 51 VG contains vegetable-grade (VG) oleic acid derived from olive oil.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C84843",
			"nciConceptName": "Montanide ISA 51 VG",
			"termId": 650426,
			"name": "Montanide ISA 51 VG",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "montanide-isa-51-vg"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "ISA 720"
				}
			],
			"definition": {
				"html": "A proprietary adjuvant, applicable for water-in-oil (W/O; 30/70 v/v) vaccine emulsion, with potential immunoadjuvant activity. Montanide ISA 720 is made of natural metabolizable non-mineral oil and a highly refined emulsifier from the mannide mono-oleate family; it is rapidly metabolized and eliminated, and may be used in various vaccines, including cancer vaccines. Upon administration, Montanide ISA 720 forms a depot at the injection site and is therefore capable of slowly releasing the antigen(s) from the injection site. This may result in enhanced cellular and humoral immune responses to the antigen vaccine.",
				"text": "A proprietary adjuvant, applicable for water-in-oil (W/O; 30/70 v/v) vaccine emulsion, with potential immunoadjuvant activity. Montanide ISA 720 is made of natural metabolizable non-mineral oil and a highly refined emulsifier from the mannide mono-oleate family; it is rapidly metabolized and eliminated, and may be used in various vaccines, including cancer vaccines. Upon administration, Montanide ISA 720 forms a depot at the injection site and is therefore capable of slowly releasing the antigen(s) from the injection site. This may result in enhanced cellular and humoral immune responses to the antigen vaccine."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C97330",
			"nciConceptName": "Montanide ISA 720",
			"termId": 702862,
			"name": "Montanide ISA 720",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "montanide-isa-720"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Singulair"
				}
			],
			"definition": {
				"html": "The orally bioavailable monosodium salt of montelukast, a selective cysteinyl leukotriene receptor antagonist with anti-inflammatory and bronchodilating activities. Montelukast selectively and competitively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, preventing binding of the inflammatory mediator leukotriene D4 (LTD4). Inhibition of LTD4 activity results in inhibition of leukotriene-mediated inflammatory events including: migration of eosinophils and neutrophils; adhesion of leukocytes to vascular endothelium, monocyte and neutrophil aggregation; increased airway edema; increased capillary permeability; and bronchoconstriction. The  CysLT1 receptor is found in a number of tissues including spleen, lung, placenta, small intestine, and nasal mucosa, and in a variety of cell types including  monocyte/macrophages, mast cells, eosinophils,\n CD34-positive hemopoietic progenitor cells,\nneutrophils and endothelial cells.\n",
				"text": "The orally bioavailable monosodium salt of montelukast, a selective cysteinyl leukotriene receptor antagonist with anti-inflammatory and bronchodilating activities. Montelukast selectively and competitively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, preventing binding of the inflammatory mediator leukotriene D4 (LTD4). Inhibition of LTD4 activity results in inhibition of leukotriene-mediated inflammatory events including: migration of eosinophils and neutrophils; adhesion of leukocytes to vascular endothelium, monocyte and neutrophil aggregation; increased airway edema; increased capillary permeability; and bronchoconstriction. The  CysLT1 receptor is found in a number of tissues including spleen, lung, placenta, small intestine, and nasal mucosa, and in a variety of cell types including  monocyte/macrophages, mast cells, eosinophils,\n CD34-positive hemopoietic progenitor cells,\nneutrophils and endothelial cells.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C47625",
			"nciConceptName": "Montelukast Sodium",
			"termId": 593502,
			"name": "montelukast sodium",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "montelukast-sodium"
		},
		{
			"preferredName": "fosfomycin tromethamine",
			"termId": 752157,
			"name": "Monurol",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "fosfomycin-tromethamine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "Mustargen-Oncovin-procarbazine-prednisone regimen"
				},
				{
					"type": "Acronym",
					"name": "MOPP"
				},
				{
					"type": "Synonym",
					"name": "mechlorethamine/prednisone/procarbazine/vincristine regimen"
				}
			],
			"definition": {
				"html": "A chemotherapy regimen consisting of mechlorethamine, vincristine (Oncovin), procarbazine and prednisone, used alone or in combination with radiation therapy for the treatment of stage I-IV Hodgkin lymphoma. Due to the increased risk of gonadal toxicity, this regimen has been widely replaced by the ABVD regimen. ",
				"text": "A chemotherapy regimen consisting of mechlorethamine, vincristine (Oncovin), procarbazine and prednisone, used alone or in combination with radiation therapy for the treatment of stage I-IV Hodgkin lymphoma. Due to the increased risk of gonadal toxicity, this regimen has been widely replaced by the ABVD regimen. "
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/MOPP",
				"text": "MOPP"
			},
			"nciConceptId": "C9619",
			"nciConceptName": "MOPP Regimen",
			"termId": 41779,
			"name": "MOPP regimen",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mopp-regimen"
		},
		{
			"aliases": [
				{
					"type": "CommonUsage",
					"name": "noni extract"
				},
				{
					"type": "Synonym",
					"name": "noni fruit juice"
				}
			],
			"definition": {
				"html": "An extract prepared from the fruit of Morinda citrifolia, a plant that yields various herbal preparations.  Morinda citrifolia fruit juice has antioxidant properties and may prevent tumorigenesis via inhibition of DNA-carcinogen adduct formation.",
				"text": "An extract prepared from the fruit of Morinda citrifolia, a plant that yields various herbal preparations.  Morinda citrifolia fruit juice has antioxidant properties and may prevent tumorigenesis via inhibition of DNA-carcinogen adduct formation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C26662",
			"nciConceptName": "Morinda Citrifolia Fruit Extract",
			"termId": 304320,
			"name": "Morinda citrifolia fruit extract",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "morinda-citrifolia-fruit-extract"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Avinza"
				},
				{
					"type": "USBrandName",
					"name": "Infumorph"
				},
				{
					"type": "USBrandName",
					"name": "Kadian"
				},
				{
					"type": "Abbreviation",
					"name": "MORPH"
				},
				{
					"type": "USBrandName",
					"name": "MS Contin"
				},
				{
					"type": "USBrandName",
					"name": "MSir"
				},
				{
					"type": "USBrandName",
					"name": "Oramorph"
				},
				{
					"type": "USBrandName",
					"name": "Oramorph SR"
				},
				{
					"type": "USBrandName",
					"name": "Roxanol"
				},
				{
					"type": "USBrandName",
					"name": "Statex SR"
				},
				{
					"type": "CASRegistryName",
					"name": "64-31-3"
				},
				{
					"type": "CASRegistryName",
					"name": "6211-15-0"
				},
				{
					"type": "NSCNumber",
					"name": "11441"
				}
			],
			"definition": {
				"html": "The sulfate salt of morphine, an opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically. Morphine binds to and activates specific opiate receptors (delta, mu and kappa), each of which are involved in controlling different brain functions. In the central nervous and gastrointestinal systems, this agent has widespread effects including analgesia, anxiolysis, euphoria, sedation, respiratory depression, and gastrointestinal system smooth muscle contraction.",
				"text": "The sulfate salt of morphine, an opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically. Morphine binds to and activates specific opiate receptors (delta, mu and kappa), each of which are involved in controlling different brain functions. In the central nervous and gastrointestinal systems, this agent has widespread effects including analgesia, anxiolysis, euphoria, sedation, respiratory depression, and gastrointestinal system smooth muscle contraction."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C669",
			"nciConceptName": "Morphine Sulfate",
			"termId": 41804,
			"name": "morphine sulfate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "morphine-sulfate"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A sustained-release tablet formulation containing the sulfate salt of the opiate alkaloid morphine with analgesic activity. Morphine binds to and activates the mu-opioid receptors in the central nervous system (CNS), thereby mimicking the effects of the endogenous opioids. Binding of morphine to opioid receptors stimulates exchange of GTP for GDP, inhibits adenylate cyclase, and decreases intracellular cAMP. This inhibits the release of various nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, noradrenaline, vasopressin, and somatostatin. In addition, morphine closes N-type voltage-gated calcium channels and opens calcium-dependent inwardly rectifying potassium channels, which results in hyperpolarization of neuronal membranes and a reduction in neuronal excitability, and subsequently, analgesia and sedation.",
				"text": "A sustained-release tablet formulation containing the sulfate salt of the opiate alkaloid morphine with analgesic activity. Morphine binds to and activates the mu-opioid receptors in the central nervous system (CNS), thereby mimicking the effects of the endogenous opioids. Binding of morphine to opioid receptors stimulates exchange of GTP for GDP, inhibits adenylate cyclase, and decreases intracellular cAMP. This inhibits the release of various nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, noradrenaline, vasopressin, and somatostatin. In addition, morphine closes N-type voltage-gated calcium channels and opens calcium-dependent inwardly rectifying potassium channels, which results in hyperpolarization of neuronal membranes and a reduction in neuronal excitability, and subsequently, analgesia and sedation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C84853",
			"nciConceptName": "Morphine Sulfate Sustained-Release Tablet",
			"termId": 651246,
			"name": "morphine sulfate sustained-release tablet",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "morphine-sulfate-sustained-release-tablet"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "monoacetyldiglyceride EC-18"
				},
				{
					"type": "CodeName",
					"name": "EC-18"
				},
				{
					"type": "ChemicalStructureName",
					"name": "1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol"
				},
				{
					"type": "ChemicalStructureName",
					"name": "9,12-octadecadienoic acid (9Z,12Z)-, 1-((acetyloxy)methyl)-2-((1-oxohexadecyl)oxy)ethyl ester"
				},
				{
					"type": "CASRegistryName",
					"name": "221139-79-3"
				}
			],
			"definition": {
				"html": "A synthetic version of a monoacetyldiacylglyceride naturally occurring in various seed oils, bovine udder and milk fat, antlers of sika deer, with potential antineoplastic activity. Although the exact mechanism of action through which mosedipimod exerts its pharmacological effect has yet to be fully identified, upon administration, mosedipimod stimulates calcium influx into T lymphocytes and increases the production of various cytokines, including interleukin (IL) -2, IL-4, IL-12, interferon-gamma (IFN-g), and granulocyte-macrophage colony-stimulating factor (GM-CSF). This stimulates the proliferation of hematopoietic stem cells, bone marrow stromal cells and immune cells, including T and B lymphocytes, dendritic cells (DCs) and macrophages. Therefore, mosedipimod may stimulate the immune system to target cancer cells. In addition, mosedipimod enhances the cytolytic activity of natural killer (NK) cells and suppresses the expression of the transmembrane protein tumor cell toll-like receptor 4 (TLR-4) on cancer cells. As activation of TLR-4 enhances immunosuppression and stimulates cancer cell growth, blocking TLR-4 expression suppresses tumor cell proliferation.",
				"text": "A synthetic version of a monoacetyldiacylglyceride naturally occurring in various seed oils, bovine udder and milk fat, antlers of sika deer, with potential antineoplastic activity. Although the exact mechanism of action through which mosedipimod exerts its pharmacological effect has yet to be fully identified, upon administration, mosedipimod stimulates calcium influx into T lymphocytes and increases the production of various cytokines, including interleukin (IL) -2, IL-4, IL-12, interferon-gamma (IFN-g), and granulocyte-macrophage colony-stimulating factor (GM-CSF). This stimulates the proliferation of hematopoietic stem cells, bone marrow stromal cells and immune cells, including T and B lymphocytes, dendritic cells (DCs) and macrophages. Therefore, mosedipimod may stimulate the immune system to target cancer cells. In addition, mosedipimod enhances the cytolytic activity of natural killer (NK) cells and suppresses the expression of the transmembrane protein tumor cell toll-like receptor 4 (TLR-4) on cancer cells. As activation of TLR-4 enhances immunosuppression and stimulates cancer cell growth, blocking TLR-4 expression suppresses tumor cell proliferation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C123775",
			"nciConceptName": "Mosedipimod",
			"termId": 775590,
			"name": "mosedipimod",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mosedipimod"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "CD20/CD3 BiMAb BTCT4465A"
				},
				{
					"type": "Synonym",
					"name": "anti-CD20 x anti-CD3 bispecific monoclonal antibody BTCT4465A"
				},
				{
					"type": "CodeName",
					"name": "RG7828"
				},
				{
					"type": "CodeName",
					"name": "BTCT 4465A"
				},
				{
					"type": "CodeName",
					"name": "BTCT-4465A"
				},
				{
					"type": "CodeName",
					"name": "RG 7828"
				}
			],
			"definition": {
				"html": "A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 bispecific monoclonal antibody BTCT4465A contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, BTCT4465A binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells.",
				"text": "A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 bispecific monoclonal antibody BTCT4465A contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, BTCT4465A binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C129691",
			"nciConceptName": "Mosunetuzumab",
			"termId": 774847,
			"name": "mosunetuzumab",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mosunetuzumab"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "AMG 706"
				},
				{
					"type": "ChemicalStructureName",
					"name": "3-pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4- pyridinylmethyl)amino]-"
				},
				{
					"type": "ChemicalStructureName",
					"name": "N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4- ylmethyl)amino]pyridine-3-carboxamide"
				}
			],
			"definition": {
				"html": "The  orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity.  Motesanib selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation.",
				"text": "The  orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity.  Motesanib selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C48374",
			"nciConceptName": "Motesanib Diphosphate",
			"termId": 391228,
			"name": "motesanib diphosphate",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "motesanib-diphosphate"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "PCI-0120"
				},
				{
					"type": "USBrandName",
					"name": "Xcytrin"
				},
				{
					"type": "Synonym",
					"name": "gadolinium texaphyrin"
				},
				{
					"type": "Synonym",
					"name": "Gd (III) Texaphryin"
				},
				{
					"type": "Abbreviation",
					"name": "Gd-Tex"
				},
				{
					"type": "INDCode",
					"name": "55583"
				},
				{
					"type": "NSCNumber",
					"name": "695238"
				}
			],
			"definition": {
				"html": "A synthetic metallotexaphyrin with radiosensitizing and chemosensitizing properties. Motexafin gadolinium accumulates in tumor cells preferentially due to their increased rates of metabolism, generating reactive oxygen species (ROS) intracellularly and lowering the tumor cell apoptotic threshold to ionizing radiation and chemotherapy.",
				"text": "A synthetic metallotexaphyrin with radiosensitizing and chemosensitizing properties. Motexafin gadolinium accumulates in tumor cells preferentially due to their increased rates of metabolism, generating reactive oxygen species (ROS) intracellularly and lowering the tumor cell apoptotic threshold to ionizing radiation and chemotherapy."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1881",
			"nciConceptName": "Motexafin Gadolinium",
			"termId": 42391,
			"name": "motexafin gadolinium",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "motexafin-gadolinium"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "PCI-0123"
				},
				{
					"type": "Synonym",
					"name": "lutetium texaphyrin"
				},
				{
					"type": "USBrandName",
					"name": "Antrin"
				},
				{
					"type": "Synonym",
					"name": "lutetium texaphrin"
				},
				{
					"type": "USBrandName",
					"name": "Lutex"
				},
				{
					"type": "USBrandName",
					"name": "Lutrin"
				},
				{
					"type": "INDCode",
					"name": "58536"
				},
				{
					"type": "NSCNumber",
					"name": "695239"
				},
				{
					"type": "CASRegistryName",
					"name": "246252-04-0"
				}
			],
			"definition": {
				"html": "A pentadentate aromatic metallotexaphyrin with photosensitizing properties. Motexafin lutetium preferentially accumulates in tumor cells due to their increased rates of metabolism and absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen, resulting in local cytotoxic effects.",
				"text": "A pentadentate aromatic metallotexaphyrin with photosensitizing properties. Motexafin lutetium preferentially accumulates in tumor cells due to their increased rates of metabolism and absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen, resulting in local cytotoxic effects."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1651",
			"nciConceptName": "Motexafin Lutetium",
			"termId": 42402,
			"name": "motexafin lutetium",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "motexafin-lutetium"
		},
		{
			"preferredName": "ibuprofen",
			"termId": 40475,
			"name": "Motrin",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "ibuprofen"
		},
		{
			"aliases": [
				{
					"type": "LexicalVariant",
					"name": "Mouse gp100 DNA Plasmid Vaccine"
				}
			],
			"definition": {
				"html": "A vaccine consisting of a plasmid DNA encoding the murine melanoma-associated antigen gp100.  Upon administration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumor cells that express the gp100 antigen, resulting in tumor cell lysis. ",
				"text": "A vaccine consisting of a plasmid DNA encoding the murine melanoma-associated antigen gp100.  Upon administration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumor cells that express the gp100 antigen, resulting in tumor cell lysis. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C48410",
			"nciConceptName": "Mouse gp100 Plasmid DNA Vaccine",
			"termId": 419686,
			"name": "mouse gp100 plasmid DNA vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mouse-gp100-plasmid-dna-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "mouse PSMA DNA"
				},
				{
					"type": "Synonym",
					"name": "mouse PSMA DNA Vaccine"
				}
			],
			"definition": {
				"html": "A vaccine consisting of a plasmid DNA encoding the murine prostate-specific membrane antigen (PSMA).  Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express PSMA, resulting in tumor cell lysis.",
				"text": "A vaccine consisting of a plasmid DNA encoding the murine prostate-specific membrane antigen (PSMA).  Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express PSMA, resulting in tumor cell lysis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C48411",
			"nciConceptName": "Mouse Prostate-Specific Membrane Antigen Plasmid DNA Vaccine",
			"termId": 394099,
			"name": "mouse prostate-specific membrane antigen plasmid DNA vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mouse-prostate-specific-membrane-antigen-plasmid-dna-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Acronym",
					"name": "RENCA Macrobead"
				}
			],
			"definition": {
				"html": "An agarose matrix containing mouse renal adenocarcinoma (RENCA) cells, with potential antineoplastic activity. The agarose-agarose macrobeads consist of two spherical agarose layers; the mouse RENCA cells are contained within the inner agarose layer. Upon placement into the abdominal cavity, the restricted mouse renal adenocarcinoma cells in the agarose macrobeads produce and release certain growth-retarding factors that inhibit the proliferation of the RENCA cells. Upon diffusion of these growth-slowing factors out of the agarose layers, these substances may inhibit cancer cell proliferation of proliferating tumors.",
				"text": "An agarose matrix containing mouse renal adenocarcinoma (RENCA) cells, with potential antineoplastic activity. The agarose-agarose macrobeads consist of two spherical agarose layers; the mouse RENCA cells are contained within the inner agarose layer. Upon placement into the abdominal cavity, the restricted mouse renal adenocarcinoma cells in the agarose macrobeads produce and release certain growth-retarding factors that inhibit the proliferation of the RENCA cells. Upon diffusion of these growth-slowing factors out of the agarose layers, these substances may inhibit cancer cell proliferation of proliferating tumors."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C91713",
			"nciConceptName": "Mouse Renal Adenocarcinoma Cell-Encapsulated Agarose-Agarose Macrobeads",
			"termId": 489176,
			"name": "mouse renal adenocarcinoma cell-encapsulated agarose-agarose macrobeads",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mouse-renal-adenocarcinoma-cell-encapsulated-agarose-agarose-macrobeads"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MOv-gamma"
				},
				{
					"type": "NSCNumber",
					"name": "673412"
				}
			],
			"definition": {
				"html": "A recombinant engineered chimeric gene derived from the murine gene encoding the variable region of monoclonal antibody MOv18 against folate-binding protein, which is often overexpressed in human ovarian cancer cells, and the gene encoding the Fc receptor for the gamma subunit of human IgG and IgE. Peripheral blood lymphocytes expressing the MOv-gamma gene may be used in the immunotherapeutic treatment of ovarian cancer.",
				"text": "A recombinant engineered chimeric gene derived from the murine gene encoding the variable region of monoclonal antibody MOv18 against folate-binding protein, which is often overexpressed in human ovarian cancer cells, and the gene encoding the Fc receptor for the gamma subunit of human IgG and IgE. Peripheral blood lymphocytes expressing the MOv-gamma gene may be used in the immunotherapeutic treatment of ovarian cancer."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2638",
			"nciConceptName": "MOv-gamma Chimeric Receptor Gene",
			"termId": 38341,
			"name": "MOv-gamma chimeric receptor gene",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mov-gamma-chimeric-receptor-gene"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "anti-folate receptor alpha-CAR-CD3zeta-4-1BB-expressing allogeneic T lymphocytes"
				},
				{
					"type": "Synonym",
					"name": "allogeneic MOv19 CAR-CD3zeta-4-1BB-expressing T lymphocytes"
				},
				{
					"type": "Synonym",
					"name": "MOv19-CAR-CD3zeta-4-1BB-expressing allogeneic T cells"
				}
			],
			"definition": {
				"html": "A preparation of allogeneic CD4-positive and CD8-positive T lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) comprised of an anti-folate receptor alpha (FR-alpha; ovarian tumor-associated antigen MOv18) single chain variable fragment (scFv) (MOv19) and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon administration, MOv19-CAR-CD3zeta-4-1BB-expressing allogeneic T lymphocytes target, bind to and induce selective toxicity in folate receptor alpha-expressing tumor cells. The costimulatory signaling domain enhances both proliferation of T cells and antitumor activity. Folate receptor alpha is a glycosylphosphatidylinositol-linked cell-surface glycoprotein that is widely expressed in certain cancers including serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer and triple negative breast cancer. In contrast, folate receptor alpha expression is limited in normal tissues.\n",
				"text": "A preparation of allogeneic CD4-positive and CD8-positive T lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) comprised of an anti-folate receptor alpha (FR-alpha; ovarian tumor-associated antigen MOv18) single chain variable fragment (scFv) (MOv19) and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon administration, MOv19-CAR-CD3zeta-4-1BB-expressing allogeneic T lymphocytes target, bind to and induce selective toxicity in folate receptor alpha-expressing tumor cells. The costimulatory signaling domain enhances both proliferation of T cells and antitumor activity. Folate receptor alpha is a glycosylphosphatidylinositol-linked cell-surface glycoprotein that is widely expressed in certain cancers including serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer and triple negative breast cancer. In contrast, folate receptor alpha expression is limited in normal tissues.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C162166",
			"nciConceptName": "MOv19 CAR-CD3zeta-4-1BB-expressing Allogeneic T-lymphocytes",
			"termId": 798634,
			"name": "MOv19 CAR-CD3zeta-4-1BB-expressing allogeneic T lymphocytes",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mov19-car-cd3zeta-4-1bb-expressing-allogeneic-t-lymphocytes"
		},
		{
			"preferredName": "meloxicam",
			"termId": 472195,
			"name": "Movalis",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "meloxicam"
		},
		{
			"preferredName": "naloxegol",
			"termId": 703418,
			"name": "Movantik",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "naloxegol"
		},
		{
			"preferredName": "meloxicam",
			"termId": 472195,
			"name": "Movatec",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "meloxicam"
		},
		{
			"preferredName": "PEG-3350/sodium sulfate/sodium chloride/potassium chloride/sodium ascorbate/ascorbic acid-based laxative",
			"termId": 742409,
			"name": "Moviprep",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": ""
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "moxetumomab pasudotox"
				},
				{
					"type": "USBrandName",
					"name": "Lumoxiti"
				},
				{
					"type": "CodeName",
					"name": "GCR-8015"
				},
				{
					"type": "CodeName",
					"name": "CAT-8015"
				},
				{
					"type": "CodeName",
					"name": "HA22"
				},
				{
					"type": "Synonym",
					"name": "immunotoxin CAT-8015"
				},
				{
					"type": "Synonym",
					"name": "anti-CD22 immunotoxin CAT-8015"
				},
				{
					"type": "LexicalVariant",
					"name": "Moxetumomab Pasudotox"
				},
				{
					"type": "CASRegistryName",
					"name": "1020748-57-5"
				}
			],
			"definition": {
				"html": "A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential antineoplastic activity. The Fv portion of anti-CD22 immunotoxin CAT-8015 binds to CD22, a cell surface receptor expressed on a variety of malignant B cells, thereby delivering the toxin moiety PE38 directly to tumor cells. Once internalized, PE38 induces caspase-mediated apoptosis via a mechanism involving mitochondrial damage and blocks translational elongation by binding to elongation factor 2 (EF-2). Moxetumomab pasudotox-tdfk exhibits a greater affinity for CD22 than its predecessor, anti-CD22 immunotoxin CAT-3888 (BL22 immunotoxin), and hence may be more effective against tumor cells expressing lower levels of CD22.",
				"text": "A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential antineoplastic activity. The Fv portion of anti-CD22 immunotoxin CAT-8015 binds to CD22, a cell surface receptor expressed on a variety of malignant B cells, thereby delivering the toxin moiety PE38 directly to tumor cells. Once internalized, PE38 induces caspase-mediated apoptosis via a mechanism involving mitochondrial damage and blocks translational elongation by binding to elongation factor 2 (EF-2). Moxetumomab pasudotox-tdfk exhibits a greater affinity for CD22 than its predecessor, anti-CD22 immunotoxin CAT-3888 (BL22 immunotoxin), and hence may be more effective against tumor cells expressing lower levels of CD22."
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/moxetumomabpasudotoxtdfk",
				"text": "Moxetumomab Pasudotox-tdfk"
			},
			"nciConceptId": "C68819",
			"nciConceptName": "Moxetumomab Pasudotox",
			"termId": 540032,
			"name": "moxetumomab pasudotox-tdfk",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "moxetumomab-pasudotox"
		},
		{
			"aliases": [
				{
					"type": "CASRegistryName",
					"name": "113507-06-5"
				}
			],
			"definition": {
				"html": "A macrocyclic lactone derived from Streptomyces cyanogriseus with antiparasitic activity. Upon administration, moxidectin may bind to glutamate-gated chloride channels (GluCl), gamma-aminobutyric acid (GABA) receptors and/or ATP-binding cassette (ABC) transporters expressed on nematode neurons and pharyngeal muscle cells. As a result, neurons or muscle cells remain at either hyperpolarization or depolarization state, thereby resulting in muscle paralysis. Moxidectin reduces the motility and fertility of the parasite and its excretion of immunomodulatory proteins, and inhibits the release of microfilariae.\n",
				"text": "A macrocyclic lactone derived from Streptomyces cyanogriseus with antiparasitic activity. Upon administration, moxidectin may bind to glutamate-gated chloride channels (GluCl), gamma-aminobutyric acid (GABA) receptors and/or ATP-binding cassette (ABC) transporters expressed on nematode neurons and pharyngeal muscle cells. As a result, neurons or muscle cells remain at either hyperpolarization or depolarization state, thereby resulting in muscle paralysis. Moxidectin reduces the motility and fertility of the parasite and its excretion of immunomodulatory proteins, and inhibits the release of microfilariae.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C73264",
			"nciConceptName": "Moxidectin",
			"termId": 801909,
			"name": "moxidectin",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "moxidectin"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MOXI"
				},
				{
					"type": "USBrandName",
					"name": "Avelox"
				},
				{
					"type": "CodeName",
					"name": "BAY 128039"
				},
				{
					"type": "USBrandName",
					"name": "Viagmox"
				}
			],
			"definition": {
				"html": "The hydrochloride salt of a fluoroquinolone antibacterial antibiotic. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species.",
				"text": "The hydrochloride salt of a fluoroquinolone antibacterial antibiotic. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C38696",
			"nciConceptName": "Moxifloxacin Hydrochloride",
			"termId": 306456,
			"name": "moxifloxacin hydrochloride",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "moxifloxacin-hydrochloride"
		},
		{
			"preferredName": "plerixafor",
			"termId": 410786,
			"name": "Mozobil",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "plerixafor"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "MNK-010"
				},
				{
					"type": "CodeName",
					"name": "MP-3549-1"
				},
				{
					"type": "Synonym",
					"name": "pegylated liposomal docetaxel prodrug MNK-010"
				}
			],
			"definition": {
				"html": "A formulation containing pegylated liposomal nanoparticles encapsulating a prodrug of the poorly water-soluble, second-generation taxane analog docetaxel, with potential antineoplastic activity. Upon intravenous administration of the liposomal docetaxel prodrug MNK-010, docetaxel is slowly released into the systemic circulation and accumulates at the tumor site due to the unique characteristics of the tumor's vasculature. In turn, docetaxel is taken up by tumor cells, and subsequently binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and induces cell death. Compared to the administration of docetaxel alone, this formulation is able to increase the delivery of docetaxel into tumors, thereby increasing docetaxel's efficacy while minimizing its toxicity. In addition, this formulation solubilizes docetaxel without the use of toxic solvents, thereby permitting the administration of larger doses of docetaxel while avoiding solvent-associated toxicity.",
				"text": "A formulation containing pegylated liposomal nanoparticles encapsulating a prodrug of the poorly water-soluble, second-generation taxane analog docetaxel, with potential antineoplastic activity. Upon intravenous administration of the liposomal docetaxel prodrug MNK-010, docetaxel is slowly released into the systemic circulation and accumulates at the tumor site due to the unique characteristics of the tumor's vasculature. In turn, docetaxel is taken up by tumor cells, and subsequently binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and induces cell death. Compared to the administration of docetaxel alone, this formulation is able to increase the delivery of docetaxel into tumors, thereby increasing docetaxel's efficacy while minimizing its toxicity. In addition, this formulation solubilizes docetaxel without the use of toxic solvents, thereby permitting the administration of larger doses of docetaxel while avoiding solvent-associated toxicity."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C116869",
			"nciConceptName": "Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010",
			"termId": 757071,
			"name": "MP-3549.1",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "pegylated-liposomal-nanoparticle-based-docetaxel-prodrug-mnk-010"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "BAY 1217389"
				}
			],
			"definition": {
				"html": "An orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1, TTK), with potential antineoplastic activity. Upon administration, the Mps1 inhibitor BAY 1217389 selectively binds to and inhibits the activity of Mps1. This inactivates the spindle assembly checkpoint (SAC), accelerates mitosis, causes chromosomal misalignment and missegregation, and mitotic checkpoint complex destabilization. This induces cell death in Mps1-overexpressing cancer cells. Mps1, a kinase expressed in proliferating normal tissues and aberrantly overexpressed in a wide range of human tumors, is activated during mitosis and is essential for proper SAC functioning and chromosome alignment. ",
				"text": "An orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1, TTK), with potential antineoplastic activity. Upon administration, the Mps1 inhibitor BAY 1217389 selectively binds to and inhibits the activity of Mps1. This inactivates the spindle assembly checkpoint (SAC), accelerates mitosis, causes chromosomal misalignment and missegregation, and mitotic checkpoint complex destabilization. This induces cell death in Mps1-overexpressing cancer cells. Mps1, a kinase expressed in proliferating normal tissues and aberrantly overexpressed in a wide range of human tumors, is activated during mitosis and is essential for proper SAC functioning and chromosome alignment. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C122707",
			"nciConceptName": "Mps1 Inhibitor BAY 1217389",
			"termId": 769545,
			"name": "Mps1 inhibitor BAY 1217389",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mps1-inhibitor-bay-1217389"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "BOS 172722"
				},
				{
					"type": "CodeName",
					"name": "BOS172722"
				},
				{
					"type": "Synonym",
					"name": "TTK inhibitor BOS172722"
				},
				{
					"type": "Synonym",
					"name": "monopolar spindle 1 inhibitor BOS172722"
				}
			],
			"definition": {
				"html": "An orally bioavailable, selective inhibitor of the serine/threonine-protein kinase monopolar spindle 1 (Mps1; TTK), with potential antineoplastic activity. Upon administration, the Mps1 inhibitor BOS172722 binds to and inhibits the activity of Mps1, a core component of the spindle assembly checkpoint (SAC). Inhibition of Mps1 activity compromises spindle assembly checkpoint, increases chromosome missegregation errors and decreases cancer cell viability. Mps1, a dual-specificity protein kinase expressed in proliferating normal tissues and aberrantly overexpressed in certain tumor types, is activated during mitosis and is essential in proper SAC function and chromosomal alignment.",
				"text": "An orally bioavailable, selective inhibitor of the serine/threonine-protein kinase monopolar spindle 1 (Mps1; TTK), with potential antineoplastic activity. Upon administration, the Mps1 inhibitor BOS172722 binds to and inhibits the activity of Mps1, a core component of the spindle assembly checkpoint (SAC). Inhibition of Mps1 activity compromises spindle assembly checkpoint, increases chromosome missegregation errors and decreases cancer cell viability. Mps1, a dual-specificity protein kinase expressed in proliferating normal tissues and aberrantly overexpressed in certain tumor types, is activated during mitosis and is essential in proper SAC function and chromosomal alignment."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C155895",
			"nciConceptName": "Mps1 Inhibitor BOS172722",
			"termId": 794872,
			"name": "Mps1 inhibitor BOS172722",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mps1-inhibitor-bos172722"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "BAY1161909"
				},
				{
					"type": "CodeName",
					"name": "BAY116-1909"
				}
			],
			"definition": {
				"html": "An orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase, with potential antineoplastic activity. Upon administration, the Mps1 kinase inhibitor BAY1161909 binds to and inhibits the activity of Mps1. This causes inactivation of the spindle assembly checkpoint (SAC), accelerated mitosis, chromosomal misalignment, chromosomal missegregation, mitotic checkpoint complex destabilization, and increased aneuploidy. This leads to the induction of cell death in cancer cells overexpressing Mps1. Mps1, a kinase expressed in proliferating normal tissues and aberrantly overexpressed in a wide range of human tumors, is activated during mitosis and is essential for SAC functioning and controls chromosome alignment.",
				"text": "An orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase, with potential antineoplastic activity. Upon administration, the Mps1 kinase inhibitor BAY1161909 binds to and inhibits the activity of Mps1. This causes inactivation of the spindle assembly checkpoint (SAC), accelerated mitosis, chromosomal misalignment, chromosomal missegregation, mitotic checkpoint complex destabilization, and increased aneuploidy. This leads to the induction of cell death in cancer cells overexpressing Mps1. Mps1, a kinase expressed in proliferating normal tissues and aberrantly overexpressed in a wide range of human tumors, is activated during mitosis and is essential for SAC functioning and controls chromosome alignment."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C116074",
			"nciConceptName": "Empesertib",
			"termId": 761238,
			"name": "Mps1 kinase inhibitor BAY1161909",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "empesertib"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "mRNA-4157"
				},
				{
					"type": "CodeName",
					"name": "mRNA 4157"
				},
				{
					"type": "Synonym",
					"name": "PCV mRNA-4157"
				},
				{
					"type": "Synonym",
					"name": "mRNA-based PCV mRNA-4157"
				}
			],
			"definition": {
				"html": "An mRNA-based individualized, therapeutic personalized cancer vaccine (PCV) targeting twenty tumor-associated antigens (TAAs) that are specifically expressed by the patient's cancer cells, with potential immunostimulatory and antineoplastic activities. The cells from the patient's tumor are analyzed, and genetic sequencing is used to identify twenty neoantigen epitopes that may elicit the strongest immune response in the patient. The sequences encoding the twenty patient-specific epitopes are transcribed and loaded onto a single mRNA molecule. Upon administration, the mRNA-based PCV mRNA-4157 is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens.",
				"text": "An mRNA-based individualized, therapeutic personalized cancer vaccine (PCV) targeting twenty tumor-associated antigens (TAAs) that are specifically expressed by the patient's cancer cells, with potential immunostimulatory and antineoplastic activities. The cells from the patient's tumor are analyzed, and genetic sequencing is used to identify twenty neoantigen epitopes that may elicit the strongest immune response in the patient. The sequences encoding the twenty patient-specific epitopes are transcribed and loaded onto a single mRNA molecule. Upon administration, the mRNA-based PCV mRNA-4157 is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C146813",
			"nciConceptName": "mRNA-based Personalized Cancer Vaccine mRNA-4157",
			"termId": 792256,
			"name": "mRNA-based personalized cancer vaccine mRNA-4157",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mrna-based-personalized-cancer-vaccine-mrna-4157"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "ECI-006"
				},
				{
					"type": "CodeName",
					"name": "ECI 006"
				},
				{
					"type": "CodeName",
					"name": "ECI006"
				}
			],
			"definition": {
				"html": "A melanoma vaccine consisting of mRNAs encoding five different melanoma tumor-associated antigens (TAAs) and a TriMix platform comprised of three mRNAs encoding for constitutively activated toll-like receptor 4 (caTLR4), CD40 ligand (CD40L), and CD70, with potential immunomodulatory and antineoplastic activities. Upon intranodal injection, mRNA based TriMix vaccine ECI-006 may stimulate the immune system to mount both humoral and cellular responses against tumor cells expressing the five TAAs specific to the vaccine, potentially decreasing cellular proliferation of cells expressing these antigens. The TriMix adjuvants CD40L and caTLR4 promote the generation of mature and active dendritic cells (DCs), and CD70 provides a costimulatory signal to CD27+ naive T cells, thereby supporting T-cell proliferation and inhibiting T-cell apoptosis.",
				"text": "A melanoma vaccine consisting of mRNAs encoding five different melanoma tumor-associated antigens (TAAs) and a TriMix platform comprised of three mRNAs encoding for constitutively activated toll-like receptor 4 (caTLR4), CD40 ligand (CD40L), and CD70, with potential immunomodulatory and antineoplastic activities. Upon intranodal injection, mRNA based TriMix vaccine ECI-006 may stimulate the immune system to mount both humoral and cellular responses against tumor cells expressing the five TAAs specific to the vaccine, potentially decreasing cellular proliferation of cells expressing these antigens. The TriMix adjuvants CD40L and caTLR4 promote the generation of mature and active dendritic cells (DCs), and CD70 provides a costimulatory signal to CD27+ naive T cells, thereby supporting T-cell proliferation and inhibiting T-cell apoptosis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C154274",
			"nciConceptName": "mRNA-based TriMix Melanoma Vaccine ECI-006",
			"termId": 794159,
			"name": "mRNA-based TriMixMelanoma vaccine ECI-006",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mrna-based-trimix-melanoma-vaccine-eci-006"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "mRNA-based TSNA boosting vaccine GRT-R902"
				},
				{
					"type": "CodeName",
					"name": "GRT-R902"
				},
				{
					"type": "CodeName",
					"name": "GRT R902"
				},
				{
					"type": "CodeName",
					"name": "GRTR902"
				},
				{
					"type": "Synonym",
					"name": "boosting cancer vaccine GRT-R902"
				}
			],
			"definition": {
				"html": "An mRNA-based, personalized cancer vaccine consisting of a self-amplifying mRNA (SAM), formulated in a lipid nanoparticle (LNP), targeting twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patients tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the mRNA-based tumor-specific neoantigen boosting vaccine GRT-R902, the mRNA is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of APCs. This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patients cancer cells that express these neoantigens. mRNA-based TSNA boosting vaccine is administered after a single dose of the adenoviral tumor-specific neoantigen priming vaccine GRT-C901. The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.",
				"text": "An mRNA-based, personalized cancer vaccine consisting of a self-amplifying mRNA (SAM), formulated in a lipid nanoparticle (LNP), targeting twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patients tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the mRNA-based tumor-specific neoantigen boosting vaccine GRT-R902, the mRNA is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of APCs. This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patients cancer cells that express these neoantigens. mRNA-based TSNA boosting vaccine is administered after a single dose of the adenoviral tumor-specific neoantigen priming vaccine GRT-C901. The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C156926",
			"nciConceptName": "mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902",
			"termId": 796480,
			"name": "mRNA-based tumor-specific neoantigen boosting vaccine GRT-R902",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mrna-based-tumor-specific-neoantigen-boosting-vaccine-grt-r902"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "mRNA-5671 vaccine"
				},
				{
					"type": "Synonym",
					"name": "mRNA-5671"
				},
				{
					"type": "CodeName",
					"name": "V941"
				},
				{
					"type": "CodeName",
					"name": "V 941"
				},
				{
					"type": "Synonym",
					"name": "mRNA 5671"
				}
			],
			"definition": {
				"html": "A lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets four of the most commonly occurring KRAS mutations (G12D, G12V, G13D, and G12C), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.\n",
				"text": "A lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets four of the most commonly occurring KRAS mutations (G12D, G12V, G13D, and G12C), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C162186",
			"nciConceptName": "mRNA-derived KRAS-targeted Vaccine V941",
			"termId": 798633,
			"name": "mRNA-derived KRAS-targeted vaccine V941",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mrna-derived-kras-targeted-vaccine-v941"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "CV9202"
				},
				{
					"type": "CodeName",
					"name": "BI 1361849"
				}
			],
			"definition": {
				"html": "A non-small cell lung cancer (NSCLC) vaccine containing six modified mRNAs, which encode six different NSCLC associated antigens, with potential antitumor and immunomodulatory activities. Upon intradermal administration, mRNA-derived lung cancer vaccine BI 1361849 may stimulate the immune system to mount both humoral and cellular responses against NSCLC cells. The six tumor-associated antigens (TAAs) encoded by these mRNAs are frequently expressed by NSCLC cells and are minimally expressed or absent in normal, healthy cells.",
				"text": "A non-small cell lung cancer (NSCLC) vaccine containing six modified mRNAs, which encode six different NSCLC associated antigens, with potential antitumor and immunomodulatory activities. Upon intradermal administration, mRNA-derived lung cancer vaccine BI 1361849 may stimulate the immune system to mount both humoral and cellular responses against NSCLC cells. The six tumor-associated antigens (TAAs) encoded by these mRNAs are frequently expressed by NSCLC cells and are minimally expressed or absent in normal, healthy cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C111574",
			"nciConceptName": "mRNA-derived Lung Cancer Vaccine BI 1361849",
			"termId": 752248,
			"name": "mRNA-derived lung cancer vaccine BI 1361849",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mrna-derived-lung-cancer-vaccine-bi-1361849"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "messenger RNA-derived prostate cancer vaccine CV9103"
				},
				{
					"type": "CodeName",
					"name": "CV9103"
				}
			],
			"definition": {
				"html": "A prostate cancer vaccine containing mRNAs encoding prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostate stem cell antigen (PSCA) and six-transmembrane epithelial antigen of the prostate (STEAP), with potential antitumor activity. Upon administration, mRNA-derived prostate cancer vaccine CV9103 may stimulate the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PSCA- and STEAP-expressing prostate tumor cells. The mRNA used in this vaccine is  modified and formulated to have enhanced translational potency and adjuvant activities. .PSA, PSMA, PSCA and STEAP may be upregulated in prostate cancer cells; their expression  in prostate cancer has been correlated with disease progression.",
				"text": "A prostate cancer vaccine containing mRNAs encoding prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostate stem cell antigen (PSCA) and six-transmembrane epithelial antigen of the prostate (STEAP), with potential antitumor activity. Upon administration, mRNA-derived prostate cancer vaccine CV9103 may stimulate the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PSCA- and STEAP-expressing prostate tumor cells. The mRNA used in this vaccine is  modified and formulated to have enhanced translational potency and adjuvant activities. .PSA, PSMA, PSCA and STEAP may be upregulated in prostate cancer cells; their expression  in prostate cancer has been correlated with disease progression."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C82654",
			"nciConceptName": "mRNA-Derived Prostate Cancer Vaccine CV9103",
			"termId": 636121,
			"name": "mRNA-derived prostate cancer vaccine CV9103",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mrna-derived-prostate-cancer-vaccine-cv9103"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "CV9104"
				},
				{
					"type": "Synonym",
					"name": "RNActive-derived prostate cancer vaccine CV9104"
				}
			],
			"definition": {
				"html": "A prostate cancer vaccine containing six messenger RNAs (mRNAs) encoding for antigens upregulated in prostate cancer, including mRNAs for prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP), and mucin 1 (MUC1), with potential antineoplastic and immunomodulating activities. Upon intradermal administration of mRNA-derived prostate cancer vaccine CV9104, this agent enters cells, the mRNAs are translated into the respective prostate specific antigens and may cause the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PAP- and MUC1-expressing prostate tumor cells. The mRNAs used in this vaccine are modified to have enhanced translational potency and adjuvant activities. PSA, PSMA, PAP and MUC1 are frequently upregulated in prostate cancer cells; their expression in prostate cancer has been correlated with disease progression.",
				"text": "A prostate cancer vaccine containing six messenger RNAs (mRNAs) encoding for antigens upregulated in prostate cancer, including mRNAs for prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP), and mucin 1 (MUC1), with potential antineoplastic and immunomodulating activities. Upon intradermal administration of mRNA-derived prostate cancer vaccine CV9104, this agent enters cells, the mRNAs are translated into the respective prostate specific antigens and may cause the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PAP- and MUC1-expressing prostate tumor cells. The mRNAs used in this vaccine are modified to have enhanced translational potency and adjuvant activities. PSA, PSMA, PAP and MUC1 are frequently upregulated in prostate cancer cells; their expression in prostate cancer has been correlated with disease progression."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C106231",
			"nciConceptName": "mRNA-derived Prostate Cancer Vaccine CV9104",
			"termId": 748869,
			"name": "mRNA-derived prostate cancer vaccine CV9104",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mrna-derived-prostate-cancer-vaccine-cv9104"
		},
		{
			"preferredName": "morphine sulfate",
			"termId": 41804,
			"name": "MS Contin",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "morphine-sulfate"
		},
		{
			"preferredName": "morphine sulfate",
			"termId": 41804,
			"name": "MSir",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "morphine-sulfate"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "APTO-253 HCl"
				},
				{
					"type": "Synonym",
					"name": "MTF-1 inhibitor LOR-253 HCl"
				},
				{
					"type": "LexicalVariant",
					"name": "MTF-1 Inhibitor LOR-253 HCl"
				},
				{
					"type": "CodeName",
					"name": "LOR-253 HCl"
				},
				{
					"type": "CodeName",
					"name": "LT-253 HCl"
				},
				{
					"type": "CASRegistryName",
					"name": "1422731-37-0"
				},
				{
					"type": "ChemicalStructureName",
					"name": "2-(6-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10]phenanthroline hydrochloride"
				}
			],
			"definition": {
				"html": "The hydrochloride salt of a small molecule inhibitor of human metal-regulatory transcription factor 1 (MTF-1) with potential antitumor activity. MTF-1 inhibitor APTO-253 inhibits MTF-1 activity and thereby induces the expression of MTF-1 dependent tumor suppressor factor Kruppel like factor 4 (KLF4). This subsequently leads to the downregulation of cyclin D1, blocking cell cycle progression and proliferation. This agent also causes decreased expression of genes involved in tumor hypoxia and angiogenesis.",
				"text": "The hydrochloride salt of a small molecule inhibitor of human metal-regulatory transcription factor 1 (MTF-1) with potential antitumor activity. MTF-1 inhibitor APTO-253 inhibits MTF-1 activity and thereby induces the expression of MTF-1 dependent tumor suppressor factor Kruppel like factor 4 (KLF4). This subsequently leads to the downregulation of cyclin D1, blocking cell cycle progression and proliferation. This agent also causes decreased expression of genes involved in tumor hypoxia and angiogenesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C95724",
			"nciConceptName": "MTF-1 Inhibitor APTO-253 HCl",
			"termId": 694483,
			"name": "MTF-1 inhibitor APTO-253 HCl",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mtf-1-inhibitor-apto-253-hcl"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "GDC-0349"
				},
				{
					"type": "CodeName",
					"name": "GDC0349"
				},
				{
					"type": "CodeName",
					"name": "RG7603"
				},
				{
					"type": "CASRegistryName",
					"name": "1207360-89-1"
				},
				{
					"type": "ChemicalStructureName",
					"name": "(S)-1-ethyl-3-(4-(4-(3-methylmorpholino)-7-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea"
				}
			],
			"definition": {
				"html": "An orally bioavailable, ATP-competitive, tetrahydroquinazoline (THQ)-based inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Upon administration, GDC-0349 selectively binds to and inhibits the activity of mTOR, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol-3 (PI3K) kinase-related kinase (PIKK) family, plays an important role in the PI3K/Akt/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.",
				"text": "An orally bioavailable, ATP-competitive, tetrahydroquinazoline (THQ)-based inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Upon administration, GDC-0349 selectively binds to and inhibits the activity of mTOR, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol-3 (PI3K) kinase-related kinase (PIKK) family, plays an important role in the PI3K/Akt/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C133227",
			"nciConceptName": "mTOR Inhibitor GDC-0349",
			"termId": 700941,
			"name": "mTOR inhibitor GDC-0349",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mtor-inhibitor-gdc-0349"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "AZD8055"
				}
			],
			"definition": {
				"html": "An inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/threonine kinase activity of mTOR, resulting in decreased expression of mRNAs necessary for cell cycle progression,  which may induce  cell cycle arrest and tumor cell apoptosis. mTOR phosphorylates transcription factors, such as S6K1 and 4E-BP1, which stimulate protein synthesis and regulate cell growth, proliferation, motility, and survival.",
				"text": "An inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/threonine kinase activity of mTOR, resulting in decreased expression of mRNAs necessary for cell cycle progression,  which may induce  cell cycle arrest and tumor cell apoptosis. mTOR phosphorylates transcription factors, such as S6K1 and 4E-BP1, which stimulate protein synthesis and regulate cell growth, proliferation, motility, and survival."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C78856",
			"nciConceptName": "mTOR Kinase Inhibitor AZD8055",
			"termId": 612860,
			"name": "mTOR kinase inhibitor AZD8055",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mtor-kinase-inhibitor-azd8055"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "OSI-027"
				},
				{
					"type": "Synonym",
					"name": "mammalian target of rapamycin kinase inhibitor OSI-027"
				}
			],
			"definition": {
				"html": "An orally bioavailable mammalian target of rapamycin (mTOR) kinase inhibitor with potential antineoplastic activity. mTOR kinase inhibitor OSI-027 binds to and inhibits both the raptor-mTOR (TOR complex 1 or TORC1) and the rictor-mTOR (TOR complex 2 or TORC2) complexes of mTOR, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR is a serine/threonine kinase that is upregulated in some tumors and plays an important role downstream in the  PI3K/Akt/mTOR signaling pathway.",
				"text": "An orally bioavailable mammalian target of rapamycin (mTOR) kinase inhibitor with potential antineoplastic activity. mTOR kinase inhibitor OSI-027 binds to and inhibits both the raptor-mTOR (TOR complex 1 or TORC1) and the rictor-mTOR (TOR complex 2 or TORC2) complexes of mTOR, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR is a serine/threonine kinase that is upregulated in some tumors and plays an important role downstream in the  PI3K/Akt/mTOR signaling pathway."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C78476",
			"nciConceptName": "mTOR Kinase Inhibitor OSI-027",
			"termId": 600513,
			"name": "mTOR kinase inhibitor OSI-027",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mtor-kinase-inhibitor-osi-027"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "ME-344"
				}
			],
			"definition": {
				"html": "An active metabolite of NV-128, a novel flavonoid small molecule inhibitor of the mammalian Target of Rapamycin (mTOR), with potential antineoplastic activity. Upon administration, mTOR1/2 Kinase inhibitor ME-344 downregulates the PIK3/AKT/mTOR pathway and results in chromatin condensation in the absence of caspase activation. Consequently, this agent induces caspase-independent cell death in tumor cells with a de-regulated PIK3/AKT/mTOR pathway or chemotherapeutic resistant cells.",
				"text": "An active metabolite of NV-128, a novel flavonoid small molecule inhibitor of the mammalian Target of Rapamycin (mTOR), with potential antineoplastic activity. Upon administration, mTOR1/2 Kinase inhibitor ME-344 downregulates the PIK3/AKT/mTOR pathway and results in chromatin condensation in the absence of caspase activation. Consequently, this agent induces caspase-independent cell death in tumor cells with a de-regulated PIK3/AKT/mTOR pathway or chemotherapeutic resistant cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C101132",
			"nciConceptName": "mTOR1/2 Kinase Inhibitor ME-344",
			"termId": 728650,
			"name": "mTOR1/2 kinase inhibitor ME-344",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mtor1-2-kinase-inhibitor-me-344"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "LXI-15029"
				},
				{
					"type": "CodeName",
					"name": "LXI15029"
				},
				{
					"type": "CodeName",
					"name": "SCC-31"
				}
			],
			"definition": {
				"html": "An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 inhibitor LXI-15029 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy.",
				"text": "An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 inhibitor LXI-15029 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C148528",
			"nciConceptName": "mTORC 1/2 Inhibitor LXI-15029",
			"termId": 792688,
			"name": "mTORC 1/2 inhibitor LXI-15029",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mtorc-1-2-inhibitor-lxi-15029"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "BI 860585"
				}
			],
			"definition": {
				"html": "An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 kinase inhibitor BI 860585 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy.",
				"text": "An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 kinase inhibitor BI 860585 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C122836",
			"nciConceptName": "mTORC1/2 Kinase Inhibitor BI 860585",
			"termId": 753378,
			"name": "mTORC1/2 kinase inhibitor BI 860585",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mtorc1-2-kinase-inhibitor-bi-860585"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "ABTL0812"
				}
			],
			"definition": {
				"html": "An orally bioavailable, lipid analogue and inhibitor of raptor-mammalian target of rapamycin (mTOR) (mTOR complex 1; mTORC1), rictor-mTOR (mTOR complex 2; mTORC2) and dihydrofolate reductase (DHFR) with potential antineoplastic activity. Upon oral administration, mTORC1/mTORC2/DHFR inhibitor ABTL0812 binds to and inhibits both mTORC1 and mTORC2, which may result in apoptosis and a decrease in proliferation in mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in some tumors; it plays an important role in the PI3K/Akt/mTOR signaling pathway which is often deregulated in cancer cells. In addition, ABTL0812 inhibits DHFR, an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid, thereby blocking tetrahydrofolate synthesis, and resulting in both the depletion of nucleotide precursors and the inhibition of DNA, RNA and protein synthesis. This leads to autophagy-induced cell death and further inhibition of cell proliferation.\n",
				"text": "An orally bioavailable, lipid analogue and inhibitor of raptor-mammalian target of rapamycin (mTOR) (mTOR complex 1; mTORC1), rictor-mTOR (mTOR complex 2; mTORC2) and dihydrofolate reductase (DHFR) with potential antineoplastic activity. Upon oral administration, mTORC1/mTORC2/DHFR inhibitor ABTL0812 binds to and inhibits both mTORC1 and mTORC2, which may result in apoptosis and a decrease in proliferation in mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in some tumors; it plays an important role in the PI3K/Akt/mTOR signaling pathway which is often deregulated in cancer cells. In addition, ABTL0812 inhibits DHFR, an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid, thereby blocking tetrahydrofolate synthesis, and resulting in both the depletion of nucleotide precursors and the inhibition of DNA, RNA and protein synthesis. This leads to autophagy-induced cell death and further inhibition of cell proliferation.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C117290",
			"nciConceptName": "mTORC1/mTORC2/DHFR Inhibitor ABTL0812",
			"termId": 763422,
			"name": "mTORC1/mTORC2/DHFR inhibitor ABTL0812",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mtorc1-mtorc2-dhfr-inhibitor-abtl0812"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "MUC-1"
				},
				{
					"type": "LexicalVariant",
					"name": "MUC-1 Antigen"
				},
				{
					"type": "Synonym",
					"name": "CA15-3 antigen"
				},
				{
					"type": "Synonym",
					"name": "cancer antigen 15-3"
				},
				{
					"type": "Synonym",
					"name": "DF3 antigen"
				},
				{
					"type": "Synonym",
					"name": "episialin"
				},
				{
					"type": "Synonym",
					"name": "glycosylated MUC-1"
				},
				{
					"type": "Synonym",
					"name": "ImMucin"
				},
				{
					"type": "Synonym",
					"name": "Muc1 Mucin"
				},
				{
					"type": "Synonym",
					"name": "Mucin Peptide MUC-1"
				},
				{
					"type": "Synonym",
					"name": "Polymorphic Epithelial Mucin"
				}
			],
			"definition": {
				"html": "MUC-1 antigen is a mammary-type apomucin, a high molecular weight transmembrane glycoprotein, of which the extracellular domain is formed by a repeating 20 amino acid sequence (in tandem) with a high content of serine and threonine on which are O-linked carbohydrate chains. MUC-1 synthesis and secretion are features of glandular epithelial tissues; MUC-1 is overexpressed in lactating breast and in breast, ovary, lung, and prostate malignancies.",
				"text": "MUC-1 antigen is a mammary-type apomucin, a high molecular weight transmembrane glycoprotein, of which the extracellular domain is formed by a repeating 20 amino acid sequence (in tandem) with a high content of serine and threonine on which are O-linked carbohydrate chains. MUC-1 synthesis and secretion are features of glandular epithelial tissues; MUC-1 is overexpressed in lactating breast and in breast, ovary, lung, and prostate malignancies."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2407",
			"nciConceptName": "MUC-1 Antigen",
			"termId": 42454,
			"name": "MUC1 antigen",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "muc-1-antigen"
		},
		{
			"aliases": [
				{
					"type": "LexicalVariant",
					"name": "MUC-1 Peptide Vaccine"
				}
			],
			"definition": {
				"html": "A cancer vaccine comprised of a synthetic peptide derived from the mucin 1 (MUC1) antigen with potential antineoplastic activity. Upon administration, MUC1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in decreased tumor growth. Overexpressed on many tumor cells, MUC1 antigen, a mammary-type apomucin, is a high-molecular-weight transmembrane glycoprotein.",
				"text": "A cancer vaccine comprised of a synthetic peptide derived from the mucin 1 (MUC1) antigen with potential antineoplastic activity. Upon administration, MUC1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in decreased tumor growth. Overexpressed on many tumor cells, MUC1 antigen, a mammary-type apomucin, is a high-molecular-weight transmembrane glycoprotein."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C53290",
			"nciConceptName": "MUC-1 Peptide Vaccine",
			"termId": 458103,
			"name": "MUC1 peptide vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "muc-1-peptide-vaccine"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A vaccine preparation containing mucus 1 (MUC1) peptide and the adjuvant poly-ICLC with potential immunostimulatory and antineoplastic activities. Upon administration, MUC1 peptide-poly-ICLC adjuvant vaccine may induce the host immune system to mount a cytotoxic T cell response against MUC1-expressing tumor cells. MUC1, a tumor associated antigen normally present on the lining of the human colon, may be overexpressed and/or mutated in a variety of cancer cell types. The adjuvant poly-ICLC, a ligand for toll-like receptor-3, induces the release of cytokines which may help boost the immune response against MUC1.",
				"text": "A vaccine preparation containing mucus 1 (MUC1) peptide and the adjuvant poly-ICLC with potential immunostimulatory and antineoplastic activities. Upon administration, MUC1 peptide-poly-ICLC adjuvant vaccine may induce the host immune system to mount a cytotoxic T cell response against MUC1-expressing tumor cells. MUC1, a tumor associated antigen normally present on the lining of the human colon, may be overexpressed and/or mutated in a variety of cancer cell types. The adjuvant poly-ICLC, a ligand for toll-like receptor-3, induces the release of cytokines which may help boost the immune response against MUC1."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C82417",
			"nciConceptName": "MUC1 Peptide-Poly-ICLC Vaccine",
			"termId": 637356,
			"name": "MUC1 peptide-poly-ICLC adjuvant vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "muc1-peptide-poly-iclc-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MUC1-KLH VAC"
				},
				{
					"type": "Synonym",
					"name": "MUC-1-KLH vaccine"
				}
			],
			"definition": {
				"html": "A peptide vaccine, containing human tumor-associated epithelial mucin (MUC1) conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with MUC1-KLH conjugate vaccine may stimulate humoral and cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing the MUC1 antigen. In this vaccine, MUC1 antigen is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in an aberrant or deglycosylated form in various cancers such as those of the breast, prostate, and ovary.  \n",
				"text": "A peptide vaccine, containing human tumor-associated epithelial mucin (MUC1) conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with MUC1-KLH conjugate vaccine may stimulate humoral and cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing the MUC1 antigen. In this vaccine, MUC1 antigen is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in an aberrant or deglycosylated form in various cancers such as those of the breast, prostate, and ovary.  \n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2232",
			"nciConceptName": "MUC1-KLH Conjugate Vaccine",
			"termId": 38032,
			"name": "MUC1-KLH conjugate vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "muc1-klh-conjugate-vaccine"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A peptide vaccine containing the human tumor-associated antigen epithelial mucin (MUC1 antigen) conjugated with keyhole limpet hemocyanin (KLH) and combined with the nonspecific immunoadjuvant QS21 with potential antineoplastic activity.  MUC1 antigen is linked with KLH, an immunostimulant and a hapten carrier, in order to enhance immune recognition; the co-administration of saponin-derived QS21 potentially amplifies the total immune response to the MUC1 antigen.  Administration of MUC1-KLH vaccine/QS21 may result in both the production of antitumor antibodies and the stimulation of a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the MUC1 antigen. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed as an aberrant or deglycosylated form in various cancers such as breast, prostate and ovarian cancers.",
				"text": "A peptide vaccine containing the human tumor-associated antigen epithelial mucin (MUC1 antigen) conjugated with keyhole limpet hemocyanin (KLH) and combined with the nonspecific immunoadjuvant QS21 with potential antineoplastic activity.  MUC1 antigen is linked with KLH, an immunostimulant and a hapten carrier, in order to enhance immune recognition; the co-administration of saponin-derived QS21 potentially amplifies the total immune response to the MUC1 antigen.  Administration of MUC1-KLH vaccine/QS21 may result in both the production of antitumor antibodies and the stimulation of a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the MUC1 antigen. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed as an aberrant or deglycosylated form in various cancers such as breast, prostate and ovarian cancers."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C11845",
			"nciConceptName": "MUC1-KLH Vaccine/QS21",
			"termId": 38033,
			"name": "MUC1-KLH vaccine/QS21",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "muc1-klh-vaccine-qs21"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "GO-203-2C"
				},
				{
					"type": "LexicalVariant",
					"name": "MUC1-targeted Peptide GO-203-2C"
				}
			],
			"definition": {
				"html": "An optimized small peptide drug candidate targeting epithelial mucin (MUC1) with antineoplastic activity. MUC1-targeted peptide GO-203-2C interacts with oncoprotein MUC1 C-terminal subunit on the cell surface, thereby impeding cell-cell interactions, signaling, and metastasis. MUC1 antigen, a membrane bound glycoprotein expressed by most glandular and ductal epithelial cells, is over-expressed in many diverse human carcinomas including those of the breast, prostate, lung, colon, pancreas, and ovary, and has been associated with poor prognosis.",
				"text": "An optimized small peptide drug candidate targeting epithelial mucin (MUC1) with antineoplastic activity. MUC1-targeted peptide GO-203-2C interacts with oncoprotein MUC1 C-terminal subunit on the cell surface, thereby impeding cell-cell interactions, signaling, and metastasis. MUC1 antigen, a membrane bound glycoprotein expressed by most glandular and ductal epithelial cells, is over-expressed in many diverse human carcinomas including those of the breast, prostate, lung, colon, pancreas, and ovary, and has been associated with poor prognosis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C95722",
			"nciConceptName": "MUC1-targeted Peptide GO-203-2C",
			"termId": 694292,
			"name": "MUC1-targeted peptide GO-2-03-2C",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "muc1-targeted-peptide-go-203-2c"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "DMUC5754A"
				}
			],
			"definition": {
				"html": "An antibody drug conjugate (ADC) consisting of a humanized IgG1 monoclonal antibody targeting the MUC16 protein (CA-125) conjugated to, via a cleavable linker, the antimicrotubulin agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. The monoclonal antibody moiety of DMUC5754A selectively binds to MUC16. After internalization of the drug conjugate and proteolytic cleavage of the linker, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M-phase growth arrest and tumor cell apoptosis. MUC16, a transmembrane protein, is overexpressed on the cell surface of more than 80 percent of ovarian cancer cells but not on healthy cells.",
				"text": "An antibody drug conjugate (ADC) consisting of a humanized IgG1 monoclonal antibody targeting the MUC16 protein (CA-125) conjugated to, via a cleavable linker, the antimicrotubulin agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. The monoclonal antibody moiety of DMUC5754A selectively binds to MUC16. After internalization of the drug conjugate and proteolytic cleavage of the linker, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M-phase growth arrest and tumor cell apoptosis. MUC16, a transmembrane protein, is overexpressed on the cell surface of more than 80 percent of ovarian cancer cells but not on healthy cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C106119",
			"nciConceptName": "Sofituzumab Vedotin",
			"termId": 699480,
			"name": "MUC16-targeted antibody-drug conjugate DMUC5754A",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "sofituzumab-vedotin"
		},
		{
			"aliases": [
				{
					"type": "ForeignBrandName",
					"name": "FORRAD"
				},
				{
					"type": "Synonym",
					"name": "oral ulder gargle"
				},
				{
					"type": "Synonym",
					"name": "oral viscous mucoadhesive hydrogel gargle"
				}
			],
			"definition": {
				"html": "An oral rinse composed of a viscous, mucoadhesive hydrogel, with potential protective and antimucositis activities. Upon gargling with the oral viscous mucoadhesive hydrogel formulation in the oral cavity, the hydrogel forms a protective barrier over the oral mucosa, which prevents inflammation of the mucosal membranes and may decrease chemotherapy- and/or radiation-induced oral mucositis.\n",
				"text": "An oral rinse composed of a viscous, mucoadhesive hydrogel, with potential protective and antimucositis activities. Upon gargling with the oral viscous mucoadhesive hydrogel formulation in the oral cavity, the hydrogel forms a protective barrier over the oral mucosa, which prevents inflammation of the mucosal membranes and may decrease chemotherapy- and/or radiation-induced oral mucositis.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C127117",
			"nciConceptName": "Mucoadhesive Hydrogel Gargle",
			"termId": 780927,
			"name": "mucoadhesive hydrogel gargle",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mucoadhesive-hydrogel-gargle"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "MuGard"
				},
				{
					"type": "Synonym",
					"name": "oral mucoadhesive protectant rinse"
				}
			],
			"definition": {
				"html": "A viscous, oral hydrogel rinse intended for the management of oral mucositis/stomatitis. Mucoadhesive oral wound rinse consists of purified water, glycerin, benzyl alcohol, sodium saccharin, carbomer homopolymer A, potassium hydroxide, citric acid, polysorbate 60 and phosphoric acid. Upon gargling and rinsing with this solution, it forms a soothing protective hydrogel coating over the oral mucosa, thereby potentially preventing or reducing chemotherapy-induced mucositis.",
				"text": "A viscous, oral hydrogel rinse intended for the management of oral mucositis/stomatitis. Mucoadhesive oral wound rinse consists of purified water, glycerin, benzyl alcohol, sodium saccharin, carbomer homopolymer A, potassium hydroxide, citric acid, polysorbate 60 and phosphoric acid. Upon gargling and rinsing with this solution, it forms a soothing protective hydrogel coating over the oral mucosa, thereby potentially preventing or reducing chemotherapy-induced mucositis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C95730",
			"nciConceptName": "Mucoadhesive Oral Wound Rinse",
			"termId": 694843,
			"name": "mucoadhesive oral wound rinse",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mucoadhesive-oral-wound-rinse"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "DHP107"
				}
			],
			"definition": {
				"html": "An orally available, mucoadhesive lipid preparation consisting of paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia, in a formulation that is comprised of a mixture of monoolein, tricarprylin, and Tween 80, with potential antineoplastic activity. Upon oral administration, DHP107 forms droplets and micelles in the intestine; these adhere to mucoepithelial cells in the gastrointestinal tract and are absorbed through lipid-based uptake mechanisms. Upon absorption, paclitaxel binds to and stabilizes tubulin molecules, which results in the inhibition of both microtubule depolymerization and cell division. This agent also induces apoptosis by both binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (Bcl-2).The mucoadhesive paclitaxel formulation does not contain P-glycoprotein inhibitors, the solvent cremophor or any other toxic solvent.\n",
				"text": "An orally available, mucoadhesive lipid preparation consisting of paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia, in a formulation that is comprised of a mixture of monoolein, tricarprylin, and Tween 80, with potential antineoplastic activity. Upon oral administration, DHP107 forms droplets and micelles in the intestine; these adhere to mucoepithelial cells in the gastrointestinal tract and are absorbed through lipid-based uptake mechanisms. Upon absorption, paclitaxel binds to and stabilizes tubulin molecules, which results in the inhibition of both microtubule depolymerization and cell division. This agent also induces apoptosis by both binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (Bcl-2).The mucoadhesive paclitaxel formulation does not contain P-glycoprotein inhibitors, the solvent cremophor or any other toxic solvent.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C107188",
			"nciConceptName": "Mucoadhesive Paclitaxel Formulation",
			"termId": 750455,
			"name": "mucoadhesive paclitaxel formulation",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mucoadhesive-paclitaxel-formulation"
		},
		{
			"preferredName": "acetylcysteine",
			"termId": 39130,
			"name": "Mucomyst",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "acetylcysteine"
		},
		{
			"preferredName": "mucoadhesive oral wound rinse",
			"termId": 694843,
			"name": "MuGard",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "mucoadhesive-oral-wound-rinse"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "AT13148"
				}
			],
			"definition": {
				"html": "An orally available, small molecule inhibitor of AGC group kinases, with potential antineoplastic activity. AT13148 inhibits, in an ATP-competitive manner, the enzymatic activity of two AGC kinases, protein kinase B (PKB or AKT) and p70S6K which play key roles in the PI3K/PKB/mTOR signaling pathway. Blockade of this pathway leads to an inhibition of cell growth and the induction of apoptosis in susceptible tumor cells. PI3K/PKB/mTOR pathway is dysregulated in greater than 50% of tumors, and is often correlated with resistance and increased tumor survival. AGC group kinases are serine/threonine kinases that are regulated by secondary messengers such as cyclic AMP and lipids.",
				"text": "An orally available, small molecule inhibitor of AGC group kinases, with potential antineoplastic activity. AT13148 inhibits, in an ATP-competitive manner, the enzymatic activity of two AGC kinases, protein kinase B (PKB or AKT) and p70S6K which play key roles in the PI3K/PKB/mTOR signaling pathway. Blockade of this pathway leads to an inhibition of cell growth and the induction of apoptosis in susceptible tumor cells. PI3K/PKB/mTOR pathway is dysregulated in greater than 50% of tumors, and is often correlated with resistance and increased tumor survival. AGC group kinases are serine/threonine kinases that are regulated by secondary messengers such as cyclic AMP and lipids."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C101786",
			"nciConceptName": "Multi-AGC Kinase Inhibitor AT13148",
			"termId": 732857,
			"name": "multi-AGC kinase inhibitor AT13148",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multi-agc-kinase-inhibitor-at13148"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "TPIV 200"
				},
				{
					"type": "CodeName",
					"name": "TPIV200"
				},
				{
					"type": "CodeName",
					"name": "TPIV-200"
				},
				{
					"type": "Synonym",
					"name": "TPIV 200 vaccine"
				},
				{
					"type": "Synonym",
					"name": "TPIV200/huFR-1"
				}
			],
			"definition": {
				"html": "A peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor 1 (FOLR1; FR-alpha), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, multi-epitope anti-folate receptor peptide vaccine TPIV 200 may induce a cytotoxic T-lymphocyte (CTL) response against FR-alpha-overexpressing tumor cells. FR-alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in various cancer cell types.\n",
				"text": "A peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor 1 (FOLR1; FR-alpha), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, multi-epitope anti-folate receptor peptide vaccine TPIV 200 may induce a cytotoxic T-lymphocyte (CTL) response against FR-alpha-overexpressing tumor cells. FR-alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in various cancer cell types.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C128898",
			"nciConceptName": "Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200",
			"termId": 782632,
			"name": "multi-epitope anti-folate receptor peptide vaccine TPIV 200",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multi-epitope-anti-folate-receptor-peptide-vaccine-tpiv-200"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "FR alpha peptide vaccine"
				},
				{
					"type": "Synonym",
					"name": "FR peptide vaccine"
				},
				{
					"type": "Abbreviation",
					"name": "HuFR-1"
				}
			],
			"definition": {
				"html": "A peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor alpha (FR alpha or FOLR1), including FR30, FR56, FR76, FR113, and FR238, with potential immunomodulating and antineoplastic activity. Upon administration, the multi-epitope FR alpha peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against FR alpha-overexpressing tumor cells. FR alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in a majority of ovarian cancers and in about 50% of breast cancers.",
				"text": "A peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor alpha (FR alpha or FOLR1), including FR30, FR56, FR76, FR113, and FR238, with potential immunomodulating and antineoplastic activity. Upon administration, the multi-epitope FR alpha peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against FR alpha-overexpressing tumor cells. FR alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in a majority of ovarian cancers and in about 50% of breast cancers."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C101777",
			"nciConceptName": "Multi-epitope Folate Receptor Alpha Peptide Vaccine",
			"termId": 732837,
			"name": "multi-epitope folate receptor alpha peptide vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multi-epitope-folate-receptor-alpha-peptide-vaccine"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "H2NVAC"
				},
				{
					"type": "Synonym",
					"name": "HER2 peptide vaccine H2NVAC"
				},
				{
					"type": "Synonym",
					"name": "HER2 specific helper T-cell epitope vaccine H2NVAC"
				}
			],
			"definition": {
				"html": "A peptide vaccine containing four immunogenic epitopes derived from the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; HER-2; ErbB2; Neu), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, multi-epitope HER2 peptide vaccine H2NVAC may induce a helper T-cell mediated immune response against HER2-overexpressing tumor cells. This may result in long-term immunopotentiation against HER2-expressing tumor cells by increasing the helper T-cell response. HER2, a tyrosine kinase receptor for epidermal growth factor (EGF), is overexpressed in various cancer cell types.",
				"text": "A peptide vaccine containing four immunogenic epitopes derived from the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; HER-2; ErbB2; Neu), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, multi-epitope HER2 peptide vaccine H2NVAC may induce a helper T-cell mediated immune response against HER2-overexpressing tumor cells. This may result in long-term immunopotentiation against HER2-expressing tumor cells by increasing the helper T-cell response. HER2, a tyrosine kinase receptor for epidermal growth factor (EGF), is overexpressed in various cancer cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C165292",
			"nciConceptName": "Multi-epitope HER2 Peptide Vaccine H2NVAC",
			"termId": 799763,
			"name": "multi-epitope HER2 peptide vaccine H2NVAC",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multi-epitope-her2-peptide-vaccine-h2nvac"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MULTI-EP MP VAC"
				}
			],
			"definition": {
				"html": "A peptide cancer vaccine consisting of a combination of peptides derived form several melanoma epitopes. Vaccination with multi-epitope melanoma peptide vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis.  This vaccine may stimulate a broader CTL response compared to single-antigen vaccines.",
				"text": "A peptide cancer vaccine consisting of a combination of peptides derived form several melanoma epitopes. Vaccination with multi-epitope melanoma peptide vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis.  This vaccine may stimulate a broader CTL response compared to single-antigen vaccines."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C38695",
			"nciConceptName": "Multi-epitope Melanoma Peptide Vaccine",
			"termId": 341632,
			"name": "multi-epitope melanoma peptide vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multi-epitope-melanoma-peptide-vaccine"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "ICT-107"
				},
				{
					"type": "Synonym",
					"name": "multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107"
				},
				{
					"type": "Synonym",
					"name": "multi-glioblastoma-peptide-pulsed autologous DC vaccine ICT-107"
				}
			],
			"definition": {
				"html": "A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells.",
				"text": "A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C124054",
			"nciConceptName": "Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107",
			"termId": 776267,
			"name": "multi-glioblastoma-peptide-targeting autologous dendritic cell vaccine ICT-107",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": ""
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "XL092"
				},
				{
					"type": "CodeName",
					"name": "XL-092"
				},
				{
					"type": "CodeName",
					"name": "XL 092"
				}
			],
			"definition": {
				"html": "An orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Upon oral administration, multi-kinase inhibitor XL092 strongly binds to and inhibits several RTKs that are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (proto-oncogene c-Met) and certain vascular endothelial growth factor receptor (VEGFR) subtypes. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.\n",
				"text": "An orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Upon oral administration, multi-kinase inhibitor XL092 strongly binds to and inhibits several RTKs that are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (proto-oncogene c-Met) and certain vascular endothelial growth factor receptor (VEGFR) subtypes. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C161598",
			"nciConceptName": "Multi-kinase Inhibitor XL092",
			"termId": 798432,
			"name": "multi-kinase inhibitor XL092",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multi-kinase-inhibitor-xl092"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "multikinase inhibitor TPX-0022"
				},
				{
					"type": "Synonym",
					"name": "MET/Src/CSF1R tyrosine kinase inhibitor TPX-0022"
				},
				{
					"type": "CodeName",
					"name": "TPX 0022"
				},
				{
					"type": "CodeName",
					"name": "TPX0022"
				},
				{
					"type": "CodeName",
					"name": "TPX-0022"
				}
			],
			"definition": {
				"html": "An orally bioavailable, multi-targeted kinase inhibitor with potential antineoplastic activity. Upon oral administration, multi-kinase inhibitor TPX-0022 binds to and inhibits three tyrosine kinases that are often overexpressed in a variety of cancer cell types, including MET (c-Met; hepatocyte growth factor receptor; HGFR) , Src, and colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; macrophage colony-stimulating factor receptor; M-CSFR) thereby disrupting their respective signaling pathways. MET, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis. Src, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival. CSF1R is a cell-surface receptor for colony stimulating factor 1 (CSF1); this receptor tyrosine kinase is overexpressed by tumor-associated macrophages (TAMs) in the tumor microenvironment (TME), and plays a major role in both immune suppression and the induction of tumor cell proliferation.",
				"text": "An orally bioavailable, multi-targeted kinase inhibitor with potential antineoplastic activity. Upon oral administration, multi-kinase inhibitor TPX-0022 binds to and inhibits three tyrosine kinases that are often overexpressed in a variety of cancer cell types, including MET (c-Met; hepatocyte growth factor receptor; HGFR) , Src, and colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; macrophage colony-stimulating factor receptor; M-CSFR) thereby disrupting their respective signaling pathways. MET, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis. Src, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival. CSF1R is a cell-surface receptor for colony stimulating factor 1 (CSF1); this receptor tyrosine kinase is overexpressed by tumor-associated macrophages (TAMs) in the tumor microenvironment (TME), and plays a major role in both immune suppression and the induction of tumor cell proliferation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C162676",
			"nciConceptName": "Multi-kinase Inhibitor TPX-0022",
			"termId": 798966,
			"name": "multi-kinase inhibitorTPX-0022",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multi-kinase-inhibitor-tpx-0022"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "EOC317"
				},
				{
					"type": "Synonym",
					"name": "MMKI EOC317"
				},
				{
					"type": "CodeName",
					"name": "ACTB-1003"
				},
				{
					"type": "CodeName",
					"name": "EDP317"
				},
				{
					"type": "CodeName",
					"name": "EOC 317"
				},
				{
					"type": "CodeName",
					"name": "EOC-317"
				},
				{
					"type": "ChemicalStructureName",
					"name": "urea, N-[4-[4-amino-6-(methoxymethyl)-7-(4-morpholinylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-fluorophenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]-"
				},
				{
					"type": "CASRegistryName",
					"name": "939805-30-8"
				}
			],
			"definition": {
				"html": "An orally available, small molecule, multi-mode kinase inhibitor (MMKI), with potential antineoplastic activity. Upon oral administration, MMKI EOC317 targets, binds to and inhibits the activity of a variety of kinases, such as phosphatidylinositol 3 kinase (PI3K), and the receptor tyrosine kinases, fibroblast growth factor receptor (FGFR), angiopoietin-1 receptor (TIE 2), and vascular endothelial growth factor receptor-2 (VEGFR-2). This inhibition may result in an induction of apoptosis of susceptible tumors cells in which these kinases are overexpressed.\n",
				"text": "An orally available, small molecule, multi-mode kinase inhibitor (MMKI), with potential antineoplastic activity. Upon oral administration, MMKI EOC317 targets, binds to and inhibits the activity of a variety of kinases, such as phosphatidylinositol 3 kinase (PI3K), and the receptor tyrosine kinases, fibroblast growth factor receptor (FGFR), angiopoietin-1 receptor (TIE 2), and vascular endothelial growth factor receptor-2 (VEGFR-2). This inhibition may result in an induction of apoptosis of susceptible tumors cells in which these kinases are overexpressed.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C164211",
			"nciConceptName": "Multi-mode Kinase Inhibitor EOC317",
			"termId": 799401,
			"name": "multi-mode kinase inhibitor EOC317",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multi-mode-kinase-inhibitor-eoc317"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "CMV-MVA triplex vaccine"
				}
			],
			"definition": {
				"html": "A vaccine consisting of an inactivated, Modified Vaccinia Ankara (MVA) viral vector encoding three herpes virus cytomegalovirus (CMV) tumor-associated antigens (TAAs), including UL83 (pp65), UL123 (IE1) and UL122 (IE2), with potential immunostimulating activity. The viral peptides expressed after administration of the multi-peptide CMV-MVA vaccine, may stimulate the immune system to mount both cytotoxic T-lymphocyte (CTL) and helper T-cell responses against CMV-infected cells. This results in cell lysis and prevents viral replication and the development of CMV disease. This vaccine also provides active immunization and protective immunity against CMV infection in CMV-negative patients. CMV infection can cause serious complications in patients receiving either allogeneic hematopoietic cell transplants (HCT) or solid organ transplants.",
				"text": "A vaccine consisting of an inactivated, Modified Vaccinia Ankara (MVA) viral vector encoding three herpes virus cytomegalovirus (CMV) tumor-associated antigens (TAAs), including UL83 (pp65), UL123 (IE1) and UL122 (IE2), with potential immunostimulating activity. The viral peptides expressed after administration of the multi-peptide CMV-MVA vaccine, may stimulate the immune system to mount both cytotoxic T-lymphocyte (CTL) and helper T-cell responses against CMV-infected cells. This results in cell lysis and prevents viral replication and the development of CMV disease. This vaccine also provides active immunization and protective immunity against CMV infection in CMV-negative patients. CMV infection can cause serious complications in patients receiving either allogeneic hematopoietic cell transplants (HCT) or solid organ transplants."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C111036",
			"nciConceptName": "Multi-peptide CMV-Modified Vaccinia Ankara Vaccine",
			"termId": 751745,
			"name": "multi-peptide CMV-Modified Vaccinia Ankara vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multi-peptide-cmv-modified-vaccinia-ankara-vaccine"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "MCS-8"
				}
			],
			"definition": {
				"html": "A supplement containing multiple, as of yet undisclosed, carotenoids, with potential chemopreventive activity. Upon oral administration of the multicarotenoid supplement MCS-8, the carotenoids may be able to exert their chemopreventive activity through multiple mechanisms of action.",
				"text": "A supplement containing multiple, as of yet undisclosed, carotenoids, with potential chemopreventive activity. Upon oral administration of the multicarotenoid supplement MCS-8, the carotenoids may be able to exert their chemopreventive activity through multiple mechanisms of action."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C121859",
			"nciConceptName": "Multicarotenoid Supplement MCS-8",
			"termId": 771725,
			"name": "multicarotenoid supplement MCS-8",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multicarotenoid-supplement-mcs-8"
		},
		{
			"aliases": [
				{
					"type": "LexicalVariant",
					"name": "autologous TARP peptide-pulsed dendritic cell vaccine"
				},
				{
					"type": "Synonym",
					"name": "multi-epitope TARP peptide-pulsed autologous dendritic cell vaccine"
				},
				{
					"type": "Synonym",
					"name": "multi-epitope TARP-pulsed autologous DC vaccine"
				},
				{
					"type": "Synonym",
					"name": "ME T-cell receptor gamma alternate reading frame protein peptide-pulsed autologous DC vaccine"
				}
			],
			"definition": {
				"html": "A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with multiple antigenic peptides derived from T-cell receptor gamma-chain alternate reading frame protein (TARP), with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, multi-epitope (ME) TARP-pulsed autologous dendritic cell vaccine may stimulate anti-tumor cytotoxic T-lymphocyte (CTL) and antibody responses against TARP-expressing cancer cells, resulting in tumor cell lysis. The highly immunogenic nuclear protein TARP is expressed in a variety of cancer cell types.",
				"text": "A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with multiple antigenic peptides derived from T-cell receptor gamma-chain alternate reading frame protein (TARP), with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, multi-epitope (ME) TARP-pulsed autologous dendritic cell vaccine may stimulate anti-tumor cytotoxic T-lymphocyte (CTL) and antibody responses against TARP-expressing cancer cells, resulting in tumor cell lysis. The highly immunogenic nuclear protein TARP is expressed in a variety of cancer cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C85470",
			"nciConceptName": "Multi-epitope TARP-pulsed Autologous Dendritic Cell Vaccine",
			"termId": 644896,
			"name": "multiepitope TARP-pulsed autologous dendritic cell vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multi-epitope-tarp-pulsed-autologous-dendritic-cell-vaccine"
		},
		{
			"preferredName": "multisubtype natural human leukocyte interferon alpha",
			"termId": 703644,
			"name": "Multiferon",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "multi-subtype-natural-human-leukocyte-interferon-alpha"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "OMN54"
				},
				{
					"type": "USBrandName",
					"name": "Aneustat"
				},
				{
					"type": "Synonym",
					"name": "MFMT OMN54"
				}
			],
			"definition": {
				"html": "An orally available, multivalent herbal formulation containing a novel mixture of whole extracts from three commonly used Chinese medicinal herbs Ganoderma lucidum (lingzhi mushroom), Salvia miltiorrhiza (Chinese sage, or danshen) and Scutellaria barbata (ban zhi lian), with potential immunomodulating, antiangiogenic, anti-inflammatory, antiproliferative and antiviral activities. Although the exact mechanism of action remains to be fully elucidated due to the complexity of the multiple phytochemicals, multifunctional/multitargeted anticancer agent OMN54 appears to work in an additive and synergistic manner by acting on a variety of signaling pathways and on multiple targets, such as vascular endothelial growth factor, nuclear factor kappa B, interleukin-1beta, fibroblast growth factor, and epidermal growth factor.",
				"text": "An orally available, multivalent herbal formulation containing a novel mixture of whole extracts from three commonly used Chinese medicinal herbs Ganoderma lucidum (lingzhi mushroom), Salvia miltiorrhiza (Chinese sage, or danshen) and Scutellaria barbata (ban zhi lian), with potential immunomodulating, antiangiogenic, anti-inflammatory, antiproliferative and antiviral activities. Although the exact mechanism of action remains to be fully elucidated due to the complexity of the multiple phytochemicals, multifunctional/multitargeted anticancer agent OMN54 appears to work in an additive and synergistic manner by acting on a variety of signaling pathways and on multiple targets, such as vascular endothelial growth factor, nuclear factor kappa B, interleukin-1beta, fibroblast growth factor, and epidermal growth factor."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C101260",
			"nciConceptName": "Multifunctional/Multitargeted Anticancer Agent OMN54",
			"termId": 729454,
			"name": "multifunctional/multitargeted anticancer agent OMN54",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multifunctional-multitargeted-anticancer-agent-omn54"
		},
		{
			"preferredName": "gadobenate dimeglumine",
			"termId": 617168,
			"name": "MultiHance",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "gadobenate-dimeglumine"
		},
		{
			"preferredName": "gadopentetate dimeglumine",
			"termId": 37987,
			"name": "MultiHance",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "gadopentetate-dimeglumine"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "4SC-203"
				}
			],
			"definition": {
				"html": "A multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). This may result in the inhibition of angiogenesis and cell proliferation in tumor cells in which these kinases are upregulated. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias (AML). VEGFRs, tyrosine kinase receptors, are overexpressed in a variety of tumor cell types and play key roles in angiogenesis.",
				"text": "A multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). This may result in the inhibition of angiogenesis and cell proliferation in tumor cells in which these kinases are upregulated. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias (AML). VEGFRs, tyrosine kinase receptors, are overexpressed in a variety of tumor cell types and play key roles in angiogenesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C90553",
			"nciConceptName": "Multikinase Inhibitor 4SC-203",
			"termId": 666086,
			"name": "multikinase inhibitor 4SC-203",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multikinase-inhibitor-4sc-203"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "AT9283"
				}
			],
			"definition": {
				"html": "A small-molecule inhibitor of  several kinases with potential antineoplastic activity. Multikinase inhibitor AT9283 binds to and inhibits Aurora kinases A and B, JAK2 (Janus kinase 2) and the kinase BCR-ABL, which may result  in the inhibition of cellular division and proliferation and the induction of apoptosis in tumor cells that overexpress these kinases. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis; JAK2 is a kinase that transduces signals from the single chain and IL-3 cytokine receptor families, and from the\n\nIFN-gamma receptors; BCR-ABL is a fusion protein with tyrosine kinase activity that is commonly found in CML.",
				"text": "A small-molecule inhibitor of  several kinases with potential antineoplastic activity. Multikinase inhibitor AT9283 binds to and inhibits Aurora kinases A and B, JAK2 (Janus kinase 2) and the kinase BCR-ABL, which may result  in the inhibition of cellular division and proliferation and the induction of apoptosis in tumor cells that overexpress these kinases. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis; JAK2 is a kinase that transduces signals from the single chain and IL-3 cytokine receptor families, and from the\n\nIFN-gamma receptors; BCR-ABL is a fusion protein with tyrosine kinase activity that is commonly found in CML."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C66947",
			"nciConceptName": "Multikinase Inhibitor AT9283",
			"termId": 534287,
			"name": "multikinase inhibitor AT9283",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multikinase-inhibitor-at9283"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "SAR103168"
				}
			],
			"definition": {
				"html": "A multikinase inhibitor with potential antineoplastic activity. Upon intravenous infusion, multikinase inhibitor SAR103168 may, through the inhibition of multiple kinases, inhibit the phosphorylation and activation of signal transducer and activator of transcription 5 (STAT5). STAT5, a protein often upregulated in cancer cells, plays a key role in signal transduction pathways and the suppression of apoptosis.\n",
				"text": "A multikinase inhibitor with potential antineoplastic activity. Upon intravenous infusion, multikinase inhibitor SAR103168 may, through the inhibition of multiple kinases, inhibit the phosphorylation and activation of signal transducer and activator of transcription 5 (STAT5). STAT5, a protein often upregulated in cancer cells, plays a key role in signal transduction pathways and the suppression of apoptosis.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C88278",
			"nciConceptName": "Multikinase Inhibitor SAR103168",
			"termId": 656309,
			"name": "multikinase inhibitor SAR103168",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multikinase-inhibitor-sar103168"
		},
		{
			"preferredName": "recombinant leukocyte interleukin",
			"termId": 42580,
			"name": "Multikine",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "recombinant-leukocyte-interleukin"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "S-588210"
				},
				{
					"type": "Synonym",
					"name": "S-488210/S-488211"
				}
			],
			"definition": {
				"html": "A cancer vaccine composed of a combination of the injectable formulations S-488210, which contains the three HLA-A*02:01-restricted peptides up-regulated lung cancer 10 (lymphocyte antigen 6K; LY6K; URLC10), cell division cycle-associated protein 1 (kinetochore protein Nuf2; NUF2; CDCA1) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3; KOC1) and S-488211, which contains the two HLA-A*02:01-restricted peptides DEP domain-containing protein 1A (DEPDC1) and M-phase phosphoprotein 1 (kinesin-like protein KIF20B; MPHOSPH1), with potential immunostimulatory and antitumor activities. Upon administration, multipeptide vaccine S-588210 may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KOC1, CDCA1, URLC10, DEPDC1 or MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth.\n",
				"text": "A cancer vaccine composed of a combination of the injectable formulations S-488210, which contains the three HLA-A*02:01-restricted peptides up-regulated lung cancer 10 (lymphocyte antigen 6K; LY6K; URLC10), cell division cycle-associated protein 1 (kinetochore protein Nuf2; NUF2; CDCA1) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3; KOC1) and S-488211, which contains the two HLA-A*02:01-restricted peptides DEP domain-containing protein 1A (DEPDC1) and M-phase phosphoprotein 1 (kinesin-like protein KIF20B; MPHOSPH1), with potential immunostimulatory and antitumor activities. Upon administration, multipeptide vaccine S-588210 may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KOC1, CDCA1, URLC10, DEPDC1 or MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C125692",
			"nciConceptName": "Multipeptide Vaccine S-588210",
			"termId": 778596,
			"name": "multipeptide vaccine S-588210",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multipeptide-vaccine-s-588210"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MASCT-I"
				},
				{
					"type": "Synonym",
					"name": "multiple TAA-loaded DC vaccine"
				},
				{
					"type": "Synonym",
					"name": "antigen-pulsed DCs MASCT-I"
				},
				{
					"type": "Synonym",
					"name": "multiple target antigen-stimulating cells-I"
				}
			],
			"definition": {
				"html": "A dendritic cell (DC) vaccine in which autologous DCs are loaded with multiple tumor-associated antigens (TAAs), with potential immunostimulating and antineoplastic activities. Upon re-infusion into the patient, the antigen-pulsed DCs stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the TAA-expressing tumor cells.",
				"text": "A dendritic cell (DC) vaccine in which autologous DCs are loaded with multiple tumor-associated antigens (TAAs), with potential immunostimulating and antineoplastic activities. Upon re-infusion into the patient, the antigen-pulsed DCs stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the TAA-expressing tumor cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C131336",
			"nciConceptName": "Multiple TAA-loaded Dendritic Cell Vaccine",
			"termId": 785719,
			"name": "multiple TAA-loaded dendritic cell vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multiple-taa-loaded-dendritic-cell-vaccine"
		},
		{
			"preferredName": "allogeneic multipotent adult progenitor cells",
			"termId": 597298,
			"name": "MultiStem",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "allogeneic-multipotent-adult-progenitor-cells"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Multiferon"
				},
				{
					"type": "Synonym",
					"name": "multisubtype natural human interferon alpha"
				}
			],
			"definition": {
				"html": "A preparation containing a mixture of multiple naturally occurring, active subtypes 1, 2, 8, 10, 14 and 21 of interferon alpha (IFN-alpha) with immunomodulating, anti-viral and anti-cancer activities. Multi-subtype natural human leukocyte IFN-alpha is purified from the leukocyte fraction of human blood challenged with Sendai virus. Upon administration, IFN-alpha subtypes bind to cell surface IFN-alpha receptors (IFNARs), resulting in an upregulation of interferon stimulated genes and related protein products. This ultimately leads to the proliferation of human B cells, activation of natural killer (NK) cells and dendritic cells (DCs), an increase in HLA-I and HLA-II expression and activation of CD8-lymphocytes. Compared to single-subtype IFN, multi-subtypes act synergistically.\n",
				"text": "A preparation containing a mixture of multiple naturally occurring, active subtypes 1, 2, 8, 10, 14 and 21 of interferon alpha (IFN-alpha) with immunomodulating, anti-viral and anti-cancer activities. Multi-subtype natural human leukocyte IFN-alpha is purified from the leukocyte fraction of human blood challenged with Sendai virus. Upon administration, IFN-alpha subtypes bind to cell surface IFN-alpha receptors (IFNARs), resulting in an upregulation of interferon stimulated genes and related protein products. This ultimately leads to the proliferation of human B cells, activation of natural killer (NK) cells and dendritic cells (DCs), an increase in HLA-I and HLA-II expression and activation of CD8-lymphocytes. Compared to single-subtype IFN, multi-subtypes act synergistically.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C97509",
			"nciConceptName": "Multi-subtype Natural Human Leukocyte Interferon Alpha",
			"termId": 703644,
			"name": "multisubtype natural human leukocyte interferon alpha",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multi-subtype-natural-human-leukocyte-interferon-alpha"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "JNJ-26483327"
				},
				{
					"type": "LexicalVariant",
					"name": "MultitargetedTyrosine Kinase Inhibitor JNJ-26483327"
				}
			],
			"definition": {
				"html": "An orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor JNJ-26483327 binds to and inhibits several members of the epidermal growth factor receptor (EGFR) family, including EGFR, HER2 and HER4; Src family kinases (Lyn, Yes, Fyn, Lck and Src); and vascular endothelial growth factor receptor type 3 (VEGFR3). By inhibiting several different signaling molecules that play crucial roles at various stages in tumorigenesis, this agent may inhibit tumor growth, invasion, migration and metastasis. In addition, JNJ-26483327 crosses the blood-brain barrier (BBB).\n",
				"text": "An orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor JNJ-26483327 binds to and inhibits several members of the epidermal growth factor receptor (EGFR) family, including EGFR, HER2 and HER4; Src family kinases (Lyn, Yes, Fyn, Lck and Src); and vascular endothelial growth factor receptor type 3 (VEGFR3). By inhibiting several different signaling molecules that play crucial roles at various stages in tumorigenesis, this agent may inhibit tumor growth, invasion, migration and metastasis. In addition, JNJ-26483327 crosses the blood-brain barrier (BBB).\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C77866",
			"nciConceptName": "Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327",
			"termId": 596693,
			"name": "multitargeted tyrosine kinase inhibitor JNJ-26483327",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multitargeted-tyrosine-kinase-inhibitor-jnj-26483327"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MULTIVIT"
				}
			],
			"definition": {
				"html": "A dietary supplement containing all or most of the vitamins that may not be readily available in the diet. Vitamins may be classified according to their solubility either in lipids (vitamins A, D, E, K, F) or in water (vitamins C, B-complex). Present in minute amounts in various foods, vitamins are essential to maintaining normal metabolism and biochemical functions.",
				"text": "A dietary supplement containing all or most of the vitamins that may not be readily available in the diet. Vitamins may be classified according to their solubility either in lipids (vitamins A, D, E, K, F) or in water (vitamins C, B-complex). Present in minute amounts in various foods, vitamins are essential to maintaining normal metabolism and biochemical functions."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1654",
			"nciConceptName": "Multivitamin",
			"termId": 43255,
			"name": "multivitamin",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "multivitamin"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "PNU 166148"
				},
				{
					"type": "LexicalVariant",
					"name": "PNU166148"
				}
			],
			"definition": {
				"html": "A water-soluble prodrug, consisting of camptothecin covalently linked to polymeric backbone methacryloylglycynamide, with potential antineoplastic activity. After entering tumor cells, the active moiety camptothecin is slowly released from mureletecan via hydrolysis of the ester linkage. Camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, binds to and stabilizes the topoisomerase I-DNA covalent complex. This inhibits the religation of topoisomerase I-mediated single-stranded DNA breaks and produces potentially lethal double-stranded DNA breaks when encountered by the DNA replication machinery, resulting in the inhibition of DNA replication and apoptosis. Compared to camtpothecin, this prodrug formulation increases camptothecin drug delivery to the tumor site while reducing systemic toxicity. ",
				"text": "A water-soluble prodrug, consisting of camptothecin covalently linked to polymeric backbone methacryloylglycynamide, with potential antineoplastic activity. After entering tumor cells, the active moiety camptothecin is slowly released from mureletecan via hydrolysis of the ester linkage. Camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, binds to and stabilizes the topoisomerase I-DNA covalent complex. This inhibits the religation of topoisomerase I-mediated single-stranded DNA breaks and produces potentially lethal double-stranded DNA breaks when encountered by the DNA replication machinery, resulting in the inhibition of DNA replication and apoptosis. Compared to camtpothecin, this prodrug formulation increases camptothecin drug delivery to the tumor site while reducing systemic toxicity. "
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2234",
			"nciConceptName": "Mureletecan",
			"termId": 43584,
			"name": "mureletecan",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mureletecan"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A plasmid DNA vaccine encoding the mouse tumor associated antigen tyrosinase-related protein-2 (TYRP2) with potential immunostimulating and antineoplastic activities. Upon administration, murine TYRP2 plasmid DNA vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing TYRP2; this vaccine may also induce an immune response against tyrosinase-related protein-1 (TYRP1).\n TYRP2 and TYRP1, melanosomal membrane glycoproteins upregulated in melanoma cells, are involved in melanin synthesis.",
				"text": "A plasmid DNA vaccine encoding the mouse tumor associated antigen tyrosinase-related protein-2 (TYRP2) with potential immunostimulating and antineoplastic activities. Upon administration, murine TYRP2 plasmid DNA vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing TYRP2; this vaccine may also induce an immune response against tyrosinase-related protein-1 (TYRP1).\n TYRP2 and TYRP1, melanosomal membrane glycoproteins upregulated in melanoma cells, are involved in melanin synthesis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C77877",
			"nciConceptName": "Murine TYRP2 Plasmid DNA Vaccine",
			"termId": 597306,
			"name": "murine TYRP2 plasmid DNA vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "murine-tyrp2-plasmid-dna-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "monoclonal antibody OKT3"
				},
				{
					"type": "LexicalVariant",
					"name": "Anti-CD3 monoclonal antibody OKT 3"
				},
				{
					"type": "Synonym",
					"name": "Anti-CD3 monoclonal antibody OKT3"
				},
				{
					"type": "LexicalVariant",
					"name": "MOAB OKT 3"
				},
				{
					"type": "Abbreviation",
					"name": "MOAB OKT3"
				},
				{
					"type": "Synonym",
					"name": "MOAB OKT3"
				},
				{
					"type": "Synonym",
					"name": "OKT3"
				},
				{
					"type": "LexicalVariant",
					"name": "monoclonal antibody OKT 3"
				},
				{
					"type": "USBrandName",
					"name": "Orthoclone OKT3"
				},
				{
					"type": "INDCode",
					"name": "6883"
				},
				{
					"type": "INDCode",
					"name": "3860"
				},
				{
					"type": "INDCode",
					"name": "3546"
				},
				{
					"type": "INDCode",
					"name": "2851"
				},
				{
					"type": "NSCNumber",
					"name": "618843"
				}
			],
			"definition": {
				"html": "A murine IgG2a monoclonal antibody with immunosuppressive activity. Muromonab-CD3 binds to and inhibits CD3 on the surface of circulating T-lymphocytes; binding of muromonab-CD3 to CD3-positive T cells  results in an early activation of this T cell subset, followed by cytokine release, and subsequently inhibition of T cell functions. This agent may cause the opsonization and elimination of CD3-positive T cells from the circulation by mononuclear phagocytes in the liver and spleen. CD3 is part of the functional T cell receptor (TCR) complex, which is necessary for antigen recognition by T cells, and is required for signal transduction.",
				"text": "A murine IgG2a monoclonal antibody with immunosuppressive activity. Muromonab-CD3 binds to and inhibits CD3 on the surface of circulating T-lymphocytes; binding of muromonab-CD3 to CD3-positive T cells  results in an early activation of this T cell subset, followed by cytokine release, and subsequently inhibition of T cell functions. This agent may cause the opsonization and elimination of CD3-positive T cells from the circulation by mononuclear phagocytes in the liver and spleen. CD3 is part of the functional T cell receptor (TCR) complex, which is necessary for antigen recognition by T cells, and is required for signal transduction."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1321",
			"nciConceptName": "Muromonab-CD3",
			"termId": 39580,
			"name": "muromonab-CD3",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "muromonab-cd3"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Muscadine Plus"
				},
				{
					"type": "USBrandName",
					"name": "Vinetra"
				},
				{
					"type": "Abbreviation",
					"name": "MSKE"
				}
			],
			"definition": {
				"html": "A nutritional supplement containing an extract of the skin of muscadine grape (Vitis rotundifolia), with anti-inflammatory, antioxidant and potential chemopreventive activities. The skin extract of the muscadine grape contains numerous phytochemicals including hydrolyzable tannins and flavonoids, such as anthocyanin 3,5-diglucosides, quercetin, myricetin, and kaempferol glycosides. Upon administration, muscadine grape skin extract (MSKE) appears to inhibit PI3K/Akt and MAPK signaling, eventually leading to apoptosis and a reduction in tumor cell proliferation.",
				"text": "A nutritional supplement containing an extract of the skin of muscadine grape (Vitis rotundifolia), with anti-inflammatory, antioxidant and potential chemopreventive activities. The skin extract of the muscadine grape contains numerous phytochemicals including hydrolyzable tannins and flavonoids, such as anthocyanin 3,5-diglucosides, quercetin, myricetin, and kaempferol glycosides. Upon administration, muscadine grape skin extract (MSKE) appears to inhibit PI3K/Akt and MAPK signaling, eventually leading to apoptosis and a reduction in tumor cell proliferation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C96231",
			"nciConceptName": "Muscadine Grape Skin Extract",
			"termId": 697625,
			"name": "muscadine grape skin extract",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "muscadine-grape-skin-extract"
		},
		{
			"preferredName": "muscadine grape skin extract",
			"termId": 697625,
			"name": "Muscadine Plus",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "muscadine-grape-skin-extract"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "APD515"
				}
			],
			"definition": {
				"html": "A liquid, oromucosal formulation containing a muscarinic agonist with potential anti-xerostomia activity. Upon application to the inside lining of the mouth, muscarinic agonist APD515 may locally act on muscarinic receptors on the salivary glands and may stimulate the production of saliva thereby relieving dryness of the mouth.",
				"text": "A liquid, oromucosal formulation containing a muscarinic agonist with potential anti-xerostomia activity. Upon application to the inside lining of the mouth, muscarinic agonist APD515 may locally act on muscarinic receptors on the salivary glands and may stimulate the production of saliva thereby relieving dryness of the mouth."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": null,
			"nciConceptName": null,
			"termId": 698992,
			"name": "muscarinic agonist APD515",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "muscarinic-agonist-apd515"
		},
		{
			"preferredName": "alprostadil",
			"termId": 360459,
			"name": "MUSE",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "alprostadil"
		},
		{
			"preferredName": "mechlorethamine hydrochloride",
			"termId": 43434,
			"name": "Mustargen",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "mechlorethamine-hydrochloride"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "DS-1001b"
				},
				{
					"type": "CodeName",
					"name": "DS-1001"
				},
				{
					"type": "CodeName",
					"name": "DS 1001"
				},
				{
					"type": "Synonym",
					"name": "mutant isocitrate dehydrogenase type 1 inhibitor DS-1001"
				}
			],
			"definition": {
				"html": "An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) mutant forms, including substitution mutations at the arginine in position 132, IDH1(R132) (IDH1-R132), with potential antineoplastic activity. Upon administration, mutant IDH-1 inhibitor DS-1001 specifically inhibits certain mutant forms of IDH1, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH1 mutations. IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG. DS-1001 minimally targets and affects wild-type IDH1, which is expressed in normal, healthy cells.",
				"text": "An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) mutant forms, including substitution mutations at the arginine in position 132, IDH1(R132) (IDH1-R132), with potential antineoplastic activity. Upon administration, mutant IDH-1 inhibitor DS-1001 specifically inhibits certain mutant forms of IDH1, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH1 mutations. IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG. DS-1001 minimally targets and affects wild-type IDH1, which is expressed in normal, healthy cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C148134",
			"nciConceptName": "Mutant IDH1 Inhibitor DS-1001",
			"termId": 792460,
			"name": "mutant IDH1 inhibitor DS-1001",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mutant-idh1-inhibitor-ds-1001"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "COTI-2"
				},
				{
					"type": "CodeName",
					"name": "COTI2"
				}
			],
			"definition": {
				"html": "An orally available third generation thiosemicarbazone and activator of mutant forms of the p53 protein, with potential antineoplastic activity. Upon oral administration, mutant p53 activator COTI-2 targets and binds to the misfolded mutant forms of the p53 protein, which induces a conformational change that normalizes p53 and restores its activity. This induces apoptosis in tumor cells in which the p53 protein is mutated. In addition, COTI-2 inhibits the activation of Akt2 and prevents the activation of the PI3K/AKT/mTOR pathway, thereby inducing apoptosis in cancer cells in which this pathway is overexpressed. p53, a tumor suppressor protein, plays a key role in controlling cellular proliferation and survival. High levels of mutant p53 are seen in many cancers and are associated with uncontrolled cellular growth.",
				"text": "An orally available third generation thiosemicarbazone and activator of mutant forms of the p53 protein, with potential antineoplastic activity. Upon oral administration, mutant p53 activator COTI-2 targets and binds to the misfolded mutant forms of the p53 protein, which induces a conformational change that normalizes p53 and restores its activity. This induces apoptosis in tumor cells in which the p53 protein is mutated. In addition, COTI-2 inhibits the activation of Akt2 and prevents the activation of the PI3K/AKT/mTOR pathway, thereby inducing apoptosis in cancer cells in which this pathway is overexpressed. p53, a tumor suppressor protein, plays a key role in controlling cellular proliferation and survival. High levels of mutant p53 are seen in many cancers and are associated with uncontrolled cellular growth."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C121951",
			"nciConceptName": "Mutant p53 Activator COTI-2",
			"termId": 772024,
			"name": "mutant p53 activator COTI-2",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mutant-p53-activator-coti-2"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "mutant p53 peptide pulsed DC vaccine"
				},
				{
					"type": "Abbreviation",
					"name": "p53 DEN"
				}
			],
			"definition": {
				"html": "A cancer vaccine consisting of autologous dendritic cells which have been pulsed with a mutant p53 peptide. Vaccination with mutant p53 peptide pulsed dendritic cells may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. Many tumor cells overexpress mutant p53 proteins, resulting in the loss of apoptosis regulation and abnormal cell proliferation.",
				"text": "A cancer vaccine consisting of autologous dendritic cells which have been pulsed with a mutant p53 peptide. Vaccination with mutant p53 peptide pulsed dendritic cells may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. Many tumor cells overexpress mutant p53 proteins, resulting in the loss of apoptosis regulation and abnormal cell proliferation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2540",
			"nciConceptName": "Mutant p53 Peptide Pulsed Dendritic Cell Vaccine",
			"termId": 43586,
			"name": "mutant p53 peptide pulsed dendritic cell vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mutant-p53-peptide-pulsed-dendritic-cell-vaccine"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "PF-06459988"
				}
			],
			"definition": {
				"html": "An orally available, small molecule, third-generation, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant (EGFRm) forms with potential antineoplastic activity. EGFR inhibitor PF-06459988 specifically binds to and inhibits mutant forms of EGFR, including the secondary acquired resistance mutation T790M, which prevents EGFR-mediated signaling and leads to cell death in EGFRm-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06459988 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that are seen with the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.",
				"text": "An orally available, small molecule, third-generation, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant (EGFRm) forms with potential antineoplastic activity. EGFR inhibitor PF-06459988 specifically binds to and inhibits mutant forms of EGFR, including the secondary acquired resistance mutation T790M, which prevents EGFR-mediated signaling and leads to cell death in EGFRm-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06459988 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that are seen with the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C119624",
			"nciConceptName": "Mutant-selective EGFR Inhibitor PF-06459988",
			"termId": 766942,
			"name": "mutant-selective EGFR inhibitor PF-06459988",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mutant-selective-egfr-inhibitor-pf-06459988"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "Modified Vaccinia Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP"
				},
				{
					"type": "Synonym",
					"name": "Modified Vaccinia Virus Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP"
				},
				{
					"type": "CodeName",
					"name": "MVA-209-FSP"
				}
			],
			"definition": {
				"html": "An off-the-shelf neoantigen boosting vaccine comprised of a modified Vaccinia virus Ankara (MVA) encoding tumor-specific neoantigens (TSNAs) derived from the same as of yet undisclosed frameshift peptides (FSPs) targeted by the priming vaccine, great ape adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, with potential immunostimulatory and antineoplastic activities. Following intramuscular administration of the priming vaccine GAd-209-FSP, the booster MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP may serve to further expand and improve the phenotyping of antigen-specific T-cells targeted to the tumor cells expressing the TSNAs.",
				"text": "An off-the-shelf neoantigen boosting vaccine comprised of a modified Vaccinia virus Ankara (MVA) encoding tumor-specific neoantigens (TSNAs) derived from the same as of yet undisclosed frameshift peptides (FSPs) targeted by the priming vaccine, great ape adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, with potential immunostimulatory and antineoplastic activities. Following intramuscular administration of the priming vaccine GAd-209-FSP, the booster MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP may serve to further expand and improve the phenotyping of antigen-specific T-cells targeted to the tumor cells expressing the TSNAs."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C162806",
			"nciConceptName": "MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP",
			"termId": 800851,
			"name": "MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mva-tumor-specific-neoantigen-boosting-vaccine-mva-209-fsp"
		},
		{
			"aliases": [
				{
					"type": "USBrandName",
					"name": "Imvamune"
				},
				{
					"type": "Synonym",
					"name": "modified vaccinia Ankara - Bavarian Nordic smallpox vaccine"
				},
				{
					"type": "Synonym",
					"name": "modified vaccinia Ankara smallpox vaccine"
				},
				{
					"type": "Synonym",
					"name": "MVA smallpox vaccine"
				},
				{
					"type": "USBrandName",
					"name": "Jynneos"
				},
				{
					"type": "ForeignBrandName",
					"name": "Imvanex"
				},
				{
					"type": "CASRegistryName",
					"name": "1026718-04-6"
				}
			],
			"definition": {
				"html": "A vaccine consisting of modified vaccinia Ankara-Bavarian Nordic (MVA-BN), a live, attenuated, non-replicating, proprietary version of the MVA virus, used for the prevention of smallpox and monkeypox, with potential antineoplastic activity. Upon intratumoral administration, MVA-BN smallpox vaccine may induce both cellular and humoral immune responses, which may lead to tumor cell lysis.",
				"text": "A vaccine consisting of modified vaccinia Ankara-Bavarian Nordic (MVA-BN), a live, attenuated, non-replicating, proprietary version of the MVA virus, used for the prevention of smallpox and monkeypox, with potential antineoplastic activity. Upon intratumoral administration, MVA-BN smallpox vaccine may induce both cellular and humoral immune responses, which may lead to tumor cell lysis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": null,
			"nciConceptName": null,
			"termId": 801908,
			"name": "MVA-BN smallpox vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mva-bn-smallpox-vaccine"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation.",
				"text": "A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": null,
			"nciConceptName": null,
			"termId": 670438,
			"name": "MVA-EBNA1/LMP2 vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mva-ebna1-lmp2-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "modified Ankara virus-mediated suicide gene delivery vector TG4023"
				},
				{
					"type": "CodeName",
					"name": "TG4023"
				}
			],
			"definition": {
				"html": "A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the suicide gene FCU1with potential antineoplastic activity. FCU1 is a bifunctional yeast cytosine deaminase (CD) / uracil phosphoribosyltransferase (UPRT) fusion gene. Upon intratumoral administration, MVA-FCU1 TG4023 enters tumor cells where FCU1 is expressed. Subsequently,  the noncytotoxic prodrug 5-fluorocytosine (5-FC) is administered systemically and is deaminated by CD in FCU1- transduced tumor cells into 5-fluorouracil (5-FU), which is then directly metabolized to 5-fluoro-uridine monophosphate (5-FUMP) by UPRT; 5-FUMP may then be further transformed to 5-fluoro-deoxyuridine\nmonophosphate (5-FdUMP), an irreversible inhibitor of thymidylate\nsynthase and, so, DNA synthesis through deprivation of deoxythymidine\ntriphosphate (dTTP). 5-FU and its active metabolites may then selectively kill tumor cells, avoiding toxicity in nonmalignant cells. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly.\n",
				"text": "A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the suicide gene FCU1with potential antineoplastic activity. FCU1 is a bifunctional yeast cytosine deaminase (CD) / uracil phosphoribosyltransferase (UPRT) fusion gene. Upon intratumoral administration, MVA-FCU1 TG4023 enters tumor cells where FCU1 is expressed. Subsequently,  the noncytotoxic prodrug 5-fluorocytosine (5-FC) is administered systemically and is deaminated by CD in FCU1- transduced tumor cells into 5-fluorouracil (5-FU), which is then directly metabolized to 5-fluoro-uridine monophosphate (5-FUMP) by UPRT; 5-FUMP may then be further transformed to 5-fluoro-deoxyuridine\nmonophosphate (5-FdUMP), an irreversible inhibitor of thymidylate\nsynthase and, so, DNA synthesis through deprivation of deoxythymidine\ntriphosphate (dTTP). 5-FU and its active metabolites may then selectively kill tumor cells, avoiding toxicity in nonmalignant cells. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C88279",
			"nciConceptName": "MVA-FCU1 TG4023",
			"termId": 656523,
			"name": "MVA-FCU1 TG4023",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mva-fcu1-tg4023"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "RO5217790"
				},
				{
					"type": "Synonym",
					"name": "recombinant vaccinia viral vector RO5217790"
				},
				{
					"type": "CodeName",
					"name": "TG4001"
				},
				{
					"type": "CodeName",
					"name": "TG 4001"
				},
				{
					"type": "CodeName",
					"name": "TG-4001"
				},
				{
					"type": "Synonym",
					"name": "MVA-HPV-IL2"
				},
				{
					"type": "CodeName",
					"name": "RG3484"
				},
				{
					"type": "CodeName",
					"name": "R3484"
				},
				{
					"type": "Synonym",
					"name": "MVA-HPV16E6/E7-IL2"
				},
				{
					"type": "Synonym",
					"name": "HPV16 E6/E7-encoding MVA vaccine TG4001"
				}
			],
			"definition": {
				"html": "A cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) strain encoding the tumor-associated antigens (TAAs) human papillomavirus type 16 (HPV16) subtypes E6 and E7, and human interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Vaccination with MVA-HPV16E6/E7-IL2 vaccine TG4001 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against HPV16 E6- and E7-expressing tumor cells.",
				"text": "A cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) strain encoding the tumor-associated antigens (TAAs) human papillomavirus type 16 (HPV16) subtypes E6 and E7, and human interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Vaccination with MVA-HPV16E6/E7-IL2 vaccine TG4001 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against HPV16 E6- and E7-expressing tumor cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C88326",
			"nciConceptName": "Tipapkinogene Sovacivec",
			"termId": 661166,
			"name": "MVA-HPV16E6/E7-IL2 vaccine TG4001",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "tipapkinogene-sovacivec"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MVA-MUC1-IL2"
				},
				{
					"type": "CodeName",
					"name": "TG4010"
				},
				{
					"type": "Synonym",
					"name": "modified vaccinia ankara encoding human MUC-1 antigen and interleukin-2 suspension"
				}
			],
			"definition": {
				"html": "A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens. Vaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against MUC1 expressing cells.",
				"text": "A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens. Vaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against MUC1 expressing cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C2241",
			"nciConceptName": "MVA-MUC1-IL2 Vaccine",
			"termId": 37853,
			"name": "MVA-MUC1-IL2 vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mva-muc1-il2-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "modified vaccinia Ankara (Bavarian Nordic) prostate cancer vaccine"
				},
				{
					"type": "Synonym",
					"name": "MVA-BN-PRO"
				}
			],
			"definition": {
				"html": "A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding genes for prostate specific antigen (PSA) and prostate acid phosphatase (PAP) with potential immunostimulatory and antineoplastic activities.  Upon administration, MVA-PSA-PAP prostate cancer vaccine\nexpresses PSA and PAP peptides, which may elicit humoral and cellular immune responses against prostate cancer cells expressing PSA and PAP. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy.\n",
				"text": "A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding genes for prostate specific antigen (PSA) and prostate acid phosphatase (PAP) with potential immunostimulatory and antineoplastic activities.  Upon administration, MVA-PSA-PAP prostate cancer vaccine\nexpresses PSA and PAP peptides, which may elicit humoral and cellular immune responses against prostate cancer cells expressing PSA and PAP. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C74064",
			"nciConceptName": "MVA-PSA/PAP Prostate Cancer Vaccine",
			"termId": 590620,
			"name": "MVA-PSA-PAP prostate cancer vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mva-psa-pap-prostate-cancer-vaccine"
		},
		{
			"aliases": [
				{
					"type": "Synonym",
					"name": "M-VAC regimen"
				},
				{
					"type": "Synonym",
					"name": "methotrexate-vinblastine-adriamycin-cisplatin regimen"
				},
				{
					"type": "Synonym",
					"name": "methotrexate-vinblastine-doxorubicin-cisplatin regimen"
				},
				{
					"type": "Synonym",
					"name": "methotrexate-vinblastine sulfate-doxorubicin hydrochloride-cisplatin regimen"
				}
			],
			"definition": {
				"html": "A regimen consisting of methotrexate, vinblastine, doxorubicin, and cisplatin used for the treatment of advanced-stage  urothelial carcinoma, including bladder  cancer.\n",
				"text": "A regimen consisting of methotrexate, vinblastine, doxorubicin, and cisplatin used for the treatment of advanced-stage  urothelial carcinoma, including bladder  cancer.\n"
			},
			"drugInfoSummaryLink": {
				"uri": "https://www.cancer.gov/about-cancer/treatment/drugs/MVAC",
				"text": "MVAC"
			},
			"nciConceptId": "C63486",
			"nciConceptName": "MVAC Regimen",
			"termId": 790968,
			"name": "MVAC regimen",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mvac-regimen"
		},
		{
			"preferredName": "bevacizumab",
			"termId": 43234,
			"name": "Mvasi",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "bevacizumab"
		},
		{
			"aliases": null,
			"definition": {
				"html": "A combination peptide vaccine of 2 chimeric peptides of the promiscuous T cell epitope derived from measles virus fusion protein (MVF; amino acid residues 288-302) co-synthesized with B-cell epitopes derived from the HER-2/neu a.a. 597-626 and HER-2/neu a.a. 266-296, with potential antineoplastic activity. Vaccination with MVF-HER-2(597-626)/MVF-HER-2(266-296) peptide vaccine may induce an active specific immune response, mounting a cytotoxic T-lymphocyte (CTL) response and an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress the HER-2 protein. The oncogenic protein HER-2, a member of the human epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in a variety of cancers and is correlated with increased tumor growth, progression and a poor prognosis. HER-2(597-626) corresponds to the binding site of trastuzumab on the extracellular domain IV of HER-2; HER-2 (266-296) corresponds to the binding site of pertuzumab on the dimerization loop of domain II of HER-2.",
				"text": "A combination peptide vaccine of 2 chimeric peptides of the promiscuous T cell epitope derived from measles virus fusion protein (MVF; amino acid residues 288-302) co-synthesized with B-cell epitopes derived from the HER-2/neu a.a. 597-626 and HER-2/neu a.a. 266-296, with potential antineoplastic activity. Vaccination with MVF-HER-2(597-626)/MVF-HER-2(266-296) peptide vaccine may induce an active specific immune response, mounting a cytotoxic T-lymphocyte (CTL) response and an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress the HER-2 protein. The oncogenic protein HER-2, a member of the human epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in a variety of cancers and is correlated with increased tumor growth, progression and a poor prognosis. HER-2(597-626) corresponds to the binding site of trastuzumab on the extracellular domain IV of HER-2; HER-2 (266-296) corresponds to the binding site of pertuzumab on the dimerization loop of domain II of HER-2."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C97344",
			"nciConceptName": "MVF-HER-2(597-626)/MVF-HER-2 (266-296) Peptide Vaccine",
			"termId": 702861,
			"name": "MVF-HER-2(597-626)-MVF-HER-2 (266-296) peptide vaccine",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mvf-her-2597-626-mvf-her-2-266-296-peptide-vaccine"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "MVX-ONCO-1"
				}
			],
			"definition": {
				"html": "A two-component, anti-cancer vaccine containing irradiated tumor cells from a patient, and a capsule implanted with a genetically modified allogeneic cell line that continuously releases granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immune-protective and -boosting activities. Upon subcutaneous injection of MVX-1-loaded macrocapsule/autologous tumor cell vaccine MVX-ONCO-1, the GM-CSF-secreting allogeneic cell capsules and the autologous irradiated cells isolated from the patient's tumor are co-localized in the patient's tissue. This permits the production of GM-CSF and exposes the immune system to the tumor-associated antigens (TAA) expressed by the autologous tumor cells at the injection site. Local expression of GM-CSF recruits and activates antigen-presenting cells (APC), which induces both antibody-dependent cell-mediated cytotoxicity (ADCC) and cytotoxic T-lymphocyte responses at the site of the injection and systemically. This may lead to tumor regression. By using the patients own irradiated cancer cells as vaccine antigens, the patient's immune system is exposed to the entire repertoire of this individual's TAAs. The encapsulated cell technology (ECT) of GM-CSF-secreting allogeneic cell capsules ensures the continuous release of GM-CSF. GM-CSF, a monomeric glycoprotein that functions as a cytokine, is a strong immune booster and plays an important role in the activation of immune system.\n",
				"text": "A two-component, anti-cancer vaccine containing irradiated tumor cells from a patient, and a capsule implanted with a genetically modified allogeneic cell line that continuously releases granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immune-protective and -boosting activities. Upon subcutaneous injection of MVX-1-loaded macrocapsule/autologous tumor cell vaccine MVX-ONCO-1, the GM-CSF-secreting allogeneic cell capsules and the autologous irradiated cells isolated from the patient's tumor are co-localized in the patient's tissue. This permits the production of GM-CSF and exposes the immune system to the tumor-associated antigens (TAA) expressed by the autologous tumor cells at the injection site. Local expression of GM-CSF recruits and activates antigen-presenting cells (APC), which induces both antibody-dependent cell-mediated cytotoxicity (ADCC) and cytotoxic T-lymphocyte responses at the site of the injection and systemically. This may lead to tumor regression. By using the patients own irradiated cancer cells as vaccine antigens, the patient's immune system is exposed to the entire repertoire of this individual's TAAs. The encapsulated cell technology (ECT) of GM-CSF-secreting allogeneic cell capsules ensures the continuous release of GM-CSF. GM-CSF, a monomeric glycoprotein that functions as a cytokine, is a strong immune booster and plays an important role in the activation of immune system.\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C123382",
			"nciConceptName": "MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1",
			"termId": 763210,
			"name": "MVX-1-loaded macrocapsule/autologous tumor cell vaccine MVX-ONCO-1",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mvx-1-loaded-macrocapsule-autologous-tumor-cell-vaccine-mvx-onco-1"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "DCR-MYC"
				},
				{
					"type": "CodeName",
					"name": "DCR-M1711"
				}
			],
			"definition": {
				"html": "A lipid nanoparticle-based formulation consisting of small-interfering RNAs (siRNAs) directed against the oncogene c-Myc encapsulated in lipids with potential antineoplastic activity. Upon intravenous administration of MYC-targeting siRNA DCR-MYC, the lipid formulation promotes the uptake by tumor cells where the siRNAs moieties are subsequently released. The siRNAs bind to c-Myc mRNAs, which may result in the inhibition of translation and expression of the c-Myc protein and leads to growth inhibition for tumor cells that are overexpressing c-Myc. c-Myc, a proto-oncogene overexpressed in a variety of cancers, is involved in cellular proliferation, differentiation, and apoptosis.",
				"text": "A lipid nanoparticle-based formulation consisting of small-interfering RNAs (siRNAs) directed against the oncogene c-Myc encapsulated in lipids with potential antineoplastic activity. Upon intravenous administration of MYC-targeting siRNA DCR-MYC, the lipid formulation promotes the uptake by tumor cells where the siRNAs moieties are subsequently released. The siRNAs bind to c-Myc mRNAs, which may result in the inhibition of translation and expression of the c-Myc protein and leads to growth inhibition for tumor cells that are overexpressing c-Myc. c-Myc, a proto-oncogene overexpressed in a variety of cancers, is involved in cellular proliferation, differentiation, and apoptosis."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C115108",
			"nciConceptName": "MYC-targeting siRNA DCR-MYC",
			"termId": 759983,
			"name": "MYC-targeting siRNA DCR-MYC",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "myc-targeting-sirna-dcr-myc"
		},
		{
			"preferredName": "clotrimazole",
			"termId": 39116,
			"name": "Mycelex",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "clotrimazole"
		},
		{
			"preferredName": "clotrimazole",
			"termId": 39116,
			"name": "Mycelex Troche",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "clotrimazole"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MCC"
				}
			],
			"definition": {
				"html": "A proprietary preparation of mycobacterial DNA oligonucleotides embedded in mycobacterial cell wall fragments derived from cultures of Mycobacterium phlei, with potential immunomodulatory and antineoplastic activities. DNA oligonucleotides in the mycobacterial cell wall-DNA complex (MCC) induce apoptosis by increasing BAX protein levels, releasing cytochrome C from mitochondria, and activating caspase-3 and -7, which results in the cleavage of poly (ADP-ribose) polymerase and the release of nuclear matrix proteins. In addition to its pro-apoptotic effect, MCC activates monocytes and macrophages to produce various cytokines, including interleukin 6 (IL-6), IL-8, IL-12, IL-18, and tumor necrosis factor alpha (TNF-a). This results in the activation of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) and  interferon gamma (IFN-gamma) synthesis.\n\n",
				"text": "A proprietary preparation of mycobacterial DNA oligonucleotides embedded in mycobacterial cell wall fragments derived from cultures of Mycobacterium phlei, with potential immunomodulatory and antineoplastic activities. DNA oligonucleotides in the mycobacterial cell wall-DNA complex (MCC) induce apoptosis by increasing BAX protein levels, releasing cytochrome C from mitochondria, and activating caspase-3 and -7, which results in the cleavage of poly (ADP-ribose) polymerase and the release of nuclear matrix proteins. In addition to its pro-apoptotic effect, MCC activates monocytes and macrophages to produce various cytokines, including interleukin 6 (IL-6), IL-8, IL-12, IL-18, and tumor necrosis factor alpha (TNF-a). This results in the activation of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) and  interferon gamma (IFN-gamma) synthesis.\n\n"
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C64765",
			"nciConceptName": "Mycobacterial Cell Wall-DNA Complex",
			"termId": 529352,
			"name": "mycobacterial cell wall-DNA complex",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mycobacterial-cell-wall-dna-complex"
		},
		{
			"aliases": [
				{
					"type": "CodeName",
					"name": "Z-100"
				}
			],
			"definition": {
				"html": "An extract from Mycobacterium tuberculosis (M. tuberculosis) containing the polysaccharide arabinomannan, with potential immunostimulating activity. Upon administration of M. tuberculosis arabinomannan Z-100, this agent may activate the immune system by increasing the expression of various cytokines, such as interferon-gamma (IFNg) and interleukin-12. This inhibits the activity of suppressor T-cells, increases T helper 1 cell (Th1) activity and may restore the balance between Th1/Th2 cells. Additionally, Z-100 may inhibit metastasis and tumor cell proliferation.",
				"text": "An extract from Mycobacterium tuberculosis (M. tuberculosis) containing the polysaccharide arabinomannan, with potential immunostimulating activity. Upon administration of M. tuberculosis arabinomannan Z-100, this agent may activate the immune system by increasing the expression of various cytokines, such as interferon-gamma (IFNg) and interleukin-12. This inhibits the activity of suppressor T-cells, increases T helper 1 cell (Th1) activity and may restore the balance between Th1/Th2 cells. Additionally, Z-100 may inhibit metastasis and tumor cell proliferation."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C118445",
			"nciConceptName": "Mycobacterium tuberculosis Arabinomannan Z-100",
			"termId": 764997,
			"name": "Mycobacterium tuberculosis arabinomannan Z-100",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mycobacterium-tuberculosis-arabinomannan-z-100"
		},
		{
			"aliases": null,
			"definition": {
				"html": "An attenuated strain of Mycobacterium w, a non-pathogenic, rapidly growing, atypical mycobacterium, with non-specific immunopotentiating properties. In addition to sharing a number of common B and T cell determinants with Mycobacterium leprae and Mycobacterium tuberculosis, Mycobacterium w (Mw) also shares an immunogenic determinant with prostate specific antigen (PSA). In vitro and in vivo studies have shown that heat-killed Mw can induce significant T-cell  responses. This agent may induce host T-cell responses against tumor cells expressing PSA. PSA is a glycoprotein secreted by prostatic epithelial and ductal cells and may be overexpressed in prostate cancer cells.",
				"text": "An attenuated strain of Mycobacterium w, a non-pathogenic, rapidly growing, atypical mycobacterium, with non-specific immunopotentiating properties. In addition to sharing a number of common B and T cell determinants with Mycobacterium leprae and Mycobacterium tuberculosis, Mycobacterium w (Mw) also shares an immunogenic determinant with prostate specific antigen (PSA). In vitro and in vivo studies have shown that heat-killed Mw can induce significant T-cell  responses. This agent may induce host T-cell responses against tumor cells expressing PSA. PSA is a glycoprotein secreted by prostatic epithelial and ductal cells and may be overexpressed in prostate cancer cells."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C70969",
			"nciConceptName": "Mycobacterium w",
			"termId": 571076,
			"name": "Mycobacterium w",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mycobacterium-w"
		},
		{
			"preferredName": "rifabutin",
			"termId": 37812,
			"name": "Mycobutin",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "rifabutin"
		},
		{
			"aliases": [
				{
					"type": "Abbreviation",
					"name": "MMF"
				},
				{
					"type": "USBrandName",
					"name": "Cellcept"
				},
				{
					"type": "NSCNumber",
					"name": "950009"
				},
				{
					"type": "CASRegistryName",
					"name": "128794-94-5"
				}
			],
			"definition": {
				"html": "The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types.",
				"text": "The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C1468",
			"nciConceptName": "Mycophenolate Mofetil",
			"termId": 42797,
			"name": "mycophenolate mofetil",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mycophenolate-mofetil"
		},
		{
			"aliases": [
				{
					"type": "ChemicalStructureName",
					"name": "4-hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (E)-"
				},
				{
					"type": "ChemicalStructureName",
					"name": "4-hexenoic acid, 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-, (E)-"
				},
				{
					"type": "Synonym",
					"name": "acide mycophenolique"
				},
				{
					"type": "Synonym",
					"name": "acido micofenolico"
				},
				{
					"type": "Synonym",
					"name": "acidum mycophenolicum"
				},
				{
					"type": "CodeName",
					"name": "Lilly-68618"
				},
				{
					"type": "CodeName",
					"name": "Ly 68618"
				},
				{
					"type": "Abbreviation",
					"name": "MPA"
				},
				{
					"type": "USBrandName",
					"name": "Myfortic"
				},
				{
					"type": "NSCNumber",
					"name": "129185"
				},
				{
					"type": "CASRegistryName",
					"name": "24280-93-1"
				}
			],
			"definition": {
				"html": "An antineoplastic antibiotic derived from various Penicillium fungal species.  Mycophenolic acid is an active metabolite of the prodrug mycophenolate mofetil.  Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), preventing the formation of guanosine monophosphate and synthesis of lymphocyte DNA that results in inhibition of lymphocyte proliferation, antibody production, cellular adhesion, and migration of T and B lymphocytes.  Mycophenolic acid also has antibacterial, antifungal, and antiviral activities.",
				"text": "An antineoplastic antibiotic derived from various Penicillium fungal species.  Mycophenolic acid is an active metabolite of the prodrug mycophenolate mofetil.  Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), preventing the formation of guanosine monophosphate and synthesis of lymphocyte DNA that results in inhibition of lymphocyte proliferation, antibody production, cellular adhesion, and migration of T and B lymphocytes.  Mycophenolic acid also has antibacterial, antifungal, and antiviral activities."
			},
			"drugInfoSummaryLink": null,
			"nciConceptId": "C673",
			"nciConceptName": "Mycophenolic Acid",
			"termId": 732227,
			"name": "mycophenolic acid",
			"firstLetter": "m",
			"type": "DrugTerm",
			"termNameType": "PreferredName",
			"prettyUrlName": "mycophenolic-acid"
		},
		{
			"preferredName": "mycophenolic acid",
			"termId": 732227,
			"name": "Myfortic",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "mycophenolic-acid"
		},
		{
			"preferredName": "magnesium hydroxide/aluminum hydroxide",
			"termId": 39600,
			"name": "Mylanta",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "aluminum-hydroxide-magnesium-hydroxide"
		},
		{
			"preferredName": "busulfan",
			"termId": 41947,
			"name": "Myleran",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "busulfan"
		},
		{
			"preferredName": "gemtuzumab ozogamicin",
			"termId": 42868,
			"name": "Mylotarg",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "gemtuzumab-ozogamicin"
		},
		{
			"preferredName": "idiotype-pulsed autologous dendritic cell vaccine APC8020",
			"termId": 584999,
			"name": "Mylovenge",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "idiotype-pulsed-autologous-dendritic-cell-vaccine-apc8020"
		},
		{
			"preferredName": "gold sodium thiomalate",
			"termId": 581226,
			"name": "Myochrysine",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "gold-sodium-thiomalate"
		},
		{
			"preferredName": "mirabegron",
			"termId": 767328,
			"name": "Myrbetriq",
			"firstLetter": "m",
			"type": "DrugAlias",
			"termNameType": "USBrandName",
			"prettyUrlName": "mirabegron"
		}
	],
	"links": null
}
